OA19219A - Pyridopyrimdinone CDK2/4/6 inhibitors. - Google Patents
Pyridopyrimdinone CDK2/4/6 inhibitors. Download PDFInfo
- Publication number
- OA19219A OA19219A OA1201900055 OA19219A OA 19219 A OA19219 A OA 19219A OA 1201900055 OA1201900055 OA 1201900055 OA 19219 A OA19219 A OA 19219A
- Authority
- OA
- OAPI
- Prior art keywords
- alkyl
- fluoroalkyl
- mmol
- cancer
- compound
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title description 63
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 title description 33
- 239000003112 inhibitor Substances 0.000 title description 33
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 274
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 181
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 165
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 160
- 239000003937 drug carrier Substances 0.000 claims description 11
- 239000000546 pharmaceutic aid Substances 0.000 claims description 9
- 239000012458 free base Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 abstract description 177
- 201000011510 cancer Diseases 0.000 abstract description 77
- 239000011780 sodium chloride Substances 0.000 abstract description 58
- 150000003839 salts Chemical class 0.000 abstract description 56
- 230000002159 abnormal effect Effects 0.000 abstract description 28
- 230000010261 cell growth Effects 0.000 abstract description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 237
- 238000005160 1H NMR spectroscopy Methods 0.000 description 190
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 178
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 153
- 239000000243 solution Substances 0.000 description 148
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 117
- -1 aliphatic hydrocarbon radical Chemical class 0.000 description 113
- 239000000543 intermediate Substances 0.000 description 110
- 235000019439 ethyl acetate Nutrition 0.000 description 104
- 239000007787 solid Substances 0.000 description 103
- 125000000623 heterocyclic group Chemical group 0.000 description 94
- 125000000217 alkyl group Chemical group 0.000 description 88
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 86
- 125000004432 carbon atoms Chemical group C* 0.000 description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 73
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 71
- 229910001868 water Inorganic materials 0.000 description 71
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 70
- 101700046984 CDK20 Proteins 0.000 description 61
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 61
- 125000001072 heteroaryl group Chemical group 0.000 description 61
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
- 239000000460 chlorine Substances 0.000 description 54
- 238000006243 chemical reaction Methods 0.000 description 51
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 51
- 229910052731 fluorine Inorganic materials 0.000 description 50
- 229910052739 hydrogen Inorganic materials 0.000 description 47
- 125000001424 substituent group Chemical group 0.000 description 47
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 46
- 229910052801 chlorine Inorganic materials 0.000 description 46
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 45
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 45
- 210000004027 cells Anatomy 0.000 description 44
- 125000003118 aryl group Chemical group 0.000 description 42
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 41
- 229910052938 sodium sulfate Inorganic materials 0.000 description 41
- 235000011152 sodium sulphate Nutrition 0.000 description 41
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 40
- 239000003795 chemical substances by application Substances 0.000 description 38
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 37
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 36
- 239000003921 oil Substances 0.000 description 36
- 235000019198 oils Nutrition 0.000 description 36
- 239000000047 product Substances 0.000 description 35
- 239000002585 base Substances 0.000 description 34
- 239000000725 suspension Substances 0.000 description 34
- 102100019396 CDK2 Human genes 0.000 description 32
- 239000010410 layer Substances 0.000 description 32
- 229910052757 nitrogen Inorganic materials 0.000 description 32
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical group CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 32
- 239000011734 sodium Substances 0.000 description 32
- 238000003756 stirring Methods 0.000 description 32
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 32
- 206010028980 Neoplasm Diseases 0.000 description 31
- 239000002253 acid Substances 0.000 description 29
- 239000012044 organic layer Substances 0.000 description 29
- 238000010898 silica gel chromatography Methods 0.000 description 29
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 description 28
- 206010006187 Breast cancer Diseases 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- 102100016490 CCNE1 Human genes 0.000 description 26
- 101700061678 CCNE1 Proteins 0.000 description 26
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 26
- 125000000753 cycloalkyl group Chemical group 0.000 description 26
- 125000003386 piperidinyl group Chemical group 0.000 description 26
- 238000004166 bioassay Methods 0.000 description 25
- 235000011089 carbon dioxide Nutrition 0.000 description 25
- 230000003287 optical Effects 0.000 description 25
- 238000004293 19F NMR spectroscopy Methods 0.000 description 24
- 238000007792 addition Methods 0.000 description 24
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 22
- 101700008359 CDK4 Proteins 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- 125000002947 alkylene group Chemical group 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 22
- 239000002246 antineoplastic agent Substances 0.000 description 21
- 230000002018 overexpression Effects 0.000 description 21
- 238000001914 filtration Methods 0.000 description 20
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 19
- 102100019398 CDK4 Human genes 0.000 description 18
- 230000003321 amplification Effects 0.000 description 18
- 238000001816 cooling Methods 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 125000005843 halogen group Chemical group 0.000 description 18
- FLKRMXAWABTWSH-UHFFFAOYSA-N piperidine-1-sulfonamide Chemical compound NS(=O)(=O)N1CCCCC1 FLKRMXAWABTWSH-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- 239000003826 tablet Substances 0.000 description 18
- 102100006130 CDK6 Human genes 0.000 description 17
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 17
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
- 125000004429 atoms Chemical group 0.000 description 17
- 238000003199 nucleic acid amplification method Methods 0.000 description 17
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 17
- 125000004093 cyano group Chemical group *C#N 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 16
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 16
- 239000000758 substrate Substances 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 102100016489 CCNE2 Human genes 0.000 description 15
- 101700041341 CCNE2 Proteins 0.000 description 15
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- 229910003204 NH2 Inorganic materials 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 125000005842 heteroatoms Chemical group 0.000 description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 14
- 229910052760 oxygen Inorganic materials 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 14
- 239000001257 hydrogen Substances 0.000 description 13
- 108091007476 CDKs Proteins 0.000 description 12
- 101710014631 CHURC1 Proteins 0.000 description 12
- DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 12
- 229940079593 drugs Drugs 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 12
- 239000003208 petroleum Substances 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- 206010033128 Ovarian cancer Diseases 0.000 description 11
- 125000003545 alkoxy group Chemical group 0.000 description 11
- 125000005418 aryl aryl group Chemical group 0.000 description 11
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 102000003909 Cyclin E Human genes 0.000 description 10
- 108090000257 Cyclin E Proteins 0.000 description 10
- 102000003903 Cyclin-Dependent Kinases Human genes 0.000 description 10
- 108090000266 Cyclin-Dependent Kinases Proteins 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- 125000002252 acyl group Chemical group 0.000 description 10
- 150000001412 amines Chemical class 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 10
- 239000000651 prodrug Substances 0.000 description 10
- 229940002612 prodrugs Drugs 0.000 description 10
- 230000002829 reduced Effects 0.000 description 10
- 230000001225 therapeutic Effects 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- FLQSRSQNICPZIH-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-amine Chemical compound CS(=O)(=O)N1CCC(N)CC1 FLQSRSQNICPZIH-UHFFFAOYSA-N 0.000 description 9
- 102000016736 Cyclins Human genes 0.000 description 9
- 108050006400 Cyclins Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- YNESATAKKCNGOF-UHFFFAOYSA-N Lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 9
- 102100014526 TBC1D8 Human genes 0.000 description 9
- 101710035852 TBC1D8 Proteins 0.000 description 9
- 230000000875 corresponding Effects 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 239000012065 filter cake Substances 0.000 description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 9
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 9
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tBuOOH Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 9
- NUJOXMJBOLGQSY-UHFFFAOYSA-N Manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 8
- AHJRHEGDXFFMBM-UHFFFAOYSA-N Palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 8
- 229960004390 Palbociclib Drugs 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminum hydride Chemical compound [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 8
- 239000002609 media Substances 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- 239000003039 volatile agent Substances 0.000 description 8
- ADJUHOQFENGHSW-UHFFFAOYSA-N (4-chloro-2-methylsulfanylpyrimidin-5-yl)methanol Chemical compound CSC1=NC=C(CO)C(Cl)=N1 ADJUHOQFENGHSW-UHFFFAOYSA-N 0.000 description 7
- 229960000583 Acetic Acid Drugs 0.000 description 7
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 7
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 7
- 101700025368 ERBB2 Proteins 0.000 description 7
- 102100016662 ERBB2 Human genes 0.000 description 7
- 102100004109 HEY1 Human genes 0.000 description 7
- 108010081348 HRT1 protein Hairy Chemical group 0.000 description 7
- 229910020008 S(O) Inorganic materials 0.000 description 7
- 235000011054 acetic acid Nutrition 0.000 description 7
- 230000002378 acidificating Effects 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- 235000011114 ammonium hydroxide Nutrition 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000005457 ice water Substances 0.000 description 7
- 150000002829 nitrogen Chemical group 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 238000007363 ring formation reaction Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 7
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- 102100019529 CCND1 Human genes 0.000 description 6
- 229920000858 Cyclodextrin Polymers 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 6
- SNNHLSHDDGJVDM-UHFFFAOYSA-N ethyl 4-chloro-2-methylsulfanylpyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(SC)N=C1Cl SNNHLSHDDGJVDM-UHFFFAOYSA-N 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- 125000005647 linker group Chemical group 0.000 description 6
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 6
- 125000004430 oxygen atoms Chemical group O* 0.000 description 6
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 238000001877 single-ion monitoring Methods 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 6
- 150000003457 sulfones Chemical class 0.000 description 6
- 150000003462 sulfoxides Chemical class 0.000 description 6
- 125000004434 sulfur atoms Chemical group 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 5
- XMDQJXIEKHMDMG-UHFFFAOYSA-N 1-methyl-6-oxabicyclo[3.1.0]hexane Chemical compound C1CCC2OC21C XMDQJXIEKHMDMG-UHFFFAOYSA-N 0.000 description 5
- 206010059512 Apoptosis Diseases 0.000 description 5
- 102100016486 CCND3 Human genes 0.000 description 5
- 102100013105 CDK1 Human genes 0.000 description 5
- 101700051654 CDK1 Proteins 0.000 description 5
- 229960005069 Calcium Drugs 0.000 description 5
- 108010058546 Cyclin D1 Proteins 0.000 description 5
- 108010058545 Cyclin D3 Proteins 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N DBU Substances C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 5
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 5
- 240000000437 Eucalyptus leucoxylon Species 0.000 description 5
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 5
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- 239000012425 OXONE® Substances 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 5
- 108010010691 Trastuzumab Proteins 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 239000000908 ammonium hydroxide Substances 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000012455 biphasic mixture Substances 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000005712 crystallization Effects 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- 230000002124 endocrine Effects 0.000 description 5
- 125000001153 fluoro group Chemical group F* 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 125000004043 oxo group Chemical group O=* 0.000 description 5
- HJKYXKSLRZKNSI-UHFFFAOYSA-I pentapotassium;hydrogen sulfate;oxido sulfate;sulfuric acid Chemical compound [K+].[K+].[K+].[K+].[K+].OS([O-])(=O)=O.[O-]S([O-])(=O)=O.OS(=O)(=O)O[O-].OS(=O)(=O)O[O-] HJKYXKSLRZKNSI-UHFFFAOYSA-I 0.000 description 5
- 230000001105 regulatory Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 229960001663 sulfanilamide Drugs 0.000 description 5
- 229960000575 trastuzumab Drugs 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- MIVUDAUOXJDARR-ZDUSSCGKSA-M (2S)-2-[(3,5-dinitrobenzoyl)amino]-2-phenylacetate Chemical compound N([C@H](C(=O)[O-])C=1C=CC=CC=1)C(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 MIVUDAUOXJDARR-ZDUSSCGKSA-M 0.000 description 4
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 4
- WDHAAJIGSXNPFO-UHFFFAOYSA-N 8H-pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CN=C2NC(=O)C=CC2=C1 WDHAAJIGSXNPFO-UHFFFAOYSA-N 0.000 description 4
- 210000004369 Blood Anatomy 0.000 description 4
- 102100006116 CDK7 Human genes 0.000 description 4
- 101700007872 CDK7 Proteins 0.000 description 4
- 239000005977 Ethylene Substances 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- 229910000949 MnO2 Inorganic materials 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Substances ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- 108091000081 Phosphotransferases Proteins 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 102000001253 Protein Kinases Human genes 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229940032147 Starch Drugs 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 230000003042 antagnostic Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 108090001123 antibodies Proteins 0.000 description 4
- 102000004965 antibodies Human genes 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000002837 carbocyclic group Chemical group 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000010192 crystallographic characterization Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000001963 growth media Substances 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 230000003000 nontoxic Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Chemical compound [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000002194 synthesizing Effects 0.000 description 4
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl N-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- 230000000699 topical Effects 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 3
- QYYQTLLGVAPKPN-UHFFFAOYSA-N 1-ethylcyclopentene Chemical compound CCC1=CCCC1 QYYQTLLGVAPKPN-UHFFFAOYSA-N 0.000 description 3
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 3
- 210000002469 Basement Membrane Anatomy 0.000 description 3
- WGQKYBSKWIADBV-UHFFFAOYSA-N Benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 210000000481 Breast Anatomy 0.000 description 3
- 206010055113 Breast cancer metastatic Diseases 0.000 description 3
- 102100003972 CDK9 Human genes 0.000 description 3
- 101700049227 CDK9 Proteins 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 206010017758 Gastric cancer Diseases 0.000 description 3
- 229960001031 Glucose Drugs 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 3
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 3
- 206010027476 Metastasis Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 230000036191 S Phase Effects 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N Seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 229960004793 Sucrose Drugs 0.000 description 3
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 3
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 3
- 229960001603 Tamoxifen Drugs 0.000 description 3
- JRMUNVKIHCOMHV-UHFFFAOYSA-M Tetra-n-butylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 3
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N Trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 3
- 230000036462 Unbound Effects 0.000 description 3
- 206010046766 Uterine cancer Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive Effects 0.000 description 3
- 125000004103 aminoalkyl group Chemical group 0.000 description 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 3
- WWGUAFRTAYMNHU-UHFFFAOYSA-N benzyl N-piperidin-4-ylcarbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1CCNCC1 WWGUAFRTAYMNHU-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229920000591 gum Polymers 0.000 description 3
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 150000002466 imines Chemical group 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000007425 microfluidic mobility shift assay Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 150000004682 monohydrates Chemical class 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 3
- LFGREXWGYUGZLY-UHFFFAOYSA-N oxophosphanyl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- DRINJBFRTLBHNF-UHFFFAOYSA-N propane-2-sulfonyl chloride Chemical compound CC(C)S(Cl)(=O)=O DRINJBFRTLBHNF-UHFFFAOYSA-N 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Substances [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
- 230000036964 tight binding Effects 0.000 description 3
- 210000004881 tumor cells Anatomy 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-(1R,3R,4S)-menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- ZFSXKSSWYSZPGQ-TYSVMGFPSA-N (1R,2R)-2-aminocyclopentan-1-ol;hydrochloride Chemical compound Cl.N[C@@H]1CCC[C@H]1O ZFSXKSSWYSZPGQ-TYSVMGFPSA-N 0.000 description 2
- MIVUDAUOXJDARR-ZDUSSCGKSA-N (2S)-2-[(3,5-dinitrobenzoyl)amino]-2-phenylacetic acid Chemical compound N([C@H](C(=O)O)C=1C=CC=CC=1)C(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 MIVUDAUOXJDARR-ZDUSSCGKSA-N 0.000 description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 2
- JJWOMLRJNXMLSO-UHFFFAOYSA-N 1-methylsulfonylpiperidine Chemical compound CS(=O)(=O)N1CCCCC1 JJWOMLRJNXMLSO-UHFFFAOYSA-N 0.000 description 2
- CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-M 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GHOKWGTUZJEAQD-ZETCQYMHSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 2
- IHGUPEYAGNJXGX-UHFFFAOYSA-N 4-(cycloheptylamino)-2-methylsulfanylpyrimidine-5-carbaldehyde Chemical compound CSC1=NC=C(C=O)C(NC2CCCCCC2)=N1 IHGUPEYAGNJXGX-UHFFFAOYSA-N 0.000 description 2
- QKRVSWPBAOCWHY-UHFFFAOYSA-N 4-(cyclopentylamino)-2-methylsulfanylpyrimidine-5-carbaldehyde Chemical compound CSC1=NC=C(C=O)C(NC2CCCC2)=N1 QKRVSWPBAOCWHY-UHFFFAOYSA-N 0.000 description 2
- VMNYMIKGYQYJHK-UHFFFAOYSA-N 4-chloro-2-methylsulfanylpyrimidine-5-carbaldehyde Chemical compound CSC1=NC=C(C=O)C(Cl)=N1 VMNYMIKGYQYJHK-UHFFFAOYSA-N 0.000 description 2
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 2
- 102100001248 AKT1 Human genes 0.000 description 2
- 101700006234 AKT1 Proteins 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 102100005858 CCNA2 Human genes 0.000 description 2
- 101700001733 CDK5 Proteins 0.000 description 2
- 102100006129 CDK5 Human genes 0.000 description 2
- KFHXBDPBFXUFKJ-UHFFFAOYSA-N CNS(=O)(=O)N1CCC(CC1)NC(OCC1=CC=CC=C1)=O Chemical compound CNS(=O)(=O)N1CCC(CC1)NC(OCC1=CC=CC=C1)=O KFHXBDPBFXUFKJ-UHFFFAOYSA-N 0.000 description 2
- SRXVGXVUYKNXQG-UHFFFAOYSA-N CS(O)(=O)=O.NC1CCN(CC1)S(=O)(=O)CCC#C Chemical compound CS(O)(=O)=O.NC1CCN(CC1)S(=O)(=O)CCC#C SRXVGXVUYKNXQG-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- ZOVQADZPCCFFQA-UHFFFAOYSA-N Cl.CC1C(N)CCC1O Chemical compound Cl.CC1C(N)CCC1O ZOVQADZPCCFFQA-UHFFFAOYSA-N 0.000 description 2
- BXGXDXVPVPXOST-UHFFFAOYSA-N Cl.CC1C(N)CCCC1O Chemical compound Cl.CC1C(N)CCCC1O BXGXDXVPVPXOST-UHFFFAOYSA-N 0.000 description 2
- 108010068192 Cyclin A Proteins 0.000 description 2
- 102000003910 Cyclin D Human genes 0.000 description 2
- 108090000259 Cyclin D Proteins 0.000 description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N Cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N Diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- 229940034984 ENDOCRINE THERAPY ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Drugs 0.000 description 2
- JIDLZYBYAFTHIL-UHFFFAOYSA-N FC(CC(C(=O)OCC1=CC=CC=C1)=C)F Chemical compound FC(CC(C(=O)OCC1=CC=CC=C1)=C)F JIDLZYBYAFTHIL-UHFFFAOYSA-N 0.000 description 2
- GRICPFVMZFLWEF-UHFFFAOYSA-N FC(CC1C(OC(OC1=O)(C)C)=O)F Chemical compound FC(CC1C(OC(OC1=O)(C)C)=O)F GRICPFVMZFLWEF-UHFFFAOYSA-N 0.000 description 2
- XZLIKWOVSHUPCV-UHFFFAOYSA-N FC(CS(=O)(=O)N1CCC(CC1)NC(OC(C)(C)C)=O)(F)F Chemical compound FC(CS(=O)(=O)N1CCC(CC1)NC(OC(C)(C)C)=O)(F)F XZLIKWOVSHUPCV-UHFFFAOYSA-N 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 229960002258 Fulvestrant Drugs 0.000 description 2
- 229940049906 Glutamate Drugs 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 229960004873 LEVOMENTHOL Drugs 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- GXHFUVWIGNLZSC-UHFFFAOYSA-N Meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- BABHEXIISLZMCJ-UHFFFAOYSA-N OCC=1C(=NC(=NC=1)SC)NC1C(C(CC1)O)C Chemical compound OCC=1C(=NC(=NC=1)SC)NC1C(C(CC1)O)C BABHEXIISLZMCJ-UHFFFAOYSA-N 0.000 description 2
- JQTACAJTRIJYMG-NXEZZACHSA-N OCC=1C(=NC(=NC=1)SC)N[C@H]1C[C@@H](CCC1)O Chemical compound OCC=1C(=NC(=NC=1)SC)N[C@H]1C[C@@H](CCC1)O JQTACAJTRIJYMG-NXEZZACHSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229920000272 Oligonucleotide Polymers 0.000 description 2
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical class N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
- 229950003687 Ribociclib Drugs 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 Xylitol Drugs 0.000 description 2
- DVCFSGVOYRHECI-UHFFFAOYSA-N [4-(cycloheptylamino)-2-methylsulfanylpyrimidin-5-yl]methanol Chemical compound CSC1=NC=C(CO)C(NC2CCCCCC2)=N1 DVCFSGVOYRHECI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 125000003725 azepanyl group Chemical group 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000002051 biphasic Effects 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- DKMROQRQHGEIOW-UHFFFAOYSA-N diethyl butanedioate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 2
- 125000006001 difluoroethyl group Chemical group 0.000 description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 229940009662 edetate Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000009261 endocrine therapy Methods 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- JTBBVVXVGZXGRB-UHFFFAOYSA-N ethyl 4-(cycloheptylamino)-2-methylsulfanylpyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(SC)N=C1NC1CCCCCC1 JTBBVVXVGZXGRB-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229940044170 formate Drugs 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 229940050411 fumarate Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002496 gastric Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000004474 heteroalkylene group Chemical group 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000008079 hexane Substances 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 2
- 238000010902 jet-milling Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 2
- 230000003211 malignant Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229940014662 pantothenate Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative Effects 0.000 description 2
- 235000015108 pies Nutrition 0.000 description 2
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000001184 potassium carbonate Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 229940086735 succinate Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 2
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000005309 thioalkoxy group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 230000003442 weekly Effects 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- UGEYAPVLXKEKMP-UHFFFAOYSA-L zinc;difluoromethanesulfinate Chemical compound FC(F)S(=O)O[Zn]OS(=O)C(F)F UGEYAPVLXKEKMP-UHFFFAOYSA-L 0.000 description 2
- TYDMZADCGUWTCH-NTSWFWBYSA-N (1R,2S)-2-methylcyclopentan-1-amine Chemical compound C[C@H]1CCC[C@H]1N TYDMZADCGUWTCH-NTSWFWBYSA-N 0.000 description 1
- NIQIPYGXPZUDDP-PHDIDXHHSA-N (1R,3R)-3-aminocyclohexan-1-ol Chemical compound N[C@@H]1CCC[C@@H](O)C1 NIQIPYGXPZUDDP-PHDIDXHHSA-N 0.000 description 1
- TYDMZADCGUWTCH-RITPCOANSA-N (1S,2R)-2-methylcyclopentan-1-amine Chemical compound C[C@@H]1CCC[C@@H]1N TYDMZADCGUWTCH-RITPCOANSA-N 0.000 description 1
- IYXUFOCLMOXQSL-UHFFFAOYSA-N (2,2-difluoroacetyl) 2,2-difluoroacetate Chemical compound FC(F)C(=O)OC(=O)C(F)F IYXUFOCLMOXQSL-UHFFFAOYSA-N 0.000 description 1
- NDQQRRVKUBPTHQ-QBIQUQHTSA-N (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO NDQQRRVKUBPTHQ-QBIQUQHTSA-N 0.000 description 1
- PUSNGFYSTWMJSK-GSZQVNRLSA-N (2R,3R,4S,5R,6R)-2,3,4-trimethoxy-6-(methoxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[(2R,3R,4S,5R,6S)-3,4,5-tris(2-hydroxypropoxy)-6-[(2R,3R,4S,5R,6R)-4,5,6-tris(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)oxan- Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](OC)O[C@@H]1COC.CC(O)CO[C@@H]1[C@@H](OCC(C)O)[C@H](OCC(C)O)[C@@H](COCC(O)C)O[C@H]1O[C@H]1[C@H](OCC(C)O)[C@@H](OCC(C)O)[C@H](OCC(C)O)O[C@@H]1COCC(C)O PUSNGFYSTWMJSK-GSZQVNRLSA-N 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 1
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 description 1
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 1
- 125000006736 (C6-C20) aryl group Chemical group 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical compound C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 description 1
- CRPTXKKKIGGDBX-UHFFFAOYSA-N (Z)-but-2-ene Chemical compound [CH2]C=CC CRPTXKKKIGGDBX-UHFFFAOYSA-N 0.000 description 1
- HPXNTHKXCYMIJL-UHFFFAOYSA-N 1,1'-bis(diphenylphosphanyl)ferrocene Chemical compound C12C3C4C5[Fe]4322346(C7(C2C6C4C37)P(C=2C=CC=CC=2)C=2C=CC=CC=2)C15P(C=1C=CC=CC=1)C1=CC=CC=C1 HPXNTHKXCYMIJL-UHFFFAOYSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-Heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-Tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- VMFCTZUYOILUMY-UHFFFAOYSA-N 1,1-difluoro-2-iodoethane Chemical compound FC(F)CI VMFCTZUYOILUMY-UHFFFAOYSA-N 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- UDGKZGLPXCRRAM-UHFFFAOYSA-N 1,2,5-thiadiazole Chemical compound C=1C=NSN=1 UDGKZGLPXCRRAM-UHFFFAOYSA-N 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- MGNZXYYWBUKAII-UHFFFAOYSA-N 1,3-Cyclohexadiene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- LMTDPKYREUZYAO-UHFFFAOYSA-N 1,4-dioxepane Chemical compound C1COCCOC1 LMTDPKYREUZYAO-UHFFFAOYSA-N 0.000 description 1
- DNWRQNQDWZNZEB-UHFFFAOYSA-N 1,4-dithiepane Chemical compound C1CSCCSC1 DNWRQNQDWZNZEB-UHFFFAOYSA-N 0.000 description 1
- FUHYSHCCRTWZAY-UHFFFAOYSA-N 1,4-oxathiepane Chemical compound C1COCCSC1 FUHYSHCCRTWZAY-UHFFFAOYSA-N 0.000 description 1
- ZNGWEEUXTBNKFR-UHFFFAOYSA-N 1,4-oxazepane Chemical compound C1CNCCOC1 ZNGWEEUXTBNKFR-UHFFFAOYSA-N 0.000 description 1
- OFJXJWVJNKEUCV-UHFFFAOYSA-N 1,5,6,7,8,8a-hexahydro-[1,3]oxazolo[3,4-a]pyridin-3-one Chemical compound C1CCCN2C(=O)OCC21 OFJXJWVJNKEUCV-UHFFFAOYSA-N 0.000 description 1
- VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical compound C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 description 1
- VSOSXKMEQPYESP-UHFFFAOYSA-N 1,6-naphthyridine Chemical compound C1=CN=CC2=CC=CN=C21 VSOSXKMEQPYESP-UHFFFAOYSA-N 0.000 description 1
- MXBVNILGVJVVMH-UHFFFAOYSA-N 1,7-naphthyridine Chemical compound C1=NC=CC2=CC=CN=C21 MXBVNILGVJVVMH-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- GBXAJMHGCMMGEQ-UHFFFAOYSA-N 1-(2,2,2-trifluoroethylsulfonyl)piperidin-4-amine Chemical compound NC1CCN(S(=O)(=O)CC(F)(F)F)CC1 GBXAJMHGCMMGEQ-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-Phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- CAKWRXVKWGUISE-UHFFFAOYSA-N 1-methylcyclopentan-1-ol Chemical compound CC1(O)CCCC1 CAKWRXVKWGUISE-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 1H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- GVLRTOYGRNLSDW-UHFFFAOYSA-N 1H-pyrazolo[3,4-b]pyridine Chemical compound C1=CC=C2C=NNC2=N1 GVLRTOYGRNLSDW-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-M 2,3-dinitrobenzoate Chemical compound [O-]C(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-M 0.000 description 1
- IZKATSCDUREBRD-UHFFFAOYSA-N 2,5,6,7,8,8a-hexahydro-1H-indolizin-3-one Chemical compound C1CCCN2C(=O)CCC21 IZKATSCDUREBRD-UHFFFAOYSA-N 0.000 description 1
- SSNMISUJOQAFRR-UHFFFAOYSA-N 2,6-naphthyridine Chemical compound N1=CC=C2C=NC=CC2=C1 SSNMISUJOQAFRR-UHFFFAOYSA-N 0.000 description 1
- HCMMECMKVPHMDE-UHFFFAOYSA-N 2,7-naphthyridine Chemical compound C1=NC=C2C=NC=CC2=C1 HCMMECMKVPHMDE-UHFFFAOYSA-N 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- PIMQWRZWLQKKBJ-SFHVURJKSA-N 2-[(2S)-1-[3-ethyl-7-[(1-oxidopyridin-1-ium-3-yl)methylamino]pyrazolo[1,5-a]pyrimidin-5-yl]piperidin-2-yl]ethanol Chemical compound C=1C(N2[C@@H](CCCC2)CCO)=NC2=C(CC)C=NN2C=1NCC1=CC=C[N+]([O-])=C1 PIMQWRZWLQKKBJ-SFHVURJKSA-N 0.000 description 1
- WSSDGZWSPMAECX-UHFFFAOYSA-N 2-azabicyclo[3.1.0]hexane Chemical compound C1CNC2CC21 WSSDGZWSPMAECX-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-M 2-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-M 0.000 description 1
- ZSTYQALWKOGXOV-UHFFFAOYSA-N 2-methoxy-2-methylpropan-1-amine Chemical compound COC(C)(C)CN ZSTYQALWKOGXOV-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- DIQOUXNTSMWQSA-UHFFFAOYSA-N 2-oxa-5-azabicyclo[2.2.1]heptane Chemical compound C1OC2CNC1C2 DIQOUXNTSMWQSA-UHFFFAOYSA-N 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- YOMXAHRCWPEIIK-UHFFFAOYSA-N 3,4-dihydro-2H-pyran;3,6-dihydro-2H-pyran Chemical compound C1COC=CC1.C1CC=CCO1 YOMXAHRCWPEIIK-UHFFFAOYSA-N 0.000 description 1
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-Hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 1
- GYLMCBOAXJVARF-UHFFFAOYSA-N 3-azabicyclo[2.2.1]heptane Chemical compound C1C2CCC1NC2 GYLMCBOAXJVARF-UHFFFAOYSA-N 0.000 description 1
- HGWUUOXXAIISDB-UHFFFAOYSA-N 3-azabicyclo[3.1.0]hexane Chemical compound C1NCC2CC21 HGWUUOXXAIISDB-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
- OLCMEOZFMPJHCK-UHFFFAOYSA-N 3-methyloxolan-3-ol Chemical compound CC1(O)CCOC1 OLCMEOZFMPJHCK-UHFFFAOYSA-N 0.000 description 1
- MNILDQSRDHCFJG-UHFFFAOYSA-N 3-oxa-8-azabicyclo[3.2.1]octane Chemical compound C1OCC2CCC1N2 MNILDQSRDHCFJG-UHFFFAOYSA-N 0.000 description 1
- FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 description 1
- YMHIEPNFCBNQQU-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-prop-2-enyl-1,3,2-dioxaborolane Chemical compound CC1(C)OB(CC=C)OC1(C)C YMHIEPNFCBNQQU-UHFFFAOYSA-N 0.000 description 1
- WULIZEOAYMSIHS-UHFFFAOYSA-N 4-chloro-5-methylpyrrolo[3,2-d]pyrimidine-6-carbaldehyde Chemical compound C1=NC(Cl)=C2N(C)C(C=O)=CC2=N1 WULIZEOAYMSIHS-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical class O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- SIKXIUWKPGWBBF-UHFFFAOYSA-N 5-bromo-2,4-dichloropyrimidine Chemical compound ClC1=NC=C(Br)C(Cl)=N1 SIKXIUWKPGWBBF-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- 101700078158 ALG1 Proteins 0.000 description 1
- 102100011141 ALK Human genes 0.000 description 1
- 101710033641 ALK Proteins 0.000 description 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 1
- 101700007241 APOC4 Proteins 0.000 description 1
- 102100011565 AXL Human genes 0.000 description 1
- 101710039535 AXL Proteins 0.000 description 1
- 101700008384 AXL1 Proteins 0.000 description 1
- 229950001573 Abemaciclib Drugs 0.000 description 1
- 208000009956 Adenocarcinoma Diseases 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N Ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 229940046844 Aromatase inhibitors Drugs 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- 241000015157 Attalea maripa Species 0.000 description 1
- 101710043792 BNA2 Proteins 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- JYZIHLWOWKMNNX-UHFFFAOYSA-N Benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N Benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N Benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N Benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- ZVEQSCRTRZHYTD-CHWSQXEVSA-N C(C1=CC=CC=C1)N[C@H]1[C@@](CCC1)(O)C Chemical compound C(C1=CC=CC=C1)N[C@H]1[C@@](CCC1)(O)C ZVEQSCRTRZHYTD-CHWSQXEVSA-N 0.000 description 1
- IRIKLLIKMPLYCS-UHFFFAOYSA-N C1(CCCC1)N1C(C(=CC2=C1N=C(N=C2)NC1CCN(CC1)S(=O)(=O)C)CC#N)=O Chemical compound C1(CCCC1)N1C(C(=CC2=C1N=C(N=C2)NC1CCN(CC1)S(=O)(=O)C)CC#N)=O IRIKLLIKMPLYCS-UHFFFAOYSA-N 0.000 description 1
- LSUBLTYDHSCPRU-UHFFFAOYSA-N C1(CCCC1)N1C(C(=CC2=C1N=C(N=C2)NC1CCN(CC1)S(=O)(=O)C)CC(=O)N)=O Chemical compound C1(CCCC1)N1C(C(=CC2=C1N=C(N=C2)NC1CCN(CC1)S(=O)(=O)C)CC(=O)N)=O LSUBLTYDHSCPRU-UHFFFAOYSA-N 0.000 description 1
- RXUJBLPCBMQLFI-UHFFFAOYSA-N C1(CCCC1)N1C(C(=CC2=C1N=C(N=C2)NC1CCN(CC1)S(=O)(=O)C)CC=C)=O Chemical compound C1(CCCC1)N1C(C(=CC2=C1N=C(N=C2)NC1CCN(CC1)S(=O)(=O)C)CC=C)=O RXUJBLPCBMQLFI-UHFFFAOYSA-N 0.000 description 1
- COPBDWPRAOVXAS-UHFFFAOYSA-N C1(CCCC1)N1C(C=CC2=C1N=C(N=C2)NC1CCN(CC1)S(=O)(=O)CCOC)=O Chemical compound C1(CCCC1)N1C(C=CC2=C1N=C(N=C2)NC1CCN(CC1)S(=O)(=O)CCOC)=O COPBDWPRAOVXAS-UHFFFAOYSA-N 0.000 description 1
- ZBJPNNCODVAXRF-UHFFFAOYSA-N C1(CCCC1)N1C(C=CC2=C1N=C(N=C2)NC1CCN(CC1)S(=O)(=O)CS(=O)(=O)C)=O Chemical compound C1(CCCC1)N1C(C=CC2=C1N=C(N=C2)NC1CCN(CC1)S(=O)(=O)CS(=O)(=O)C)=O ZBJPNNCODVAXRF-UHFFFAOYSA-N 0.000 description 1
- PFJVPPHRFDWODX-UHFFFAOYSA-N C1(CCCCCC1)N1C(C=CC2=C1N=C(N=C2)NC1CCN(CC1)S(=O)(=O)N)=O Chemical compound C1(CCCCCC1)N1C(C=CC2=C1N=C(N=C2)NC1CCN(CC1)S(=O)(=O)N)=O PFJVPPHRFDWODX-UHFFFAOYSA-N 0.000 description 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- KHSMJZJPAVHCKI-SUMWQHHRSA-N CC1=CC2=C(N=C(N=C2)NC2CCN(CC2)S(=O)(=O)C)N(C1=O)[C@H]1[C@H](CCC1)C Chemical compound CC1=CC2=C(N=C(N=C2)NC2CCN(CC2)S(=O)(=O)C)N(C1=O)[C@H]1[C@H](CCC1)C KHSMJZJPAVHCKI-SUMWQHHRSA-N 0.000 description 1
- 101700038562 CCND1 Proteins 0.000 description 1
- 101710024720 CCT5 Proteins 0.000 description 1
- 102100007290 CD274 Human genes 0.000 description 1
- 101710012053 CD274 Proteins 0.000 description 1
- 101700048555 CDK2 Proteins 0.000 description 1
- 101710025159 CMPK1 Proteins 0.000 description 1
- KXBLTZDCYOUCLP-UHFFFAOYSA-N CS(=O)(=O)N1CCC(CC1)NC=1N=CC2=C(N=1)NC(C=C2)=O Chemical compound CS(=O)(=O)N1CCC(CC1)NC=1N=CC2=C(N=1)NC(C=C2)=O KXBLTZDCYOUCLP-UHFFFAOYSA-N 0.000 description 1
- 101700036390 CWH41 Proteins 0.000 description 1
- 102100002212 CXCR4 Human genes 0.000 description 1
- 101710003734 CXCR4 Proteins 0.000 description 1
- WWRLTWOMYXGCKB-WCBMZHEXSA-N C[C@@H]1[C@@H](CCC1)NC1=NC(=NC=C1C=O)SC Chemical compound C[C@@H]1[C@@H](CCC1)NC1=NC(=NC=C1C=O)SC WWRLTWOMYXGCKB-WCBMZHEXSA-N 0.000 description 1
- WWRLTWOMYXGCKB-SCZZXKLOSA-N C[C@H]1[C@H](CCC1)NC1=NC(=NC=C1C=O)SC Chemical compound C[C@H]1[C@H](CCC1)NC1=NC(=NC=C1C=O)SC WWRLTWOMYXGCKB-SCZZXKLOSA-N 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N Camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 229960004117 Capecitabine Drugs 0.000 description 1
- 229940077731 Carbohydrate nutrients Drugs 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229940105329 Carboxymethylcellulose Drugs 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 210000003793 Centrosome Anatomy 0.000 description 1
- 229940112822 Chewing Gum Drugs 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229940001468 Citrate Drugs 0.000 description 1
- JZWPGBISPLAZMD-WBMJQRKESA-N ClC1=CC2=C(N=C(N=C2)NC2CCN(CC2)S(=O)(=O)C)N(C1=O)[C@@H]1[C@@H](CCC1)C Chemical compound ClC1=CC2=C(N=C(N=C2)NC2CCN(CC2)S(=O)(=O)C)N(C1=O)[C@@H]1[C@@H](CCC1)C JZWPGBISPLAZMD-WBMJQRKESA-N 0.000 description 1
- PFGMZHAOYLGYMA-KXBFYZLASA-N ClC1=CC2=C(N=C(N=C2)NC2CCN(CC2)S(=O)(=O)C)N(C1=O)[C@@H]1[C@@](CCC1)(C)O Chemical compound ClC1=CC2=C(N=C(N=C2)NC2CCN(CC2)S(=O)(=O)C)N(C1=O)[C@@H]1[C@@](CCC1)(C)O PFGMZHAOYLGYMA-KXBFYZLASA-N 0.000 description 1
- 229940090805 Clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N Clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 229960001681 Croscarmellose Sodium Drugs 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229960000913 Crospovidone Drugs 0.000 description 1
- 238000006969 Curtius rearrangement reaction Methods 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N Cycloheptane Chemical compound C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- CHVJITGCYZJHLR-UHFFFAOYSA-N Cycloheptatriene Chemical compound C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N Cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-L D-glucarate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O DSLZVSRJTYRBFB-LLEIAEIESA-L 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 230000003350 DNA copy number gain Effects 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- NNBZCPXTIHJBJL-UHFFFAOYSA-N Decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 1
- 229950006137 Dexfosfoserine Drugs 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229950009859 Dinaciclib Drugs 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229940112141 Dry Powder Inhaler Drugs 0.000 description 1
- 102000008807 EC 2.7.11.- Human genes 0.000 description 1
- 108030004416 EC 2.7.11.- Proteins 0.000 description 1
- 102100016041 EZH2 Human genes 0.000 description 1
- 101700041849 EZH2 Proteins 0.000 description 1
- 229950005627 Embonate Drugs 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229940095399 Enema Drugs 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 229950000206 Estolate Drugs 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 240000001414 Eucalyptus viminalis Species 0.000 description 1
- 101710038729 F2R Proteins 0.000 description 1
- QIEKHLDZKRQLLN-FOIQADDNSA-N FC(C1=CC2=C(N=C(N=C2)NC2CCN(CC2)S(=O)(=O)C)N(C1=O)[C@H]1[C@](CCC1)(C)O)F Chemical compound FC(C1=CC2=C(N=C(N=C2)NC2CCN(CC2)S(=O)(=O)C)N(C1=O)[C@H]1[C@](CCC1)(C)O)F QIEKHLDZKRQLLN-FOIQADDNSA-N 0.000 description 1
- 108091008101 FGF receptors Proteins 0.000 description 1
- 102000027757 FGF receptors Human genes 0.000 description 1
- 102100004573 FLT3 Human genes 0.000 description 1
- 101710009074 FLT3 Proteins 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229960002737 Fructose Drugs 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N Furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 230000004707 G1/S transition Effects 0.000 description 1
- 102100014450 GLS Human genes 0.000 description 1
- 101710042164 GLS Proteins 0.000 description 1
- 101710003491 GLU1 Proteins 0.000 description 1
- 229960001731 GLUCEPTATE Drugs 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N Gentisic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- 206010065430 HER-2 positive breast cancer Diseases 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 101700042119 HSP83 Proteins 0.000 description 1
- 102100017052 HSP90AA1 Human genes 0.000 description 1
- 101710033238 HSP90AA1 Proteins 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- LJQLCJWAZJINEB-UHFFFAOYSA-N Hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F LJQLCJWAZJINEB-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 102100008614 IDO1 Human genes 0.000 description 1
- 101710031171 IDO1 Proteins 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L Iron(II) chloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L Iron(II) sulfate Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N Isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 229940001447 Lactate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N Lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 210000004324 Lymphatic System Anatomy 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101710012566 MNAT1 Proteins 0.000 description 1
- 229960002160 Maltose Drugs 0.000 description 1
- 230000036676 Maximum tolerable dose Effects 0.000 description 1
- 229940041616 Menthol Drugs 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N Methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
- 210000001853 Microsomes, Liver Anatomy 0.000 description 1
- 210000000214 Mouth Anatomy 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- UZWDCWONPYILKI-UHFFFAOYSA-N N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 1
- 108060009214 NRK Proteins 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitroxyl Chemical group O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- SBUOERUWDGLPAL-UHFFFAOYSA-N O=S1(=O)CC2(C1)CCCCC2 Chemical compound O=S1(=O)CC2(C1)CCCCC2 SBUOERUWDGLPAL-UHFFFAOYSA-N 0.000 description 1
- DECPWVARNFVFKY-UHFFFAOYSA-N O=S1(=O)COCC2CCCCN12 Chemical compound O=S1(=O)COCC2CCCCN12 DECPWVARNFVFKY-UHFFFAOYSA-N 0.000 description 1
- FSGOOLFEOBWDMQ-UHFFFAOYSA-N OC(=O)C(F)(F)F.NC1CCN(CC1)S(=O)(=O)CC(F)(F)F Chemical compound OC(=O)C(F)(F)F.NC1CCN(CC1)S(=O)(=O)CC(F)(F)F FSGOOLFEOBWDMQ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N OC(=O)C(N)CCCNC(N)=N Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- PYYZJGHKVXFHHT-UHFFFAOYSA-N OC1C(C(CC1)NC(OC(C)(C)C)=O)C Chemical compound OC1C(C(CC1)NC(OC(C)(C)C)=O)C PYYZJGHKVXFHHT-UHFFFAOYSA-N 0.000 description 1
- GUPQXDHWDBBGNX-YIZRAAEISA-N O[C@@H]1CC[C@@H]([C@H](C1)C(=O)OCC)C Chemical compound O[C@@H]1CC[C@@H]([C@H](C1)C(=O)OCC)C GUPQXDHWDBBGNX-YIZRAAEISA-N 0.000 description 1
- LVYLJKBJOBWYTP-BXKDBHETSA-N O[C@]1([C@@H](CCC1)NC1=NC(=NC=C1C=O)SC)C Chemical compound O[C@]1([C@@H](CCC1)NC1=NC(=NC=C1C=O)SC)C LVYLJKBJOBWYTP-BXKDBHETSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N Octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 206010070577 Oestrogen receptor positive breast cancer Diseases 0.000 description 1
- 229940049964 Oleate Drugs 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 102100014579 PARP1 Human genes 0.000 description 1
- 101700036247 PARP1 Proteins 0.000 description 1
- 101700053624 PARP2 Proteins 0.000 description 1
- 101700027237 PROA Proteins 0.000 description 1
- 229960001592 Paclitaxel Drugs 0.000 description 1
- 229910002666 PdCl2 Inorganic materials 0.000 description 1
- XCRBXWCUXJNEFX-UHFFFAOYSA-N Peroxybenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 description 1
- 229940066842 Petrolatum Drugs 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N Phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N Phenylpropanoic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 102000003993 Phosphatidylinositol 3-Kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-Kinases Proteins 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N Phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N Phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OKBMCNHOEMXPTM-UHFFFAOYSA-M Potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N Pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J Pyrophosphate Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N Quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- 108020004532 RAS Proteins 0.000 description 1
- 102100017730 RORA Human genes 0.000 description 1
- 102100002050 ROS1 Human genes 0.000 description 1
- 101710027587 ROS1 Proteins 0.000 description 1
- 239000007759 RPMI Media 1640 Substances 0.000 description 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- PLWWRZBHDZBOOP-UHFFFAOYSA-N S(=O)(=O)=C1NCCC(C1)N Chemical class S(=O)(=O)=C1NCCC(C1)N PLWWRZBHDZBOOP-UHFFFAOYSA-N 0.000 description 1
- 101700021542 SMO Proteins 0.000 description 1
- 102100015930 SMOX Human genes 0.000 description 1
- 101700076839 SMOX Proteins 0.000 description 1
- 101710009384 SRC Proteins 0.000 description 1
- 229940081974 Saccharin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940085605 Saccharin Sodium Drugs 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229950000055 Seliciclib Drugs 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- RMBAVIFYHOYIFM-UHFFFAOYSA-M Sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- 229960000391 Sorbitan trioleate Drugs 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 102100014437 TDO2 Human genes 0.000 description 1
- 101710006302 TDO2 Proteins 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 229950002757 Teoclate Drugs 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M Tetra-n-butylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N Thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229940074410 Trehalose Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N Triphenylphosphine oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- CITILBVTAYEWKR-UHFFFAOYSA-L Zinc trifluoromethanesulfonate Chemical compound [Zn+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F CITILBVTAYEWKR-UHFFFAOYSA-L 0.000 description 1
- YNOGYQAEJGADFJ-YFKPBYRVSA-N [(2S)-oxolan-2-yl]methanamine Chemical compound NC[C@@H]1CCCO1 YNOGYQAEJGADFJ-YFKPBYRVSA-N 0.000 description 1
- PRXRUNOAOLTIEF-XDTJCZEISA-N [2-[(2R,3S,4R)-4-hydroxy-3-[(Z)-octadec-9-enoyl]oxyoxolan-2-yl]-2-[(Z)-octadec-9-enoyl]oxyethyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@@H](O)[C@@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-XDTJCZEISA-N 0.000 description 1
- MATKNHPQPWMJIT-TUAOUCFPSA-N [Si](C)(C)(C(C)(C)C)O[C@@H]1CC[C@@H]([C@H](C1)C(=O)O)C Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H]1CC[C@@H]([C@H](C1)C(=O)O)C MATKNHPQPWMJIT-TUAOUCFPSA-N 0.000 description 1
- XURTUYOQCFXTMD-MJBXVCDLSA-N [Si](C)(C)(C(C)(C)C)O[C@@H]1CC[C@@H]([C@H](C1)C(=O)OCC)C Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H]1CC[C@@H]([C@H](C1)C(=O)OCC)C XURTUYOQCFXTMD-MJBXVCDLSA-N 0.000 description 1
- CKOATGFPPVZGKD-JQVVWYNYSA-N [Si](C1=CC=CC=C1)(C1=CC=CC=C1)(C(C)(C)C)O[C@@H]1CC[C@@H]([C@H](C1)N)C Chemical compound [Si](C1=CC=CC=C1)(C1=CC=CC=C1)(C(C)(C)C)O[C@@H]1CC[C@@H]([C@H](C1)N)C CKOATGFPPVZGKD-JQVVWYNYSA-N 0.000 description 1
- LCADJBUDLVRLOQ-JDBUMTGOSA-N [Si](C1=CC=CC=C1)(C1=CC=CC=C1)(C(C)(C)C)O[C@@H]1CC[C@@H]([C@H](C1)NC(OCC1=CC=CC=C1)=O)C Chemical compound [Si](C1=CC=CC=C1)(C1=CC=CC=C1)(C(C)(C)C)O[C@@H]1CC[C@@H]([C@H](C1)NC(OCC1=CC=CC=C1)=O)C LCADJBUDLVRLOQ-JDBUMTGOSA-N 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 235000019647 acidic taste Nutrition 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229920002892 amber Polymers 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045698 antineoplastic Taxanes Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 101700004528 arp Proteins 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 150000005347 biaryls Chemical class 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000037348 biosynthesis Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- DWRHSVMNAYQMBM-UHFFFAOYSA-N but-3-yne-1-sulfonyl chloride Chemical compound ClS(=O)(=O)CCC#C DWRHSVMNAYQMBM-UHFFFAOYSA-N 0.000 description 1
- JUPMBRMEHSUGLE-UHFFFAOYSA-N butenyl Chemical compound CCC=[CH] JUPMBRMEHSUGLE-UHFFFAOYSA-N 0.000 description 1
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Inorganic materials [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M caprate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 201000011231 colorectal cancer Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- VXVVUHQULXCUPF-UHFFFAOYSA-N cycloheptanamine Chemical compound NC1CCCCCC1 VXVVUHQULXCUPF-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- CYKDRLQDTUXOBO-UHFFFAOYSA-N cyclopropan-1,1-diyl Chemical group [C]1CC1 CYKDRLQDTUXOBO-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 229940042397 direct acting antivirals Cyclic amines Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 150000002081 enamines Chemical group 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 description 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 1
- HZNQVAOLVRFZBE-UHFFFAOYSA-N ethenylcyclohexane Chemical group C=C[C]1CCCCC1 HZNQVAOLVRFZBE-UHFFFAOYSA-N 0.000 description 1
- KVXNKFYSHAUJIA-UHFFFAOYSA-M ethoxyethane;acetate Chemical compound CC([O-])=O.CCOCC KVXNKFYSHAUJIA-UHFFFAOYSA-M 0.000 description 1
- FVPISMANESAJQZ-UHFFFAOYSA-N ethyl 2-diethoxyphosphoryl-2-fluoroacetate Chemical compound CCOC(=O)C(F)P(=O)(OCC)OCC FVPISMANESAJQZ-UHFFFAOYSA-N 0.000 description 1
- FIOFMYNFIRAGTI-UHFFFAOYSA-N ethyl 2-methyl-4-oxocyclopent-2-ene-1-carboxylate Chemical compound CCOC(=O)C1CC(=O)C=C1C FIOFMYNFIRAGTI-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 101710014417 fksA Proteins 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-L galactarate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C([O-])=O DSLZVSRJTYRBFB-DUHBMQHGSA-L 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000002489 hematologic Effects 0.000 description 1
- MVFGXYPEQHIKIX-UHFFFAOYSA-M heptane;acetate Chemical compound CC([O-])=O.CCCCCCC MVFGXYPEQHIKIX-UHFFFAOYSA-M 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-L hex-2-ynedioate Chemical compound [O-]C(=O)CCC#CC([O-])=O KKLGDUSGQMHBPB-UHFFFAOYSA-L 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000003054 hormonal Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- IKGLACJFEHSFNN-UHFFFAOYSA-N hydron;triethylazanium;trifluoride Chemical compound F.F.F.CCN(CC)CC IKGLACJFEHSFNN-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000003463 hyperproliferative Effects 0.000 description 1
- 101700048563 ido Proteins 0.000 description 1
- PQWQQQGKMHENOC-UHFFFAOYSA-N imidazo[1,2-c]pyrimidine Chemical compound C1=NC=CC2=NC=CN21 PQWQQQGKMHENOC-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-M isobutyrate Chemical compound CC(C)C([O-])=O KQNPFQTWMSNSAP-UHFFFAOYSA-M 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M laurate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- OCZDCIYGECBNKL-UHFFFAOYSA-N lithium;alumanuide Chemical compound [Li+].[AlH4-] OCZDCIYGECBNKL-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005244 lung non-small cell carcinoma Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 200000000023 metastatic cancer Diseases 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000394 mitotic Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000003232 mucoadhesive Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000007838 multiplex ligation-dependent probe amplification Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000001539 ovarian carcinoma Diseases 0.000 description 1
- 201000003707 ovarian clear cell carcinoma Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- AHVQYHFYQWKUKB-UHFFFAOYSA-N oxan-4-amine Chemical compound NC1CCOCC1 AHVQYHFYQWKUKB-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- LKZAAHOOIJSWQR-UHFFFAOYSA-R palladium;triphenylphosphanium Chemical compound [Pd].[Pd].C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 LKZAAHOOIJSWQR-UHFFFAOYSA-R 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-L pamoate(2-) Chemical class C1=CC=C2C(CC3=C4C=CC=CC4=CC(=C3O)C([O-])=O)=C(O)C(C([O-])=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-L 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 229960004723 phenylbutyrate Drugs 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L phosphate Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- NJRWNWYFPOFDFN-UHFFFAOYSA-L phosphonate(2-) Chemical compound [O-][P]([O-])=O NJRWNWYFPOFDFN-UHFFFAOYSA-L 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 210000001850 polyploid cell Anatomy 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-M propane-1-sulfonate Chemical compound CCCS([O-])(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- DVUBDHRTVYLIPA-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine Chemical compound C1=CC=CN2N=CC=C21 DVUBDHRTVYLIPA-UHFFFAOYSA-N 0.000 description 1
- WMLBCGHQVFIUDI-UHFFFAOYSA-N pyrazolo[3,4-c]pyridine Chemical compound C1=NC=C[C]2C=NN=C21 WMLBCGHQVFIUDI-UHFFFAOYSA-N 0.000 description 1
- LAWCSURIBCQREM-UHFFFAOYSA-N pyrazolo[4,3-c]pyridine Chemical compound C1=CN=C[C]2C=NN=C21 LAWCSURIBCQREM-UHFFFAOYSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M pyridine-4-carboxylate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- IIVUJUOJERNGQX-UHFFFAOYSA-M pyrimidine-5-carboxylate Chemical compound [O-]C(=O)C1=CN=CN=C1 IIVUJUOJERNGQX-UHFFFAOYSA-M 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- NISJKLIMPQPAQS-UHFFFAOYSA-N pyrrolo[1,2-b]pyridazine Chemical compound C1=CC=NN2C=CC=C21 NISJKLIMPQPAQS-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000007342 radical addition reaction Methods 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 108020001180 rasD Proteins 0.000 description 1
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 1
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 239000000849 selective androgen receptor modulator Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000001743 silencing Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(E)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 description 1
- WRYSLFYACKIPNN-UHFFFAOYSA-M sodium;difluoromethanesulfinate Chemical compound [Na+].[O-]S(=O)C(F)F WRYSLFYACKIPNN-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 230000003381 solubilizing Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- KXCAEQNNTZANTK-UHFFFAOYSA-N stannane Chemical compound [SnH4] KXCAEQNNTZANTK-UHFFFAOYSA-N 0.000 description 1
- 229910000080 stannane Inorganic materials 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 230000000152 swallowing Effects 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 229930003347 taxol Natural products 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- KHMWMTRMLBAZOI-UHFFFAOYSA-N tert-butyl N-(3-hydroxy-2-methylcyclohexyl)carbamate Chemical compound CC1C(O)CCCC1NC(=O)OC(C)(C)C KHMWMTRMLBAZOI-UHFFFAOYSA-N 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000006223 tetrahydrofuranylmethyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000006173 tetrahydropyranylmethyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000003441 thioacyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108090000464 transcription factors Proteins 0.000 description 1
- 102000003995 transcription factors Human genes 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- BSUNTQCMCCQSQH-UHFFFAOYSA-N triazine Chemical compound C1=CN=NN=C1.C1=CN=NN=C1 BSUNTQCMCCQSQH-UHFFFAOYSA-N 0.000 description 1
- 150000008523 triazolopyridines Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 238000006692 trifluoromethylation reaction Methods 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical class CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N β-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
Abstract
This invention relates to compounds of general Formula (I)
Description
PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS
Reference to Sequence Listing
This application is being filed electronically via EFS-Web and includes an electronically submitted sequence listing in .txt format. The .txt file contains a sequence listing entitled PC72302SEQLISTING_ST25.txt created on July 17, 2017 and having a size of 2 KB. The sequence listing contained in this .txt file is part of the spécification and is herein incorporated by reference in its entirety.
Field of the Invention
The présent invention relates to compounds of Formulae (I) to (VII), and their pharmaceutically acceptable salts, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds, salts and compositions of the présent invention are useful for treating or ameliorating abnormal cell proliférative disorders, such as cancer.
Background
Cyclin-dependent kinases (CDKs) are important cellular enzymes that perform essential functions in regulating eukaryotic cell division and prolifération. The cyclin-dependent kinase catalytic units are activated by regulatory subumts known as cyclins. At least sixteen mammalian cyclins hâve been identified (Johnson DG, Walker CL. Cyclins and Cell Cycle Checkpoints. Annu. Rev. Pharmacol. Toxicol. (1999) 39:295-312). Cyclin B/CDK1, cyclin A/CDK2, cyclin E/CDK2, cyclin D/CDK4, cyclm D/CDK6, and likely other hétérodynes are important regulators of cell cycle progression. Additional functions of cyclin/CDK hétérodynes include régulation of transcription, DNA repair, différentiation and apoptosis (Morgan DO. Cyclin-dependent kinases: engines, docks, and microprocessors. Annu. Rev. Cell. Dev. Biol. (1997) 13:261-291).
Cyclin-dependent kinase inhibitors hâve been demonstrated to be useful in treating cancer. Increased activity or temporally abnormal activation of cyclin-dependent kinases has been shown to resuit in the development of human tumors, and human tumor development is commonly associated with alterations in either the CDK proteins themselves or their regulators (Cordon-Cardo C. Mutations of cell cycle regulators: biological and clinical implications for human neoplasia. Am. J. Pathol. (1995) 147 545-560· Karp JE, Broder S. Molecular foundations of cancer: new targets for intervention. Nat. Med. (1995) 1:309-320; Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. (1996) 68:67-108). Amplifications of the regulatory subunits of CDKs and cyclins, and mutation, gene délétion, or transcriptional silencing of endogenous CDK inhibitors hâve also been reported (Smalley et al. Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res (2008) 68: 5743-52).
Clinical trials for the CDK4/6 inhibitors palbociclib, ribociclib and abemaciclib are ongoing for breast and other cancers, as single agents or in combination with other therapeutics. Palbociclib and ribociclib hâve been approved for treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with aromatase inhibitors in postmenopausal women, and for palbociclib, in combination with fulvestrant after disease progression following endocrine therapy, (O’Leary et al. Treating cancer with sélective CDK4/6 inhbitors. Nature Reviews (2016) 13:417-430). While CDK4/6 inhibitors hâve shown significant clinical efficacy in ER-positive metastatic breast cancer, as with other kinases their effects may be limited over time by the development of primary or acquired résistance.
Overexpression of CDK2 is associated with abnormal régulation of cell-cycle. The cyclin E/CDK2 complex plays and important rôle in régulation of the G1/S transition, histone biosynthesis and centrosome duplication. Progressive phosphorylation of Rb by cyclin D/Cdk4/6 and cyclin E/Cdk2 releases the G1 transcription factor, E2F, and promûtes S-phase entry. Activation of cyclin A/CDK2 during early S-phase promûtes phosphorylation of endogenous substrates that permit DNA réplication and inactivation of E2F, for S-phase completion. (Asghar et al. The history and future of targeting cyclin-dependent kinases in cancer therapy, Nat. Rev. Drug. Discov. 2015; 14(2): 130-146).
Cyclin E, the regulatory cyclin for CDK2, is frequently overexpressed in cancer. Cyclin E amplification or overexpression has long been associated with poor outcomes in breast cancer. (Keyomarsi et al., Cyclin E and survival in patients with breast cancer. N Engl J Med. (2002) 347:1566-75). Cyclin E2 (CCNE2) overexpression is associated with endocrine résistance in breast cancer cells and CDK2 inhibition has been reported to restore sensitivity to tamoxifen or CDK4 inhibitors in tamoxifen-resistant and CCNE2 overexpressing cells. (Caldon et al., Cyclin E2 overexpression is associated with endocrine résistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Mol Cancer Ther. (2012) 11:1488-99; Herrera-Abreu et al., Early Adaptation and Acquired Résistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer, Cancer Res. (2016) 76: 2301-2313). Cyclin E amplification also reportedly contributes to trastuzumab résistance in HER2+ breast cancer. (Scaltriti et al. Cyclin E amplification/overexpression is a mechanism of trastuzumab résistance in HER2+ breast cancer patients, Proc Natl Acad Sci. (2011) 108: 3761-6). Cyclin E overexpression has also been reported to play a rôle in basal-like and triple négative breast cancer (TNBC), as well as inflammatory breast cancer. (Elsawaf & Sinn, Triple Négative Breast Cancer: Clinical and Histological Corrélations, Breast Care (2011) 6:273-278; Alexander et al., Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer, Oncotarget (2017) 8: 14897-14911.)
Amplification or overexpression of cyclin E1 (CCNE1) is also associated with poor outcomes in ovarian, gastric, endométrial and other cancers. (Nakayama et al., Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer, Cancer (2010) 116: 2621-34; Etemadmoghadam et al., Résistance to CDK2 Inhibitors Is Associated with Sélection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer, Clin Cancer Res (2013) 19: 5960-71; Au-Yeung et al., Sélective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by CyclinDependent Kinase 2 and AKT Inhibition, Clin. Cancer Res. (2017) 23:1862-1874; Ayhan et al., CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis, Modem Pathology (2017) 30: 297-303; Ooi et al., Gene amplification of CCNE1, CCND1, and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization, Hum Pathol. (2017) 61: 58-67; Noske et al., Détection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endométrial cancer, Oncotarget (2017) 8: 14794-14805).
The small molécule inhibitor, dinaciclib (MK-7965) inhibits CDK1, CDK2, CDK5 and CDK9 and is currently in clinical development for breast and hematological cancers. Seliciclib (roscovitine or CYC202), which inhibits CDK2, CDK7 and CDK9, is being investigated for treatment of advanced solid tumors in conjunction with chemotherapy. Despite significant efforts, there are no approved agents targeting CDK2 to date. Cicenas et al. Highlights of the Latest Advances in Research on CDK Inhibitors. Cancers, (2014) 6:2224-2242. There remains a need to discover CDK inhibitors having novel activity profiles, in particular those targeting CDK2.
Summary
The présent invention provides, in part, compounds of Formulae (I) to (VII), and pharmaceutically acceptable salts thereof. Such compounds can inhibit the activity of CDKs, including CDK2, CDK4 and/or CDK6, thereby effecting biological functions. Also provided are pharmaceutical compositions and médicaments, comprising the compounds or salts of the invention, alone or in combination with additional anticancer therapeutic agents or palliative agents.
The présent invention also provides, in part, methods for preparing the compounds, pharmaceutically acceptable salts and compositions of the invention, and methods of using the foregoing.
In one aspect, the invention provides a compound of Formula (I):
R4
or a pharmaceutically acceptable sait thereof, wherein:
R1 is 3-10 membered heterocyclyl substituted by R5Aor Cs-Cs cycloalkyl substituted by R5B, where said 3-10 membered heterocyclyl and Cs-Cs cycloalkyl are optionally further substituted by one or more R6;
each R2 is independently F, OH, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy;
R2A and R2B are independently H, F, OH, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy;
where each said C1-C4 alkyl and C1-C4 fluoroalkyl in R2, R2A and R2B is independently optionally substituted by OH, C1-C4 alkoxy or C1-C4 fluoroalkoxy;
R3 is H, F, Cl, NH2, C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH, CN, C1-C4 alkoxy, C1-C4 fluoroalkoxy, CONH2 and COOH;
R4 is H, C1-C2 alkyl or C1-C2 fluoroalkyl;
R5A is SO2R7, SO2NR8R9, NHSO2R7 or NHSO2NR8R9;
R5B is NHSO2R7 or NHSO2NR8R9;
each R6 is independently F, OH, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy;
R7 is C1-C4 alkyl, C1-C4 fluoroalkyl, -L-(C3-Cs cycloalkyl), -L-(5-6 membered heterocyclyl) or -L-(5-6 membered heteroaryl);
R8 and R9 are independently H, C1-C4 alkyl, C1-C4 fluoroalkyl, -l_-(C3-C8 cycloalkyl), -L-(5-6 membered heterocyclyl) or -L-(5-6 membered heteroaryl); or
R8 and R9 may be taken together with the nitrogen atom to which they are attached to form a 5-6 membered heterocyclyl;
where each said C1-C4 alkyl and C1-C4 fluoroalkyl in R7, R8 and R9 is optionally substituted by OH, C1-C4 alkoxy, C1-C4 fluoroalkoxy or SO2Me, and each said C3-C8 cycloalkyl, 5-6 membered heterocyclyl and 5-6 membered heteroaryl in R7, R8 and R9 is optionally substituted by C1-C4 alkyl, OH, C1-C4 alkoxy or C1-C4 fluoroalkoxy;
L is a bond or C1-C4 alkylene, where said C1-C4 alkylene is optionally substituted by OH, C1-C4 alkoxy or C1-C4 fluoroalkoxy;
p is 0, 1,2, 3 or 4;
q is 0, 1,2 or 3; and r is 0, 1 or 2.
In another aspect, the invention provides a pharmaceutical composition comprising a compound of any one of the formulae described herein, or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier or excipient. In some embodiments, the pharmaceutical composition comprises two or more pharmaceutically acceptable carriers and/or excipients.
The invention also provides therapeutic methods and uses comprising administering a compound of the invention, or a pharmaceutically acceptable sait thereof.
In another aspect, the invention provides a method for the treatment of abnormal cell growth, in particular cancer, in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable sait thereof. Compounds of the invention may be administered as single agents, or may be administered in combination with other anti-cancer therapeutic agents, in particular standard of care agents appropriate for the particular cancer.
In a further aspect, the invention provides a method for the treatment of abnormal cell growth, in particular cancer, in a subject in need thereof, comprising administering to the subject an amount of a compound of the invention, or a pharmaceutically acceptable sait thereof, in combination with an amount of an additional anti-cancer therapeutic agent, which amounts are together effective in treating said abnormal cell growth.
In another aspect, the invention relates to a compound of the invention, or a pharmaceutically acceptable sait thereof, for use as a médicament, in particular a médicament for treatment of cancer.
In another aspect, the invention relates to a compound of the invention, of a pharmaceutically acceptable sait thereof, for use in the treatment of abnormal cell growth, in particular cancer, in a subject.
In a further aspect, the invention provides the use of a compound of the invention, or a pharmaceutically acceptable sait thereof, for the treatment of abnormal cell growth, in particular cancer, in a subject.
In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of abnormal cell growth in a subject in need thereof, which composition comprises a compound of the invention, or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier or excipient.
In yet another aspect, the invention provides the use of a compound of any one of the formulae described herein, or a pharmaceutically acceptable sait thereof, for the préparation of a médicament for the treatment of abnormal cell growth in a subject.
In frequent embodiments of the foregoing compounds, methods and uses, the abnormal cell growth is cancer.
In some embodiments, the methods and uses provided resuit in one or more of the following effects: (1) inhibiting cancer cell prolifération; (2) inhibiting cancer cell invasiveness; (3) inducing apoptosis of cancer cells; (4) inhibiting cancer cell metastasis; or (5) inhibiting angiogenesis.
In another aspect, the invention provides a method for the treatment of a disorder mediated by CDK2 in a subject, comprising administering to the subject a compound of the invention, or a pharmaceutically acceptable sait thereof, in an amount that is effective for treating said disorder, in particular cancer. In some embodiments, the disorder is cancer that is characterized by amplification or overexpression of CCNE1 and/or CCNE2.
In another aspect, the invention provides a method for the treatment of a disorder mediated by CDK2, CDK4 and/or CDK6 in a subject, comprising administering to the subject a compound of the invention, or a pharmaceutically acceptable sait thereof, in an amount that is effective for treating said disorder, in particular cancer. In some embodiments, the disorder is cancer that is characterized by amplification or overexpression ofCCNEI and/or CCNE2.
In some embodiments, the methods and uses described herein further comprise administering to the subject an amount of an additional anticancer therapeutic agent or a palliative agent, which amounts are together effective in treating said abnormal cell growth. Each of the embodiments of the compounds of the présent invention described below can be combined with one or more other embodiments of the compounds of the présent invention described herein not inconsistent with the embodiment(s) with which it is combined.
In addition, each of the embodiments below describing the invention envisions within its scope the pharmaceutically acceptable salts of the compounds of the invention. Accordingly, the phrase “or a pharmaceutically acceptable sait thereof’ is implicit in the description of ail compounds described herein.
Brief Description of the Drawings
Figure 1 shows cyclin E1/2 (CCNE1/2) amplification frequency by tumortype (http://oasis.pfizer.com/).
Figure 2 shows in vitro IC50 data for the compound of Example 10 and palbociclib in (A) Ovcar3 (CCNE amplified ovarian carcinoma) Rb ELISA assay; (B) HCC1806 (CCNE amplified breast carcinoma) Rb ELISA assay; (C) Ovcar3 cell prolifération assay; and (D) HCC1806 cell prolifération assay.
Figure 3 shows tumor growth inhibition for the compound of Example 2 in Ovcar3 mouse tumor xenograft model at 10mpk PO QD, 50mpk PO QD and 50mpk PO BID.
Figure 4 shows tumor growth inhibition for the compound of Example 10 in HCC1806 mouse tumor xenograft model at 30mpk PO BID, 50mpk PO BID and 75mpk PO BID.
Detailed Description
The présent invention may be understood more readily by reference to the following detailed description of the preferred embodiments of the invention and the Examples included herein. It is to be understood that the terminology used herein is for the purpose of describing spécifie embodiments only and is not intended to be limiting. It is further to be understood that unless specifically defined herein, the terminology used herein is to be given its traditional meaning as known in the relevant art.
As used herein, the singular form a, an, and the include plural references unless indicated otherwise. For example, a substituent includes one or more substituents.
The invention described herein suitably may be practiced in the absence of any element(s) not specifically disclosed herein. Thus, for example, in each instance herein any of the terms comprising, consisting essentially of, and consisting of' may be replaced with either of the other two terms.
Alkyl refers to a saturated, monovalent aliphatic hydrocarbon radical including straight chain and branched chain groups having the specified number of carbon atoms. Alkyl substituents typically contain 1 to 20 carbon atoms (“C1-C20 alkyl”), preferably 1 to 12 carbon atoms (“C1-C12 alkyl”), more preferably 1 to 8 carbon atoms (“C-i-Cs alkyl”), or 1 to 6 carbon atoms (“C1-C6 alkyl”), or 1 to 4 carbon atoms (“C1-C4 alkyl”). Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, n-heptyl, n-octyl and the like. Alkyl groups may be substituted or unsubstituted. In particular, unless otherwise specified, alkyl groups may be substituted by one or more halo groups, up to the total number of hydrogen atoms présent on the alkyl moiety. Thus, C1-C4 alkyl includes halogenated alkyl groups, and in particular fluorinated alkyl groups, having 1 to 4 carbon atoms, e.g., trifluoromethyl or difluoroethyl (i.e., CF3 and -CH2CHF2).
Alkyl groups described herein as optionally substituted may be substituted by one or more substituent groups, which are selected independently unless otherwise indicated. The total number of substituent groups may equal the total number of hydrogen atoms on the alkyl moiety, to the extent such substitution makes chemical sense. Optionally substituted alkyl groups typically contain from 1 to 6 optional substituants, sometimes 1 to 5 optional substituants, preferably from 1 to 4 optional substituants, or more preferably from 1 to 3 optional substituants.
Optional substituent groups suitable for alkyl include, but are not limited to C3-Cs cycloalkyl, 3-12 membered heterocyclyl,C6-Ci2 aryl and 5-12 membered heteroaryl, halo, =0 (oxo), =S (thiono), =N-CN, =N-ORX, =NRX, -CN, -C(O)RX, -CO2RX, -C(O)NRxRy, -SRX, -SORX, -SO2Rx, -SO2NRxRy, -NO2, -NRxRy, -NRxC(O)Ry, -NRxC(O)NRxRy, NRXC(O)ORX, -NRxSO2Ry, -NRxSO2NRxRy, -ORX, -OC(O)RX and -OC(O)NRxRy; wherein each Rx and Ry is independently H, Ci-C8 alkyl, Ci-C8 acyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, 3-12 membered heterocyclyl, Ce-Ci2 aryl, or 5-12 membered heteroaryl, or Rx and Ry may be taken together with the N atom to which they are attached to form a 3-12 membered heterocyclyl or 5-12 membered heteroaryl, each optionally containing 1, 2 or 3 additional heteroatoms selected from O, N and S(O)q where q is 0-2; each Rx and Ry is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, =0, =S, =N-CN, =N-OR', =NR', -CN, -C(O)R', -CO2R', -C(O)NR'2i -SOR', -SO2R', -SO2NR'2, NO2, -NR'2i -NR'C(O)R’, -NR'C(O)NR'2, -NR'C(O)OR', -NR'SO2R', -NR'SO2NR'2i -OR', OC(O)R' and -OC(O)NR'2, wherein each R' is independently H, Ci-Cs alkyl, Ci-C8 acyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, 3-12 membered heterocyclyl, Ce-Ci2 aryl, or C5-Ci2 heteroaryl; and wherein each said C3-C8 cycloalkyl, 3-12 membered heterocyclyl, Ce-Ci2 aryl and 5-12 membered heteroaryl is optionally substituted as further defined herein.
Typical substituent groups on alkyl include halo, -OH, C1-C4 alkoxy, -O-C6-Ci2 aryl, -CN, =0, -COORX, -OC(O)RX, -C(O)NRxRy, -NRxC(O)Ry, -NRxRy, C3-Cs cycloalkyl, C6-Ci2 aryl, 5-12 membered heteroaryl and 3-12 membered heterocyclyl; where each Rx and Ry is independently H or C1-C4 alkyl, or Rx and Ry may be taken together with the N to which they are attached form a 3-12 membered heterocyclyl or 5-12 membered heteroaryl ring, each optionally containing 1, 2 or 3 additional heteroatoms selected from O, N and S(O)q where q is 0-2; wherein each said C3-C8 cycloalkyl, C6-C12 aryl,
5-12 membered heteroaryl and 3-12 membered heterocyclyl is optionally substituted by 1 to 3 substituents independently selected from the group consisting of halo, -OH, =0, C1-C4 alkyl, C1-C4 alkoxy, Ci-Ce haloalkyl, Ci-Ce hydroxyalkyl, C1-C4 alkoxy-Ci-Ce alkyl, -CN, -NH2, -NH(Ci-C4 alkyl) and -N(Ci-C4 alkyl)2.
In some embodiments, alkyl is optionally substituted by one or more substituents, and preferably by 1 to 3 substituents, which are independently selected from the group consisting of halo, -OH, C1-C4 alkoxy, -O-C6-C12 aryl, -CN, =0, -COORX, -OC(O)RX, -C(O)NRxRy, -NRxC(O)Ry, -NRxRy, C3-C8 cycloalkyl, C6-C12 aryl, 5-12 membered heteroaryl and 3-12 membered heterocyclyl; where each Rx and Ry is independently H or C1-C4 alkyl, or Rx and Ry may be taken togetherwith the N to which they are attached form a 3-12 membered heterocyclyl or 5-12 membered heteroaryl ring, each optionally containing 1, 2 or 3 additional heteroatoms selected from O, N and S(O)x where x is 0-2; and each said C3-C8 cycloalkyl, C6-C12 aryl, 5-12 membered heteroaryl and 3-12 membered heterocyclyl is optionally substituted by 1 to 3 substituents independently selected from the group consisting of halo, -OH, =0, C1-C4 alkyl, C1-C4 alkoxy, C1-C6 haloalkyl, Ci-Ce hydroxyalkyl, C1-C4 alkoxy-Ci-Ce alkyl, -CN, -NH2, -NH(Ci-C4 alkyl) and -N(Ci-C4 alkyl)2.
In other embodiments, alkyl is optionally substituted by one or more substituent, and preferably by 1 to 3 substituents, independently selected from the group consisting of halo, -OH, C1-C4 alkoxy, -CN, -NRxRy, C3-C8 cycloalkyl, 3-12 membered heterocyclyl, C6-C12 aryl and 5-12 membered heteroaryl; where each Rx and Ry is independently H or C1-C4 alkyl, or Rx and Ry may be taken togetherwith the N to which they are attached form a 3-12 membered heterocyclyl or 5-12 membered heteroaryl ring, each optionally containing 1,2 or 3 additional heteroatoms selected from O, N and S(O)X where x is 0-2; and where each said cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by 1 to 3 substituents independently selected from the group consisting of halo, -OH, =0, C1-C4 alkyl, C1-C4 alkoxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C4 alkoxy-Ci-Ce alkyl, -CN, -NH2, -NH(Ci-C4 alkyl) and -N(Ci-C4 alkyl)2.
In some instances, substituted alkyl groups are specifically named by reference to the substituent group. For example, “haloalkyl” refers to an alkyl group having the specified number of carbon atoms that is substituted by one or more halo substituents, and typically contain 1-6 carbon atoms, or preferably 1-4 carbon atoms or 1-2 carbon atoms and 1, 2 or 3 halo atoms (Le., “C-i-Ce haloalkyl”, C1-C4 haloalkyl” or C1-C2 haloalkyl”). More specifically, fluorinated alkyl groups may be specifically referred to as fluoroalkyl groups, e.g., C1-C6, C1-C4 or C1-C2 fluoroalkyl groups, which are typically substituted by1, 2 or 3 fluoro atoms. Thus, a C1-C4 fluoroalkyl includes trifluoromethyl (-CF3), difluoromethyl (-CF2H), fluoromethyl (-CFH2), difluoroethyl (-CH2CF2H), and the like.
Similarly, “hydroxyalkyl” refers to an alkyl group having the specified number of carbon atoms that is substituted by one or more hydroxy substituents, and typically contain 1-6 carbon atoms, preferably 1-4 carbon atoms, and 1, 2 or 3 hydroxy (Le., “Ci-C6 hydroxyalkyl”). Thus, C-i-Ce hydroxyalkyl includes hydroxymethyl (-CH2OH) and
2-hydroxyethyl (-CH2CH2OH).
“Alkoxyalkyl” refers to an alkyl group having the specified number of carbon atoms that is substituted by one or more alkoxy substituents. Alkoxyalkyl groups typically contain 1-6 carbon atoms in the alkyl portion and are substituted by 1, 2 or 3 C1-C4 alkyoxy substituents. Such groups are sometimes described herein as C1-C4 alkyoxy-Ci-Ce alkyl.
“Aminoalkyl” refers to alkyl group having the specified number of carbon atoms that is substituted by one or more substituted or unsubstituted amino groups, as such groups are further defined herein. Aminoalkyl groups typically contain 1-6 carbon atoms in the alkyl portion and are substituted by 1, 2 or 3 amino substituents. Thus, a C1-C6 aminoalkyl includes, for example, aminomethyl (-CH2NH2), A/,A/-dimethylaminoethyl (-CH2CH2N(CH3)2), 3-(/\/-cyclopropylamino)propyl (-CH2CH2CH2NH-cPr) and /V-pyrrolidinylethyl (-ChbChb-N-pyrrolidinyl).
Alkenyl refers to an alkyl group, as defined herein, consisting of at least two carbon atoms and at least one carbon-carbon double bond. Typically, alkenyl groups hâve 2 to 20 carbon atoms (“C2-C20 alkenyl”), preferably 2 to 12 carbon atoms (“C2-C12 alkenyl”), more preferably 2 to 8 carbon atoms (“C2-C8 alkenyl”), or 2 to 6 carbon atoms (“C2-C6 alkenyl”), or 2 to 4 carbon atoms (“C2-C4 alkenyl”). Représentative examples include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-, 2-, or 3-butenyl, and the like. Alkenyl groups are unsubstituted or substituted by the same groups that are described herein as suitable for alkyl.
Alkynyl refers to an alkyl group, as defined herein, consisting of at least two carbon atoms and at least one carbon-carbon triple bond. Alkynyl groups hâve 2 to 20 carbon atoms (“C2-C20 alkynyl”), preferably 2 to 12 carbon atoms (“C2-C12 alkynyl”), more preferably 2 to 8 carbon atoms (“C2-C8 alkynyl”), or 2 to 6 carbon atoms (“C2-C6 alkynyl”), or 2 to 4 carbon atoms (“C2-C4 alkynyl”). Représentative examples include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-, 2-, or 3-butynyl, and the like. Alkynyl groups are unsubstituted or substituted by the same groups that are described herein as suitable for alkyl.
Alkylene as used herein refers to a divalent hydrocarbyl group having the specified number of carbon atoms which can link two other groups together. Sometimes it refers to a group -(CH2)t- where t is 1-8, and preferably t is 1-4. Where specified, an alkylene can also be substituted by other groups and may include one or more degrees of unsaturation (i.e., an alkenylene or alkynlene moiety) or rings. The open valences of an alkylene need not be at opposite ends of the chain. Thus branched alkylene groups such as -CH(Me)- , -CH2CH(Me)- and -C(Me)2- are also included within the scope of the term 'alkylenes', as are cyclic groups such as cyclopropan-1,1-diyl and unsaturated groups such as ethylene (-CH=CH-) or propylene (-CH2-CH=CH-). Where an alkylene group is described as optionally substituted, the substituents include those typically présent on alkyl groups as described herein.
Heteroalkylene refers to an alkylene group as described above, wherein one or more non-contiguous carbon atoms of the alkylene chain are replaced by -N(R)-, -O- or -S(O)X-, where R is H or a suitable substituent group (e.g., R6) and x is 0-2. For example, the group -O-(CH2)i-4- is a ‘C2-C5’-heteroalkylene group, where one of the carbon atoms of the corresponding alkylene is replaced by O.
“Alkoxy” refers to a monovalent -O-alkyl group, wherein the alkyl portion has the specified number of carbon atoms. Alkoxy groups typically contain 1 to 8 carbon atoms (“Ci-Ce alkoxy”), or 1 to 6 carbon atoms (“Ci-Ce alkoxy”), or 1 to 4 carbon atoms (“C1-C4 alkoxy”). For example, C1-C4 alkoxy includes methoxy, ethoxy, isopropoxy, tert-butyloxy (i.e., -OCH3, -OCH2CH3, -OCH(CH3)2, -OC(CH3)3), and the like. Alkoxy groups are unsubstituted or substituted on the alkyl portion by the same groups that are described herein as suitable for alkyl. In particular, alkoxy groups may be optionally substituted by one or more halo atoms, and in particular one or more fluoro atoms, up to the total number of hydrogen atoms présent on the alkyl portion. Such groups are referred to as “haloalkoxy” (or, where fluorinated, more specifically as “fluoroalkoxy”) groups having the specified number of carbon atoms and substituted by one or more halo substituents, Typically such groups contain from 1-6 carbon atoms, preferably 1-4 carbon atoms, and sometimes 1-2 carbon atoms, and 1, 2 or 3 halo atoms (i.e., “C1-C6 haloalkoxy”, “C1-C4 haloalkoxy” or “C1-C2 haloalkoxy”). More specifically, fluorinated alkyl groups may be specifically referred to as fluoroalkoxy groups, e.g., Ci-Ce, C1-C4 or C1-C2 fluoroalkoxy groups, which are typically substituted by 1, 2 or 3 fluoro atoms. Thus, a C1-C4 fluoroalkoxy includes trifluoromethyloxy (-OCF3), difluoromethyloxy (-OCF2H), fluoromethyloxy (-OCFH2), difluoroethyloxy (-OCH2CF2H), and the like.
Similarly, “thioalkoxy” refers to a monovalent -S-alkyl group, wherein the alkyl portion has the specified number of carbon atoms, and is optionally substituted on the alkyl portion by the same groups that are described herein as suitable for alkyl. For example, a C1-C4 thioalkoxy includes -SCH3 and -SCH2CH3.
Cycloalkyl refers to a non-aromatic, saturated or partially unsaturated carbocyclic ring System containing the specified number of carbon atoms, which may be a monocyclic, spirocyclic, bridged or fused bicyclic or polycyclic ring System that is connected to the base molécule through a carbon atom of the cycloalkyl ring. Typically, the cycloalkyl groups of the invention contain 3 to 12 carbon atoms (“C3-C12 cycloalkyl”), preferably 3 to 8 carbon atoms (“Cs-Cs cycloalkyl”). Représentative examples include,
e.g., cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptatriene, adamantane, and like. Cycloalkyl groups are unsubstituted or substituted by the same groups that the are described herein as suitable for alkyl.
Illustrative examples of cycloalkyl rings include, but are not limited to, the following:
cyclopentane (cyclopentanyl)
cyclopentene (cyclopentenyl)
cyclohexane (cyclohexanyl)
cyclohexene (cyclohexanyl) cyclobutane (cyclobutanyl) cyclopropane (cyclopropanyl)
cycloheptene (cycloheptenyl) octahydropentalene (octahydropentalenyl) cycloheptane (cycloheptanyl) octahydroindane (octahydroindanyl) decahydronaphthalene (decahydronapthalenyl)
adamantane (adamantyl)
bicyclo[2.2.2]octane (bicyclo[2.2.2]octanyl) bicyclo[1.1.1]pentane bicyclo[2.2.1]heptane (bicycio[ 1.1.1 Jpentanyl) (bicyclo[2.2.1]heptanyl)
Cycloalkylalkyl is used to describe a cycloalkyl ring, typically a Cs-Cs cycloalkyl, which is connected to the base molécule through an alkylene linker, typically a C1-C4 alkylene. Cycloalkylalkyl groups are sometimes described by the total number of carbon atoms in the carbocyclic ring and linker, and typically contain from 4-12 carbon atoms (“C4-C12 cycloalkylalkyl”). Thus a cyclopropylmethyl group is a C4-cycloalkylalkyl group and a cyclohexylethyl is a Cs-cycloalkylalkyl. Cycloalkylalkyl groups are unsubstituted or substituted on the cycloalkyl and/or alkylene portions by the same groups that are described herein as suitable for alkyl groups. Sometimes cycloalkylalkyl groups are described herein, as -L- Cs-Cs-cycloalkyl, where the cycloalkyl group has the number of carbon atoms indicated and -L- refers to an alkylene linker. It will be understood that when -L -is a bond, the group is cycloalkyl.
The terms heterocyclyl, heterocyclic or “heteroalicyclic” are used interchangeably herein to refer to a non-aromatic, saturated or partially unsaturated ring System containing the specified number of ring atoms, including at least one heteroatom selected from N, O and S as a ring member, where ring S atoms are optionally substituted by one or two oxo groups (i.e., S(O)x, where x is 0, 1 or 2) and where the heterocyclic ring is connected to the base molécule via a ring atom, which may be C or
N. Heterocyclic rings include rings which are spirocyclic, bridged, or fused to one or more other heterocyclic or carbocyclic rings, where such spirocyclic, bridged, or fused rings may themselves be saturated, partially unsaturated or aromatic to the extent unsaturation or aromaticity makes chemical sense, provided the point of attachment to the base molécule is an atom of the heterocyclic portion of the ring System. Preferably, heterocyclic rings contain 1 to 4 heteroatoms selected from N, O, and S(O)q as ring members, and more preferably 1 to 2 ring heteroatoms, provided that such heterocyclic rings do not contain two contiguous oxygen atoms. Heterocyclyl groups are unsubstituted or substituted by suitable substituent groups, for example the same groups that are described herein as suitable for alkyl, aryl or heteroaryl. Such substituents may be présent on the heterocycylic ring attached to the base molécule, or on a spirocyclic, bridged or fused ring attached thereto. In addition, ring N atoms are optionally substituted by groups suitable for an amine, e.g., alkyl, acyl, carbamoyl, sulfonyl substituents, and the like.
Heterocycles typically include 3-12 membered heterocyclyl groups, preferably 310 membered heterocyclyl groups, and more preferably 5-6 membered heterocyclyl groups, in accordance with the définition herein.
Illustrative examples of saturated heterocycles include, but are not limited to:
oxirane thiarane (oxiranyl) (thiaranyl) aziridine (aziridinyl) oxetane (oxetanyl) thiatane (thiatanyl) azetidine (azetidinyl) tetrahydrofuran (tetrahydrofuranyl)
tetrahydrothiophene (tetrahydrothiophenyl) pyrrolidine (pyrrolidinyl) tetrahydropyran tetrahydrothiopyran piperidine (tetrahydropyranyl) (tetrahydrothiopyranyl) (piperidinyl)
morpholine 1,4-dithiane piperazine (morpholinyl) (1,4-dithianyl) (piperazinyl)
1,4-dioxane 1,4-oxathiarane (1,4-dioxanyl) (1,4-oxathiaranyl) thiomorpholine (thiomorpholinyl)
oxepane thiepane azepane (oxepanyl) (thiepanyl) (azepanyl)
1,4-dioxepane (1,4-dioxepanyl)
1,4-oxa thiepane (1,4-oxathiepanyl)
1,4-oxaazepane (1,4-oxaazepanyl)
1,4-thieazepane (1,4-thieazapanyl)
1,4-diazepane (1 ,-diazepanyl)
1,4-dithiepane (1,4-dithiepanyl)
Illustrative examples of partially unsaturated heterocycles include, but are not limited to:
2H-pyran (2H-pyranyl)
3,4-dihydro-2H-pyran 5,6-dihydro-2H-pyran (3,4-dihydro-2H-pryanyl) (5,6-dihydro-2H-pyranyl)
1,2,3,4-tetrahydropyridine (1,2,3,4-tetrahydropyridinyl)
1,2,5,6-tetrahydropyridine (1,2,5,6-tetrahyrodpyridinyl)
Illustrative examples of bridged, fused and spiro heterocycles include, but are not limited to:
3-azabicyclo[3.1.0]hexane
2-azabicyclo[3.1.0]hexane
8-azabicyclo[2.2.1]octane
H
2-oxa-5-azabicyclo[2.2.1]heptane
3-oxooctahydroindolizine
3-oxa-8-azabicyclo[3.2.1]octane
2-azabicyclo[2.2.1]heptane
1,1 -dioxidohexahydropyrido[1,2]thiazolo[2,3-a]pyridine
3-oxohexahydro[1,3]oxazolo[3,4-a]pyridine
2,2-dioxido-2-thiaspiro[3,5]nonane
1,1 -dioxidohexahydropyrido[1,2-d][1,3,4]oxathiazine
In frequent embodiments, heterocyclic groups contain 3-12 ring members, including both carbon and non-carbon heteroatoms, and preferably 4-7 ring members. In certain preferred embodiments, substituent groups comprising 3-12 membered heterocycles are selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, diazepanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, morpholinyl and thiomorpholinyl rings, each of which are optionally substituted as described for the particular substituent group, to the extent such substitution makes chemical sense.
It is understood that no more than two N, O or S atoms are ordinarily connected sequentially, except where an oxo group is attached to N or S to form a nitro or sulfonyl group, or in the case of certain heteroaromatic rings, such as triazine, triazole, tetrazole, oxadiazole, thiadiazole, and the like.
The term heterocyclylalkyl may be used to describe a heterocyclic group of the specified size that is connected to the base molécule through an alkylene linker of the specified length. Typically, such groups contain an optionally substituted 3-12 membered heterocycle attached to the base molécule through a C1-C4 alkylene linker. Where so indicated, such groups are optionally substituted on the alkylene portion by the same groups that are described herein as suitable for alkyl groups and on the heterocyclic portion by groups described as suitable for heterocyclic rings. Sometimes heterocyclylalkyl groups are described herein as -L-heterocyclylalkyl, where the heterocyclylalkyl group has the number of ring atoms indicated and -L- refers to an alkylene linker. It will be understood that when -L -is a bond, the group is heterocyclyl.
Aryl or “aromatic” refer to an optionally substituted monocyclic or fused bicyclic or polycyclic ring System having the well-known characteristics of aromaticity, wherein at least one ring contains a completely conjugated pi-electron System. Typically, aryl groups contain 6 to 20 carbon atoms (C6-C20 aryl) as ring members, preferably 6 to 14 carbon atoms (Ce-Cu aryl) or more preferably, 6 to 12 carbon atoms (C6-C12 aryl). Fused aryl groups may include an aryl ring (e.g., a phenyl ring) fused to another aryl or heteroaryl ring, or fused to a saturated or partially unsaturated carbocyclic or heterocyclic ring, provided the point of attachment to the base molécule on such fused ring Systems is an atom of the aromatic portion of the ring System. Examples, without limitation, of aryl groups include phenyl, biphenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, and tetrahydronaphthyl. The aryl group is unsubstituted or substituted as further described herein.
Similarly, heteroaryl or “heteroaromatic” refer to monocyclic or fused bicyclic or polycyclic ring Systems having the well-known characteristics of aromaticity that contain the specified number of ring atoms and include at least one heteroatom selected from N, O and S as a ring member in an aromatic ring. The inclusion of a heteroatom permits aromaticity in 5-membered rings as well as 6-membered rings. Typically, heteroaryl groups contain 5 to 20 ring atoms (“5-20 membered heteroaryl”), preferably 5 to 14 ring atoms (“5-14 membered heteroaryl”), and more preferably 5 to 12 ring atoms (“5-12 membered heteroaryl”). Heteroaryl rings are attached to the base molécule via a ring atom of the heteroaromatic ring, such that aromaticity is maintained. Thus,
6-membered heteroaryl rings may be attached to the base molécule via a ring C atom, while 5-membered heteroaryl rings may be attached to the base molécule via a ring C or N atom. Heteroaryl groups may also be fused to another aryl or heteroaryl ring, or fused to a saturated or partially unsaturated carbocyclic or heterocyclic ring, provided the point of attachment to the base molécule on such fused ring Systems is an atom of the heteroaromatic portion of the ring System. Examples of unsubstituted heteroaryl groups often include, but are not limited to, pyrrole, furan, thiophene, pyrazole, imidazole, isoxazole, oxazole, isothiazole, thiazole, triazole, oxadiazole, thiadiazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine, benzofuran, benzothiophene, indole, benzimidazole, indazole, quinoline, isoquinoline, purine, triazine, naphthryidine and carbazole. In frequent preferred embodiments, 5- or 6-membered heteroaryl groups are selected from the group consisting of pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, triazolyl, pyridinyl and pyrimidinyl, pyrazinyl or pyridazinyl rings. The heteroaryl group is unsubstituted or substituted as further described herein.
Aryl, heteroaryl and heterocyclyl moieties described herein as optionally substituted may be substituted by one or more substituent groups, which are selected independently unless otherwise indicated. The total number of substituent groups may equal the total number of hydrogen atoms on the aryl, heteroaryl or heterocyclyl moiety, to the extent such substitution makes chemical sense and aromaticity is maintained in the case of aryl and heteroaryl rings. Optionally substituted aryl, heteroaryl or heterocyclyl groups typically contain from 1 to 5 optional substituents, sometimes 1 to 4 optional substituents, preferably 1 to 3 optional substituents, or more preferably from
1-2 optional substituents.
Optional substituent groups suitable for aryl, heteroaryl and heterocyclyl rings include, but are not limited to: Ci-Cs alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl,
3-12 membered heterocyclyl, C6-C12 aryl and 5-12 membered heteroaryl; and halo, =0, -CN, -C(O)RX, -CO2Rx, -C(O)NRxRy, - SRX, -SORX, -SO2RX, -SO2NRxRy, -NO2, -N RxRy, -NRxC(O)Ry, -NRxC(O)NRxRy, -NRXC(O)ORX, -NRxSO2Ry, -NRxSO2NRxRy, -ORX, -OC(O)RX and -OC(O)NRxRy; where each Rx and Ry is independently H, Ci-Cs alkyl, Ci-Ce acyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, 3-12 membered heterocyclyl, C6-C12 aryl, or 5-12 membered heteroaryl, or Rx and Ry may be taken together with the N atom to which they are attached to form a 3-12 membered heterocyclyl or 5-12 membered heteroaryl, each optionally containing 1, 2 or 3 additional heteroatoms selected from O, N and S(O)q where q is 0-2; each Rx and Ry is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, =O, =S, =N-CN, =N-OR', =NR', -CN, -C(O)R', -CO2R', -C(O)NR’2,
SR', -SOR', -SO2R', -SO2NR'2, -NO2, -NR'2, -NR'C(O)R', -NR'C(O)NR'2, -NR'C(O)OR', NR'SO2R', -NR'SO2NR'2, -OR', -OC(O)R' and -OC(O)NR'2, wherein each R' is independently H, Ci-Cs alkyl, Ci-Ce acyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl,
3-12 membered heterocyclyl, C6-C12 aryl, or 5-12 membered heteroaryl; and each said Ci-Cs alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, 3-12 membered heterocyclyl, C6-C12 aryl and 5-12 membered heteroaryl is optionally substituted as further defined herein.
In typical embodiments, optional substitution on aryl, heteroaryl and heterocyclyl rings includes one or more substituents, and preferably 1 to 3 substituents, independently selected from the group consisting of halo, Ci-Cs alkyl, -OH, Ci-Cs
I 19 alkoxy, -CN, =0, -C(O)RX, -COORX, -OC(O)RX, -C(O)NRxRy, -NRxC(O)Ry, -SRX, SORX, -SO2Rx, -SO2NRxRy, -NO2, -NRxRy, -NRxC(O)Ry, -NRxC(O)NRxRy, -NRxC(O)ORy -NRxSO2Ry, -NRxSO2NRxRy, -OC(O)RX, -OC(O)NRxRy, C3-C8 cycloalkyl, 3-12 membered heterocyclyl, Ce-Ci2 aryl, 5-12 membered heteroaryl, -O-(C3-C8 cycloalkyl),-0-(3-12 membered heterocyclyl), -O-(Ce-Ci2 aryl) and -0-(5-12 membered heteroaryl); where each Rx and Ry is independently H or C1-C4 alkyl, or Rx and Ry may be taken together with the N to which they are attached form a 3-12 membered heterocyclyl or 5-12 membered heteroaryl ring, each optionally containing 1, 2 or 3 additional heteroatoms selected from O, N and S(0)q where q is 0-2; and wherein each 10 said Ci-Os alkyl, Ci-Cs alkoxy, C3-C8 cycloalkyl, 3-12 membered heterocyclyl, Ce-Ci2 aryl, 5-12 membered heteroaryl, -O-(C3-C8 cycloalkyl),-0-(3-12 membered heterocyclyl), -O-(Ce-Ci2 aryl) and -0-(5-12 membered heteroaryl) that is described as an optional substituent or is part of Rx or Ry is optionally substituted by 1 to 3 substituents independently selected from the group consisting of halo, -OH, =0, C1-C4 15 alkyl, C1-C4 alkoxy, Ci-Οθ haloalkyl, C-i-Ce hydroxyalkyl, C1-C4 alkoxy-C-i-Ce alkyl, -CN, -NH2, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2 and N-pyrrolidinyl.
Examples of monocyclic heteroaryl groups include, but are not limited to:
H ô | ô | ô | O | H ô N |
pyrrole (pyrrolyl) | furan (furanyl) | thiophene (thiophenyl) | pyrazole (pyrazolyl) | imidazole (imidazolyl) |
i/ | ô N | O | ô N | A O |
isoxazole (isoxazolyl) | oxazole (oxazolyl) | isothiazole (isothiazolyl) | thiazolyl (thiazolyl) | 1,2,3-triazole (1,2,3-triazolyl) |
N-N
1,3,4-triazole (1,3,4-triazolyl)
1-oxa-2,3-diazole (1-oxa-2,3-diazolyl)
1-oxa-2,4-diazole (1-oxa-2,4-diazolyl)
Λ
N, ,N
1-oxa-2,5-diazole (1-oxa-2,5-diazolyl)
1-oxa-3,4-diazole (1-oxa-3,4-diazolyl)
1-thia-2,3-diazole (1 -thia-2,3-diazolyl)
1-thia-2,4-diazole (1-thia-2,4-diazolyl)
N N
1-thia-2,5-diazole (1 -thia-2,5-diazolyl)
1-thia-3,4-diazole tetrazole pyridine (1 -thia-3,4-diazolyl) (tetrazolyl) (pyridinyl) pyridazine (pyridazinyl) pyrimidine (pyrimidinyl)
pyrazine (pyrazinyl)
Illustrative examples of fused ring heteroaryl groups include, but are not limited to:
benzotriazole (benzotriazolyl) pyrrolo[2,3-b]pyridine pyrrolo[2,3-c]pyridine pyrrolo[3,2-c]pyridine (pyrrolo[2,3-b]pyridinyl) (pyrrolo[2,3-c]pyridinyl) (pyrrolo[3,2-c]pyridinyl)
pyrrolo[3,2-b]pyridine (pyrrolo[3,2-b]pyridinyl) imidazo[4,5-b]pyridine (imidazo[4,5-b]pyridinyl) imidazo[4,5-c]pyridine (imidazo[4,5-c]pyridinyl) pyrazolo[4,3-d]pyridine (pyrazolo[4,3-d]pyidinyl)
pyrazolo[4,3-c]pyridine (pyrazolo[4,3-c]pyidinyl) pyrazolo[3,4-c]pyridine (pyrazolo[3,4-c]pyidinyl) pyrazolo[3,4-b]pyridine (pyrazolo[3,4-b]pyidinyl) isoindole (isoindolyl)
indazole purine (indazolyl) (purinyl) indolizine imidazo[1,2-a]pyridine imidazo[1,5-a]pyridine (indolininyl) (imidazo[1,2-a]pyridinyl) (imidazo[1,5-a]pyridinyI)
pyrazolo[1,5-a]pyridine (pyrazolo[1,5-a] pyridiny I) pyrrolo[1,2-b]pyridazine (pyrrolo[1-2,b]pyridazinyl) imidazo[1,2-c]pyrimidine (imidazo[1,2-c]pyrimidinyl)
quinoline (quinoliny I) isoquinoline (isoquinolinyl) cinnoline (cinnolinyl) quinazoline (azaquinazoline)
quinoxaline (quinoxalinyl)
CO phthalazine (phthalazinyl)
1,6-naphthyridine (1,6-naphthyridinyl)
1,7-naphthyridine (1,7-naphthyridinyl)
1,8-naphthyridine (1,8-naphthyridinyl)
1,5-naphthyridine (1,5-naphthyridinyl)
2,6-naphthyridine (2,6-naphthyridinyl)
2,7-naphthyridine (2,7-naphthyridinyl)
pyrido[3,2-d]pyrimidine (pyrido[3,2-d]pyrimidinyl) pyrido[4,3-d]pyrimidine (pyrido[4,3-d]pyrimidinyl) pyrido[3,4-d]pyrimidine (pyrido[3,4-d]pyrimidinyl)
pyrido[2,3-d]pyrimidine (pyrido[2,3-d]pyrimidinyl) pyrido[2,3-b]pyrazine (pyrido[2,3-b]pyrazinyl) pyrido[3,4-b]pyrazine (pyrido[3,4-b]pyrazinyl)
pyrimido[5,4-d]pyrimidine (pyrimido[5,4-d]pyrimidinyl) pyrazino[2,3-b]pyrazine (pyrazino[2,3-b]pyrazinyl) pyrimido[4,5-d]pyrimidine (pyrimido[4,5-d]pyrimidinyl)
An arylalkyl group refers to an aryl group as described herein which is linked to the base molécule through an alkylene or similar linker. Arylalkyl groups are described by the total number of carbon atoms in the ring and linker. Thus a benzyl group is a Cï-arylalkyl group and a phenylethyl is a Ce-arylalkyL Typically, arylalkyl groups contain
7-16 carbon atoms (“C7-C16 arylalkyl”), wherein the aryl portion contains 6-12 carbon atoms and the alkylene portion contains 1-4 carbon atoms. Such groups may also be represented as -C1-C4 alkylene-C6-Ci2 aryl.
Heteroarylalkyl refers to a heteroaryl group as described above that is attached to the base molécule through an alkylene linker, and differs from arylalkyl in that at least one ring atom of the aromatic moiety is a heteroatom selected from N, O and S.
Heteroarylalkyl groups are sometimes described herein according to the total number of non-hydrogen atoms (i.e., C, N, S and O atoms) in the ring and linker combined, excluding substituent groups. Thus, for example, pyridinylmethyl may be referred to as a “C7”-heteroarylalkyl. Typically, unsubstituted heteroarylalkyl groups contain 6-20 non-hydrogen atoms (including C, N, S and O atoms), wherein the heteroaryl portion typically contains 5-12 atoms and the alkylene portion typically contains 1-4 carbon atoms. Such groups may also be represented as -C1-C4 alkylene-5-12 membered heteroaryl. Sometimes heteroarylalkyl groups are described herein as -Lheteroarylalkyl, where the heteroarylalkyl group has the number of ring atoms indicated and -L- refers to an alkylene linker. It will be understood that when -L -is a bond, the group is heteroaryl.
Similarly, “arylalkoxy” and “heteroarylalkoxy” refer to aryl and heteroaryl groups, attached to the base molécule through a heteroalkylene linker (i.e., -O-alkylene-), wherein the groups are described according to the total number of non-hydrogen atoms (i.e., C, N, S and O atoms) in the ring and linker combined. Thus, -O-CH2-phenyl and O-CHz-pyridinyl groups would be referred to as Cs-arylalkoxy and Cs-heteroarylalkoxy groups, respectively.
Where an arylalkyl, arylalkoxy, heteroarylalkyl or heteroarylalkoxy group is described as optionally substituted, the substituents may be on either the divalent linker portion or on the aryl or heteroaryl portion of the group. The substituents optionally présent on the alkylene or heteroalkylene portion are the same as those described above for alkyl or alkoxy groups generally, while the substituents optionally présent on the aryl or heteroaryl portion are the same as those described above for aryl or heteroaryl groups generally.
Hydroxy refers to an -OH group.
“Acyloxy” refers to a monovalent group -OC(O)alkyl, wherein the alkyl portion has the specified number of carbon atoms (typically Ci-Ce, preferably C1-C6 or C1-C4) that are optionally substituted by groups suitable for alkyl. Thus, C1-C4 acyloxy includes an -OC(O)Ci-C4 alkyl substituent, e.g., -OC(O)CH3.
“Acyl” refers to a monovalent group -C(O)alkyl, wherein the alkyl portion has the specified number of carbon atoms (typically Ci-Cs, preferably Ci-Ce or C1-C4) and may be optionally substituted by groups suitable for alkyl, e.g., by F, OH or alkoxy. Thus, optionally substituted -C(O)Ci-C4 alkyl includes unsubstituted acyl groups, such as -C(O)CHs (i.e., acetyl) and -C(O)CH2CH3 (i.e., propionyl), as well as substituted acyl groups such as -C(O)CFs (trifluoroacetyl), -C(O)CH2OH (hydroxyacetyl), -C(O)CH2OCH3 (methoxyacetyl), -C(O)CF2H (difluoroacetyl), and the like.
“Acylamino” refers to a monovalent group, -NHC(O)alkyl or -NRC(O)alkyl, wherein the alkyl portion has the specified number of carbon atoms (typically Ci-Cs, preferably Ci-Ce or C1-C4) and is optionally substituted by groups suitable for alkyl. Thus, C1-C4 acylamino includes an -NHC(O)Ci-C4 alkyl substituent, e.g., -NHC(O)CH3.
“Aryloxy” or “heteroaryloxy” refer to optionally substituted -O-aryl or O-heteroaryl, in each case where aryl and heteroaryl are as further defined herein.
“Arylamino” or “heteroarylamino” refer to optionally substituted NH-aryl, -NR-aryl, -NH-heteroaryl or -NR-heteroaryl, in each case where aryl and heteroaryl are as further defined herein and R represents a substituent suitable for an amine, e.g., an alkyl, acyl, carbamoyl orsulfonyl group, or the like.
Cyano refers to a -C=N group.
Unsubstituted amino refers to a group -NH2. Where the amino is described as substituted or optionally substituted, the term includes groups of the form -NRxRy, where each or Rx and Ry is independently H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, acyl, thioacyl, aryl, heteroaryl, cycloalkylalkyl, arylalkyl or heteroarylalkyl, in each case having the specified number of atoms and optionally substituted as described herein. For example, “alkylamino” refers to a group -NRxRy, wherein one of Rx and Ry is an alkyl moiety and the other is H, and “dialkylamino” refers to -NRxRy wherein both of Rx and Ry are alkyl moieties, where the alkyl moieties having the specified number of carbon atoms (e.g., -NH-C1-C4 alkyl or -N(Ci-C4 alkyl)2). Typically, alkyl substituents on amines contain 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms, or more preferably 1 to 4 carbon atoms. The term also includes forms wherein Rx and Ry are taken together with the N atom to which they are attached to form a 3-12 membered heterocyclyl or 5-12 membered heteroaryl ring, each of which may itself be optionally substituted as described herein for heterocyclyl or heteroaryl rings, and which may contain 1 to 3 additional heteroatoms selected from N, O and S(O)x where x is 0-2 as ring members, provided that such rings do not contain two contiguous oxygen atoms.
“Halogen” or “halo” refers to fluoro, chloro, bromo and iodo (F, Cl, Br, I). Preferably, halo refers to fluoro or chloro (F or Cl).
Optional or optionally means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs and instances in which it does not.
The terms “optionally substituted” and “substituted or unsubstituted” are used interchangeably to indicate that the particular group being described may hâve no non-hydrogen substituents (Le., unsubstituted), or the group may hâve one or more non-hydrogen substituents (Le., substituted). If not otherwise specified, the total number of substituents that may be présent is equal to the number of H atoms présent on the unsubstituted form of the group being described. Where an optional substituent is attached via a double bond, such as an oxo (=0) substituent, the group occupies two available valences, so the total number of other substituents that are included is reduced by two. In the case where optional substituents are selected independently from a list of alternatives, the selected groups are the same or different. Throughout the disclosure, it will be understood that the number and nature of optional substituent groups will be limited to the extent that such substitutions make chemical sense.
In one aspect, the invention provides a compound of Formula (I):
R4
or a pharmaceutically acceptable sait thereof, wherein:
R1 is 3-10 membered heterocyclyl substituted by R5Aor Cs-Cs cycloalkyl substituted by R5B, where said 3-10 membered heterocyclyl and Cs-Cs cycloalkyl are optionally further substituted by one or more R6;
each R2 is independently F, OH, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy;
R2A and R2B are independently H, F, OH, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy;
where each said C1-C4 alkyl and C1-C4 fluoroalkyl in R2, R2A and R2B is independently optionally substituted by OH, C1-C4 alkoxy or C1-C4 fluoroalkoxy; R3 is H, F, Cl, NH2, C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH, CN, C1-C4 alkoxy, C1-C4 fluoroalkoxy, CONH2 and COOH;
R4 is H, C1-C2 alkyl or C1-C2 fluoroalkyl;
R5A is SO2R7, SO2NR8R9, NHSO2R7 or NHSO2NR8R9;
R5B is NHSO2R7 or NHSO2NR8R9;
each R6 is independently F, OH, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy;
R7 is C1-C4 alkyl, C1-C4 fluoroalkyl, -L-(C3-C8 cycloalkyl), -L-(5-6 membered heterocyclyl) or -L-(5-6 membered heteroaryl);
R8 and R9 are independently H, C1-C4 alkyl, C1-C4 fluoroalkyl, -L-(C3-Cs cycloalkyl), -L-(5-6 membered heterocyclyl) or-L-(5-6 membered heteroaryl); or
R8 and R9 may be taken together with the nitrogen atom to which they are attached to form a 5-6 membered heterocyclyl;
where each said C1-C4 alkyl and C1-C4 fluoroalkyl in R7, R8 and R9 is optionally substituted by OH, C1-C4 alkoxy, C1-C4 fluoroalkoxy or SO2Me, and each said C3-C8 cycloalkyl, 5-6 membered heterocyclyl and 5-6 membered heteroaryl in R7, R8 and R9 is optionally substituted by C1-C4 alkyl, OH, C1-C4 alkoxy or C1-C4 fluoroalkoxy;
L is a bond or C1-C4 alkylene, where said C1-C4 alkylene is optionally substituted by C1-C4 alkyl, OH, C1-C4 alkoxy or C1-C4 fluoroalkoxy;
p is 0, 1,2, 3 or 4;
q is 0, 1 or 2; and r is 0, 1 or 2.
In some embodiments, the compound of Formula (I) has the absolute stereochemistry as shown in Formula (l-A), (l-B) or (l-C):
or a pharmaceutically acceptable sait thereof, where R1, R2, R2A, R2B, R3, R4, R5A,
R5B, R6, R7, R8, R9, p, q and r are defined as for Formula (I).
Each of the aspects and embodiments described herein with respect to Formula (I) is also applicable to compounds of Formula (l-A), (l-B) or (l-C).
In compounds of Formula (I), R1 is 3-10 membered heterocyclyl substituted by R5Aor C3-C8 cycloalkyl substituted by R5B, where said 3-10 membered heterocyclyl and C3-C8 cycloalkyl are optionally further substituted by one or more R6.
In some embodiments of Formula (I), R1 is 3-10 membered heterocyclyl substituted by R5Aand optionally further substituted by one or more R6. In some such embodiments, R1 is 5-6 membered heterocyclyl substituted by R5A and optionally further substituted by one or more R6. In some such embodiments, R1 is 5-6 membered heterocyclyl substituted by R5A. In particular embodiments, R1 is a 5-6 membered nitrogen-containing heterocyclyl substituted by R5A. In some such embodiments, R1 is a piperidinyl or pyrrolidinyl ring. In spécifie embodiments, R1 is a piperidin-4-yl, piperidin3-yl or pyrrolidin-3-yl. In frequent embodiments, R1 is a 5-6 membered nitrogencontaining heterocyclyl which is ΛΖ-substituted by R5A. In frequent embodiments, R1 is a piperidin-4-yl for which Λ/1 of the piperidinyl ring is substituted by R5A. In other embodiments, R1 is a piperidin-3-yl for which Λ/1 of the piperidinyl ring is substituted by R5A. In further embodiments, R1 is a pyrrolidin-3-yl for which Λ/1 of the pyrrolidinyl ring is substituted by R5A.
In each of the foregoing embodiments, R1 is optionally further substituted by one or more R6. In some embodiments, R1 is optionally further substituted by one, two or three R6. In further embodiments, R1 is optionally further substituted by one or two R6. In some embodiments, R1 is a 3-10 membered nitrogen-containing heterocyclyl substituted by R5A and further substituted by one, two or three R6, where each R6 is independently F, OH, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, as further described herein. In some embodiments, R1 is a 3-10 membered nitrogencontaining heterocyclyl substituted by R5A and further substituted by one or two R6, where each R6 is independently F or CH3.
In particular embodiments, R1 is a 5-6 membered nitrogen-containing heterocyclyl that is /V-substituted by R5A, which is selected fromthe group consisting of:
r5A where the * represents the point of attachment to the 2-amino substituent. In particular embodiments, R1 is
r5A
In some such embodiments, R5Ais SO2R7 or SO2NR8R9.
In compounds of Formula (I), R5A is SO2R7, SO2NR8R9, NHSO2R7 or NHSO2NR8R9, where R7, R8 and R9 are as defined for Formula (I) and further described herein. In some embodiments of Formula (I), R1 is 3-10 membered heterocyclyl and R5A is SO2R7 or SO2NR8R9. In other embodiments, R1 is 3-10 membered heterocyclyl and R5A is NHSO2R7 or NHSO2NR8R9.
In some embodiments of Formula (I), R1 is 3-10 membered heterocyclyl and R5A is SO2R7 or SO2NR8R9. In some such embodiments, R1 is piperidinyl or pyrrolidinyl and R5Ais SO2R7 or SO2NR8R9. In particular embodiments, R1 is a piperidin-4-yl, piperidin3-yl or pyrrolidin-3-yl and R5Ais SO2R7 or SO2NR8R9. In frequent embodiments, R1 is a piperidin-4-yl for which Λ/1 of the piperidinyl ring is substituted by R5A, where R5A is SO2R7 or SO2NR8R9. In other embodiments, R1 is a piperidin-3-yl for which Λ/1 of the piperidinyl ring is substituted by R5A, where R5A is SO2R7 or SO2NR8R9. In other embodiments, R1 is a pyrrolidin-3-yl for which N of the pyrrolidinyl ring is substituted by R5A, where R5A is SO2R7 or SO2NR8R9. In each of the foregoing embodiments, R1 is optionally further substituted by one or more R6.
In some embodiments of Formula (I), R1 is 5-6 membered heterocyclyl and R5Ais SO2R7. In other embodiments of Formula (I), R1 is 5-6 membered N-containing heterocyclyl and R5A is SO2R7. In frequent embodiments, R1 is 5-6 membered Ncontaining heterocyclyl substituted at N by R5A, where R5A is SO2R7. In some such embodiments, R7 is CH3. In spécifie embodiments, R1 is a piperidin-4-yl substituted at Λ/1 by R5A, where R5A is SO2R7and R7 is CH3.
In still other embodiments of Formula (I), R1 is 5-6 membered heterocyclyl and R5A is SO2NR8R9. In some such embodiments, R8 and R9 are independently H or CH3. In particular embodiments, R1 is a piperidin-4-yl substituted at Λ/1 by R5A, where R5A is SO2NR8R9 and R8 and R9 are independently H or CH3.
In other embodiments of Formula (I), R1 is C3-C8 cycloalkyl, where said C3-C8 cycloalkyl is substituted by R5B and optionally further substituted by one or more R6. In some such embodiments, R1 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. In each of the foregoing, R1 is substituted by R5B and optionally further substituted by one or more R6. In other embodiments of Formula (I), R5B is NHSO2R7 or NHSO2NR8R9.
In compounds of Formula (I), R7 is C1-C4 alkyl, C1-C4 fluoroalkyl, -L-(C3-Cs cycloalkyl), -L-(5-6 membered heterocyclyl) or-L-(5-6 membered heteroaryl), where R7 is optionally substituted as described for Formula (I) above.
In compounds of Formula (I), L is a bond or C1-C4 alkylene, where said C1-C4 alkylene is optionally substituted by OH, C1-C4 alkoxy or C1-C4 fluoroalkoxy. In some embodiments, R7 is C1-C4 alkyl, optionally substituted by OH, C1-C4 alkoxy, C1-C4 fluoroalkoxy or SO2Me. In particular embodiments, R7 is C1-C4 alkyl. In some such embodiments, R7 is CH3. In other such embodiments, R7 is CH2CH3. In further embodiments, R7 is C1-C4 alkyl, optionally substituted by OH, OCHsor SO2Me. In some embodiments, R7 is C1-C4 fluoroalkyl. In some such embodiments, R7 is CH2F, CHF2, CH2CF2H, CF3 or CH2CF3.
In further embodiments, R7 is -l_-(C3-C8 cycloalkyl), where said Cs-Cs cycloalkyl is optionally substituted by C1-C4 alkyl, OH, C1-C4 alkoxy or C1-C4 fluoroalkoxy. In some such embodiments, L is a bond and R7 is cyclopropyl, cyclobutyl, cyclopentyl. In other such embodiments, L is methylene (i.e. -CH2-) and R7 is cyclopropylmethyl, cyclobutylmethyl or cyclopentylmethyl.
In still other embodiments, R7 is -L-(5-6 membered heterocyclyl) or -L-(5-6 membered heteroaryl), where said 5-6 membered heterocyclyl and 5-6 membered heteroaryl are optionally substituted by C1-C4 alkyl, OH, C1-C4 alkoxy or C1-C4 fluoroalkoxy. In some such embodiments, L is a bond, methylene or ethylene moiety (i.e., bond, -CH2- or -CH2CH2-) and R7 is an optionally substituted 5-6 membered heteroaryl selected from the group consisting of pyrazolyl, imidazolyl, thiazolyl or thiadiazolyl. In some such embodiments, L is a bond. In other such embodiments, L is a bond, methylene or ethylene and R7 is an optionally substituted 5-6 membered heterocyclyl. In a spécifie embodiment, L is a bond and R7 is d ioxid otetra hyd roth ioph e nyl.
In some embodiments R5A is SO2R7, where R7 is selected from each of the foregoing embodiments described for R7. In some embodiments, R5A is SO2R7 and R7 is C1-C4 alkyl optionally substituted by OH, C1-C4 alkoxy, C1-C4 fluoroalkoxy or SO2Me. In particular embodiments, R5Ais SO2R7 and R7 is C1-C4 alkyl. In spécifie embodiments of each of the foregoing embodiments of R7, R1 is piperidinyl or pyrrolidinyl, in particular piperidin-4-yl, piperidin-3-yl or pyrrolidin-3-yl, and R5Ais SO2R7.
In compounds of Formula (I), R8 and R9 are independently H, C1-C4 alkyl, C1-C4 fluoroalkyl, -L-(C3-Cs cycloalkyl), -L-(5-6 membered heterocyclyl) or -L-(5-6 membered heteroaryl); or R8 and R9 may be taken together with the nitrogen atom to which they are attached to form a 5-6 membered heterocyclyl, where R8 and R9 are optionally substituted as described for Formula (I) above or further described herein.
In some embodiments of Formula (I), R8 and R9 are independently H or C1-C4 alkyl. In some such embodiments, R8 and R9 are independently H or CH3. In some embodiments, both R8 and R9 are H. In other embodiments, R8 is H and R9 is CH3. In still other embodiments, both R8 and R9 are CH3. In further embodiments, one of R8 and R9 is H and the other is C1-C4 alkyl or C1-C4 fluoroalkyl, each optionally substituted as described herein. In some such embodiments, R8 is H and R9 is C1-C4 alkyl or C1-C4 fluoroalkyl, optionally substituted by OH or C1-C4 alkoxy, In still other embodiments, one of R8 and R9 is H and the other is -L-(C3-Ce cycloalkyl), -L-(5-6 membered heterocyclyl) or -L-(5-6 membered heteroaryl), each optionally substituted as described herein. In some such embodiments, R8 is H and R9 is -L-(5-6 membered heterocyclyl), where L is a bond, methylene or ethylene. In spécifie embodiments, R8 is H and R9 is tetrahydrofuranyl or tetrahydropyranyl, wherein L is a bond, or tetrahydrofuranylmethyl or tetrahydropyranylmethyl, wherein L is methylene. In some such embodiments, L is a bond.
In some embodiments R5Ais SO2NR8R9 where R8 and R9 are selected from each of the foregoing embodiments described for R8 and R9. In particular embodiments of each of the foregoing embodiments of R8 and R9, R1 is piperidinyl or pyrrolidinyl, in particular piperidin-4-yl, piperidin-3-yl or pyrrolidin-3-yl, and R5Ais SO2NR8R9.
In some embodiments of Formula (I), R8 and R9 are taken together with the nitrogen atom to which they are attached to form a 5-6 membered heterocyclyl, where said 5-6 membered heterocyclyl is optionally substituted by C1-C4 alkyl, OH, C1-C4 alkoxy or C1-C4 fluoroalkoxy. In some such embodiments, R8 and R9 are taken together with the nitrogen atom to which they are attached to form an optionally substituted piperidinyl ring. In addition to the N to which R8 and R9 are attached, said 5-6 membered heterocyclyl may optionally include an additional heteroatom selected from N, O and S as a ring member, where ring S atoms are optionally substituted by one or two oxo groups (i.e., S(O)x, where x is 0, 1 or 2). In some such embodiments, R8 and R9 are taken together with the nitrogen atom to which they are attached to form an optionally substituted pyrrolidinyl ring. In further embodiments, R8 and R9 are taken together with the nitrogen atom to which they are attached to form an optionally substituted morpholinyl or a piperazinyl ring.
In compounds of Formula (I), each R6 is independently F, OH, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy. In frequent embodiments, R6 is absent. In some such embodiments, each R6 is independently F or C1-C4 alkyl. In some embodiments, R1 is a 5-6 membered nitrogen-containing heterocyclyl substituted by R5A and further substituted by one, two or three R6, where each R6 is independently F or C1-C4 alkyl. In some such embodiments, R1 is a 5-6 membered nitrogen-containing heterocyclyl substituted by R5A and further substituted by one R6, where R6 is F. In other embodiments, R1 is a 5-6 membered nitrogen-containing heterocyclyl substituted by R5A and further substituted by one or two R6, where each R6 is CH3.
In compounds of Formula (I), p is 0, 1, 2, 3 or 4, where p is an integer that represents the number of optional substituent groups, R2.
In compounds of Formula (I), each R2 is independently F, OH, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by OH, C1-C4 alkoxy or C1-C4 fluoroalkoxy. In frequent embodiments, p is 0 and R2 is absent. In other embodiments, p is 1 or 2. In some embodiments, p is 1 or 2, and each R2 is independently F, OH or C1-C4 alkyl. In some embodiments, p is 1 or 2, and each R2 is independently F, OH or CH3. In some such embodiments p is 1 and R2 is F or CH3.
In compounds of Formula (I), R2A and R2B are independently H, F, OH, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by OH, C1-C4 alkoxy or C1-C4 fluoroalkoxy.
In some embodiments, R2A and R2B are independently H, OH or C1-C4 alkyl. In particular embodiments, R2A and R2B are independently H, OH or CH3.
In preferred embodiments of Formula (I), at least one of R2A and R2B is not H. In particular embodiments, R2A and R2B are independently H, F, OH, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, provided at least one of R2A and R2B is not H. In spécifie embodiments, R2A and R2B are independently H, OH or CH3, provided at least one of R2A and R2B is not H.
In some embodiments of Formula (I), one of R2A and R2B is OH and the other is CH3. In other embodiments, one of R2A and R2B is OH and the other is H. In other embodiments, one of R2A and R2B is H and the other is CH3.
In spécifie embodiments of Formula (I), (l-A), (l-B) or (l-C), R2A is OH and R2B is CH3. In other such embodiments, R2A is OH and R2B is H. In further embodiments, R2A is H and R2B is CH3.
In further embodiments of Formula (I), (l-A), (l-B) or (l-C), R2B is OH and R2A is CH3. In other such embodiments, R2B is OH and R2A is H. In further embodiments, R2B is H and R2A is CH3.
In compounds of Formula (I), R3 is H, F, Cl, NH2, C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH, CN, C1-C4 alkoxy, C1-C4 fluoroalkoxy, CONH2 and COOH. In some embodiments of Formula (I), R3 is H, F, Cl, C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl or C1-C4 fluoroalkyl are optionally substituted by OH. In other embodiments, R3 is H, F, Cl, CH3, CH2CH2OH, CF2H or CH2CF2H. In other embodiments of Formula (I), R3 is F, Cl, C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH, CN, C1-C4 alkoxy, C1-C4 fluoroalkoxy, CONH2 and COOH. In some such embodiments, R3 is F, Cl, CH3, CH2CH2OH, CF2H or CH2CF2H. In some embodiments of Formula (I), R3 is H.
In other embodiments of Formula (I), R3 is F or Cl. In some such embodiments, R3 is F. In other such embodiments, R3 is Cl.
In other embodiments of Formula (I), R3 is NHa.ln some embodiments of Formula (I), R3 is C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH, CN, C1-C4 alkoxy, C1-C4 fluoroalkoxy, CONH2 and COOH. In some such embodiments, R3 is C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH.
In some embodiments of Formula (I), R3 is C1-C4 alkyl, optionally substituted by OH, CN, C1-C4 alkoxy, C1-C4 fluoroalkoxy, CONH2 and COOH. In some such embodiments, R3 is C1-C2 alkyl, optionally substituted by OH, CN, C1-C4 alkoxy, C1-C4 fluoroalkoxy, CONH2 and COOH. In some embodiments of Formula (I), R3 is C1-C2 alkyl, optionally substituted by OH. In some embodiments, R3 is CH3 or CH2CH3. In some embodiments, R3 is CH2OH, CH2CH2OH, CH2OCH3 or CH2CH2OCH3. In other embodiments, R3 is CH2CN, CH2CONH2 or CH2COOH.
In other embodiments of Formula (I), R3 is C1-C4 fluoroalkyl, optionally substituted by OH, CN, C1-C4 alkoxy, C1-C4 fluoroalkoxy, CONH2 and COOH. In some such embodiments, R3 is C1-C2 fluoroalkyl, optionally substituted by OH, CN, C1-C4 alkoxy, C1-C4 fluoroalkoxy, CONH2 and COOH. In some embodiments of Formula (I), R3 is C1-C2 alkyl, optionally substituted by OH.
In some embodiments, R3 is C1-C4 fluoroalkyl. In other embodiments, R3 is C1-C2 fluoroalkyl. In spécifie embodiments, R3 is CF3, CHF2, CH2F, CH2CF3, CH2CHF2 or CH2CH2F. In certain embodiments, R3 is CHF2 or CH2CHF2. In some such embodiments, R3 is CHF2. In other such embodiments, R3 is CH2CHF2.
In compounds of Formula (I), R4 is H, C1-C2 alkyl or C1-C2 fluoroalkyl. In frequent embodiments, R4 is H. In some embodiments, R4 is C1-C2 alkyl, such as CH3.
In particular embodiments, R4 is H and R3 is C1-C4 fluoroalkyl. In some such embodiments, R4 is H and R3 is C1-C2 fluoroalkyl. In spécifie embodiments, R4 is H and R3 isCF3, CHF2, CH2F, CH2CF3, CH2CHF2or CH2CH2F. In certain preferred embodiments, R4 is H and R3 is CHF2 or CH2CHF2.
In some embodiments of each of the foregoing embodiments described for R3, R4 is H. In other embodiments of each of the foregoing embodiments described for R3, R4 is C1-C2 alkyl or C1-C2 fluoroalkyl. In particular embodiments of each of the foregoing embodiments described for R3, R4 is CH3, CH2CH3, CF3, CHF2, CH2F, CH2CF3, CH2CHF2 or CH2CH2F.
In compounds of Formula (I), q is 0, 1 or 2; and r is 0, 1 or 2. In some embodiments, q is 1 and r is 0. In other embodiments, q is 0 and r is 1. In other embodiments, q is 1 and r is 1. In still other embodiments, q is 2 and r is 0. In further embodiments, q is 2 and r is 1. In some embodiments, the sum of q and r is 0, 1,2 or 3. In some such embodiments, the ring comprising q and r is a cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl ring, substituted by R2A and R2B and optionally substituted by R2. In preferred embodiments, the ring comprising q and r is a cyclopentyl or cyclohexyl ring. In some embodiments, the sum of q and r is less than or equal to 3. In other embodiments, the sum of q and r is less than or equal to 2. In still other embodiments, the sum of q and r is 1 or 2.
In certain preferred embodiments, the invention provides a compound of Formula (I), (l-A), (l-B) and (l-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is 3-10 membered heterocyclyl substituted by R5A;
p is 0 and R2 is absent;
q is 1 and r is 0; or q is 1 and r is 1 ;
R2A and R2B are independently H, OH or C1-C4 alkyl;
R3 is H, F, Cl, C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH;
R4 is H;
R5A is SO2R7 or SO2NR8R9;
R6 is absent;
R7 is C1-C4 alkyl; and
R8 and R9 are independently H or C1-C4 alkyl.
In other preferred embodiments, the invention provides a compound of Formula (I), (l-A), (l-B) and (l-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is 3-10 membered heterocyclyl substituted by R5A; or
R1 is 3-10 membered heterocyclyl substituted by R5A, where said 3-10 membered heterocyclyl is optionally further substituted by one or two R6;
p is 0 and R2 is absent; or p is 1 or 2, and each R2 is independently F, OH or CH3;
q is 1 and r is 0; or q is 0 and r is 1 ; or q is 1 and r is 1 ;
R2A and R2B are independently H, OH or C1-C4 alkyl, provided at least one of R2A and R2B is not H;
R3 is F, Cl, C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH; or
R3 is C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH; or
R3 is C1-C4 fluoroalkyl; or
R3 is C1-C2 fluoroalkyl;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R6 is absent; or each R6 is independently F or CH3;
R7 is C1-C4 alkyl; and
R8 and R9 are independently H or C1-C4 alkyl.
In further preferred embodiments, the invention provides a compound of Formula (I), (l-A), (l-B) and (l-C), or a pharmaceutically acceptable sait thereof, having three or more of the following features:
R1 is 5-6 membered heterocyclyl substituted by R5A; or
R1 is 5-6 membered heterocyclyl substituted by R5A, where said 5-6 membered heterocyclyl is optionally further substituted by one or two R6;
p is 0 and R2 is absent;
q is 1 and r is 0; or q is 1 and r is 1 ;
R2A and R2B are independently H, OH or C1-C4 alkyl, provided at least one of R2A and R2B is not H;
R3 is F, Cl, C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH; or
R3 is C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH; or
R3 is C1-C4 fluoroalkyl; or
R3 is C1-C2 fluoroalkyl;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R6 is absent; or each R6 is independently F or CH3;
R7 is C1-C4 alkyl; and
R8 and R9 are independently H or C1-C4 alkyl.
In other preferred embodiments, the invention provides a compound of Formula (I), (l-A), (l-B) and (l-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is piperidinyl, preferably piperidin-4-yl, substituted on Λ/1 by R5A;
p is 0 and R2 is absent;
q is 1 and r is 0;
R2A and R2B are independently H, OH or CH3;
R3 is H, F, Cl, CH3, CH2CH2OH, CF2H or CH2CF2H;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R6 is absent;
R7 is CH3; and
R8 and R9 are independently H or CH3.
In still other preferred embodiments, the invention provides a compound of Formula (I), (l-A), (l-B) and (l-C), or a pharmaceutically acceptable sait thereof, having three or more of the following features:
R1 is piperidinyl, preferably piperidin-4-yl, substituted on Λ/1 by R5A;
p is 0 and R2 is absent;
q is 1 and r is 0; or q is 1 and r is 1; R2A and R2B are independently H, OH or CH3, provided at least one of R2A and R2B is not H;
R3 is C1-C4 fluoroalkyl; or
R3 is C1-C2 fluoroalkyl; or
R3 is CF2H orCH2CF2H;
R4 is H;
R5A is SO2R7 or SO2NR8R9;
R6 is absent;
R7 is CH3; and
R8 and R9 are independently H or CH3.
In further preferred embodiments, the invention provides a compound of Formula (I), (l-A), (l-B) and (l-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is piperidinyl, preferably piperidin-4-yl, substituted on Λ/1 by R5A;
p is 0 and R2 is absent;
q is 1 and r is 0;
one of R2A and R2B is OH and the other is CH3; or one of R2A and R2B is OH and the other is H; or one of R2A and R2B is H and the other is CH3;
R3 is H, F, Cl, CH3, CH2CH2OH, CF2H or CH2CF2H;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R6 is absent;
R7 is CH3; and
R8 and R9 are independently H or CH3.
In other preferred embodiments, the invention provides a compound of Formula (I), (l-A), (l-B) and (l-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is piperidin-4-yl, substituted on Λ/1 by R5A;
p is 0 and R2 is absent;
q is 1 and r is 0;
R2A is OH and R2B is H; or
R2A is OH and R2B is CH3; or
R2A is H and R2B is CH3;
R3 is C1-C4 fluoroalkyl; or
R3 is C1-C2 fluoroalkyl; or
R3 is CF2H orCH2CF2H;
R4 is H;
R5Ais SO2R7;
R6 is absent; and
R7 is CH3.
In spécifie embodiments, the invention provides compounds of Formula (l-B), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is piperidin-4-yl, substituted on Λ/1 by R5A;
p is 0 and R2 is absent;
q is 1 and r is 0;
R2A is H or OH and R2B is H or CH3; or
R2A is OH and R2B is H; or
R2A is OH and R2B is CH3; or
R2A is H and R2B is CH3; or
R2A is H and R2B is H;
R3 is H, F, Cl, CH3, CH2CH2OH, CF2H or CH2CF2H;
R4 is H;
R5A is SO2R7, where R7 is CH3; or
R5A is SO2NR8R9 where R8 is H or CH3 and R9 is CH3; and
R6 is absent.
In another aspect, the invention provides a compound of Formula (II), (ll-A), (ll-B) or(ll-C):
or a pharmaceutically acceptable sait thereof, where R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9 and p are defined as for Formula (I).
The embodiments described herein for Formula (I) with respect to R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9 and p are also applicable to compounds of Formulae (II), (ll-A), (ll-B) and (ll-C) to the extent they are not inconsistent.
In certain preferred embodiments, the invention provides a compound of Formula (II), (ll-A), (ll-B) and (ll-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is 3-10 membered heterocyclyl substituted by R5A;
p is 0 and R2 is absent;
R2A and R2B are independently H, OH or C1-C4 alkyl;
R3 is H, F, Cl, C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R6 is absent;
R7 is C1-C4 alkyl; and
R8 and R9 are independently H or C1-C4 alkyl.
In other preferred embodiments, the invention provides a compound of Formula (II), (ll-A), (ll-B) and (ll-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is 3-10 membered heterocyclyl substituted by R5A; or
R1 is 3-10 membered heterocyclyl substituted by R5A, where said 3-10 membered heterocyclyl is optionally further substituted by one or two R6;
p is 0 and R2 is absent; or p is 1 or 2, and each R2 is independently F, OH or CH3;
R2A and R2B are independently H, OH or C1-C4 alkyl, provided at least one of R2A and R2B is not H;
R3 is F, Cl, C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH; or
R3 is C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH; or
R3 is C1-C4 fluoroalkyl; or
R3 is C1-C2 fluoroalkyl; R4 is H;
R5A is SO2R7 or SO2NR8R9;
R6 is absent; or each R6 is independently F or CH3;
R7 is C1-C4 alkyl; and
R8 and R9 are independently H or C1-C4 alkyl.
In other preferred embodiments, the invention provides a compound of Formula (II), (Il-A), (ll-B) and (ll-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is 5-6 membered heterocyclyl substituted by R5A; or
R1 is 5-6 membered heterocyclyl substituted by R5A, where said 5-6 membered heterocyclyl is optionally further substituted by one or more R6;
p is 0 and R2 is absent; R2A and R2B are independently H, OH or C1-C4 alkyl, provided at least one of R2A and R2B is not H;
R3 is F, Cl, C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH; or
R3 is C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH; or
R3 is C1-C4 fluoroalkyl; or
R3 is C1-C2 fluoroalkyl;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R6 is absent; or each R6 is independently F or CH3;
R7 is C1-C4 alkyl; and
R8 and R9 are independently H or C1-C4 alkyl.
In still other preferred embodiments, the invention provides a compound of Formula (II), (ll-A), (ll-B) and (ll-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is piperidinyl, preferably piperidin-4-yl, substituted on Λ/1 by R5A;
p is 0 and R2 is absent;
R2A and R2B are independently H, OH or CH3;
R3 is H, F, Cl, CH3, CH2CH2OH, CF2H orCH2CF2H;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R6 is absent;
R7 is CH3; and
R8 and R9 are independently H orCHs.
In other preferred embodiments, the invention provides a compound of Formula (II), (ll-A), (ll-B) and (ll-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is piperidinyl, preferably piperidin-4-yl, substituted on Λ/1 by R5A;
p is 0 and R2 is absent;
R2A and R2B are independently H, OH or CH3, provided at least one of R2A and R2B is not H;
R3 is C1-C4 fluoroalkyl; or
R3 is C1-C2 fluoroalkyl; or
R3 is CF2H orCH2CF2H;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R6 is absent;
R7 is CH3; and
R8 and R9 are independently H orCHs.
In further preferred embodiments, the invention provides a compound of Formula (II), (ll-A), (ll-B) and (ll-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is piperidinyl, preferably piperidin-4-yl, substituted on Λ/1 by R5A;
p is 0 and R2 is absent;
one of R2A and R2B is OH and the other is CH3; or one of R2A and R2B is OH and the other is H; or one of R2A and R2B is H and the other is CH3;
R3 is H, F, Cl, CH3, CH2CH2OH, CF2H or CH2CF2H;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R6 is absent;
R7 is CH3; and
R8 and R9 are independently H or CH3.
In further preferred embodiments, the invention provides compounds of Formula (ll-B), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is piperidin-4-yl, substituted on Λ/1 by R5A;
p is 0 and R2 is absent;
R2A is OH and R2B is H; or
R2A is OH and R2B is CH3; or
R2A is H and R2B is CH3; or
R3 is C1-C4 fluoroalkyl; or
R3 is C1-C2 fluoroalkyl; or
R3 is CF2H orCH2CF2H;
R4 is H;
R5Ais SO2R7;
R6 is absent; and
R7 is CH3.
In further preferred embodiments, the invention provides compounds of Formula (ll-B), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is piperidin-4-yl, substituted on Λ/1 by R5A;
p is 0 and R2 is absent;
R2A is H or OH and R2B is H or CH3; or
R2A is OH and R2B is H; or
R2A is OH and R2B is CH3; or
R2A is H and R2B is CH3; or
R2A is H and R2B is H;
R3 is H, F, Cl, CH3, CH2CH2OH, CF2H or CH2CF2H;
R4 is H;
R5Ais SO2R7, where R7 is CH3; or
R5A is SO2NR8R9, where R8 is H or CH3 and R9 is CH3; and
R6 is absent.
In another aspect, the invention provides a compound of Formula (III), (Ill-A), (III-
B) or(lll-C):
(lll-B) (lll-C) or a pharmaceutically acceptable sait thereof, where R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9 and p are defined as for Formula (I).
The embodiments described herein for Formula (I) with respect to R1, R2, R2A,
R2B, R3, R4, R5A, R5B, R6, R7, R8, R9 and p are also applicable to compounds of Formulae (III), (lll-A), (lll-B) and (lll-C) to the extent they are not inconsistent.
In certain preferred embodiments, the invention provides a compound of Formula (III), (lll-A), (lll-B) and (lll-C), or a pharmaceutically acceptable sait thereof, having two 10 or more of the following features:
R1 is 3-10 membered heterocyclyl substituted by R5A;
p is 0 and R2 is absent;
R2A and R2B are independently H, OH or C1-C4 alkyl;
R3 is H, F, Cl, C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH;
R4 is H;
R5A is SO2R7 or SO2NR8R9;
R6 is absent;
R7 is C1-C4 alkyl; and
R8 and R9 are independently H or C1-C4 alkyl.
In other embodiments, the invention provides a compound of Formula (III), (Ill-A), (Ill-B) and (Ill-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is 3-10 membered heterocyclyl substituted by R5A; or
R1 is 3-10 membered heterocyclyl substituted by R5A, where said 3-10 membered heterocyclyl is optionally further substituted by one or two R6;
p is 0 and R2 is absent; or p is 1 or 2, and each R2 is independently F, OH or CH3;
R2A and R2B are independently H, OH or C1-C4 alkyl, provided at least one of R2A and R2B is not H;
R3 is F, Cl, C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH; or
R3 is C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH; or
R3 is C1-C4 fluoroalkyl; or
R3 is C1-C2 fluoroalkyl;
R4 is H;
R5A is SO2R7 or SO2NR8R9;
R6 is absent; or each R6 is independently F or CH3;
R7 is C1-C4 alkyl; and
R8 and R9 are independently H or C1-C4 alkyl.
In other preferred embodiments, the invention provides a compound of Formula (III), (lll-A), (lll-B) and (Ill-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is 5-6 membered heterocyclyl substituted by R5A; or
R1 is 5-6 membered heterocyclyl substituted by R5A, where said 5-6 membered heterocyclyl is optionally further substituted by one or more R6;
p is 0 and R2 is absent;
R2A and R2B are independently H, OH or C1-C4 alkyl, provided at least one of R2A and R2B is not H;
R3 is F, Cl, C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH; or
R3 is C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH; or
R3 is C1-C4 fluoroalkyl; or
R3 is C1-C2 fluoroalkyl;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R6 is absent; or each R6 is independently F or CH3;
R7 is C1-C4 alkyl; and
R8 and R9 are independently H orCi-C4 alkyl.
In other preferred embodiments, the invention provides a compound of Formula (III), (ll-A), (lll-B) and (lll-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is piperidinyl, preferably piperidin-4-yl, substituted on Λ/1 by R5A;
p is 0 and R2 is absent;
R2A and R2B are independently H, OH or CH3;
R3 is H, F, Cl, CH3, CH2CH2OH, CF2H or CH2CF2H;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R6 is absent;
R7 is CH3; and
R8 and R9 are independently H or CH3.
In other preferred embodiments, the invention provides a compound of Formula (III), (lll-A), (lll-B) and (lll-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is piperidinyl, preferably piperidin-4-yl, substituted on Λ/1 by R5A;
p is 0 and R2 is absent;
R2A and R2B are independently H, OH or CH3, provided at least one of R2A and R2B is not H;
R3 is C1-C4 fluoroalkyl; or
R3 is C1-C2 fluoroalkyl; or
R3 is CF2H or CH2CF2H;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R6 is absent;
R7 is CH3; and
R8 and R9 are independently H or CH3.
In further preferred embodiments, the invention provides a compound of Formula (III), (lll-A), (lll-B) and (IIl-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is piperidinyl, preferably piperidin-4-yl, substituted on Λ/1 by R5A;
p is 0 and R2 is absent;
one of R2A and R2B is OH and the other is CH3; or one of R2A and R2B is OH and the other is H; or one of R2A and R2B is H and the other is CH3;
R3 is H, F, Cl, CH3, CH2CH2OH, CF2H or CH2CF2H;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R6 is absent;
R7 is CH3; and
R8 and R9 are independently H or CH3.
In another aspect, the invention provides a compound of Formula (IV), (IV-A), (IV-B) or (IV-C):
(IV)
(IV-A)
(IV-B) (IV-C) or a pharmaceutically acceptable sait thereof, where R1, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8 and R9 are defined as for Formula (I).
The embodiments described herein for Formula (I) with respect to R1, R2A, R2B, 5 R3, R4, R5A, R5B, R6, R7, R8 and R9 are also applicable to compounds of Formulae (IV), (IV-A), (IV-B) and (IV-C) to the extent they are not inconsistent.
In spécifie embodiments, the compounds of Formula (IV), (IV-A), (IV-B) and (IV-
C) hâve the structure:
(iv-b)
(iv-c)
(iv-f) (iv-g) or a pharmaceutically acceptable sait thereof, where R1, R3, R4, R5A, R5B, R6, R7, R8 and R9 are defined as for Formula (I).
In certain preferred embodiments, the invention provides a compound of Formula (IV), (IV-A), (IV-B) and (IV-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is 3-10 membered heterocyclyl substituted by R5A;
R2A and R2B are independently H, OH or C1-C4 alkyl;
R3 is H, F, Cl, C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R6 is absent;
R7 is C1-C4 alkyl; and
R8 and R9 are independently H or C1-C4 alkyl.
In another preferred embodiments, the invention provides a compound of Formula (IV), (IV-A), (IV-B) and (IV-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is 3-10 membered heterocyclyl substituted by R5A;
R2A and R2B are independently H, OH or C1-C4 alkyl, provided at least one of R2A and R2B is not H;
R3 is F, Cl, C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH; or
R3 is C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH; or
R3 is C1-C4 fluoroalkyl; or
R3 is C1-C2 fluoroalkyl; R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R6 is absent;
R7 is C1-C4 alkyl; and
R8 and R9 are independently H or C1-C4 alkyl.
In another preferred embodiments, the invention provides a compound of Formula (IV), (IV-A), (IV-B) and (IV-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features;
R1 is 5-6 membered heterocyclyl substituted by R5A;
R2A and R2B are independently H, OH or C1-C4 alkyl, provided at least one of R2A and R2B is not H;
R3 is F, Cl, C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH; or
R3 is C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH; or
R3 is C1-C4 fluoroalkyl; or
R3 is C1-C2 fluoroalkyl; R4 is H;
R5AisSO2R7 or SO2NR8R9;
R6 is absent;
R7 is C1-C4 alkyl; and
R8 and R9 are independently H or C1-C4 alkyl.
In other preferred embodiments, the invention provides a compound of Formula (IV), (IV-A), (IV-B) and (IV-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is piperidinyl, preferably piperidin-4-yl, substituted on Λ/1 by R5A;
R2A and R2B are independently H, OH or CH3;
R3 is H, F, Cl, CH3, CH2CH2OH, CF2H or CH2CF2H;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R6 is absent;
R7 is CH3; and
R8 and R9 are independently H or CH3.
In another preferred embodiments, the invention provides a compound of Formula (IV), (IV-A), (IV-B) and (IV-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is piperidinyl, preferably piperidin-4-yl, substituted on Λ/1 by R5A;
R2A and R2B are independently H, OH or CH3, provided at least one of R2A and R2B is not H;
R3 is C1-C4 fluoroalkyl; or
R3 is C1-C2 fluoroalkyl; or
R3 is CF2H orCH2CF2H;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R6 is absent;
R7 is CH3; and
R8 and R9 are independently H or CH3.
In further preferred embodiments, the invention provides a compound of Formula (IV), (IV-A), (IV-B) and (IV-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is piperidinyl, preferably piperidin-4-yl, substituted on Λ/1 by R5A;
one of R2A and R2B is OH and the other is CH3; or one of R2A and R2B is OH and the other is H; or one of R2A and R2B is H and the other is CH3;
R3 is H, F, Cl, CH3, CH2CH2OH, CF2H or CH2CF2H;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R6 is absent;
R7 is CH3; and
R8 and R9 are independently H or CH3.
In further preferred embodiments, the invention provides compounds of Formula (IV-B), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is piperidin-4-yl, substituted on Λ/1 by R5A;
R2A is OH and R2B is H; or
R2A is OH and R2B is CH3; or
R2A is H and R2B is CHs; or
R3 is C1-C4 fluoroalkyl; or
R3 is C1-C2 fluoroalkyl; or
R3 is CF2H orCH2CF2H;
R4 is H;
R5AisSO2R7;
R6 is absent; and
R7 is CH3.
In further preferred embodiments, the invention provides compounds of Formula (IV-B), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is piperidin-4-yl, substituted on Λ/1 by R5A;
R2A is H or OH and R2B is H or CH3; or
R2A is OH and R2B is H; or
R2A is OH and R2B is CH3; or
R2A is H and R2B is CH3; or
R2A is H and R2B is H;
R3 is H, F, Cl, CH3, CH2CH2OH, CF2H or CH2CF2H;
R4 is H;
R5A is SO2R7, where R7 is CH3; or
R5A is SO2NR8R9, where R8 is H or CH3 and R9 is CH3; and
R6 is absent.
In other preferred embodiments, the invention provides compounds of Formula (iv), (iv-a), (iv-b) or (iv-c), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is piperidin-4-yl, substituted on Λ/1 by R5A;
R3 is C1-C4 fluoroalkyl; or
R3 is C1-C2 fluoroalkyl; or
R3 is CF2H or CH2CF2H;
R4 is H;
R5A is SO2R7, where R7 is CH3; or
R5A is SO2NR8R9, where R8 is H or CH3 and R9 is CH3; and
R6 is absent.
In other preferred embodiments, the invention provides compounds of Formula (iv-f) or (iv-g), or a pharmaceutically acceptable sait thereof, wherein:
R1 is piperidin-4-yl, substituted on Λ/1 by R5A;
R5A is SO2R7, where R7 is CH3; or
R5A is SO2NR8R9’ where R8 is H or CH3 and R9 is CH3; and
R6 is absent.
In another aspect, the invention provides a compound of Formula (V), (V-A), (V-
B) or (V-C):
(V) (V-A)
R4 R4
(V-B) (V-C) or a pharmaceutically acceptable sait thereof, where R1. R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8 and R9 are defined as for Formula (I).
The embodiments described herein for Formula (I) with respect to R1, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8 and R9 are also applicable to compounds of Formulae (V), (V-A), (V-B) and (V-C) to the extent they are not inconsistent.
In spécifie embodiments, the compounds of Formula (V), (V-A), (V-B) and (V-C) hâve the structure:
(v-c)
(v-f) (v-g) or a pharmaceutically acceptable sait thereof, where R1, R3, R4, R5A, R5B,R6, R7, R8 and R9 are defined as for Formula (I).
In certain preferred embodiments, the invention provides a compound of Formula (V), (V-A), (V-B) and (V-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is 3-10 membered heterocyclyl substituted by R5A;
R2A and R2B are independently H, OH or C1-C4 alkyl;
R3 is H, F, Cl, C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH;
R4 is H;
R5A is SO2R7 or SO2NR8R9;
R6 is absent;
R7 is C1-C4 alkyl; and
R8 and R9 are independently H orCi-C4 alkyl.
In another preferred embodiments, the invention provides a compound of Formula (V), (V-A), (V-B) and (V-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is 3-10 membered heterocyclyl substituted by R5A; or
R1 is 3-10 membered heterocyclyl substituted by R5A, where said 3-10 membered heterocyclyl is optionally further substituted by one or two R6;
R2A and R2B are independently H, OH or C1-C4 alkyl, provided at least one of R2A and R2B is not H;
R3 is F, Cl, C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH; or
R3 is C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH; or
R3 is C1-C4 fluoroalkyl; or
R3 is C1-C2 fluoroalkyl;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R6 is absent; or each R6 is independently F or CH3;
R7 is C1-C4 alkyl; and
R8 and R9 are independently H or C1-C4 alkyl.
In another preferred embodiments, the invention provides a compound of Formula (V), (V-A), (V-B) and (V-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is 5-6 membered heterocyclyl substituted by R5A; or
R1 is 5-6 membered heterocyclyl substituted by R5A, where said 5-6 membered heterocyclyl is optionally further substituted by one or two R6;
R2A and R2B are independently H, OH or C1-C4 alkyl, provided at least one of R2A and R2B is not H;
R3 is F, Cl, C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH; or
R3 is C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH; or
R3 is C1-C4 fluoroalkyl; or
R3 is C1-C2 fluoroalkyl;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R6 is absent; or each R6 is independently F or CH3;
R7 is C1-C4 alkyl; and
R8 and R9 are independently H or C1-C4 alkyl.
In other preferred embodiments, the invention provides a compound of Formula (V), (V-A), (V-B) and (V-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is piperidinyl, preferably piperidin-4-yl, substituted on Λ/1 by R5A;
R2A and R2B are independently H, OH or CH3;
R3 is H, F, Cl, CH3, CH2CH2OH, CF2H or CH2CF2H;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R6 is absent;
R7 is CH3; and
R8 and R9 are independently H or CH3.
In another preferred embodiments, the invention provides a compound of Formula (V), (V-A), (V-B) and (V-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is piperidinyl, preferably piperidin-4-yl, substituted on Λ/1 by R5A;
R2A and R2B are independently H, OH or CH3, provided at least one of R2A and R2B is not H;
R3 is C1-C4 fluoroalkyl; or
R3 is C1-C2 fluoroalkyl; or
R3 is CF2H orCH2CF2H;
R4 is H;
R5Ais SO2R7 orS02NR8R9;
R6 is absent;
R7 is CH3; and
R8 and R9 are independently H orCHs.
In further preferred embodiments, the invention provides a compound of Formula (V), (V-A), (V-B) and (V-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R1 is piperidinyl, preferably piperidin-4-yl, substituted on Λ/1 by R5A;
one of R2A and R2B is OH and the other is CH3; or one of R2A and R2B is OH and the other is H; or one of R2A and R2B is H and the other is CH3;
R3 is H, F, Cl, CH3, CH2CH2OH, CF2H or CH2CF2H;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R6 is absent;
R7 is CH3; and
R8and R9are independently H orCHs.
In another aspect, the invention provides a compound of Formula (VI), (Vl-A), (Vl-B) or (Vl-C):
(VI) I (VI-A)
or a pharmaceutically acceptable sait thereof, where R2A, R2B, R3, R4, R5A, R7, R8 and R9 are defined as for Formula (I).
The embodiments described herein for Formula (I) with respect to R2A, R2B, R3,
R4, R5A, R5B,R6, R7, R8 and R9 are also applicable to compounds of Formulae (VI), (VI-
A), (Vl-B) and (Vl-C) to the extent they are not inconsistent.
In certain preferred embodiments, the invention provides a compound of Formula (VI), (Vl-A), (Vl-B) and (Vl-C), or a pharmaceutically acceptable sait thereof, having two 10 or more of the following features:
R2A and R2B are independently H, OH or C1-C4 alkyl;
R3 is H, F, Cl, C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R7 is C1-C4 alkyl; and
R8 and R9 are independently H or C1-C4 alkyl.
In other preferred embodiments, the invention provides a compound of Formula (VI), (Vl-A), (Vl-B) and (Vl-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R2A and R2B are independently H, OH or C1-C4 alkyl, provided at least one of R2A and R2B is not H;
R3 is C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH; or
R3 is C1-C4 fluoroalkyl; or
R3 is C1-C2 fluoroalkyl; or
R3 is CF2H or CH2CF2H;
R4 is H;
R5A is SO2R7 or SO2NR8R9;
R7 is C1-C4 alkyl; or
R7 is CH3; and
R8 and R9 are independently H orCi-C4 alkyl; or
R8 and R9 are independently H or CH3.
In other preferred embodiments, the invention provides a compound of Formula (VI), (Vl-A), (Vl-B) and (Vl-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R2A and R2B are independently H, OH or CH3;
R3 is H, F, Cl, CH3, CH2CH2OH, CF2H orCH2CF2H;
R4 is H;
R5A is SO2R7 or SO2NR8R9;
R7 is CH3; and
R8 and R9 are independently H or CH3.
In further preferred embodiments, the invention provides a compound of Formula (VI), (Vl-A), (Vl-B) and (Vl-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
one of R2A and R2B is OH and the other is CH3; or one of R2A and R2B is OH and the other is H; or one of R2A and R2B is H and the other is CH3;
R3 is H, F, Cl, CH3, CH2CH2OH, CF2H or CH2CF2H;
R4 is H;
R5A is SO2R7 or SO2NR8R9;
R7 is CHs; and
R8 and R9 are independently H orCHa.
In further preferred embodiments, the invention provides compounds of Formula (Vl-B), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R2A is H or OH and R2B is H or CH3; or
R2A is OH and R2B is H; or
R2A is OH and R2B is CH3; or
R2A is H and R2B is CH3; or
R2A is H and R2B is H;
R3 is H, F, Cl, CH3, CH2CH2OH, CF2H or CH2CF2H;
R4 is H; and
R5A is SO2R7, where R7 is CH3; or
R5A is SO2NR8R9· where R8 is H or CH3and R9 is CH3.
In further preferred embodiments, the invention provides compounds of Formula (Vl-B), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
one of R2A and R2B is OH and the other is CH3; or one of R2A and R2B is OH and the other is H; or one of R2A and R2B is H and the other is CH3; or
R2A is OH and R2B is H; or
R2A is OH and R2B is CH3; or
R2A is H and R2B is CH3;
R3 is C1-C4 fluoroalkyl; or
R3 is C1-C2 fluoroalkyl; or
R3 is CF2H orCH2CF2H;
R4 is H; and
R5AisSO2R7; and
R7 is CH3.
In another aspect, the invention provides a compound of Formula (VII), (Vll-A), (Vll-B) or(VII-C):
or a pharmaceutically acceptable sait thereof, where R2A, R2B, R3, R4, R5A, R7, R8 and R9 are defined as for Formula (I).
The embodiments described herein for Formula (I) with respect to R2A, R2B, R3,
R4, R5A, R7, R8 and R9 are also applicable to compounds of Formulae (VII), (Vll-A), (VUES) and (Vll-C) to the extent they are not inconsistent.
In certain preferred embodiments, the invention provides a compound of Formula (VII), (Vll-A), (Vll-B) and (Vll-C), or a pharmaceutically acceptable sait thereof, having 10 two or more of the following features:
R2A and R2B are independently H, OH or C1-C4 alkyl;
R3 is H, F, Cl, C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R7 is C1-C4 alkyl; and
R8 and R9 are independently H or C1-C4 alkyl.
In other preferred embodiments, the invention provides a compound of Formula (VII), (Vll-A), (Vll-B) and (Vll-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R2A and R2B are independently H, OH or C1-C4 alkyl, provided at least one of R2A and R2B is not H;
R3 is C1-C4 alkyl or C1-C4 fluoroalkyl, where said C1-C4 alkyl and C1-C4 fluoroalkyl are optionally substituted by OH; or
R3 is C1-C4 fluoroalkyl; or
R3 is C1-C2 fluoroalkyl; or
R3 is CF2H or CH2CF2H;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R7 is C1-C4 alkyl; or
R7 is CH3; and
R8 and R9 are independently H or C1-C4 alkyl; or
R8 and R9 are independently H or CH3.
In other preferred embodiments, the invention provides a compound of Formula (VII), (Vll-A), (Vll-B) and (Vll-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
R2A and R2B are independently H, OH or CH3;
R3 is H, F, Cl, CH3, CH2CH2OH, CF2H or CH2CF2H;
R4 is H;
R5Ais SO2R7 or SO2NR8R9;
R7 is CH3; and
R8 and R9 are independently H or CH3.
In further preferred embodiments, the invention provides a compound of Formula (VII), (Vll-A), (Vll-B) and (Vll-C), or a pharmaceutically acceptable sait thereof, having two or more of the following features:
one of R2A and R2B is OH and the other is CH3; or one of R2A and R2B is OH and the other is H; or one of R2A and R2B is H and the other is CH3;
R3 is H, F, Cl, CH3, CH2CH2OH, CF2H or CH2CF2H;
R4 is H;
R5A is SO2R7 or SO2NR8R9;
R7 is CH3; and
R8 and R9 are independently H or CH3.
In another aspect, the invention provides a compound selected from the group consisting of:
8-cyclopentyl-2-{[1-(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-cf]pyrimidin7(8/-/)-one;
8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-{[1-(methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)-one;
8-[(1R,3R)-3-hydroxycyclohexyl]-2-{[1-(methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-c/]pyrimidin-7(8/-/)-one;
4-({6-(2-hydroxyethyl)-8-[(1R,2S)-2-methylcyclopentyl]-7-oxo-7,8dihydropyrido[2,3-d]pyrimidin-2-yl}amino)-/\/-methylpipendine-1-sulfonamide;
(+)-6-fluoro-8-[(1R*,2R*)-2-hydroxy-2-methylcyclopentyl]-2-{[1(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-c(]pyrimidin-7(8H)-one;
(-)-6-fluoro-8-[(1R*,2R*)-2-hydroxy-2-methylcyclopentyl]-2-{[1(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)-one;
(+)-6-(2,2-difluoroethyl)-8-[(1 R*, 2R*)-2-hydroxy-2-methylcyclopentyl]-2-{[1(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)-one;
(-)-6-(2,2-difluoroethyl)-8-[(1/?*,2R*)-2-hydroxy-2-methylcyclopentyl]-2-{[1(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-c/]pyrimidin-7(8/-/)-one;
6-chloro-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-{[1(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)-one; and
6-(difluoromethyl)-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-{[1(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one;
or a pharmaceutically acceptable sait thereof.
In another aspect, the invention provides a compound selected from the group consisting of:
(-)-6-(difluoromethyl)-8-[(1R*,3R*)-3-hydroxycyclopentyl]-2-{[1-(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-c/]pyrimidin-7(8H)-one;
(+)-6-(difluoromethyl)-8-[(1R*,3R*)-3-hydroxycyclopentyl]-2-{[1-(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-c/]pyrimidin-7(8/-/)-one;
(8-cyclopentyl-2-{[1-(methylsulfonyl)piperidin-4-yl]amino}-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)acetonitrile;
8-cyclopentyl-6-(2-hydroxyethyl)-2-{[1-(propan-2-ylsulfonyl)piperidin-4yl]amino}pyrido[2,3-c/]pyrimidin-7(8/-/)-one;
6-amino-2-{[1-(but-3-yn-1-ylsulfonyl)piperidin-4-yl]amino}-8-cyclopentylpyrido[2,3-
d]pyrimidin-7(8/-/)-one;
8-cyclopentyl-6-ethenyl-2-{[1-(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-
d]pyrimidin-7(8H)-one;
8-cyclopentyl-2-{[1-(methylsulfonyl)piperidin-4-yl]amino}-6-(prop-2-en-1yl)pyrido[2,3-d]pyrimidin-7(8/-/)-one; and
6-(2,2-difluoroethyl)-8-[(1R,3R)-3-hydroxycyclohexyl]-2-{[1-(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-c/]pyrimidin-7(8H)-one;
or a pharmaceutically acceptable sait thereof.
In another aspect, the invention provides a compound selected from the group consisting of the compounds exemplified in Table 1, comprising Examples 11-132 and 141-226, inclusive, or a pharmaceutically acceptable sait thereof. In another aspect, the invention provides a compound selected from the group consisting of the compounds exemplified in Examples 1 to 226 herein, or a pharmaceutically acceptable sait thereof.
The compounds of the invention were optimized for selectivity against CDK2 versus CDK1. Preferably, compounds showed at least 20-fold selectivity for CDK2 versus CDK1, and more preferably, compounds showed at least 30-fold selectivity for CDK2 versus CDK1. Compounds of the invention were also optimized to enhance physicochemical properties, such as increased aqueous solubility and decreased clearance in human liver microsome (HLM) models.
A pharmaceutical composition refers to a mixture of one or more of the compounds described herein, or a pharmaceutically acceptable sait, solvaté, hydrate or prodrug thereof as an active ingrédient, and at least one pharmaceutically acceptable carrier or excipient. In some embodiments, the pharmaceutical composition comprises two or more pharmaceutically acceptable carriers and/or excipients. In other embodiments, the pharmaceutical composition further comprises at least one additional anticancer therapeutic agent.
In another aspect the invention provides a pharmaceutical composition comprising a compound of one of the formulae described herein, or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier or excipient. In some embodiments, the pharmaceutical composition comprises two or more pharmaceutically acceptable carriers and/or excipients.
In some embodiments, the pharmaceutical composition further comprises at least one additional anti-cancer therapeutic agent or a palliative agent. In some such embodiments, the at least one additional agent is an anti-cancer therapeutic agent as described below. In some such embodiments, the combination provides an additive, greater than additive, or synergistic anti-cancer effect.
In one aspect, the invention provides a method for the treatment of abnormal cell growth in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable sait thereof.
In another aspect, the invention provides a method for the treatment of abnormal cell growth in a subject in need thereof, comprising administering to the subject an amount of a compound of the invention, or a pharmaceutically acceptable sait thereof, in combination with an amount of an additional therapeutic agent (e.g., an anticancer therapeutic agent), which amounts are together effective in treating said abnormal cell growth.
In frequent embodiments of the methods provided herein, the abnormal cell growth is cancer._Compounds of the invention may be administered as single agents, or may be administered in combination with other anti-cancer therapeutic agents, in particular standard of care agents appropriate for the particular cancer.
In some embodiments, the methods provided resuit in one or more of the following effects: (1) inhibiting cancer cell prolifération; (2) inhibiting cancer cell invasiveness; (3) inducing apoptosis of cancer cells; (4) inhibiting cancer cell metastasis; or (5) inhibiting angiogenesis.
In another aspect, the invention provides a method for the treatment of a disorder mediated by CDK2, CDK4 and/or CDK6, in a subject, such as certain cancers, comprising administering to the subject a compound of the invention, or a pharmaceutically acceptable sait thereof, in an amount that is effective for treating said disorder.
Unless indicated otherwise, ail référencés herein to the inventive compounds include référencés to salts, solvatés, hydrates and complexes thereof, and to solvatés, hydrates and complexes of salts thereof, including polymorphs, stereoisomers, and isotopically labelled versions thereof.
Compounds of the invention may exist in the form of pharmaceutically acceptable salts such as, e.g., acid addition salts and base addition salts of the compounds of one of the formulae provided herein. As used herein, the term “pharmaceutically acceptable sait” refers to those salts which retain the biological effectiveness and properties of the parent compound. The phrase “pharmaceutically acceptable salt(s)”, as used herein, unless otherwise indicated, includes salts of acidic or basic groups which may be présent in the compounds of the formulae disclosed herein.
For example, the compounds of the invention that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animais, it is often désirable in practice to initially isolate the compound of the présent invention from the reaction mixture as a pharmaceutically unacceptable sait and then simply couvert the latter back to the free base compound by treatment with an alkaline reagent and subsequently couvert the latter free base to a pharmaceutically acceptable acid addition sait. The acid addition salts of the base compounds of this invention can be prepared by treating the base compound with a substantially équivalent amount of the selected minerai or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or éthanol. Upon évaporation of the solvent, the desired solid sait is obtained. The desired acid sait can also be precipitated from a solution of the free base in an organic solvent by adding an appropriate minerai or organic acid to the solution.
The acids that may be used to préparé pharmaceutically acceptable acid addition salts of such basic compounds of those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1’-methylene-bis-(2-hydroxy-3-naphthoate)] salts.
Examples of salts include, but are not limited to, acetate, acrylate, benzenesulfonate, benzoate (such as chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, and methoxybenzoate), bicarbonate, bisulfate, bisulfite, bitartrate, borate, bromide, butyne-1,4-dioate, calcium edetate, camsylate, carbonate, chloride, caproate, caprylate, clavulanate, citrate, decanoate, dihydrochloride, dihydrogenphosphate, edetate, edislyate, estolate, esylate, ethylsuccinate, formate, fumarate, gluceptate, gluconate, glutamate, glycollate, glycollylarsanilate, heptanoate, hexyne-1,6-dioate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, γ-hydroxybutyrate, iodide, isobutyrate, isothionate, lactate, lactobionate, laurate, malate, maleate, malonate, mandelate, mesylate, metaphosphate, methane-sulfonate, methylsulfate, monohydrogenphosphate, mucate, napsylate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, nitrate, oleate, oxalate, pamoate (embonate), palmitate, pantothenate, phenylacetates, phenylbutyrate, phenylpropionate, phthalate, phospate/diphosphate, polygalacturonate, propanesulfonate, propionate, propiolate, pyrophosphate, pyrosulfate, salicylate, stéarate, subacetate, suberate, succinate, sulfate, sulfonate, sulfite, tannate, tartrate, teoclate, tosylate, triethiodode and valerate salts.
Illustrative examples of suitable salts include organic salts derived from amino acids, such as glycine and arginine, ammonia, primary, secondary, and tertiary amines and cyclic amines, such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnésium, manganèse, iron, copper, zinc, aluminum and lithium.
The compounds of the invention that include a basic moiety, such as an amino group, may form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above.
Those compounds of the invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali métal or alkaline-earth métal salts and particularly, the sodium and potassium salts. These salts are ail prepared by conventional techniques. The chemical bases which are used as reagents to préparé the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds herein. These salts may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali métal hydroxide or alkaline earth métal hydroxide, or the like. These salts can also be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali métal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product.
The chemical bases that may be used as reagents to préparé pharmaceutically acceptable base salts of the compounds of the invention that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to, those derived from such pharmacologically acceptable cations such as alkali métal cations (e.g., potassium and sodium) and alkaline earth métal cations (e.g., calcium and magnésium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines.
Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.
For a review on suitable salts, see Handbook of Pharmaceutical Salts: Properties, Sélection, and Use by Stahl and Wermuth (Wiley-VCH, 2002). Methods for making pharmaceutically acceptable salts of compounds of the invention are known to one of skill in the art.
Salts of the présent invention can be prepared according to methods known to those of skill in the art. A pharmaceutically acceptable sait of the inventive compounds can be readily prepared by mixing together solutions of the compound and the desired acid or base, as appropriate. The sait may precipitate from solution and be collected by filtration or may be recovered by évaporation of the solvent. The degree of ionization in the sait may vary from completely ionized to almost non-ionized.
It will be understood by those of skill in the art that the compounds of the invention in free base form having a basic functionality may be converted to the acid addition salts by treating with a stoichiometric excess of the appropriate acid. The acid addition salts of the compounds of the invention may be reconverted to the corresponding free base by treating with a stoichiometric excess of a suitable base, such as potassium carbonate or sodium hydroxide, typically in the presence of aqueous solvent, and at a température of between about 0° C and 100° C. The free base form may be isolated by conventional means, such as extraction with an organic solvent. In addition, acid addition salts of the compounds of the invention may be interchanged by taking advantage of differential solubilities of the salts, volatilities or acidities of the acids, or by treating with the appropriately loaded ion exchange resin. For example, the interchange may be affected by the reaction of a sait of the compounds of the invention with a slight stoichiometric excess of an acid of a lower pK than the acid component of the starting sait. This conversion is typically carried out at a température between about 0°C and the boiling point of the solvent being used as the medium for the procedure. Similar exchanges are possible with base addition salts, typically via the intermediacy of the free base form.
The compounds of the invention may exist in both unsolvated and solvated forms. When the solvent or water is tightly bound, the complex will hâve a well-defined stoichiometry independent of humidity. When, however, the solvent or water is weakly bound, as in channel solvatés and hygroscopic compounds, the water/solvent content will be dépendent on humidity and drying conditions. In such cases, non-stoichiometry will be the norm. The term ‘solvaté’ is used herein to describe a molecular complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molécules, for example, éthanol. The term ‘hydrate’ is employed when the solvent is water. Pharmaceutically acceptable solvatés in accordance with the invention include hydrates and solvatés wherein the solvent of crystallization may be isotopically substituted, e.g. D2O, de-acetone, de-DMSO.
Also included within the scope of the invention are complexes such as clathrates, drug-host inclusion complexes wherein, in contrast to the aforementioned solvatés, the drug and host are présent in stoichiometric or non-stoichiometric amounts. Also included are complexes of the drug containing two or more organic and/or inorganic components which may be in stoichiometric or non-stoichiometric amounts. The resulting complexes may be ionized, partially ionized, or non-ionized. For a review of such complexes, see J Pharm Sci, 64 (8), 1269-1288 by Haleblian (August 1975), the disclosure of which is incorporated herein by reference in its entirety.
The invention also relates to prodrugs of the compounds of the formulae provided herein. Thus, certain dérivatives of compounds of the invention which may hâve little or no pharmacological activity themselves can, when administered to a patient, be converted into the inventive compounds, for example, by hydrolytic cleavage. Such dérivatives are referred to as ‘prodrugs’. Further information on the use of prodrugs may be found in ‘Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Sériés (T Higuchi and W Stella) and ‘Bioreversible Carriers in Drug Design’, Pergamon Press, 1987 (ed. E B Roche, American Pharmaceutical Association), the disclosures of which are incorporated herein by reference in their entireties.
Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities présent in the inventive compounds with certain moieties known to those skilled in the art as ‘pro-moieties’ as described, for example, in Design of Prodrugs by H Bundgaard (Elsevier, 1985), the disclosure of which is incorporated herein by reference in its entirety.
Some non-limiting examples of prodrugs in accordance with the invention include:
(i) where the compound contains a carboxylic acid functionality (-COOH), an ester thereof, for example, replacement of the hydrogen with (Ci-Cs)alkyl;
(ii) where the compound contains an alcohol functionality (-OH), an ether thereof, for example, replacement of the hydrogen with (Ci-C6)alkanoyloxymethyl, or with a phosphate ether group; and (iii) where the compound contains a primary or secondary amino functionality (-NH2 or -NHR where R Ψ H), an amide thereof, for example, replacement of one or both hydrogens with a suitably metabolically labile group, such as an amide, carbamate, urea, phosphonate, sulfonate, etc.
Further examples of replacement groups in accordance with the foregoing examples and examples of other prodrug types may be found in the aforementioned references.
Finally, certain inventive compounds may themselves act as prodrugs of other of the inventive compounds.
Also included within the scope of the invention are métabolites of compounds of the formulae described herein, Le., compounds formed in vivo upon administration of the drug.
The compounds of the formulae provided herein may hâve asymmetric carbon atoms. The carbon-carbon bonds of the compounds of the invention may be depicted herein using a solid line (-----), a solid wedge C”^-), or a dotted wedge ( — 'iii)
The use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that ail possible stereoisomers (e.g. spécifie enantiomers, racemic mixtures, etc.) at that carbon atom are included. The use of either a solid or dotted wedge to depict bonds to asymmetric carbon atoms is meant to indicate that only the stereoisomer shown is meant to be included. It is possible that compounds of the invention may contain more than one asymmetric carbon atom. In those compounds, the use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that ail possible stereoisomers are meant to be included and the attached stereocenter. For example, unless stated otherwise, it is intended that the compounds of the invention can exist as enantiomers and diastereomers or as racemates and mixtures thereof. The use of a solid line to depict bonds to one or more asymmetric carbon atoms in a compound of the invention and the use of a solid or dotted wedge to depict bonds to other asymmetric carbon atoms in the same compound is meant to indicate that a mixture of diastereomers is présent.
Compounds of the invention that hâve chiral centers may exist as stereoisomers, such as racemates, enantiomers, or diastereomers.
Stereoisomers of the compounds of the formulae herein can include cis and trans isomers, optical isomers such as (R) and (S) enantiomers, diastereomers, géométrie isomers, rotational isomers, atropisomers, conformational isomers, and tautomers of the compounds of the invention, including compounds exhibiting more than one type of isomerism; and mixtures thereof (such as racemates and diastereomeric pairs).
Also included are acid addition or base addition salts wherein the counterion is optically active, for example, d-lactate or l-lysine, or racemic, for example, dl-tartrate or dl-arginine.
When any racemate crystallizes, crystals of two different types are possible. The first type is the racemic compound (true racemate) referred to above wherein one homogeneous form of crystal is produced containing both enantiomers in equimolar amounts. The second type is the racemic mixture or conglomerate wherein two forms of crystal are produced in equimolar amounts each comprising a single enantiomer.
The compounds of the invention may exhibit the phenomena of tautomerism and structural isomerism. For example, the compounds may exist in several tautomeric forms, including the enol and imine form, and the keto and enamine form and géométrie isomers and mixtures thereof. Ail such tautomeric forms are included within the scope of compounds of the invention. Tautomers exist as mixtures of a tautomeric set in solution. In solid form, usually one tautomer prédominâtes. Even though one tautomer may be described, the présent invention includes ail tautomers of the compounds of the formulae provided.
In addition, some of the compounds of the invention may form atropisomers (e.g., substituted biaryls). Atropisomers are conformational stereoisomers which occur when rotation about a single bond in the molécule is prevented, or greatly slowed, as a resuit of steric interactions with other parts of the molécule and the substituents at both ends of the single bond are unsymmetrical. The interconversion of atropisomers is slow enough to allow séparation and isolation under predetermined conditions. The energy barrier to thermal racemization may be determined by the steric hindrance to free rotation of one or more bonds forming a chiral axis.
Where a compound of the invention contains an alkenyl or alkenylene group, géométrie cis/trans (or Z/E) isomers are possible. Cis/trans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallization.
Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a sait or dérivative) using, for example, chiral high pressure liquid chromatography (HPLC) or superfluid critical chromatography (SFC).
Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound contains an acidic or basic moiety, an acid or base such as tartaric acid or
1-phenylethylamine. The resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to one skilled in the art.
Chiral compounds of the invention (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% isopropanol, typically from 2 to 20%, and from 0 to 5% of an alkylamine, typically 0.1% diethylamine. Concentration of the eluate affords the enriched mixture.
Stereoisomeric conglomérâtes may be separated by conventional techniques known to those skilled in the art; see, for example, “Stereochemistry of Organic Compounds” by E L Eliel (Wiley, New York, 1994), the disclosure of which is incorporated herein by reference in its entirety.
The enantiomeric purity of compounds described herein may be described in terms of enantiomeric excess (ee), which indicates the degree to which a sample contains one enantiomer in greater amounts than the other. A racemic mixture has an ee of 0%, while a single completely pure enantiomer has an ee of 100%. Similarly, diastereomeric purity may be described in terms of diasteriomeric excess (de).
The présent invention also includes isotopically-labeled compounds, which are identical to those recited in one of the formulae provided, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.
Examples of isotopes that may be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as, but not limited to, 2H, 3H, 13C, 14C, 15N, 18O, 170,31P, 32P, 35S, 18F, and 36CI. Certain isotopically-labeled compounds of the invention, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of préparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically-labeled compounds of the invention may generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples and Préparations below, by substituting an isotopically-labeled reagent for a non-isotopically-labeled reagent.
Compounds of the invention intended for pharmaceutical use may be administered as crystalline or amorphous products, or mixtures thereof. They may be obtained, for example, as solid plugs, powders, or films by methods such as précipitation, crystallization, freeze drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose.
Therapeutic Methods and Uses
The invention further provides therapeutic methods and uses comprising administering the compounds of the invention, or pharmaceutically acceptable salts thereof, alone or in combination with other therapeutic agents or palliative agents.
In one aspect, the invention provides a method for the treatment of abnormal cell growth in a subject comprising administering to the subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable sait thereof. In frequent embodiments, the abnormal cell growth is cancer.
In another aspect, the invention provides a method for the treatment of cancer in a subject comprising administering to the subject an amount of a compound of the invention, or a pharmaceutically acceptable sait thereof, in combination with an amount of an additional anticancer therapeutic agent, which amounts are together effective in treating said cancer.
Compounds of the invention include compounds of any of the formulae described herein, or a pharmaceutically acceptable sait thereof.
In still another aspect, the invention provides a method of inhibiting cancer cell prolifération in a subject, comprising administering to the subject a compound of the invention, or a pharmaceutically acceptable sait thereof, in an amount effective to inhibit cell prolifération.
In another aspect, the invention provides a method of inhibiting cancer cell invasiveness in a subject, comprising administering to the subject a compound of the invention, or a pharmaceutically acceptable sait thereof, in an amount effective to inhibit cell invasiveness.
In another aspect, the invention provides a method of inducing apoptosis in cancer cells in a subject, comprising administering to the subject a compound of the invention, or a pharmaceutically acceptable sait thereof, in an amount effective to induce apoptosis.
In frequent embodiments of the methods provided herein, the abnormal cell growth is cancer characterized by amplification or overexpression of CCNE1 and/or CCNE2. In some embodiments of the methods provided herein, the subject is identified as having a cancer characterized by amplification or overexpression of CCNE1 and/or CCNE2.
In frequent embodiments of the methods provided herein, the abnormal cell growth is cancer, wherein the cancer is selected from the group consisting of breast cancer, ovarîan cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer (including NSCLC, SCLC, squamous cell carcinoma or adenocarcinoma), esophageal cancer, head and neck cancer, colorectal cancer, kidney cancer (including RCC), liver cancer (including HCC), pancreatic cancer, stomach (Le., gastric) cancer and thyroid cancer. In further embodiments of the methods provided herein, the cancer is selected from the group consisting of breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer, esophageal cancer, liver cancer, pancreatic cancer and stomach cancer. In some such embodiments, the cancer is characterized by amplification or overexpression of CCNE1 and/orCCNE2.
In some embodiments, the cancer is selected from the group consisting of breast cancer and ovarian cancer. In some such embodiments, the cancer is breast cancer or ovarian cancer characterized by amplification or overexpression of CCNE1 and/or CCNE2. In some such embodiments, the cancer is (a) breast cancer or ovarian cancer;
(b) characterized by amplification or overexpression of cyclin E1 (CCNE1) or cyclin E2 (CCNE2); or (c) both (a) and (b).
In some embodiments, the cancer is ovarian cancer. In some such embodiments, the ovarian cancer is characterized by amplification or overexpression of CCNE1 and/or CCNE2.
In other embodiments, the cancer is breast cancer, including, e.g., ERpositiive/HR-positive breast cancer, HER2-negative breast cancer; ER-positiive/HRpositive breast cancer, HER2-positive breast cancer; triple négative breast cancer (TNBC); or inflammatory breast cancer. In some embodiments, the breast cancer is endocrine résistant breast cancer, trastuzumab résistant breast cancer, or breast cancer demonstrating primary or acquired résistance to CDK4/CDK6 inhibition. In some embodiments, the breast cancer is advanced or metastatic breast cancer. In some embodiments of each of the foregoing, the breast cancer is characterized by amplification or overexpression of CCNE1 and/or CCNE2.
In some embodiments, the compound of the invention is administered as first line therapy. In other embodiments, the compound of the invention is administered as second (or later) line therapy. In some embodiments, the compound of the invention is administered as second (or later) line therapy following treatment with an endocrine therapeutic agent and/or a CDK4/CDK6 inhibitor. In some embodiments, the compound of the invention is administered as second (or later) line therapy following treatment with an endocrine therapeutic agent. In some embodiments, the compound of the invention is administered as second (or later) line therapy following treatment with a CDK4/CDK6 inhibitor. In some embodiments, the compound of the invention is administered as second (or later) line therapy following treatment with one or more chemotherapy regimens, e.g., including taxanes or platinum agents. In some embodiments, the compound of the invention is administered as second (or later) line therapy following treatment with HER2 targeted agents, e.g., trastuzumab. The term therapeutically effective amount as used herein refers to that amount of a compound being administered which will relieve to some extent one or more of the symptoms of the disorder being treated. In reference to the treatment of cancer, a therapeutically effective amount refers to that amount which has the effect of (1) reducing the size of the tumor, (2) inhibiting (that is, slowing to some extent, preferably stopping) tumor metastasis, (3) inhibiting to some extent (that is, slowing to some extent, preferably stopping) tumor growth or tumor invasiveness, and/or (4) relieving to some extent (or, preferably, eliminating) one or more signs or symptoms associated with the cancer.
As used herein, subject refers to a human or animal subject. In certain preferred embodiments, the subject is a human.
The term treating, as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term treatment, as used herein, unless otherwise indicated, refers to the act of treating as treating is defined immediately above. The term “treating” also includes adjuvant and neo-adjuvant treatment of a subject.
The terms “abnormal cell growth” and “hyperproliferative disorder” are used interchangeably in this application.
“Abnormal cell growth”, as used herein, unless otherwise indicated, refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition). Abnormal cell growth may be benign (not cancerous), or malignant (cancerous).
Abnormal cell growth includes the abnormal growth of: (1) tumor cells (tumors) that show increased expression of CDK2; (2) tumors that proliferate by aberrant CDK2 activation; (3) tumors characterized by amplification or overexpression of CCNE1 and/or CCNE2; and (4) tumors that are résistant to endocrine therapy, HER2 antagonists or CDK4/6 inhibition.
The term “additional anticancer therapeutic agent” as used herein means any one or more therapeutic agent, other than a compound of the invention, that is or can be used in the treatment of cancer, such as agents derived from the following classes: mitotic inhibitors, alkylating agents, antimetabolites, antitumor antibiotics, topoisomerase I and II inhibitors, plant alkaloids, hormonal agents and antagonists, growth factor inhibitors, radiation, inhibitors of protein tyrosine kinases and/or serine/threonine kinases, cell cycle inhibitors, biological response modifiers, enzyme inhibitors, antisense oligonucleotides or oligonucleotide dérivatives, cytotoxics, and immuno-oncology agents.
As used herein “cancer” refers to any malignant and/or invasive growth or tumor caused by abnormal cell growth. Cancer includes solid tumors named for the type of cells that form them, cancer of blood, bone marrow, or the lymphatic System. Examples of solid tumors include sarcomas and carcinomas. Cancers of the blood include, but are not limited to, leukemia, lymphoma and myeloma. Cancer also includes primary cancer that originates at a spécifie site in the body, a metastatic cancer that has spread from the place in which it started to other parts of the body, a récurrence from the original primary cancer after remission, and a second primary cancer that is a new primary cancer in a person with a history of previous cancer of a different type from the latter one.
In some embodiments of the methods provided herein, the cancer is selected from the group consisting of breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer, esophageal cancer, liver cancer, pancreatic cancer and stomach cancer. In some such embodiments, the cancer is characterized by amplification or overexpression of CCNE1 and/or CCNE2.
Dosage Forms and Reqimens
Administration of the compounds of the invention may be effected by any method that enables delivery of the compounds to the site of action. These methods include oral routes, intraduodenal routes, parentéral injection (including intravenous, subeutaneous, intramuscular, intravascular or infusion), topical, and rectal administration.
Dosage regimens may be adjusted to provide the optimum desired response. For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parentéral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form, as used herein, refers to physically discrète units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The spécification for the dosage unit forms of the invention are dictated by and directly dépendent on (a) the unique characteristics of the chemotherapeutic agent and the particular therapeutic or prophylactic effect to be achieved, and (b) the limitations inhérent in the art of compounding such an active compound for the treatment of sensitivity in individuals.
Thus, the skilled artisan would appreciate, based upon the disclosure provided herein, that the dose and dosing regimen is adjusted in accordance with methods well-known in the therapeutic arts. That is, the maximum tolerable dose can be readily established, and the effective amount providing a détectable therapeutic benefit to a patient may also be determined, as can the temporal requirements for administering each agent to provide a détectable therapeutic benefit to the patient. Accordingly, while certain dose and administration regimens are exemplified herein, these examples in no way limit the dose and administration regimen that may be provided to a patient in practicing the présent invention.
It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated, and may include single or multiple doses. It is to be further understood that for any particular subject, spécifie dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition. For example, doses may be adjusted based on pharmacokinetic or pharmacodynamie parameters, which may include clinical effects such as toxic effects and/or laboratory values. Thus, the présent invention encompasses intra-patient dose-escalation as determined by the skilled artisan. Determining appropriate dosages and regimens for administration of the chemotherapeutic agent are well-known in the relevant art and would be understood to be encompassed by the skilled artisan once provided the teachings disclosed herein.
The amount of the compound of the invention administered will be dépendent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discrétion of the prescribing physician. However, an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to about 7 g/day, preferably about 0.1 to about 2.5 g/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adéquate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.
Formulations and Routes of Administration
As used herein, a pharmaceutically acceptable carrier refers to a carrier or diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
The pharmaceutical acceptable carrier may comprise any conventional pharmaceutical carrier or excipient. The choice of carrier and/or excipient will to a large extent dépend on factors such as the particular mode of administration, the effect of the carrier or excipient on solubility and stability, and the nature of the dosage form.
Suitable pharmaceutical carriers include inert diluents or fillers, water and various organic solvents (such as hydrates and solvatés). The pharmaceutical compositions may, if desired, contain additional ingrédients such as flavorings, binders, excipients and the like. Thus for oral administration, tablets containing various excipients, such as citric acid may be employed together with various disintegrants such as starch, alginic acid and certain complex silicates and with binding agents such as sucrose, gelatin and acacia. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose dérivatives, gelatin, vegetable oils and polyethylene glycols. Additionally, lubricating agents such as magnésium stéarate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed in soft and hard filled gelatin capsules. Non-limiting examples of materials, therefore, include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or élixirs are desired for oral administration the active compound therein may be combined with various sweetening or flavoring agents, coloring matters or dyes and, if desired, emulsifying agents or suspending agents, together with diluents such as water, éthanol, propylene glycol, glycerin, or combinations thereof.
The pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution suspension, for parentéral injection as a stérile solution, suspension or émulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
Exemplary parentéral administration forms include solutions or suspensions of active compounds in stérile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms may be suitably buffered, if desired.
The pharmaceutical composition may be in unit dosage forms suitable for single administration of précisé dosages.
Pharmaceutical compositions suitable for the delivery of compounds of the invention and methods for their préparation will be readily apparent to those skilled in the art. Such compositions and methods for their préparation can be found, for example, in ‘Remington’s Pharmaceutical Sciences’, 19th Edition (Mack Publishing Company, 1995), the disclosure of which is incorporated herein by reference in its entirety.
The compounds of the invention may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth.
Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi- and nano-particulates, gels, solid solution, liposome, films (including muco-adhesive), ovules, sprays and liquid formulations.
Liquid formulations include suspensions, solutions, syrups and élixirs. Such formulations may be used as fillers in soft or hard capsules and typically include a carrier, for example, water, éthanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
The compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11 (6), 981-986 by Liang and Chen (2001), the disclosure of which is incorporated herein by reference in its entirety.
For tablet dosage forms, depending on dose, the drug may make up from 1 wt% to 80 wt% of the dosage form, more typically from 5 wt% to 60 wt% of the dosage form. In addition to the drug, tablets generally contain a disintegrant. Examples of disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinized starch and sodium alginate. Generally, the disintegrant will comprise from 1 wt% to 25 wt%, preferably from 5 wt% to 20 wt% of the dosage form.
Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinized starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose. Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate.
Tablets may also optionally include surface active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc. When présent, surface active agents are typically in amounts of from 0.2 wt% to 5 wt% of the tablet, and glidants typically from 0.2 wt% to 1 wt% of the tablet.
Tablets also generally contain lubricants such as magnésium stéarate, calcium stéarate, zinc stéarate, sodium stearyl fumarate, and mixtures of magnésium stéarate with sodium lauryl sulphate. Lubricants generally are présent in amounts from 0.25 wt% to 10 wt%, preferably from 0.5 wt% to 3 wt% of the tablet.
Other conventional ingrédients include anti-oxidants, colorants, flavoring agents, preservatives and taste-masking agents.
Exemplary tablets contain up to about 80 wt% drug, from about 10 wt% to about 90 wt% binder, from about 0 wt% to about 85 wt% diluent, from about 2 wt% to about 10 wt% disintegrant, and from about 0.25 wt% to about 10 wt% lubricant.
Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded before tableting. The final formulation may include one or more layers and may be coated or uncoated; or encapsulated.
The formulation of tablets is discussed in detail in “Pharmaceutical Dosage Forms: Tablets, Vol. 1”, by H. Lieberman and L. Lachman, Marcel Dekker, N.Y., N.Y., 1980 (ISBN 0-8247-6918-X), the disclosure of which is incorporated herein by reference in its entirety.
Solid formulations for oral administration may be formulated to be immédiate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
Suitable modifiée! release formulations are described in U.S. Patent No. 6,106,864. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles can be found in Verma et al, Pharmaceutical Technology On-line, 25(2), 1-14 (2001). The use of chewing gum to achieve controlled release is described in WO 00/35298. The disclosures of these references are incorporated herein by reference in their entireties.
Parentéral Administration
The compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internai organ. Suitable means for parentéral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subeutaneous. Suitable devices for parentéral administration include needle (including micro needle) injectors, needle-free injectors and infusion techniques.
Parentéral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a stérile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as stérile, pyrogen-free water.
The préparation of parentéral formulations under stérile conditions, for example, by lyophilization, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
The solubility of compounds of the invention used in the préparation of parentéral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.
Formulations for parentéral administration may be formulated to be immédiate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release. Thus compounds of the invention may be formulated as a solid, semi-solid, or thixotropic liquid for administration as an implanted depot providing modified release of the active compound. Examples of such formulations include drug-coated stents and PGLA microspheres.
The compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibers, bandages and microemulsions. Liposomes may also be used. Typical carriers include alcohol, water, minerai oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol. Pénétration enhancers may be incorporated; see, for example, J Pharm Sci, 88 (10), 955-958 by Finnin and Morgan (October 1999). Other means of topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and micro needle or needle-free (e.g. Powderject™, Bioject™, etc.) injection. The disclosures of these references are incorporated herein by reference in their entireties.
Formulations for topical administration may be formulated to be immédiate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
The compounds of the invention can also be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aérosol spray from a pressurized container, pump, spray, atomizer (preferably an atomizer using electrohydrodynamics to produce a fine mist), or nebulizer, with or without the use of a suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane. For intranasal use, the powder may include a bioadhesive agent, for example, chitosan or cyclodextrin.
The pressurized container, pump, spray, atomizer, or nebulizer contains a solution or suspension of the compound(s) of the invention comprising, for example, éthanol, aqueous éthanol, or a suitable alternative agent for dispersing, solubilizing, or extending release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
Prior to use in a dry powder or suspension formulation, the drug product is micronized to a size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenization, or spray drying.
Capsules (made, for example, from gelatin or HPMC), blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as l-leucine, mannitol, or magnésium stéarate. The lactose may be anhydrous or in the form of the monohydrate, preferably the latter. Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.
A suitable solution formulation for use in an atomizer using electrohydrodynamics to produce a fine mist may contain from 1pg to 20mg of the compound of the invention per actuation and the actuation volume may vary from 1μΙ_ to 100μΙ_. A typical formulation includes a compound of the invention, propylene glycol, stérile water, éthanol and sodium chloride. Alternative solvents which may be used instead of propylene glycol include glycerol and polyethylene glycol.
Suitable flavors, such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations of the invention intended for inhaled/intranasal administration.
Formulations for inhaled/intranasal administration may be formulated to be immédiate and/or modified release using, for example, poly(DL-lactic-coglycolic acid (PGLA). Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
In the case of dry powder inhalers and aérosols, the dosage unit is determined by means of a valve which delivers a metered amount. Units in accordance with the invention are typically arranged to administer a metered dose or “puff” containing a desired mount of the compound of the invention. The overall daily dose may be administered in a single dose or, more usually, as divided doses throughout the day.
Compounds of the invention may be administered rectally or vaginally, for example, in the form of a suppository, pessary, or enema. Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.
Formulations for rectal/vaginal administration may be formulated to be immédiate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
Compounds of the invention may also be administered directly to the eye or ear, typically in the form of drops of a micronized suspension or solution in isotonie, pH-adjusted, stérile saline. Other formulations suitable for ocular and aurai administration include ointments, biodégradable (e.g. absorbable gel sponges, collagen) and non-biodegradable (e.g. silicone) implants, wafers, lenses and particulate or vesicular Systems, such as niosomes or liposomes. A polymer such as crossed-linked polyacrylic acid, polyvinylalcohol, hyaluronic acid, a cellulosic polymer, for example, hydroxypropylmethylcellulose, hydroxyethylcellulose, or methyl cellulose, or a heteropolysaccharide polymer, for example, gelan gum, may be incorporated together with a preservative, such as benzalkonium chloride. Such formulations may also be delivered by iontophoresis.
Formulations for ocular/aural administration may be formulated to be immédiate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted, orprogrammed release.
Other Technologies
Compounds of the invention may be combined with soluble macromolecular entities, such as cyclodextrin and suitable dérivatives thereof or polyethylene glycol-containing polymers, in order to improve their solubility, dissolution rate, taste-masking, bioavailability and/or stability for use in any of the aforementioned modes of administration.
Drug-cyclodextrin complexes, for example, are found to be generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes may be used. As an alternative to direct complexation with the drug, the cyclodextrin may be used as an auxiliary additive, i.e. as a carrier, diluent, or solubilizer. Most commonly used for these purposes are alpha-, beta- and gamma-cyclodextrins, examples of which may be found in PCT Publication Nos. WO 91/11172, WO 94/02518 and WO 98/55148, the disclosures of which are incorporated herein by reference in their entireties.
Dosage
The amount of the active compound administered will be dépendent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discrétion of the prescribing physician. However, an effective dosage is typically in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 0.01 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.07 to about 7000 mg/day, preferably about 0.7 to about 2500 mg/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adéquate, while in other cases still larger doses may be used without causing any harmful side effect, with such larger doses typically divided into several smaller doses for administration throughout the day.
Kit-of-Parts
Inasmuch as it may désirable to administer a combination of active compounds, for example, for the purpose of treating a particular disease or condition, it is within the scope of the présent invention that two or more pharmaceutical compositions, at least one of which contains a compound in accordance with the invention, may conveniently be combined in the form of a kit suitable for coadministration of the compositions. Thus the kit of the invention includes two or more separate pharmaceutical compositions, at least one of which contains a compound of the invention, and means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is the familiar blister pack used for the packaging of tablets, capsules and the like.
The kit of the invention is particularly suitable for administering different dosage forms, for example, oral and parentéral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit typically includes directions for administration and may be provided with a memory aid.
Combination Therapy
As used herein, the term “combination therapy” refers to the administration of a compound of the invention together with an at least one additional pharmaceutical or médicinal agent (e.g., an anti-cancer agent), either sequentially or simultaneously.
As noted above, the compounds of the invention may be used in combination with one or more additional anti-cancer agents. The efficacy of the compounds of the invention in certain tumors may be enhanced by combination with other approved or experimental cancer thérapies, e.g., radiation, surgery, chemotherapeutic agents, targeted thérapies, agents that inhibit other signaling pathways that are dysregulated in tumors, and other immune enhancing agents, such as PD-1 antagonists and the like.
When a combination therapy is used, the one or more additional anti-cancer agents may be administered sequentially or simultaneously with the compound of the invention. In one embodiment, the additional anti-cancer agent is administered to a mammal (e.g., a human) prior to administration of the compound of the invention. In another embodiment, the additional anti-cancer agent is administered to the mammal after administration of the compound of the invention. In another embodiment, the additional anti-cancer agent is administered to the mammal (e.g., a human) simultaneously with the administration of the compound of the invention.
The invention also relates to a pharmaceutical composition for the treatment of abnormal cell growth in a mammal, including a human, which comprises an amount of a compound of the invention, as defined above (including hydrates, solvatés and polymorphs of said compound or pharmaceutically acceptable salts thereof), in combination with one or more (preferably one to three) anti-cancer therapeutic agents.
In particular embodiments, a compound of the invention may be administered in combination with one or more: targeted agents, such as inhibitors of PI3 kinase, mTOR, PARP, IDO, TDO, ALK, ROS, MEK, VEGF, FLT3, AXL, ROR2, EGFR, FGFR, Src/Abl, RTK/Ras, Myc, Raf, PDGF, AKT, c-Kit, erbB, CDK4/CDK6, CDK5, CDK7, CDK9, SMO, CXCR4, HER2, GLS1, EZH2 or Hsp90, or immunomodulatory agents, such as PD-1 or PD-L1 antagonists, 0X40 agonists or4-1BB agonists.
In other embodiments, a compound of the invention may be administered in combination with a standard of care agent, such as tamoxifen, docetaxel, paclitaxel, cisplatin, capecitabine, gemcitabine, vinorelbine, exemestane, letrozole, fulvestrant, anastrozole or trastuzumab.
Synthetic Methods
Compounds of the invention are prepared according to the exemplary procedures provided herein and modifications thereof known to those of skill in the art.
The following abbreviations are used throughout the Examples: “Ac” means acetyl, “AcO” or “OAc” means acetoxy, “ACN” means acetonitrile, “aq” means aqueous, “atm” means atmosphere(s), “BOC”, “Boc” or “boc” means N-tert-butoxycarbonyl, “Bn” means benzyl, “Bu” means butyl, “nBu” means normal-butyl, “tBu” means terf-butyl, “DBU” means 1,8-diazabicyclo[5.4.0]undec-7-ene, “Cbz” means benzyloxycarbonyl, “DCM” (CH2CI2) means methylene chloride, “de” means diastereomeric excess, “DEA” means diethylamine, “DIPEA” means diisopropyl ethyl amine, “DMA” means N,Ndimethylacetamide, “DME” means 1,2-dimethoxyethane, DMF means A/,A/-dimethyl formamide, “DMSO means dimethylsulfoxide, “EDTA” means ethylenediaminetetraacetic acid, “ee” means enantiomeric excess, “Et” means ethyl, “EtOAc” means ethyl acetate, “EtOH” means éthanol, “HOAc” or “AcOH” means acetic acid, “i-Pr” or “’Pr” means isopropyl, ΊΡΑ” means isopropyl alcohol, “LAH” means lithium aluminum hydride, “LHMDS” means lithium hexamethyldisilazide (lithium bis(trimethylsilyl)amide), “mCPBA” means meta-chloroperoxy-benzoic acid, “Me” means methyl, “MeOH” means methanol, “MS” means mass spectrometry, MTBE means methyl terf-butyl ether, “NCS” means N-chlorosuccinimide, “Ph” means phenyl, “TBHP” means ferf-butyl hydroperoxide, “TFA” means trifluoroacetic acid, “THF” means tetrahydrofuran, “SFC” means supercritical fluid chromatography, “TLC” means thin layer chromatography, “Rf” means rétention fraction, means approximately, “rt” means rétention time, “h” means hours, “min” means minutes, “equiv” means équivalents, “sat.” means saturated.
Préparation of Synthetic Intermediates
Intermediate 1 : (±)-4-{[( 1 F?*,2R*)-2-hydroxy-2-methylcyclopentyl]amino}-2(methylsulfanyl)pyrimidine-5-carbaldehyde.
A solution of 1-methyl-6-oxabicyclo[3.1.0]hexane (CAS# 16240-42-9, 330 g, 3.36 mol) in ammonium hydroxide (28 wt% in water, 1.5 L) was stirred at 85 °C for 24 h. The solution was concentrated to a brown gum, the gum dissolved in water (2.0 L) and THF (200 mL), and the solution cooled to 0 °C. Sodium hydroxide (287 g, 7.16 mol) and benzyl chloroformate (587 g, 3.44 mol) were added dropwise. The resulting mixture was stirred at room température for 18 h, then extracted with DCM (1000 mL x 3). The combined organic layers were washed with sat. aq NaCI (500 mL), dried over sodium sulfate, and concentrated. The residue was purified by silica gel chromatography (eluting with 10-33% EtOAc in petroleum ether), to give a yellow solid (550 g, 77% pure by NMR). This solid was washed by petroleum ether/EtOAc (3000 mL/100 mL) and petroleum ether/MTBE (2000 mL/500 mL) to give (±)-benzyl [(1R*,2R*)-2-hydroxy-2methylcyclopentyl]carbamate (1a, 239 g, 28%, 90% pure by NMR) as a pale yellow solid. 1H NMR (400 MHz, DMSO-cfe) δ = 7.37 (t, J=3.9 Hz, 5H), 5.16-4.95 (m, 3H), 4.44 (s, 1H), 3.81-3.68 (m, 1H), 2.15-1.99 (m, 1H), 1.59 (br s, 4H), 1.45-1.31 (m, 1H), 1.19-
1.11 (m, 3H).
A solution of (±)-benzyl [(1R*,2R*)-2-hydroxy-2-methylcyclopentyl]carbamate (1a, (109 g, 437 mmol) in MeOH (1000 mL) was treated with wet Pd/C (11 g). The black suspension was stirred at 20 °C under hydrogen (20 psi) for 18 h. After removal of the solids by filtration, the filtrate was concentrated to give (±)-(1R*,2R*)-2-amino-1methylcyclopentanol (1b, 48.0 g, 95%) as a pale yellow gum. 1H NMR (400 MHz, DMSO-cfe) δ = 2.86 (t, J=6.9 Hz, 1H), 1.99-1.86 (m, 1H), 1.60-1.49 (m, 4H), 1.28-1.17 (m, 1H), 1.08 (s, 3H).
A solution of [4-chloro-2-(methylsulfanyl)pyrimidin-5-yl]methanol (CAS# 104414559-6, 6.6 g, 35 mmol), (±)-(1R*,2R*)-2-amino-1-methylcyclopentanol (1b, 4.4 g, 46 mmol) and triethylamine (14.5 mL, 104 mmol) in ACN (86 mL) was stirred in a 50 °C oil bath for 16 h. The reaction solution was evaporated to dryness. Water (25 mL), sat. aq NaCI (25 mL) and sat. aq NaHCOe (25 mL) were added to the residue, and the mixture extracted with EtOAc (200 mL x 3). The combined organics were dried over sodium sulfate, and concentrated to dryness. The residue (9.3 g light yellow gum) was suspended in EtOAc (50 mL) with sonication to produce a thick white slurry. This slurry was heated at 60 °C with stirring. Heptane (~150 mL) was added slowly to the heated suspension, then the mixture allowed to cool to room température overnight. The resulting solid was collected by filtration, rinsed with heptane (30 mL), and dried to give (±)-(1R*,2R*)-2-{[5-(hydroxymethyl)-2-(methylsulfanyl)pyrimidin-4-yl]amino}-1methylcyclopentanol (1c, 6.91 g, 74%) as a white solid. 1H NMR (400 MHz, DMSO-cfe) δ = 7.82 (s, 1H), 6.32 (d, J=7.9 Hz, 1H), 5.27 (t, J=5.4 Hz, 1H), 4.66 (s, 1H), 4.36 (d, J=5.3 Hz, 2H), 4.30 (q, J=7.7 Hz, 1H), 2.42 (s, 3H), 2.22-2.10 (m, 1H), 1.75-1.56 (m, 4H), 1.52-1.39 (m, 1 H), 1.09 (s, 3H). MS: 270 [M+H]+.
Manganèse dioxide (33.4 g, 384 mmol) was added to a suspension of (±)(1 R*, 2R*)-2-{[5-(hydroxymethyl)-2-(methylsulfanyl)pyrimidin-4-yl]amino}-1 -methylcyclopentanol (1c, 6.9 g, 25.6 mmol) in EtOAc (384 mL), and the mixture stirred in a 50 °C oil bath for 7 h, and then at room température overnight. Solids were removed by filtration. The flask and filter cake were washed with EtOAc (~300 mL). The combined filtrâtes were filtered again to remove a small amount of residual black solid, then concentrated to give (±)-4-{[(1 R*,2R*)-2-hydroxy-2-methylcyclopentyl]amino}-2-(methylsulfanyl)pyrimidine-5-carbaldehyde (Intermediate 1, 5.84 g, 85%) as an off-white solid. 1H NMR (400 MHz, CDCh) δ = 9.72 (s, 1H), 8.66 (br s, 1H), 8.35 (s, 1H), 4.39 (ddd, J=6.5, 8.2,
9.5 Hz, 1H), 4.15 (br s, 1H), 2.57 (s, 3H), 2.33-2.23 (m, 1H), 2.03-1.92 (m, 1H), 1.91-
1.70 (m, 3H), 1.68-1.56 (m, 1 H), 1.17 (s, 3H). MS: 268 [M+H]+.
Intermediate 2: 4-{[(1 R,2R)-2-hydroxy-2-methylcyclopentyl]amino}-2-(methylsulfanyl)pyrimidine-5-carbaldehyde.
CAS# 16240-42-9
nh2 h2o
o2i
O2I
EtOH
OH (+/-) 2a
2b-RR no2
NH2 °2N
O
O
H
H2O/EtOAc
nh2 (R/Λ’ΌΗ no2 o2n
O
H 9
Ν^Α,θΘ
H2O/EtOAc
1) aq HCl
2) aq NaOH
NH îr;/oh
2b-00
96% ee
1) aq HCl
2) aq NaOH
NH
OH
O2I
O2I
EtOH
H2 (1 atm)
20% Pd(OH)2/C
2-propanol
2b-RR
2b-00
98% ee
2c
DIPEA
2-propanol
MnO2
EtOAc
A 150 mL sealable flask was charged with water (50.9 mL) and benzylamine (10.9 g, 11.1 mL, 102 mmol), then purged with nitrogen for 5 min, before 1-methyl-6oxabicyclo[3.1.0]hexane (CAS# 16240-42-9, 10 g, 102 mmol) was added. The flask was sealed and heated at 100 °C for 18 h, at which time a biphasic mixture was observed. After cooling to room température the flask was further cooled in an ice-water bath. Concentrated aqueous HCl (~12 M, 13 mL) was added to bring the pH to 1. The organic impurities were extracted with EtOAc (150 mL) and set aside. The acidic aqueous layer was cooled in an ice-water bath and adjusted to pH 10 using 5N aq NaOH. The resulting biphasic mixture was extracted with EtOAc (250 mL x 3). The combined organic extracts were dried over sodium sulfate and concentrated to a brown oil. The remaining benzylamine was evaporated under higher vacuum (~5 mmHg) at 80 °C for several h, until 1HNMR of a sample showed only ~20 mole% benzylamine remaining. The residual oil was triturated with heptane (100 mL), causing white crystals to form. The crystals were collected by filtration and dried to give (±)-(1R*,2R*)-2-(benzylamino)1-methylcyclopentanol (2a, 13 g, 62%) as a white crystalline solid. 1H NMR (400 MHz, CDCh) δ = 7.36-7.31 (m, 4H), 7.28-7.23 (m, 1H), 3.91-3.85 (m, 1H), 3.79-3.74 (m, 1H), 2.86 (dd, J=7.8, 8.5 Hz, 1H), 2.12-2.03 (m, 1H), 1.75-1.53 (m, 5H), 1.37-1.27 (m, 1H), 1.22 (s, 3H).
A magnetically-stirred solution of (±)-(1R*,2R*)-2-(benzylamino)-1methylcyclopentanol (2a, 100 g, 487 mmol) and EtOH (700 mL) in a 1 L flask was heated in an 80 °C oil bath for 30 min. A separate 5 L, three-neck flask equipped with an overhead stirrer, internai thermometer, and water-cooled condenser was charged with (2S)-[(3,5-dinitrobenzoyl)amino](phenyl)ethanoic acid (CAS#74927-72-3, 84.1 g, 244 mmol, 0.5 equiv) and EtOH (1.4 L). This flask was also heated in an 80 °C oil bath with stirring until the solid dissolved, ~15 min, and stirring continued for another 30 min. The hot solution of amine 2a from the first flask was poured via funnel, in a steady flow over 1 min, into the hot, mechanically stirred solution of chiral acid in the second flask. The transfer was quantitated with EtOH (10 mL). The reaction mixture remained clear for about 1 min, then précipitation began. After 5 min, a thick white suspension had formed, but did not hinder mechanical stirring. Stirring was continued at 80 °C for 4 h, then heating was discontinued and the mixture was stirred while gradually cooling to room température overnight. The resulting solid was collected by filtration, washed with EtOH (350 mL), and dried in a vacuum oven (10 mmHg, 40 °C) for 1.5 days, affording (1 R,2R)-A/-benzyl-2-hydroxy-2-methylcyclopentanaminium (2S)-[(3,5dinitrobenzoyl)amino](phenyl)acetate (2b-RR, 110.22 g, 82%) as a white solid. 1H NMR (400 MHz, DMSO-cfe) δ = 9.64 (d, J=7.Q Hz, 1H), 9.09 (d, J=2.1 Hz, 2H), 8.96 (t, J=2.1 Hz, 1H), 7.55-7.48 (m, 2H), 7.43-7.23 (m, 8H), 5.47 (d, J=7.1 Hz, 1H), 4.02-3.75 (m, 2H), 2.86 (t, J=8.0 Hz, 1H), 2.03-1.87 (m, 1H), 1.66-1.48 (m, 4H), 1.48-1.32 (m, 1H), 1.17 (s, 3H). MS: 206 [M+H]+ for amine cation. A small-molecule X-ray crystal structure of this sait confirmed absolute (1F?,2F?) stereochemistry on the cyclopentane ring.
The chiral sait (1F?,2F?)-/\/-benzyl-2-hydroxy-2-methylcyclopentanaminium (2S)[(3,5-dinitrobenzoyl)amino](phenyl)acetate (2b-RR, 110.22 g, 200.2 mmol) was suspended in water (500 mL) and EtOAc (700 mL) in a 2 L separatory funnel. Aqueous HCl (4 M, 200 mL, 800 mmol) was added and the mixture agitated for ~30 seconds. A clear biphasic mixture was obtained. The layers were separated, and the organic layer was further washed with aqueous HCl (0.2 M, 125 mL x 2). The acidic aqueous layers were combined, split into two portions, and each portion cooled in an ice-water bath. Aqueous NaOH (4 N, 150 mL, 600 mmol) was added to each portion to bring the pH to
10. A white suspension formed at this pH. The two portions were combined, diluted with sat. aq NaCI (150 mL), and extracted with EtOAc (250 mL x 4). The combined organic extracts were dried over sodium sulfate and evaporated to give (1F?,2F?)-2(benzylamino)-l-methylcyclopentanol (2b-00, 41.4 g, 100%, 96%ee). 1H NMR (400 MHz, DMSO-cfe) δ = 7.36-7.25 (m, 4H), 7.24-7.16 (m, 1H), 4.23 (s, 1H), 3.78-3.65 (m, 2H), 2.70 (t, J=7.5 Hz, 1H), 1.86 (dt, J=3.9, 7.8 Hz, 1H), 1.73 (br s, 1H), 1.62-1.44 (m, 4H), 1.35-1.23 (m, 1H), 1.12 (s, 3H). Chiral purity: 96% ee. Chiral SFC/MS analysis was performed on a Chiralpak AS-3, 4.6 x 100mm, 3pm column heated to 25°C and eluted with a mobile phase of CO2 and 5% diethylamine in éthanol (20mM v/v) in 1 min flowing at 3.5 mL/min and maintained at160bar outlet pressure. A gradient to 50% modifier in 3 min was added to elute any remaining counter ions. The détection was APCI(+)MS monitored from 100-800 Da with single ion monitoring (SIM) at 206 Da. The product peak had a rétention time of 1.81 min. Optical rotation of a sample made by this method gave [q]d22 -42.6 (c 1.0, MeOH).
Sinœ higher chiral purity was desired, the classical resolution was repeated on the enantio-enriched amine: A solution of (1R,2R)-2-(benzylamino)-1methylcyclopentanol (2b-00, (41.0 g, 200 mmol, 96%ee) in EtOH (200 ml_) was heated at 80 °C with stirring for 30 minutes. A separate 2 L, three-necked flask equipped with an overhead stirrer, internai thermometer and water-cooled condenser was charged with (2S)-[(3,5-dinitrobenzoyl)amino](phenyl)ethanoic acid (CAS#74927-72-3, 67 g, 194 mmol, 0.97 equiv; since amine was ~96%ee) and EtOH (1.3 L). This flask was stirred and heated at 80 °C (internai) until the solid dissolved (-15 min) then for 30 min more. The hot amine solution was added to the hot acid solution through a funnel in a steady flow (less than 1 min), and the transfer quantitated with EtOH (10 mL). Précipitation began in about 1 min, and by 5 min a thick white suspension had formed, though stirring was not hindered. Stirring was continued at 80 °C for 4 h, then heating was discontinued and the reaction stirred and allowed to gradually cool to room température overnight. The resulting solid was collected by filtration, washed with EtOH (350 mL) and dried (10 mmHg, 40 °C) for 1.5 days to give (1R,2R)-A/-benzyl-2-hydroxy-2methylcyclopentanaminium (2S)-[(3,5-dinitrobenzoyl)amino](phenyl)acetate (2b-RR, 106 g, 99%). 1H NMR (400 MHz, DMSO-de) δ = 9.66 (d, J=7.0 Hz, 1H), 9.09 (d, J=2.1 Hz, 2H), 8.96 (t, J=2.1 Hz, 1H), 7.55-7.46 (m, 2H), 7.44-7.22 (m, 8H), 5.48 (d, J=7.1 Hz, 1H), 4.63 (brs, 1H), 3.96-3.79 (m, 2H), 3.66-2.97 (m, 2H), 2.84 (t, J=7.9 Hz, 1H), 2.001.85 (m, 1H), 1.64-1.48 (m, 4H), 1.45-1.32 (m, 1H), 1.16 (s, 3H). MS: 206 [M+H]+ for amine cation.
A stirred suspension of (1R,2R)-/\/-benzyl-2-hydroxy-2-methylcyclopentanaminium (2S)-[(3,5-dinitrobenzoyl)amino](phenyl)acetate (2b-RR, 106 g, 193 mmol) in water (500 mL) and EtOAc (700 mL) was treated with aq HCl (4 M, 193 mL, 770 mmol) and agitated for -30 seconds. A clear biphasic mixture was obtained. The layers were separated, and the aqueous layer was extracted with more EtOAc (125 mL x 2). The organic layers were set aside. The acidic aqueous layer was cooled in an icewater bath, and basified to pH 10 with aq NaOH (4 N, 289 mL, 6 equiv, 1160 mmol). The resulting white suspension was diluted with sat. aq NaCI (300 mL) and extracted with EtOAc (700 mL x 4). The combined organic extracts were dried over sodium sulfate, and evaporated to give (1 R,2R)-2-(benzylamino)-1-methylcyclopentanol (2b-00,
38.5 g, 97%, 98%ee). 1H NMR (400 MHz, CDCb) δ = 7.38-7.30 (m, 4H), 7.27-7.23 (m, 1H), 3.94-3.75 (m, 2H), 2.88 (dd, J=7.8, 8.4 Hz, 1H), 2.16-2.03 (m, 1H), 1.79-1.57 (m, 4H), 1.53-1.39 (m, 2H), 1.38-1.28 (m, 1H), 1.25 (s, 3H). MS: 206 [M+H]+. Chiral purity:
98% ee. Chiral SFC/MS analysis was performed on a Chiralpak AS-3, 4.6 x 100mm, 3pm column heated to 25°C and eluted with a mobile phase of CO2 and 5% diethylamine in éthanol (20mM v/v) in 1 min flowing at 3.5 mL/min and maintained at160bar outlet pressure. A gradient to 50% modifier in 3 min was added to elute any remaining counter ions. The détection was APCI(+)MS monitored from 100-800 Da with single ion monitoring (SIM) at 206 Da. The product peak had a rétention time of 1.82 min. Optical rotation of this batch was not determined.
To a nitrogen-filled 3-L three-necked flask was added 20%-Pd(OH)2/C (Aldrich 212911-10G, Lot #SHBC7570V, 3.85 g) and 2-propanol (260 mL). A solution of (1F?,2R)-2-(benzylamino)-1-methylcyclopentanol (2b-00, 38.5 g, 188 mmol, 98%ee) in
2-propanol (1300 mL) was added. The transfer was quantitated with 2-propanol (30 mL). The solution was purged with hydrogen gas for -2 min, and then stirred at room température under a hydrogen atmosphère (three balloons) for 16 h. The balloons were replenished with hydrogen and stirring continued at room température for 6 h, at which time 1H NMR of an aliquot indicated the reaction was complété. The reaction mixture was purged with nitrogen, and the catalyst removed by filtration through a Celite® cake. The flask and filter cake were washed with 2-propanol (500 mL). A small aliquot of the combined filtrate was evaporated for analysis. The remainder of the filtrate was concentrated under reduced pressure (~10 mmHg, 20 °C) to about 350 mL, and the crude (1R,2F?)-2-amino-1-methylcyclopentanol (2c) used directly in the next step without further purification. 1H NMR (400 MHz, CDCI3) δ = 3.03 (t, J=7.4 Hz, 1H), 2.19-2.01 (m, 1H), 1.83-1.58 (m, 4H), 1.42 (s, 3H), 1.35-1.25 (m, 1H), 1.22 (s, 3H). MS: 116 [M+H]+. Chiral SFC analysis: 96% ee. Chiral SFC/MS analysis was performed on a ChiroSil RCA (+), 4.6 x 150 mm 5μ column heated to 40°C and eluted with a mobile phase of 20% ACN, 60% formic Acid in MeOH(1% v/v), 20% ammonium formate in MeOH (20mM w/v) flowing at 1.5 mL/min. The détection was ESI (+) MS monitored from 100650 Da with single ion monitoring (SIM) at 116 Da. The product peak had a rétention time of 2.09 min. Optical rotation of a previous batch made by this method gave [o]d22 -37.7 (c0.3, MeOH).
To the crude solution of (1F?,2/?)-2-amino-1-methylcyclopentanol (2c, 188 mmol theoretical) in 2-propanol (-350 mL) was added solid [4-chloro-2(methylsulfanyl)pyrimidin-5-yl]methanol (CAS# 1044145-59-6, 34.8 g, 182 mmol) and DIPEA (95.3 mL, 547 mmol). The mixture was degassed with nitrogen and stirred under a nitrogen atmosphère at room température for 15 min, then at 80 °C for 40 h. The volatiles were removed, and the residual oil (95 g) was partitioned between EtOAc (800 mL) and sat. aq NaCI (250 mL). The aq layer was further extracted with EtOAc (500 mL x 3). The combined organic extracts were dried over sodium sulfate and evaporated to give an oil (75 g). This oil was dissolved in EtOAc (200 mL), and the clear solution heated at 60 °C. Some white solid was observed 5 min after initiation of heating. When at 60 °C, heptane (400 mL) was slowly added to the suspension, and stirring continued at 60 °C for 15 min. The suspension was cooled to room température, and then cooled in an ice-water bath for 15 min. The resulting precipitate was collected by filtration and dried to give (1/?,2/?)-2-{[5-(hydroxymethyl)-2-(methylsulfanyl)pyrimidin-4-yl]amino}-1methylcyclopentanol (2d, 47.8 g, 97%, 98%ee). 1H NMR (400 MHz, CDCh) δ = 7.76 (s, 1H), 6.01 (d, J=4.6 Hz, 1H), 5.31 (brs, 1H), 4.55 (s, 2H), 4.26 (ddd, J=5.7, 8.2, 10.5 Hz, 1H), 2.50 (s, 3H), 2.21 (ddd, J=3.5, 8.2, 12.1 Hz, 1H), 1.97 (dt, J=3.5, 7.7 Hz, 1H), 1.891.76 (m, 2H), 1.75-1.63 (m, 1H), 1.60-1.50 (m, 2H), 1.11 (s, 3H). MS: 270 [M+H]+. Optical rotation: [a]D 22 +37.7 (c 1.0, MeOH). Chiral purity: 98% ee. Chiral SFC/MS analysis was performed on a Chiralpak IC-3, 4.6 x 150mm, 3pm column heated to 25°C and eluted with a mobile phase of CO2 and 30% ammonia in methanol (20mM v/v) flowing at 4.0 mL/min and maintained at 160 bar outlet pressure. The product peak had a rétention time of 1.85 min.
To a 2L, 3-necked flask equipped with a mechanical stirrer and a reflux condenser was added solid manganèse dioxide (10 pm mesh, reagent grade, 278 g, 2660 mmol), EtOAc (1.2 L, 0.14 M) and solid (1F?,2R)-2-{[5-(hydroxymethyl)-2(methylsulfanyl)pyrimidin-4-yl]amino}-1-methylcyclopentanol (2d, 47.7 g, 177 mmol). The mixture was stirred under nitrogen and heated in a 50 °C oil bath for 4 h. More manganèse dioxide (80 g) was added; stirring and heating were continued for another 16 h, until the reaction was complété by LCMS. The solid was removed by filtration, and the flask and filter cake were washed with EtOAc (1 L). The combined filtrâtes were refiltered to completely remove trace insolubles, and then evaporated to give 4{[(1F?,2R)-2-hydroxy-2-methylcyclopentyl]amino}-2-(methylsulfanyl)pyrimidine-5carbaldehyde (Intermediate 2, 43.8 g, 93%, >98%ee) as a white solid. 1H NMR (400 MHz, CDCh) δ = 9.73 (s, 1H), 8.66 (br s, 1H), 8.35 (s, 1H), 4.39 (ddd, J=6.5, 8.2, 9.6 Hz, 1H), 4.16 (s, 1H), 2.57 (s, 3H), 2.33-2.22 (m, 1H), 2.03-1.92 (m, 1H), 1.89-1.68 (m, 3H), 1.68-1.56 (m, 1H), 1.17 (s, 3H). MS: 268 [M+H]+. Optical rotation [o]d22 +12.7 (c 1.0, CHCh). Chiral purity: >98% ee. Chiral SFC/MS analysis was performed on a Chiralpak IC-3, 4.6 x 150mm, 3pm column heated to 25°C and eluted with a mobile phase of CO2 and 30% ammonia in methanol (20mM v/v) flowing at 4.0 mL/min and maintained at 160 bar outlet pressure. The product peak had a rétention time of 2.83 min.
Intermediate 3: 4-{[( 1 R’,3R)-3-hydroxycyclohexyl]amino}-2-(methylsulfanyl)pyrimidine-
5-carbaldehyde.
3a
Intermediate 3
ΌΗ
A solution of [4-chloro-2-(methylsulfanyl)pyrimidin-5-yl]methanol (CAS# 104414559-6, 3.5 g, 18.4 mmol), (1 R,3R)-3-aminocyclohexanol (3.34 g, 22.0 mmol) [Brocklehurst, C.E.; Laumen, K.; La Vecchia, L.; Shaw, D.; Vogtle, M. Org. Process Res. Dev. 2011, 15, 294. [o]d22 -4.9 (c 1.2, MeOH)], and DIPEA (11.9 g, 16.3 mL) in EtOH (40 mL) was stirred at 85 °C for 20 h. After cooling to room température, the mixture was partitioned between water and DCM. The organics were concentrated to dryness and purified by silica gel chromatography (eluting with 0-30% MeOH in DCM) to give (1R,3R)-3-{[5-(hydroxymethyl)-2-(methylsulfanyl)pyrimidin-4-yl]amino}cyclohexanol (3a, 4.80 g, 97%) as a yellow foam. 1H NMR (400 MHz, CDCh) δ = 7.62-7.47 (m, 1H), 6.05 (d, J=7.5 Hz, 1H), 4.58-4.31 (m, 3H), 4.02 (brd, J=3.0 Hz, 1H), 2.54-2.34 (m, 3H), 1.88-1.71 (m, 4H), 1.70-1.52 (m, 3H), 1.43 (br s, 1H). MS: 270 [M+H]+- Optical rotation: [q]d22 +0.14 (c 2.8, MeOH). Chiral purity: >95%ee. Chiral SFC/MS analysis was performed on a Chiralpak AD-3, 4.6 x 150mm, 3pm column heated to 40°C and eluted with a mobile phase of CO2 and a gradient of 5 to 40% EtOH (0.05%DEA) over 5.5 min, flowing at 2.5 mL/min. Flow at 40% EtOH (0.05%DEA) was continued for 3 min to elute any remaining counter ions. The product peak had a rétention time of 3.79 min.
A suspension of (1R,3R)-3-{[5-(hydroxymethyl)-2-(methylsulfanyl)pyrimidin-4yl]amino}cyclohexanol (3a, 4.80 g, 17.8 mmol) and manganèse dioxide (15.5 g, 178 mmol) in chloroform (70 mL) was stirred at room température for 18 h. The mixture was filtered, the flask and filter cake rinsed with EtOAc (100 mL) and THF (100 mL), and the combined filtrâtes concentrated to dryness. The residue was purified by silica gel chromatography (eluting with 0-40% EtOAc in petroleum ether) to give 4-{[(1 R,3R)-3hydroxycyclohexyl]amino}-2-(methylsulfanyl)pyrimidine-5-carbaldehyde (Intermediate 3, 3.70 g, 80%) as a yellow gum. 1H NMR (400 MHz, CDCh) δ = 9.69 (s, 1 H), 8.61 (br s, 1H), 8.30 (s, 1H), 4.75-4.49 (m, 1H), 4.27-4.01 (m, 1H), 2.56 (s, 3H), 2.00-1.87 (m, 2H), 1.87-1.56 (m, 6H). MS: 268 [M+H]+. Optical rotation: [a]D 22 +2.8 (c 1.4, MeOH). Chiral purity: 96%. Chiral SFC/MS analysis was performed on a Chiralpak AD-3, 4.6 x 150mm, 3pm column heated to 40°C and eluted with a mobile phase of CO2 and a gradient of 5 to 40% EtOH (0.05%DEA) over 5.5 min, flowing at 2.5 mL/min. Flow at 40% EtOH (0.05%DEA) was continued for 3 min to elute any remaining counter ions. The product peak had a rétention time of 4.42 min.
Intermediate 4: 4-{[( 1 R,2R)-2-hydroxycyclopentyl]amino}-2-(methylsulfanyl)pyrimidine5-carbaldehyde.
S N NH
Intermediate 4
By the same method as Intermediate 3, (1R,2R)-2-aminocyclopentanol hydrochloride (CAS# 68327-11-7) was used to produce 4-{[(1 R,2R)-2hydroxycyclopentyl]amino}-2-(methylsulfanyl)pyrimidine-5-carbaldehyde (Intermediate
4). 1H NMR (400 MHz, CDCh) δ = 9.70 (s, 1H); 8.72-8.62 (m, 1H), 8.34 (s, 1H), 4.244.14 (m, 1H), 4.12-4.02 (m, 1H), 3.97 (s, 1H), 2.57 (s, 3H), 2.34-2.21 (m, 1H), 2.13-2.01 (m, 1 H), 1.93-1.60 (m, 4H). MS: 254 [M+H]+.
Intermediate 5: 4-(cycloheptylamino)-2-(methylsulfanyl)pyrimidine-5-carbaldehyde.
DI PEA '0'
O
CAS 5909-24-0
THF
5a
LAH
THF
A suspension of ethyl 4-chloro-2-(methylsulfanyl)pyrimidine-5-carboxylate (CAS# 5909-24-0, 16 g, 68.7 mmol), cycloheptylamine (9.34 g, 82.5 mmol) and DIPEA (17.8 g, 138 mmol) in THF (150 mL) was stirred at room température for 18 h. Solvents were evaporated, the residue dissolved in water (150 mL), and the solution extracted with EtOAc (150 mL x 2). The combined organics were washed with sat. aq NaCI (150 mL x
2), dried over sodium sulfate, and concentrated to give ethyl 4-(cycloheptylamino)-2(methylsulfanyl)pyrimidine-5-carboxylate (5a, 21 g, 99%) as yellow oil. MS: 310 [M+H]+.
A cooled (5 °C) solution of ethyl 4-(cycloheptylamino)-2(methylsulfanyl)pyrimidine-5-carboxylate (5a, 21 g, 67.9 mmol) in THF (200 mL) was treated LAH (2.5 M solution in THF, 81.4 mL, 204 mmol) in portions over 1.5 h. The resulting suspension stirred at 5 to 10 °C for an additional hour, then at room température for 18 h. The mixture was cooled slightly (15 °C), then water (10 mL) and 2 N NaOH (10 mL) were added dropwise to quench any residual LAH. After stirring for 1 hour at room température, the suspension was filtered, and the flask and filter cake were rinsed with THF (300 mL x 4). The combined filtrâtes were concentrated to remove most of the solvent. The residue was partitioned between water (100 mL) and EtOAc (250 mL x 2). The combined organic layers were washed with sat. aq NaCI (100 mL), dried over sodium sulfate, and concentrated to dryness. The crude product was recrystallized from petroleum ether/EtOAc (200 mL/50 mL) to give [4(cycloheptylamino)-2-(methylsulfanyl)pyrimidin-5-yl]methanol (5b, 13.6 g, 75%) as a white solid. MS: 268 [M+H]+.
Manganèse dioxide (43.3 g, 860 mmol) was added to a solution of [4(cycloheptylamino)-2-(methylsulfanyl)pyrimidin-5-yl]methanol (5b, 13.6 g, 50 mmol) in chloroform (200 mL), and the resulting suspension stirred at room température for 15 h. The solids were removed by filtration. The flask and filter cake were rinsed with DCM (150 mL x 4). The combined filtrâtes were filtered again to remove trace solids, and concentrated to give 4-(cycloheptylamino)-2-(methylsulfanyl)pyrimidine-5-carbaldehyde (Intermediate 5, 12.9 g, 98%) as a yellow oil. . 1H NMR (400 MHz, CDCh) δ = 9.68 (s,
1H), 8.63 (br s, 1H), 8.28 (s, 1H), 4.36-4.32 (m, 1H), 2.55 (s, 3H), 2.03-1.99 (m, 2H),
1.67-1.58 (m, 10H). MS: 266 [M+H]+.
Intermediate 6: 4-{[(1 R,2S)-2-methylcyclopentyl]amino}-2-(methylsulfanyl)pyrimidine-5carbaldehyde.
Intermediate 6
By the same method as Intermediate 5, (1R,2S)-2-methylcyclopentanamine [Wiehl, W.; Frahm, A. W. Chem. Ber. 1986, 119, 2668] was used to produce 4{[(1R,2S)-2-methylcyclopentyl]amino}-2-(methylsulfanyl)pyrimidine-5-carbaldehyde (Intermediate 6). 1H NMR (400 MHz, CDCh) δ = 9.70 (s, 1H), 8.67 (br s, 1H), 8.29 (s, 1H), 4.65-4.58 (m, 1H), 2.55 (s, 3H), 2.32-2.23 (m, 1H), 2.11-2.02 (m, 1H), 1.95-1.77 (m, 2H), 1.70-1.62 (m, 2H), 1.46-1.37 (m, 1H), 0.93 (d, J=6.8, 3H). MS: 252 [M+H]+.
Intermediate 7: 4-{[(1 S,2R)-2-methylcyclopentyl]amino}-2-(methylsulfanyl)pyrimidine-5 carbaldehyde.
Intermediate 7
By the same method as Intermediate 5, (1 S,2R)-2-methylcyclopentanamine [Wiehl, W.; Frahm, A. W. Chem. Ber. 1986, 119, 2668] was used to produce 4{[(1S,2R)-2-methylcyclopentyl]amino}-2-(methylsulfanyl)pyrimidine-5-carbaldehyde (Intermediate 7). 1H NMR (400 MHz, CDCh) δ = 9.68 (s, 1H), 8.73-8.59 (m., 1H), 8.27 (s, 1H), 4.67-4.52 (m, 1H), 2.53 (s, 3H), 2.29-2.20 (m, 1H), 2.12-1.99 (m, 1H), 1.92-1.75 (m, 2H), 1.63 (s, 2H), 1.45-1.34 (m, 1H), 0.91 (d, J=7.0, 3H). MS: 252 [M+H]+.
Intermediate 8: (±)-4-{[(1 R*,3R*)-3-hydroxycyclopentyl]amino}-2-(methylsulfanyl)pyrimidine-5-carbaldehyde.
THF
HCI/dioxane
Intermediate 8
To a cooled (0 °C) solution of (±)-frans-(3-hydroxy-cyclopentyl)-carbamic acid tert-butyl ester (2.03 g, 10.1 mmol) [Kulagowski, J.J. et al. J. Med. Chem. 2012 55, 5901] in 1,4-dioxane (20 mL) was added HCl (4.0 ml_ solution in 1,4-dioxane, 20 mL, 80 mmol), and the mixture stirred at 0 °C for 1 h and at room température for 3 h. The solvents were evaporated, the residue dissolved DCM (50 mL), and a solution of NaOH (502.2 mg, 12.6 mmol) in water (1.5 mL) was added. After stirring at room température for 1 h, the reaction mixture was dried over a mixture of anhydrous sodium carbonate and anhydrous sodium sulfate, filtered, and concentrated to give (±)-trans-(3-hydroxycyclopentyl amine (8a, 0.68 g, 67%) as an amber liquid, which was used without further purification in the following reaction. 1H NMR (400 MHz, DMSO-c/6) δ = 4.29 (br s, 1H), 4.19-4.10 (m, 1H), 3.35 (quin, J=6.4 Hz, 1H), 1.93-1.80 (m, 2H), 1.64 (ddd, J=3.4, 6.9, 13.0 Hz, 1H), 1.54 (br s, 2H), 1.41-1.32 (m, 2H), 1.19-1.07 (m, 1H).
A solution of 4-chloro-2-(methylsulfanyl)pyrimidine-5-carbaldehyde (613.7 mg, 3.25 mmol) [Zheng, K.; Min Park, C.; Iqbal, S. Hernandez, P.; Park, H.; LoGrasso, P.V.; Feng, Y. ACS Med. Chem. Lett. 2015, 6, 413], (±)-trans-(3-hydroxy-cyclopentyl amine (8a, 0.68 g, 6.7 mmol), and DIPEA (3.0 mL, 17 mmol) in EtOH (32.5 mL) was heated in a 70 °C oil bath for 18 h. Solvents were evaporated and the residue partitioned between sat. aq NaHCOs (50 mL) and EtOAc (50 mL x 3). The combined organic layers were
100 dried over magnésium sulfate, filtered, and concentrated. The brown gummy residue was dissolved in ACN (20 mL), causing a precipitate to form. The slurry was concentrated to dryness, leaving crude imine diadduct (8b, 0.90 g, 82%) as a dark yellow solid, with minor impurities. 1H NMR (400 MHz, DMSO-cfe) δ = 9.96 (d, J=6.8 Hz, 1H), 8.29 (s, 1H), 8.14 (s, 1H), 4.60 (d, J=3.9 Hz, 1H), 4.58 (d, J=3.9 Hz, 1H), 4.51 (sxt, J=6.8 Hz, 1H), 4.34-4.27 (m, 1H), 4.26-4.19 (m, 1H), 3.88 (quin, J=6.0 Hz, 1H), 2.47 (s, 3H), 2.25-2.14 (m, 1H), 2.10-1.78 (m, 5H), 1.77-1.68 (m, 1H), 1.63-1.45 (m, 4H), 1.38 (tdd, J=6.2, 8.7, 12.7 Hz, 1H).
The crude imine diadduct (8b, 0.90 g) was dissolved in THF (20 mL) and treated with HCl (4.0 M solution in 1,4-dioxane, 4.1 mL, 16.4 mmol). A light-colored precipitate formed immediately on contact with the acid, hindering stirring. More THF (10 mL) was added and the mixture manually shaken and sonicated until stirring could be reestablished, then continued stirring at room température for 2 h. The reaction mixture was diluted with EtOAc (50 mL). While stirring, sat. aq NaHCOs (30 mL) was added dropwise, causing mild gas évolution. The layers of the resulting clear, biphasic solution were separated and the aqueous layer further extracted with EtOAc (50 mL). The combined organic layers were dried over magnésium sulfate, filtered, and concentrated to give (±)-4-{[(1 R*,3R*)-3-hydroxycyclopentyl]amino}-2-(methylsulfanyl)pyrimidine-5carbaldehyde (Intermediate 8, 659.9 mg, 74% from 4-chloro-2(methylsulfanyl)pyrimidine-5-carbaldehyde) as a brown oil. 1H NMR (400 MHz, DMSOcfe) δ = 9.74 (s, 1H), 8.52 (s, 1H), 8.54 (br s, 1H), 4.72-4.61 (m, 1H), 4.59 (d, J=3.8 Hz, 1H), 4.28-4.19 (m, 1H), 2.52 (s, 3H), 2.26-2.14 (m, 1H), 2.04-1.88 (m, 2H), 1.66 (ddd, J=5.9, 7.8, 13.4 Hz, 1H), 1.58-1.41 (m, 2H). MS: 254 [M+H]+.
Intermediate 9: 4-amino-/\/-methylpiperidine-1-sulfonamide
CAS# 182223-54-7
1) SO2CI2,
Et3N, DCM
2) CH3NH2,
THF
Intermediate 9
A solution of benzyl 4-piperidinylcarbamate (CAS# 182223-54-7, 7.0 g, 27 mmol) and triethylamine (3.27 g, 32.3 mmol) in DCM (80 mL) was added to a chilled (0 °C) solution of suIfuryl chloride (3.99 g, 29.6 mmol) in DCM (70 mL), slowly enough to keep the internai température below 10 °C. The cooling bath was removed and the mixture
101 stirred at room température for 2 h. The reaction mixture was cooled again to 0 °C, then a solution of methylamine (2.0 M in THF, 26.9 mL, 53.8 mmol) and more triethylamine (15 mL, 108 mmol) in DCM (50 mL) was added dropwise, keeping the internai température below 10 °C. The resulting suspension was stirred at room température for 15 h. Because LCMS indicated the presence of residual chlorosulfonyl intermediate, the solution was cooled to 0 °C and more methylamine (2.0 M in THF, 40 mL, 80 mmol) added. Stirring was continued at room température for 3 h, at which time no chlorosulfonyl intermediate could be detected by LCMS. The reaction was partitioned between water (100 mL) and DCM (150 mL x 2). The combined organic extracts were dried, concentrated, and purified by silica gel chromatography (eluting with 50-80% EtOAc in petroleum ether) to give benzyl [1-(methylsulfamoyl)piperidin-4-yl]carbamate (9a, 4.0 g, 90% purity, 45% yield) as a white solid. 1H NMR (400 MHz, CDCh) δ = 7.427.31 (m, 5H), 5.17-5.06 (m, 2H), 4.73 (d, 7=6.5 Hz, 1H), 4.12 (q, 7=4.9 Hz, 1H), 3.67 (d, 7=12.3 Hz, 3H), 2.97-2.88 (m, 2H), 2.72 (d, 7=5.3 Hz, 3H), 2.03 (d, J=11.3 Hz, 2H), 1.57-1.46 (m, 2H). MS: 350 [M+Na]+.
A suspension of benzyl [1-(methylsulfamoyl)piperidin-4-yl]carbamate (9a, 4.0 g, 12 mmol) and Pd/C(50% H2O, 2 g) in THF (100 mL) was deoxygenated and purged with hydrogen (3 cycles), then stirred under a hydrogen balloon at room température for 4 h. The suspension was filtered, and the filtrate concentrated to give crude product (2.3 g, 85% purity, 100% yield) as a white solid.
Multiple batches made by this method were combined to give 45 g of crude product, which was then recrystallized from hot DCM to give pure 4-amino-/Vmethylpiperidine-1-sulfonamide (Intermediate 9, 40 g, 89%). 1H NMR (400 MHz, DMSO-d6) δ = 3.45-3.37 (m, 2H), 2.75-2.59 (m, 3H), 2.50 (s, 3H), 1.78-1.67 (m, 2H), 1.30-1.15 (m, 2H). MS: 194 [M+H]+.
Intermediate 10: 4-amino-A/-(2-methoxy-2-methylpropyl)piperidine-1-sulfonamide.
O
Intermediate 10
By the method of Intermediate 9, 2-methoxy-2-methylpropan-1-amine was used to synthesize 4-amino-A/-(2-methoxy-2-methylpropyl)piperidine-1 -sulfonamide (Intermediate 10). 1H NMR (400 MHz, CDCI3) δ = 4.54-4.42 (m, 1H), 3.67 (d, 7-12.3
102
Hz, 2H), 3.19 (s, 3H), 3.01 (d, J=5.8 Hz, 2H), 2.88-2.76 (m, 3H), 1.89 (d, J=10.5 Hz,
2H), 1.39 (d, J=9.3 Hz, 2H), 1.21 (s, 6H)
Intermediate 11;4-amino-/\/-(tetrahydro-2/-/-pyran-4-yl)piperidine-1-sulfonamide.
Intermediate 11
By the method of Intermediate 9, 4-aminotetrahydropyran was used to synthesize the compound4-amino-A/-(tetrahydro-2/-/-pyran-4-yl)piperidine-1 -sulfonamide (Intermediate 11). 1H NMR (400 MHz, CDCh) δ = 4.24-4.13 (m, 1H), 3.95 (td, J=3.6,
11.7 Hz, 2H), 3.77-3.74 (m, 1H), 3.67 (d, J=12.5 Hz, 2H), 3.43 (dt, J=2.3, 11.7 Hz, 3H), 2.89-2.77 (m, 3H), 2.02-1.86 (m, 5H), 1.59-1.48 (m, 2H), 1.46-1.38 (m, 3H)
Other 4-amino-A/-alkyl-piperidine-1-sulfonamides were synthesîzed by the method of Intermediate 9 and used crude, without purification or characterization, in the préparation of the example compounds of Table 1.
Intermediate 12: 1-[(2,2,2-trifluoroethyl)sulfonyl]piperidin-4-amine trifluoroacetate.
CAS# 73874-95-0
CAS# 1648-99-3
DCM
Et3N
12a
TFA
DCM
Intermediate 12
To an ice-bath-cooled solution of 4-(N-Boc-amino)piperidine (300 mg, 1.5 mmol) and triethylamine (303 mg, 3 mmol1) in DCM (10 mL) was added 2,2,2trifluoroethanesulfonyl chloride (301 mg, 1.65 mmol), and the mixture stirred at room température for 2 h. The resulting precipitate was collected by filtration and dried under vacuum to give tert-butyl {1-[(2,2,2-trifluoroethyl)sulfonyl]piperidin-4-yl}carbamate (12a, 300 mg, 58%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 4.47 (q, J=10.2 Hz, 2H), 3.63-3.51 (m, 2H), 3.44-3.36 (m, 1H), 3.01-2.83 (m, 2H), 1.80 (d, J=10.5 Hz, 2H), 1.47-1.27 (m, 2H), 1.39 (s, 9H).
Trifluoroacetic acid (1 mL) was added to a solution of tert-butyl {1-[(2,2,2trifluoroethyl)sulfonyl]piperidin-4-yl}carbamate (12a, 300 mg, 0.87 mmol) in DCM (10 mL), and the mixture stirred at room température for 14 h. Volatiles were evaporated
103 and the residue dried under vacuum to give 1-[(2,2,2-trifluoroethyl)sulfonyl]piperidin-4amine TFA sait (Intermediate 12, 300 mg, 74%) as a white gum. 1H NMR (400 MHz, DMSO-d6) δ = 8.05 (br s, 3H), 4.65-4.35 (m, 2H), 3.70 (d, J=12.8 Hz, 2H), 3.20 (d, J=4.8 Hz, 1H), 2.95 (t, J=11.7 Hz, 2H), 1.98 (d, J=10.5 Hz, 2H), 1.66-1.38 (m, 2H).
Intermediate 13: 1-(but-3-yn-1-ylsulfonyl)piperidin-4-amine methanesulfonate.
CAS# 73874-95-0
DCM
MeSO3H
DCM
Intermediate 13
NH2 •MsOH
A solution of but-3-yne-1-sulfonyl chloride (653 mg, 4.3 mmol) in DCM (36 ml_) under nitrogen was cooled in an acetone/dry ice bath. Solid 4-(N-Boc-amino)piperidine (714 mg, 3.6 mmol) was partially dissolved in DCM (8 mL) and was added via syringe. Triethylamine (646 pl_, 4.6 mmol) was added dropwise over 1 minute. The mixture was stirred in the cooling bath under nitrogen for 30 minutes. While still cooled, the reaction was diluted with saturated aqueous NaHCOs (10 mL) and deionized water (10 mL). The mixture was extracted with DCM (50 mL). The organic layer was dried over sodium sulfate and evaporated to give terf-butyl (1-(but-3-yn-1-ylsulfonyl)piperidin-4yl)carbamate (13a, 1.08 g, 96%) as a white solid. 1H NMR (400 MHz, CDCh) δ = 4.45 (brs, 1H), 3.76 (d, J=12.7 Hz, 2H), 3.66-3.48 (m, 1H), 3.17-3.08 (m, 2H), 3.03-2.88 (m, 2H), 2.70 (dt, J=2.7, 7.6 Hz, 2H), 2.17-2.07 (m, 1H), 2.03 (dd, J=2.9, 13.1 Hz, 2H), 1.541.35 (m, 11 H).
To a solution of terf-butyl (1-(but-3-yn-1-ylsulfonyl)piperidin-4-yl)carbamate (13a, 253 mg, 0.8 mmol) in DCM (8 mL) was added methanesulfonic acid (318 pL, 4.8 mmol), and the resulting solution stirred at room température for 30 minutes. The volatiles were evaporated and the residue suspended in ethyl ether (15 mL). The ether was decanted and the solid dried under high vacuum at room température to give 1-(but-3-yn-119219
104 ylsulfonyl)piperidin-4-amine methanesulfonate (Intermediate 13, 248 mg, 99%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 7.90 (br s, 3H), 3.65 (d, J=12.7 Hz, 2H), 3.27 (t, J=7.5 Hz, 2H), 2.93 (t, J=11.4 Hz, 2H), 2.57 (dt, J=2.6, 7.5 Hz, 2H), 2.36 (s, 5H), 1.96 (d, J=10.5 Hz, 2H), 1.51 (dq, J=3.9, 12.0 Hz, 2H). MS: 217 [M+H]+.
Intermediate 14: (+/-)-c/s-3-fluoro-1 -(methylsulfonyl)piperidin-4-amine.
14a Intermediate 14
Racemic c/s-(3-fluoro-piperidin-4-yl)-carbamic acid benzyl ester [Array Biopharma Inc. Patent: Triazolopyridine Compounds as PIM Kinase Inhibitors, WO2010/22081 A1, 2010] was sulfonylated by the method of Intermediate 12 and deprotected by the method of Intermediate 9 to give (+/-)-c/s-3-fluoro-1(methylsulfonyl)piperidin-4-amine (Intermediate 14) as a light yellow solid. 1H NMR (400 MHz, CDsOD) δ = ppm 4.66 (d, J=48.4 Hz, 1H), 4.01-3.94 (m, 1H), 3.78-3.74 (m, 1H), 3.00 (dd, J=36.9, 14.0 Hz, 1H), 2.98-2.91 (m, 1H), 2.88 (s, 3H), 2.82 (t, J=8 Hz, 1H), 1.79-1.73 (m, 2H). MS: 197 [M+H]+.
Other alkyl- and aryl-substituted sulfonylpiperidin-4-amines were synthesized by the methods of Intermediate 9, Intermediate 12, or Intermediate 13 and used crude, without purification or characterization, in the préparation of the example compounds on Table 1.
Intermediate 15: (±)-(1R*,2R*)-2-amino-1-ethylcyclopentan-1-ol.
CAS# 2146-38-5
15a
1) NH4OH, h2o
2) CbzCI, NaOH, H2O, THF
15b
H2
Pd/C
MeOH
Intermediate 15
105
Epoxidation of 1-ethylcyclopentene (CAS#2146-38-5) followed by ring opening and Cbz-deprotection by the method of Intermediate 1 afforded (±)-(1R*,2R*)-2-amino1-ethylcyclopentan-1-ol (Intermediate 15) as a yellow gum. 1H NMR (400 MHz, DMSOd6) δ = 2.86 (dd, J=3.5, 6.3 Hz, 1H), 2.03-1.92 (m, 1H), 1.63-1.51 (m, 4H), 1.41-1.35 (m, 2H), 1.20 (ddd, J=3.9, 7.2, 13.1 Hz, 1H), 0.87 (t, J=7.5 Hz, 3H).
Intermediate 15 was further elaborated by the method of Intermediate 2 and Method A to make Examples 194 and 195, as shown in Table 1.
Intermediate 16: (±)-(1 R*,2S*,4R*)-4-((terï-butyldiphenylsilyl)oxy)-2-methylcyclopentan1-amine.
H2 (30 psi)
Pd/C
EtOAc
16a
NaBH4
EtOH
NaOH
1. TBDPSCI, DBU
CH3CN
2. NaN3, Zn(TfO)2, TBAB, Boc2O, THF then, tBuOH
To a solution of ethyl 2-methyl-4-oxocyclopent-2-ene-1-carboxylate [Dolby, L. J. et al. J. Org. Chem. 1968, 33(12), 4508] (24.0 g, 119 mmol) in EtOAc (500 mL) was added 10 wt% Pd/C (6.0 g). Hydrogen gas was bubbled through the mixture for about 5 minutes, then the mixture was stirred under 30 psi hydrogen for 48 h. The hydrogen source was removed and the mixture was purged with nitrogen for 5 minutes. The Pd/C was filtered off using a pad of Celite®, which was washed with ethyl acetate. The filtrate was concentrated to afford 24 g yellow oil. The crude oil was purified via silica gel chromatography (eluting with petroleum ether/EtOAc 10/1 to 3/1) to give (±)-ethyl (1R*,2S*)-2-methyl-4-oxocyclopentane-1-carboxylate (16a, 19.3 g, 80%) as an oil. 1H NMR (400 MHz, CDCI3) δ = 4.16-4.09 (m, 2H), 3.15-3.08 (m, 1H), 2.63 (td, J=7.4, 14.6 Hz, 1H), 2.58-2.49 (m, 1H), 2.36-2.24 (m, 2H), 2.13-2.04 (m, 1H), 1.22 (t, J=7.2 Hz, 3H), 1.00 (d, J=7.0 Hz, 3H).
106
A solution of (±)-ethyl (1R*,2S*)-2-methyl-4-oxocyclopentane-1-carboxylate (16a, 10 g, 59 mmol) in éthanol (300 mL) was chilled to 0 °C under nitrogen. Sodium borohydride (1.11 g, 29.4 mmol) was added in small portions. The reaction was allowed to stir at 0 °C for 1 hour. The reaction was quenched by the slow addition of sat. aq. ammonium chloride solution (50 mL), followed by water (50 mL) to dissolve any solids. Ethanol was removed under reduced pressure and the aqueous residue extracted with MTBE (2 x 300 mL). The combined organics were washed with sat. aq. NaCI (500 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give (±)-ethyl (1R*,2S*,4R*)-4-hydroxy-2-methylcyclopentane-1-carboxylate (16b, 9.9 g, 97%) as a yellow oil. 1H NMR (400 MHz, CDCI3) δ = 4.24-4.16 (m, 1H), 4.14-4.03 (m, 2H), 3.57 (brs, 1H), 2.74 (dt, J=3.8, 7.4 Hz, 1H), 2.29-2.11 (m, 2H), 2.04-1.95 (m, 1H), 1.89 (td, J=3.6, 14.2 Hz, 1H), 1.35-1.26 (m, 1H), 1.23-1.18 (m, 3H), 0.95 (d, J=6.8 Hz, 3H).
A mixture of (±)-ethyl (1R*,2S*,4R*)-4-hydroxy-2-methylcyclopentane-1carboxylate (16b, 9.9 g, 57 mmol) in aqueous NaOH (115 mL of 1 M, 115 mmol) was stirred at room température for 18 h. MTBE (100 mL) was added and the layers separated. The aqueous layer was cooled to 0 °C and acidified to pH 1 by slow addition of aqueous HCl (5N). The aqueous suspension was extracted with EtOAc (4 x 200 mL). The combined organic layers were washed with sat. aq. NaCI (100 mL), dried over anhydrous magnésium sulfate, filtered and concentrated to give (±)-(1R*,2S*,4R*)-4hydroxy-2-methylcyclopentane-1-carboxylic acid (16c, 7.9 g, 95%) as a yellow oil. 1H NMR (400 MHz, DMSO-d6) δ = 12.01 (br s, 1H), 4.67 (br s, 1H), 4.02 (t, J=6.9 Hz, 1H),
2.67 (q, J=7.9 Hz, 1H), 2.19 (td, J=7.1, 14.1 Hz, 1H), 2.03-1.93 (m, 2H), 1.81-1.67 (m, 1H), 1.28-1.15 (m, 1H), 0.93 (d, J=6.3 Hz, 3H).
A solution of (±)-(1R*,2S*,4R*)-4-hydroxy-2-methylcyclopentane-1-carboxylic acid (16c, 7.9 g, 55 mmol), tert-butyl(chloro)diphenylsilane (TBDPSCI, 15.8 g, 57.5 mmol), and DBU (10 g, 66 mmol) in acetonitrile (200 mL) was stirred at room température for 15 h. The reaction mixture was concentrated and partitioned between DCM and sat. aq. ammonium chloride. The organic layer was washed with sat. aq. NaCI over sodium sulfate, concentrated, and purified by silica gel chromatography (eluting with 100% DCM to DCM/MeOH 20/1) to give (±)-(1R*,2S*,4R*)-4-((tertbutyldiphenylsilyl)oxy)-2-methylcyclopentane-1-carboxylic acid (18 g, 85%) as an impure yellow oil which was used in the next step without further purification.
107
To a solution of (±)-(1R*,2S*,4R*)-4-((tert-butyldiphenylsilyl)oxy)-2methylcyclopentane-1-carboxylic acid (700 mg, 1.83 mmol), sodium azide (297 mg, 4.57 mmol), tetrabutylammonium bromide (TBAB, 118 mg, 0.366 mmol), and zinc triflate (200 mg, 0.549 mmol) in THF (20 mL) was added di-fert-butyl dicarbonate (599 mg, 2.74 mmol). The mixture was stirred in a sealed tube under argon at 60 °C for 24 h, then terf-butanol (67.8 mg, 0.915 mmol) was added via syringe. Stirring was continues at 60 °C for another 24 h. The mixture was cooled to room température and quenched with 10% aqueous NaNCh (10 mL). Ethyl acetate was added and the biphasic mixture stirred for 30 min at room température. The two layers were separated, and the organic layer was washed successively with sat. aq. NH4CI (15 mL), and brine (15 mL). The organic solution was dried over sodium sulfate, filtered, and concentrated to give crude 16d as yellow oil. A total of seven individual batches were run separately on 700 mg scale as described above, then the batches were combined and purified via silica gel chromatography (petroleum ether/EtOAc 10/1) to give (±)-tert-butyl ((1R*,2S*,4R*)-4((tert-butyldiphenylsilyl)oxy)-2-methylcyclopentyl)carbamate (16d, 3.3 g, 56% from a total of seven batches of 700 mg each). MS: 476.1 [M+H]+, 1H NMR (400 MHz, DMSOd6) δ = 7.62-7.57 (m, 4H), 7.48-7.40 (m, 6H), 6.59 (d, J=8.8 Hz, 1H), 4.13 (t, J=6.1 Hz, 1H), 3.77-3.61 (m, 1H), 1.99-1.82 (m, 3H), 1.66 (td, J=6.6, 12.9 Hz, 1H), 1.37 (s, 10H), 1.00 (s, 9H), 0.88 (d, J=6.5 Hz, 3H). 2D NMR analysis confirmed the relative stereochemical assignment of ail cis.
Trifluoroacetic acid (10 mL) was added to a solution of (±)-tert-butyl ((1R*,2S*,4R*)-4-((tert-butyldiphenylsilyl)oxy)-2-methylcyclopentyl)carbamate (16d, 1.9 g, 4.2 mmol) in DCM (30 mL), and the solution was stirred at room température for 2 h. The reaction solution was concentrated, the residue diluted with DCM (100 mL), and sat. aq. NaHCOs (50 mL) was added to neutralize residual acid. The layers were separated and aqueous layer extracted with DCM (100 mL). The combined organic layers were dried, filtered and concentrated to give the crude (±)-(1 R*,2S*,4R*)-4-((tertbutyldiphenylsilyl)oxy)-2-methylcyclopentan-1-amine (Intermediate 16, 1.5 g) as an oil. 1H NMR (400 MHz, CDCI3) δ = 7.72 (dd, J=1.8, 7.8 Hz, 1H), 7.66 (ddd, J=1.5, 3.5, 7.8 Hz, 3H), 7.48-7.32 (m, 6H), 4.30-4.19 (m, 1H), 3.08 (d, J=4.3 Hz, 1H), 2.03-1.90 (m, 2H), 1.79 (br s, 1H), 1.68 (td, J=3.2, 13.9 Hz, 1H), 1.51-1.39 (m, 1H), 1.13-0.95 (m, 12H).
Intermediate 16 was further elaborated using the method of Intermediate 5, via SNAr addition to ethyl 4-chloro-2-(methylsulfanyl)pyrimidine-5-carboxylate, réduction of
108 the ester by LAH, and oxidation of the resulting alcohol by MnÜ2. The tertbutyldiphenylsilyl protecting group was incidentally cleaved during LAH réduction. Subséquent synthesis following Method A produced Examples 199 and 200, as shown in Table 1.
Intermedia te 17 (±)-(1R*,3S*,4S*)-3-amino-4-fluorocyclohexan-1-ol hydrochloride.
In a sealed polypropylene vessel a solution of (±)-(ieri-butyl (1 S*,3R*,6R*)-3(benzyloxy)-7-azabicyclo[4.1.0]heptane-7-carboxylate [Crotti, P. et al. J. Org. Chem. 1995, 60, 2514] (4.0 g, 13 mmol) and triethylamine trihydrofluoride (12.8 g, 79.2 mmol) in acetonitrile (10 mL) was stirred at 90 °C for 18 h. After cooling to room température, the mixture was partitioned between water and ethyl acetate. The organic layer was washed with sat. aq. NaCI, dried over sodium sulfate, concentrated, and purified by silica gel chromatography (eluting with petroleum ether/EtOAc 10/1 to 1/1) to afford 2.4 g of the desired product but with 85% purity by HPLC. This material was further purified by préparative HPLC to afford (±)-tert-butyl ((1 S*,2S*,5R*)-5-(benzyloxy)-2fluorocyclohexyl)carbamate (17a, 1.88 g, 44%) as white solid. 1H NMR (400 MHz, CD3OD) δ = 7.47-7.18 (m, 5H), 4.62-4.48 (m, 2H), 4.40-4.18 (m, 1H), 3.92 (brdd, J=3.9, 10.7 Hz, 1H), 3.78-3.68 (m, 1H), 2.16 (br dd, J=1.8, 11.0 Hz, 1H), 2.04-1.84 (m, 3H), 1.57-1.39 (m, 11 H).
A solution of (±)-tert-butyl ((1 S*,2S*,5R*)-5-(benzyloxy)-2fluorocyclohexyl)carbamate (17a, 1.88 g, 5.81 mmol) and Pd(OH)2/C (1.0 g) in methanol (100 mL) was stirred under 45 psi hydrogen at room température for 18 h. The catalyst was filtered off and the filtrate concentrated to afford (±)-tert-butyl ((1S*,2S*,5R*)-2fluoro-5-hydroxycyclohexyl)carbamate (17b, 1.36 g, 100%) as white solid which was used without further purification. 1H NMR (400 MHz, CD3OD) δ = 4.42-4.15 (m, 1H),
109
4.04-3.86 (m, 2H), 3.33 (td, J=1.6, 3.3 Hz, 1H), 2.00-1.82 (m, 3H), 1.81-1.71 (m, 1H), 1.62-1.50 (m, 2H), 1.46 (s, 9H).
To a solution of (±)-tert-butyl ((1S*,2S*,5R*)-2-fluoro-5hydroxycyclohexyl)carbamate (17b,1.36 g, 5.83 mmol) in MeOH (20 ml_) was added 4 M HCl in MeOH (20 mL, 80 mmol). The mixture was stirred at room température for 1 hour, then concentrated and lyophilized to give (±)-(1R*,3S*,4S*)-3-amino-4fluorocyclohexan-1-ol hydrochloride (Intermediate 17, 0.985 g, 100%) as a white hygroscopic solid. MS: 134.1 [M+H]+, 1H NMR (400 MHz, D2O) δ = 4.75-4.52 (m, 1H), 4.23-4.09 (m, 1H), 3.69-3.53 (m, 1H), 2.22-2.03 (m, 2H), 1.95-1.80 (m, 2H), 1.75-1.61 (m, 2H), 19F NMR (376MHz, D2O) δ = -179.8 (s, 1F).
Intermediate 17 was used without further purification as described for Intermediate 3 and Method A to afford Examples 217-220 shown in Table 1.
Intermediate 18: (1 S,2S,5R)-5-((fert-butyldiphenylsilyl)oxy)-2-methylcyclohexan-1amine.
TBDMSCI Imidazole
DMF
18a
18b
DPPA
Et3N
BnOH
Toluene
H2(1 atm)
10% Pd/C
MeOH
'OTBDMS
Intermediate 18
A solution of ethyl (1 S,2S,5R)-5-hydroxy-2-methylcyclohexane-1-carboxylate [Raw, A.S. and Jang, E.B. Tetrahedron 2000, 56, 3285-3290] (6.25 g, 33.6 mmol), imidazole (6.85 g, 101 mmol), and tert-butyl(chloro)diphenylsilane (18.4 g, 67.1 mmol) in DMF (80 mL) was stirred at 20 °C for 40 h. The reaction was quenched with deionized water (200 mL) and extracted with ethyl acetate (3 x 80 mL). The combined organics were washed with sat. aq. NaCI, dried over sodium sulfate, concentrated, and purified by silica gel chromatography (eluting with ethyl acetate in pet. ether) to give ethyl (1 S,2S,5R)-5-((tert-butyldimethylsilyl)oxy)-2-methylcyclohexane-1 -carboxylate
110 (18a, 10.5 g, 74%) as a light yellow oil. 1H NMR (400 MHz, CDCI3) δ = 7.72-7.62 (m, 4H), 7.47-7.35 (m, 6H), 4.21-4.02 (m, 3H), 2.67-2.50 (m, 1H), 1.87-1.77 (m, 1H), 1.691.58 (m, 3H), 1.52-1.32 (m, 3H), 1.26 (t, J=7.2 Hz, 3H), 1.10-1.07 (m, 9H), 0.95 (d, J=6.0 Hz, 3H).
A mixture of sodium hydroxide (4.71 g, 118 mmol) and (1 S,2S,5F?)-5-((tertbutyldimethylsilyl)oxy)-2-methylcyclohexane-1-carboxylate (18a, 5.0 g, 11.8 mmol) in éthanol (80 mL) and deionized water (80 mL) was stirred at 80 °C for 15 h. The volatiles were evaporated and the aqueous residue neutralized to pH 6 with 1N HCl. The product was extracted with ethyl acetate (3 x 100 mL). The combined organics were washed with sat. aq. NaCI, dried over sodium sulfate, concentrated, and purified by silica gel chromatography (eluting with ethyl acetate in pet. ether) to give (1S,2S,5R)-5-((fertbutyldimethylsilyl)oxy)-2-methylcyclohexane-1-carboxylic acid (18b, 2.55 g, 55%) as a light grey solid. Chiral SFC showed no epimerization. [Major peak at rt 2.72 min, Chiral SFC method: Column: ChiralCel OJ-H 150x4.6mm I.D., 5pm. Mobile phase: A: CO2 B: éthanol (0.05% DEA). Gradient: from 5% to 40% of B in 5.5min and hold 40% for 3 min, then 5% of B for 1.5 min. Flow rate: 2.5mL/min Column température at 40 °C].
A solution of (1 S,2S,5R)-5-((tert-butyldimethylsilyl)oxy)-2-methylcyclohexane-1carboxylic acid (18b, 4.0 g, 10.1 mmol), triethylamine (3.1 g, 30.3 mmol), and diphenyl phosphoryl azide (DPPA, 4.2 g, 15.1 mmol) in toluene (100 mL) was stirred at 110 °C for 3 h. Benzyl alcohol (5.5 g, 50.4 mmol) was added and stirring continued at 110 °C for 32 h more. After cooling to room température, the reaction was concentrated and the residue was purified by silica gel chromatography (eluting with ethyl acetate in pet. ether) to give benzyl ((1 S,2S,5R)-5-((tert-butyldiphenylsilyl)oxy)-2methylcyclohexyl)carbamate (18c, 2.8 g, 55%) as an oil. 1H NMR (400 MHz, CDCI3) δ =
7.79-7.62 (m, 4H), 7.48-7.31 (m, 11 H), 5.26-5.07 (m, 2H), 4.49-4.37 (m, 1H), 4.18-4.05 (m, 1H), 3.92-3.71 (m, 1H), 2.11-1.92 (m, 1H), 1.78-1.60 (m, 3H), 1.35-1.19 (m, 3H), 1.14-1.01 (m, 12H). MS; 524 [M+Na]+.
Benzyl ((1S,2S,5R)-5-((fert-butyldiphenylsilyl)oxy)-2-methylcyclohexyl)carbamate (18c, 3.50 g, 6.98 mmol) in methanol (75 mL) was treated with 10% palladium on carbon (350 mg) and stirred at 30 °C under a hydrogen balloon for 16 h. The catalyst was removed by filtration and the filtrate was evaporated to give (1 S,2S,5R)-5-((tertbutyldiphenylsilyl)oxy)-2-methylcyclohexan-1-amine (Intermediate 18, 2.5 g, 98%) as an Oil. 1HNMR (400 MHz, CDCI3) δ = 7.77-7.61 (m, 4H), 7.47-7.35 (m, 6H), 4.26-4.09
111 (m, 1H), 2.95-2.77 (m, 1H), 1.91-1.83 (m, 1H), 1.67-1.58 (m, 3H), 1.53-1.43 (m, 1H), 1.35-1.23 (m, 1H), 1.20-1.12 (m, 2H), 1.09 (s, 12H). MS: 368 [M+H]+.
Intermediate 18 was employed in synthesis using the methods of Intermediate 3 and Method A, with silyl deprotection by TBAF as an additional step before thioether oxidation with OXONE®, to produce Example 216, as shown in Table 1.
Intermediate 19: (±)-(3S*,4R*)-4-((5-(hydroxymethyl)-2-(methylthio)pyrimidin-4yl)amino)-3-methyltetrahydrofuran-3-ol.
Intermediate 19
By the method of Intermediate 5, 5νΑγ addition of ethyl 4-chloro-2(methylsulfanyl)pyrimidine-5-carboxylate (CAS# 5909-24-0) (6.0 g, 26 mmol), and (±)(3S*,4R*)-4-amino-3-methyltetrahydrofuran-3-ol hydrochloride [Eli Lilly and Co. Patent: Sélective Androgen Receptor Modulators. WO 2013/055577 A1,2013] (6.1 g, 28 mmol) with diisopropylethyl amine (20 g, 155 mmol) in éthanol (120 mL) afforded (±)-ethyl 4(((3R*4S*)-4-hydroxy-4-methyltetrahydrofuran-3-yl)amino)-2-(methylthio)pyrimidine-5carboxylate (19a, 6.2 g, 77%), which was then reduced by LAH (1.91 g, 50.5 mmol) in THF (150 mL). After aqueous workup, the major isomer was isolated by préparative HPLC, to give (±)-(3S*4R*)-4-((5-(hydroxymethyl)-2-(methylthio)pyrimidin-4-yl)amino)-
3-methyltetrahydrofuran-3-ol (Intermediate 19, 1.51 g, 33%) as a white solid. 1H NMR (400 MHz, CDCh) δ = 7.80 (s, 1H), 6.08 (d, J=6.0 Hz, 1H), 4.65-4.56 (m, 3H), 4.36 (dd, J=9.16, 7.65 Hz, 1H), 3.90 (d, J=9.0 Hz,1H), 3.76 (d, J=9.3 Hz, 1H), 3.65 (dd, J=9.16, 6.90 Hz, 1H), 2.54-2.49 (m, 3H), 1.26 (s, 3H).
Intermediate 19 was oxidized to the corresponding aldéhyde using MnO2 by the method of Intermediate 5, and further elaborated by Method A to synthesize Examples 197 and 198 and Example 198, as shown in Table 1
112
Intermediate 20: (±)-(1 R*,2S*,3R*)-3-((5-(hydroxymethyl)-2-(methylthio)pyrimidin-4yl)amino)-2-methylcyclopentan-1-ol.
Intermediate 21 : (±)-(1 /?*,2/?*,3S*)-3-((5-(hydroxymethyl)-2-(methylthio)pyrimidin-4yl)amino)-2-methylcyclopentan-1-ol.
Intermediate 22: (±)-(1 R*,2R*,3R*)-3-((5-(hydroxymethyl)-2-(methylthio)pyrimidin-4yl)amino)-2-methylcyclopentan-1-ol.
EtOAc h2 Pd(OH)2 DIPEA
1) KOH, H2O
2) (Boc)2O
dioxane
HCl
20a 20b
(+/-)-(1 R* 2S*,3R*) (+/-)-(1 R4,2R*,3S*) (+/-)-(1 R* 2R*,3R*)
Intermediate 20 Intermediate 21 Intermediate 22
A suspension of /V-(2-methyl-3-oxocyclopent-1-en-1-yl)acetamide [Huang, K.; Guan, Z.-H.; Zhang, X., Tel Lett., 2014, 55, 1686 - 1688] (17.6 g, 115 mmol), 20% Pd(OH)2 (wet) (4.4 g, 28.8 mmol), and DIPEA (37.2 g, 288 mmol) in ethyl acetate (80 mL) was hydrogenated in a stainless steel reactor at 20 Bar and 80 °C for 18 h. The catalyst was removed by filtration through a bed of Celite®, and the filter cake washed with ethyl acetate (100 mL) and water (100 mL). The biphasic filtrate layers were separated, and the aqueous layer extracted with ethyl acetate (3 x 30 mL). The combined organics were dried over sodium sulfate and concentrated to give a mixture of diastereomers of /V-(3-hydroxy-2-methylcyclopentyl)acetamide (20a, 2.32 g), as a yellow oil. A different mixture of 20a diastereomers remained in the aqueous layer, which were not isolated but carried on in solution. Both fractions were taken to the next step without further purification.
113
Solid potassium hydroxide (8.21g, 146 mmol) was added portion wise to a solution of /V-(3-hydroxy-2-methylcyclopentyl)acetamide (20a, 2.30 g, from the organic extracts above) in water (100 mL). The mixture was heated to 90 °C for 72 h. After cooling the solution to room température, di-tert-butyl-dicarbonate (6.39 g, 29.3 mmol) and tetrahydrofuran (150.0 mL) were added. The reaction was stirred at room température for 48 h. After aqueous work-up the products were purified by silica gel chromatography (eluting with 0-80% ethyl acetate/heptane) to give terï-butyl (3-hydroxy-
2-methylcyclopentyl)carbamate (20b, 3.15 g) as a mixture of diastereomers. The aqueous layer from the first step, containing a different mixture of 20a diastereomers, was hydrolyzed and Boc-protected by the same procedure to give a second batch of 20b (10.1 g, mixture of diastereomers).
A solution of tert-butyl (3-hydroxy-2-methylcyclopentyl)carbamate (20b, 9.3 g,
43.2 mmol) in 1,4-dioxane (50 mL) was treated with hydrochloric acid (216 mL of a 4M solution in 1,4-dioxane, 864 mmol), and stirred at room température for 2 h. The volatiles were evaporated, leaving crude 3-amino-2-methylcyclopentan-1-ol hydrochloride (20c, 7.0 g) as a mixture of diastereomers, which was used in the subséquent reaction without further purification. The other batches of 20b were treated similarly to obtain batches of 20c with different mixtures of diastereomers.
A solution of crude 3-amino-2-methylcyclopentan-1-ol hydrochloride (20c, 7.0 g,
60.78 mmol, mixture of diastereomers), diisopropylethyl amine (39.3 g, 304 mmol), [4chloro-2-(methylsulfanyl)pyrimidin-5-yl]methanol (CAS# 1044145-59-6) (11.6 g, 60.8 mmol) in DMSO (20 mL) was heated to 50 °C for 48 h. Triethylamine (18.5 g, 182 mmol) was added, and heating continued for 20 h more. The reaction mixture was poured into ice/water and extracted with ethyl acetate (3 x100 mL). The combined organics were washed with saturated aqueous NaCI (3 x 100 mL), washed with deionized water (100 mL), dried over sodium sulfate and concentrated to give 3-((5-(hydroxymethyl)-2(methylthio)pyrimidin-4-yl)amino)-2-methylcyclopentan-1-ol as a mixture of diastereomers. The other batches of 20c were treated similarly to obtain different mixtures of diastereomers.
The various mixtures of 3-((5-(hydroxymethyl)-2-(methylthio)pyrimidin-4yl)amino)-2-methylcyclopentan-1-ol diastereomers were resolved into four separate racemic pairs over several steps by crystallization, flash chromatography, and nonchiral préparative HPLC. Stereochemistry of the resulting enantiomeric pairs was determined by 2-D NMR.
114 (±)-(1R*,2S*,3R*)-3-((5-(hydroxymethyl)-2-(methylthio)pyrimidin-4-yl)amino)-2methylcyclopentan-1-ol (Intermediate 20): 1H NMR (400 MHz, DMSO-d6) δ = 7.81 (s, 1H), 6.46 (d, J=7.8 Hz, 1H), 5.10 (t, J=5.5 Hz, 1H), 4.43 (d, J=4.2 Hz, 1H), 4.33 (d, J=5.5 Hz, 2H), 4.24 (quin, J=8.5 Hz, 1H), 3.99 (d, J=3.0 Hz, 1H), 2.42 (s, 3H), 2.12-2.23 (m, 1H), 1.87-2.00 (m, 1H), 1.75-1.87 (m, 1H), 1.46-1.59 (m, 1H), 1.27-1.41 (m, 1H),
0.94 (d, J=6.8 Hz, 3H). MS: 270 [M+H]+.
(±)-(1R*,2R*,3S*)-3-((5-(hydroxymethyl)-2-(methylthio)pyrimidin-4-yl)amino)-2methylcyclopentan-1-ol (Intermediate 21): 1H NMR (400 MHz, DMSO-d6) δ = 7.81 (s, 1H), 6.57 (d, J=7.8 Hz, 1H), 5.11 (t, J=5.5 Hz, 1H), 4.73 (d, J=4.Q Hz, 1H), 4.32 (d, J=5.5 Hz, 2H), 3.86-4.13 (m, 1H), 3.48-3.69 (m, 1H), 2.40 (s, 3H), 1.93-2.08 (m, 1H),
1.79-1.93 (m, 1H), 1.65-1.79 (m, 1H), 1.44-1.62 (m, 2H), 0.98 (d, J=6.8 Hz, 3H). MS: 270 [M+H]+.
(±)-(1R*,2R*,3R*)-3-((5-(hydroxymethyl)-2-(methylthio)pyrimidin-4-yl)amino)-2methylcyclopentan-1-ol (Intermediate 22): 1H NMR (400 MHz, DMSO-d6) δ = 7.81 (s, 1H), 6.34 (d, J=7.9 Hz, 1H), 5.21 (t, J=5.4 Hz, 1H), 4.57-4.70 (m, 2H), 4.25-4.41 (m, 2H), 3.74 (quin, J=5.1 Hz, 1H), 2.34-2.46 (m, 3H), 2.00-2.12 (m, 2H), 1.89-2.00 (m, 1H), 1.49-1.63 (m, 1 H), 1.31-1.47 (m, 1 H), 0.74 (d, J=7.2 Hz, 3H). MS: 270 [M+H]+.
The fourth of the four possible pairs of enantiomers was also isolated, but not used in further synthesis. (±)-(1/?*,2S*,3S*)-3-((5-(hydroxymethyl)-2-(methylthio)pyrimidin-4-yl)amino)-2-methylcyclopentan-1-ol: 1H NMR (400 MHz, DMSO-d6) δ = 7.78 (s, 1H), 6.64 (d, J=8.7 Hz, 1H), 5.13 (t, J=5.2 Hz, 1H), 4.75 (d, J=3.4 Hz, 1H), 4.44-4.62 (m, 1H), 4.30 (s, 2H), 3.89-4.05 (m, 1H), 2.41 (s, 3H), 1.91-2.04 (m, 2H), 1.73-1.81 (m, 1H), 1.54-1.73 (m, 2H), 0.89 (d, J=7.1 Hz, 3H). MS: 270 [M+H]+.
Intermediate 20, Intermediate 21, and Intermediate 22 were separately oxidized to the corresponding aldéhydes by MnO2 using the method of Intermediate 1, and further elaborated by Method A and other general synthetic methods described herein to synthesize Examples 201-210 shown in Table 1.
Intermediate 23: (±)-(1 S*,2R*,3S*)-3-((5-(hydroxymethyl)-2-(methylthio)pyrimidin-4yl)amino)-2-methylcyclohexan-1-ol
HCl
1,4-dioxane
DMSO
Intermediate 23
A solution of /V-(2-methyl-3-oxocyclohex-1-en-1-yl)acetamide [CAS# 36887-93-1] (20 g, 120 mmol), DIPEA (38.8 g, 300 mmol) and 20 % Pd/C (2 g, 12 mmol) in ethyl acetate (80 mL) was hydrogenated in a stainless steel vessel under 20 bar hydrogen at 80 °C for 20 h. The reaction mixture was filtered while still hot, and the filter cake washed with hot ethyl acetate. The combined filtrate was concentrated and the solid residue crystallized in DCM/heptane to give a mixture of diastereomers of A/-(3-hydroxy2-methylcyclohexyl)acetamide (23a, 10.0g, 51%) as a white solid.
Solid potassium hydroxide (22.9 g, 409 mmol) was added portion wise to a solution of A/-(3-hydroxy-2-methylcyclohexyl)acetamide (23a, 7.0 g, 40 mmol) in water (200.0 mL). The reaction was heated to 100 °C for 24 h and then to 90 °C for 72 h more. The solution was cooled to room température and di-tert-butyl dicarbonate (9.8 g, 45.0 mmol) and tetrahydrofuran (150 mL) were added. Stirring was continued at room température for 48 h. The solution was extracted with ethyl acetate (3 x 100 mL) and the organics were combined, dried over sodium sulfate and concentrated. The residue was purified by silica gel chromatography (eluting with 0-100% ethyl acetate in heptane) to give teri-butyl (3-hydroxy-2-methylcyclohexyl)carbamate (23b, 2.50 g, 30%) as a diastereomeric mixture. 1H NMR (400 MHz, CDCh) δ = 4.20-4.60 (m, 1H), 3.84-4.04 (m, 1H), 3.44-3.66 (m, 1H), 1.89-2.02 (m, 1H), 1.67-1.88 (m, 2H), 1.49-1.58 (m, 1H), 1.45 (s, 9H), 1.14-1.42 (m, 2H), 0.95-1.12 (m, 3H).
A solution of tert-butyl (3-hydroxy-2-methylcyclohexyl)carbamate (23b, 2.50g, 10.9 mmol) in 1,4-dioxane (100 mL) was treated with hydrochloric acid (40.9 mL of a 4M
116 solution in 1,4-dioxane, 164 mmol), and stirred at room température for 20 h. The volatiles were removed and the residue dried in a vacuum oven for 72 h to give a mixture of diastereomers of 3-amino-2-methylcyclohexan-1-ol hydrochloride (23c, 1.68 g, 93%) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ = 7.57-8.28 (m, 3H), 3.58-
3.78 (m, 1H), 2.55-3.19 (m, 1H), 1.71-2.01 (m, 1H), 1.60-1.71 (m, 1H), 1.51-1.60 (m, 2H), 1.06-1.51 (m, 3H), 0.70-1.06 (m, 3H).
A solution of [4-chloro-2-(methylsulfanyl)pyrimidin-5-yl]methanol (CAS# 104414559-6) (2 g, 10.5 mmol), 3-amino-2-methylcyclohexan-1-ol hydrochloride (23c 1.5 g, 11.7 mmol, mixture of diastereomers) and DIPEA (4.5 g, 35.1 mmol) in DMSO (20.0 mL) was heated to 50 °C for 20 h, then poured over ice/water and extracted with ethyl acetate (3 x 100 mL). The organics were washed with sat. aq. NaCI (3 x 50 mL), dried over sodium sulfate, concentrated, and purified by silica gel chromatography, eluting with 0-100% ethyl acetate in heptane. This method was adéquate to separate the desired diastereomer, (+)-(1 S*, 2R*,3S*)-3-((5-(hydroxymethyl)-2-(methylthio)pyrimidin-4yl)amino)-2-methylcyclohexan-1-ol (Intermediate 23, 169 mg, 5.7%, the least polar of the product peaks) as a white solid. The relative stereochemistry was determined by 2-D NMR. 1H NMR (400 MHz, DMSO-d6) δ = 7.79 (s, 1H), 6.30 (d, J=8.6 Hz, 1H), 5.12 (t, J=5.5 Hz, 1H), 4.36 (d, J=3.9 Hz, 1H), 4.32 (d, J=5.5 Hz, 2H), 4.05-4.17 (m, 1H), 3.77 (brs, 1H), 2.41 (s, 3H), 1.78-1.94 (m, 1H), 1.68-1.75 (m, 1H), 1.54-1.65 (m, 1H), 1.331.50 (m, 2H), 1.11-1.29 (m, 2H), 0.89 (d, J=6.8 Hz, 3H). MS: 284 [M+H]+.
Intermediate 23 was oxidized to the corresponding aldéhyde with MnO2, then further elaborated by Method A to make Examples 221 and 222 shown in Table 1.
Examples
General Methods and Représentative Examples
Method A (Aldol cyclization)
Example 1: 8-cyclopentvl-2-{[1-(methvlsulfonvl)piperidin-4-vl1amino}pvrido[2,3ç/]pyrimidin-7(8/-/)-one
117
Ο
1Α 1Β
DMSO
Example 1
To a solution of 4-(cyclopentylamino)-2-(methylsulfanyl)pyrimidine-5carbaldehyde [VanderWel, et al. J. Med. Chem. 2005, 48, 2371] (2.0 g, 8.4 mmol) in anhydrous THF (50 mL) was added EtOAc (2.23 g, 25.3 mmol) at -70 °C. The mixture was stirred at this température for 15 min, then LHMDS (1.0 M in THF, 29.5 mmol, 29.5 mL) was added dropwise. The reaction was stirred at -70 °C for 30 min and then at 20 °C for 16 h. The solution was cooled in an ice bath, quenched with water, and then extracted with EtOAc (50 mL x 3). The combined organic layers were washed with aq NH4CI (30 mL), and sat. aq NaCI (30 mL), dried over sodium sulfate, and concentrated. The residue was purified by silica gel chromatography (eluting with petroleum ether/EtOAc 10/1 to 3/1) to give 8-cyclopentyl-2-(methylsulfanyl)pyrido[2,3-cT|pyrimidin7(8H)-one (1A, 2.01 g, 91%) as a white solid. MS: 262 [M+H]+.
OXONE®, (23.5 g, 38.3 mmol) was added to a cooled (0 °C) solution of 8cyclopentyl-2-(methylsulfanyl)pyrido[2,3-c/]pyrimidin-7(8H)-one (1A, 5.0 g, 19.13 mmol) in THF (100 mL) and water (20 mL), and the mixture stirred at room température for 2 h. The mixture was diluted with EtOAc (300 mL), washed with water (100 mL), dried over sodium sulfate, and concentrated to give crude 8-cyclopentyl-2(methylsulfonyl)pyrido[2,3-d]pyrimidin-7(8/-/)-one (1B, 5.40 g, 96%) as a gray solid. MS: 315 [M+Na]+.
A solution of crude 8-cyclopentyl-2-(methylsulfonyl)pyrido[2,3-c/]pyrimidin-7(8/-/)one (1B, 5.40 g, 17.0 mmol), 4-amino-1-methanesulfonylpiperidine (CAS# 402927-97-3, 5.34 g, 24.9 mmol) and DIPEA (14.7 mL, 82.8 mmol) in DMSO (70 mL) was stirred at 65 °C for 18 h. The reaction mixture was diluted with DCM (150 mL), washed with aq NH4CI (80 mL x 2), dried over sodium sulfate, and concentrated to dryness. The crude
118 product was recrystallized with 1/2 EtOAc:petroleum ether (50 mL) to give 8cyclopentyl-2-{[1-(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-c/]pyrimidin-7(8/-/)-one (Example 1, 4.65 g, 72%) as a gray solid. 1H NMR (400 MHz, DMSO-d6) δ = 8.68-8.54 (m, 1H), 7.88 (d, J=6.3 Hz, 1H), 7.68 (d, J=9.3 Hz, 1H), 6.28-6.16 (m, 1H), 5.92-5.74 (m, 1H), 4.02-3.82 (m, 1H), 3.58 (d, J=10.8 Hz, 2H), 2.96-2.82 (m, 5H), 2.33 (d, J=1.8 Hz, 1H), 2.19 (brs, 1H), 2.03-1.91 (m, 4H), 1.78-1.55 (m, 6H). MS: 392 [M+H]+.
Example 2: 8-[(1R,2R)-2-hvdroxv-2-methylcvclopentvll-2-{[1-(methvlsulfonvl)piperidin-
4-vl1amino}pvridor2,3-cnpvrimidin-7(8H)-one
Example 2
To a 2L three-necked flask equipped with a mechanical stirrer and an internai thermometer was added solid 4-{[(1R,2R)-2-hydroxy-2-methylcyclopentyl]amino}-2(methylsulfanyl)pyrimidine-5-carbaldehyde (Intermediate 2, 34.2 g, 128 mmol), THF (400 mL), and EtOAc (33.4 mL, 333 mmol). The solution was purged with nitrogen and cooled in a MeOH-ice bath to -5 °C internai. Via cannula, LHMDS (1.0 M solution in THF, 4 x 100 mL freshly opened bottles, 400 mmol) was added, slowly enough to keep the internai température at -5 °C. A light yellow precipitate began to form after -300 mL LHMDS solution had been added. Stirring was continued as the mixture was allowed to gradually warm to room température overnight. The resulting red solution was cooled in an ice-water bath to -3 °C internai, then EtOH (224 mL, 3840 mmol) was added via cannula, slowly enough to keep the internai temp at -3 °C internai. The mixture was stirred in the ice bath for 1 hour, then the cooling bath was removed, the solution allowed to warm to 20 °C internai, and stirring continued for 1 h. The solvents were
119 evaporated, the residue diluted with water (180 mL) and sat. aq NaCI (180 mL), and the aqueous layer extracted with EtOAc (700 mL, then 600 mL x 2). The combined organic extracts were dried over sodium sulfate and concentrated to a light yellow-brown foam (43.8 g). This foam was dissolved in EtOAc (70 mL) and sonicated to induce précipitation. The resulting solid was collected by filtration, rinsed with EtOAc (10 mL), and dried to give 8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2(methylsulfanyl)pyrido[2,3-c/]pyrimidin-7(8/-/)-one (2A, 21.4 g, 58%, >99%ee) as a white solid. 1H NMR (400 MHz, CDCIs) δ = 8.61 (s, 1H), 7.56 (d, J=9.4 Hz, 1H), 6.60 (d, J=9.4 Hz, 1H), 5.84 (t, J=8.6 Hz, 1H), 2.92-2.76 (m, 1H), 2.64 (s, 3H), 2.34-2.19 (m, 2H), 2.132.01 (m, 2H), 2.00-1.81 (m, 2H), 1.16 (s, 3H). MS: 292 [M+H]+. Optical rotation: [a]D 22 = -12.9 (c 1.0, MeOH). Chiral purity: >99%ee. Chiral SFC/MS analysis was performed on a Chiralpak AD-3, 4.6 x 100mm, 3pm column heated to 25 °C and eluted with a mobile phase of CO2 and 40% methanol flowing at 4.0 mL/min and maintained at 120 bar outlet pressure. The product peak had a rétention time of 0.85 min.
The mother liquor from the above précipitation was evaporated to dryness. The residue (24.5 g) was dissolved in EtOAc (30 mL) and the solution sonicated to induce précipitation. After filtration and drying, a second crop of 8-[(1R,2R)-2-hydroxy-2methylcyclopentyl]-2-(methylsulfanyl)pyrido[2,3-c/]pyrimidin-7(8H)-one (2A, 4.70 g, 13%, >99% ee) was obtained as a white solid. The total yield for both crops was 26.1 g (71% at >99%ee) after crystallization.
A solution of 8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-(methylsulfanyl)pyrido[2,3-d]pyrimidin-7(8/-/)-one (2A, >99% ee, 2.33 g, 8 mmol), 2-MeTHF (40 mL), water (8 mL) and OXONE® (12.3 g, 20 mmol) was stirred at room température for 4 h. The solution was cooled in a water bath, diluted with water (10 mL) and sat. aq NaCI (10 mL), and extracted with EtOAc (80 mL x 3). The combined organic extracts were dried over sodium sulfate, evaporated to a dark oil (3.76 g), and purified by silica gel chromatography (eluting with a gradient of 20-100% EtOAc in heptane) to give 8[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-(methylsulfonyl)pyrido[2,3-c/]pyrimidin-7(8H)one (2B, 2.2 g, 84%) as a foamy solid. 1H NMR (400 MHz, CDCI3) δ = 8.96 (s, 1H), 7.74 (d, J=9.5 Hz, 1H), 6.90 (d, J=9.4 Hz, 1H), 5.77 (t, J=8.5 Hz, 1H), 3.40 (s, 3H), 2.92-2.73 (m, 1H), 2.36-2.25 (m, 1H), 2.19-2.08 (m, 2H), 2.03-1.85 (m, 2H), 1.14 (s, 3H). MS: 306 [M-18]+.
A solution of 8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-(methylsulfonyl)pyrido[2,3-c/]pyrimidin-7(8/-/)-one (2B, 800 mg, 2.47 mmol), and 4-amino-1
120 methanesulfonylpiperidine (CAS# 402927-97-3, 970 mg, 5.44 mmol) in 2-MeTHF (12.4 mL) was heated in a 60 °C oil bath for 24 h. After cooling to room température, the mixture was partitioned between EtOAc (80 mL), water (10 mL) and sat. aq NaHCOs (10 mL). The aqueous layer was further extracted with EtOAc (60 mL x 2). The combined organic extracts were dried over sodium sulfate and evaporated to dryness. The residue (1.23 g) was dissolved in EtOAc (11 mL), seed crystals were added, and the solution allowed to stand at room température overnight. The resulting solid was collected by filtration, rinsed with EtOAc (3 mL) and dried to give 8-[(1 R,2R)-2-hydroxy2-methylcyclopentyl]-2-{[1-(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-c/]pyrimidin7(8/7)-one (Example 2, 680 mg, 63%, >99%ee) as a white solid. 1H NMR (400 MHz, CDCh) δ = 8.43 (s, 1H), 7.45 (d, 7=9.3 Hz, 1H), 6.36 (d, 7=9.4 Hz, 1H), 5.73 (t, 7=8.4 Hz, 1H), 5.34 (brs, 1H), 4.01 (br s, 1H), 3.88-3.74 (m, 2H), 3.01-2.89 (m, 2H), 2.83 (s, 4H), 2.36 (brs, 1H), 2.29-2.14 (m, 3H), 2.03 (dt, 7=2.9, 6.3 Hz, 2H), 1.98-1.89 (m, 1H), 1.88-1.81 (m, 1H), 1.78-1.60 (m, 2H), 1.18 (s, 3H). MS: 422 [M+H]+. Optical rotation: [o]d22 -17.0 (c 1.0, CHCh). Chiral purity: >99% ee. Chiral SFC/MS analysis was performed on a Lux Cellulose-1,4.6 x 100mm, 3pm column heated to 25 °C and eluted with a mobile phase of CO2 and 5-60% methanol gradient in 3.0 min flowing at 4.0 mL/min and maintained at 120 bar outlet pressure. The product peak had a rétention time of 2.37 min.
The filtrate from the above crystallization was concentrated to dryness, the residue dissolved in EtOAc (50 mL), and the solution washed with aq HCl (0.1 M, 12.4 mL). The organic layer was washed with sat. aq NaHCOs (20 mL), dried over sodium sulfate, and concentrated, affording a second batch of 8-[(1R,2/?)-2-hydroxy-2methylcyclopentyl]-2-{[1-(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-c/]pyrimidin7(8/7)-one (Example 2, 361 mg, 31%, 94% total yield), with NMR and LCMS spectra consistent with the first crop.
Example 3: 8-[(1R,3R)-3-hvdroxvcyclohexyll-2-{[1-(methylsulfonyl)piperidin-4-yl1amino}pyrido[2,3-cflpyrimidin-7(8/-/)-one
121
Intermediate 3
3A 3B
DIEA
DMSO
A solution of LHMDS (1.0 M in THF, 60.7 mL, 60.7 mmol) was added dropwise to a chilled (-70 °C) solution of EtOAc (3.56 g, 40.4 mmol) in THF (40 mL). The mixture was stirred at 0 °C for 30 min, then a solution of 4-{[(1/?,3/?)-3hydroxycyclohexyl]amino}-2-(methylsulfanyl)pyrimidine-5-carbaldehyde (Intermediate 3, 2.70 g, 10.1 mmol) in THF (10 mL) was added dropwise. When addition was complété, stirring was continued at room température for 18 h. The solution was quenched with water (40 mL) and extracted with EtOAc (40 mL x 3). The combined organic extracts were dried over sodium sulfate, concentrated, and the residue purified by silica gel chromatography (eluting with 0-4% MeOH in DCM) to give 8-[(1F?,3F?)-3hydroxycyclohexyl]-2-(methylsulfanyl)pyrido[2,3-d]pyrimidin-7(8/-/)-one (3A, 1.46 g, 50%) as a light yellow solid. 1H NMR (400 MHz, CDCh) δ = 8.57 (s, 1H), 7.53 (d, J=9.3 Hz, 1H), 6.58 (br d, J=9.3 Hz, 1H), 6.02 (br s, 1H), 4.37 (t, J=2.6 Hz, 1H), 2.97 (br s, 1H), 2.66-2.61 (m, 3H), 1.96-1.69 (m, 6H), 1.61 (br t, J=13.4 Hz, 2H). MS: 292 [M+H]+. Optical rotation: [o]d22 +15.2 (c 1.8, MeOH).
Solid OXONE® (13.8 g, 22.4 mmol) was added in portions to a chilled (0 °C) solution of 8-[( 1 R,3R)-3-hydroxycyclohexyl]-2-(methylsulfanyl)pyrido[2,3-c(]pyrimidin7(8H)-one (3A, 2.18 g, 7.48 mmol) in THF (30 mL) and water (20 mL). The mixture was stirred for 2 h, as it was allowed to gradually warm to ~15 °C. The solution was diluted with EtOAc (50 mL) and washed with water (50 mL). The organic layer was dried over sodium sulfate and concentrated to give an ~3:1 mixture of sulfone 8-[(1 F?,3F?)-3hydroxycyclohexyl]-2-(methylsulfonyl)pyrido[2,3-c/]pyrimidin-7(8/-/)-one and sulfoxide 8[(1F?,3R)-3-hydroxycyclohexyl]-2-(methylsulfinyl)pyrido[2,3-c/]pyrimidin-7(8H)-one (3B,
122
1.80 g, 79%) as a light yellow solid. MS: 330 [M+Na]+ for sulfoxide; 346 [M+Na]+ for sulfone.
A solution of the sulfone/sulfoxide mixture prepared above (1.80 g, 5.6 mmol), 4amino-1-methanesulfonylpiperidine (CAS# 402927-97-3, 2.08 g, 11.7 mmol), and DIPEA (3.60 g, 34.9 mL) in DMSO (30 ml_) was stirred in a 60 °C oil bath for 2 h, then at room température overnight. The mixture was partitioned between DCM (30 mL) and water (30 mL x 2). The organic layer was washed with sat. aq NaCI (30 mL), dried over sodium sulfate, and concentrated. The residue was purified by silica gel chromatography (eluting with 0-3% MeOH in DCM) to give 8-[(1 R,3R)-3hydroxycyclohexyl]-2-{[1-(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-d]pyrimidin7(8/-/)-one (Example 3, 2.12 g, 90%) as a yellow solid. 1H NMR (400 MHz, CDCh) δ = 8.38 (s, 1 H), 7.41 (d, J=9.3 Hz, 1 H), 6.32 (br d, J=8.3 Hz, 1 H), 5.94 (br d, J=9.0 Hz, 1 H),
5.68 (br s, 1H), 4.34 (br s, 1H), 3.97 (br s, 1H), 3.86-3.76 (m, 2H), 3.02-2.86 (m, 3H), 2.86-2.78 (m, 3H), 2.67 (brd, J=8.5 Hz, 1H), 2.21 (br d, J=11.5 Hz, 2H), 1.87-1.52 (m, 8H). MS: 444 [M+Na]+. Optical rotation: [o]d22 +7.9 (c 0.11, CHCI3). Chiral purity: 99% ee. Chiral SFC/MS analysis was performed on a Lux Cellulose-2 4.6x150 mm, 3pm column heated to 40 °C and eluted with a mobile phase of CO2 and 40% EtOH (0.05% DEA) flowing at 2.5 mL/min. The product peak had a rétention time of 5.69 min.
Example 4: 4-({6-(2-hydroxyethvl)-8-f(1/?,2S)-2-methylcvclopentyll-7-oxo-7,8dihvdropvridor2,3-cHpvrimidin-2-yl}amino)-/\/-methvlpipendine-1-sulfonamide·
Intermediate 6 4A
1) Oxone, THF
Intermediate 9
DIPEA, DMSO
Example 4
123
A solution of LHMDS (1.0 M in THF, 3.58 mL, 3.58 mmol) was added dropwise to a chilled (-78 °C) solution of ethyl y-hydroxybutyrate (237 mg, 1.79 mmol) in anhydrous THF (3 mL). The reaction was stirred for 20 min, then a solution of 4-{[(1R,2S)-2methylcyclopentyl]amino}-2-(methylsulfanyl)pyrimidine-5-carbaldehyde (Intermediate 6, 150 mg, 0.597 mmol) in THF (2 mL) was added dropwise. The mixture was gradually warmed to room température with stirring for 18 h. The reaction was quenched with acetic acid (573 mg, 9.55 mmol) and partitioned between water and EtOAc. The aqueous layer was further extracted with EtOAc (20 mL x 3). The combined organic layers were washed with sat. aq NaCI, dried over sodium sulfate, filtered, concentrated, and purified by silica gel chromatography (eluting with 0-2% MeOH in DCM) to give 6(2-hydroxyethyl)-8-[(1F?,2S)-2-methylcyclopentyl]-2-(methylsulfanyl)pyrido[2,3d]pyrimidin-7(8H)-one (4A, 181 mg, 95%) as a yellow oil. MS: 320 [M+H]+.
Solid OXONE® (523 mg, 0.85 mmol) was added to a chilled (0 °C) solution of 6(2-hydroxyethyl)-8-[(1R,2S)-2-methylcyclopentyl]-2-(methylsulfanyl)pyrido[2,3d]pyrimidin-7(8/-/)-one (4A, 181 mg, 0.567 mmol) in THF (6 mL) and water (3 mL). The resulting mixture was stirred at room température for 1 h. Water (10 mL) was added, and the mixture extracted with EtOAc (20 mL x 3). The combined organics were washed with sat. aq NaCI, dried over sodium sulfate, filtered, and concentrated to a yellow solid (178.2 mg). LCMS showed this to be a ~4:3 mixture of sulfone and sulfoxide products. This mixture was dissolved in DMSO (5 mL), 4-amino-/V-methylpiperidine-1-sulfonamide (Intermediate 9, 147 mg, 0.76 mmol) and DIPEA (196 mg, 1.52 mmol) were added, and the resulting solution stirred at 85 °C for 16 h. After cooling to rt, the mixture was partitioned between water (15 mL) and EtOAc (20 mL x 3). The combined organics were washed with sat. aq NaCI (20 mL x 3), dried over sodium sulfate, filtered, concentrated, and purified by silica gel chromatography (eluting with 0-3% MeOH in DCM). The material thus obtained (182 mg, 81% purity by LCMS) was further purified by préparative HPLC [DuraShell 150x25 mm x 5 pm column; water (0.05% NH4OH)ACN] to give 4-({6-(2-hydroxyethyl)-8-[(1R,2S)-2-methylcyclopentyl]-7-oxo-7,8dihydropyrido[2,3-c/]pyrimidin-2-yl}amino)-A/-methylpiperidine-1-sulfonamide (Example 4, 90 mg, 38%) as an off-white solid. 1H NMR (400 MHz, CDCh) δ = 8.37 (s, 1H), 7.36 (s, 1H), 5.97 (q, J=8.9 Hz, 1H), 4.59-4.45 (m, 1H), 4.08-3.93 (m, 1H), 3.83 (br s, 2H), 3.77-3.64 (m, 2H) 3.15-2.92 (m, 1H) 2.80 (t, J=5.8 Hz, 2H), 2.74 (d, J=5.5 Hz, 3H), 2.722.60 (m, 1H), 2.41-2.27 (m, 1H), 2.19-2.10 (m, 2H), 2.09-1.99 (m, 1H), 1.86 (d, J=11.8 Hz, 1H), 1.73-1.47 (m, 3H), 0.75 (d, J=7.0 Hz, 3H). MS: 465 [M+H]+. Optical rotation:
I 124
[o]d22 -10.3 (c 0.5 MeOH). Chiral purity: >99% ee. Chiral SFC/MS analysis was performed on a Chiracel OD-3 4.6 x 100mm, 3pm column heated to 40 °C and eluted with a mobile phase of CO2 and a gradient of 5 to 40% EtOH (0.05%DEA) over 5.5 min, flowing at 2.8 mL/min. Flow at 40% EtOH (0.05%DEA) was continued for 2.5 min to 5 elute any remaining counter ions. The product peak had a rétention time of 4.049 min.
Method B (Wittig cyclization)
Example 5: (+)-6-fluoro-8-[(1R*,2R*)-2-hydroxy-2-methvlcyclopentyl1-2-{[110 (methylsulfonvl)piperidin-4-yllamino}pyridof2,3-d]pvrimidin-7(8H)-one
Example Θ: (-)-6-fluoro-8-[(1R*,2R*)-2-hydroxy-2-methvlcvclopentyl]-2-{[1(methylsulfonyl)piperidin-4-vnaminoÎpyrido[2,3-cilpyrimidin-7(8/-/)-one
Example 5
Example 6
To a cooled (-70 °C) solution of ethyl (diethoxyphosphoryl)(fluoro)acetate (407 pl_, 2 mmol) in THF (15 mL) under a nitrogen atmosphère was added dropwise n-BuLi (1.6 M in hexanes, 1.9 mL, 3 mmol), then the mixture was stirred at -70 °C for 40 min. To this solution was added a solution of (±)-4-{[(1R*,2R*)-2-hydroxy-219219
125 methylcyclopentyl]amino}-2-(methylsulfanyl)pyrimidine-5-carbaldehyde (Intermediate 1, 267 mg, 1 mmol) in THF (5 mL). The mixture was stirred and allowed to warm gradually to room température overnight. The solution was then cooled in an ice-water bath, EtOH (2 mL) was added, followed by sat. aq NaHCOs (10 mL) and EtOAc (80 mL). The layers were separated, the organic layer was dried over sodium sulfate, concentrated to dryness, and the residue purified by silica gel chromatography (eluting with 40% heptane/60% EtOAc) to give (±)-6-fluoro-8-[(1R*,2R*)-2-hydroxy-2-methylcyclopentyl]-2(methylsulfanyl)pyrido[2,3-d]pyrimidin-7(8/-/)-one (5A, 218 mg, 71%). 1H NMR (400 MHz, CDCh) δ = 8.64 (s, 1H), 7.30 (d, J=7.5 Hz, 1H), 5.94 (t, J=8.4 Hz, 1H), 2.87-2.72 (m, 1H), 2.65 (s, 3H), 2.36-2.25 (m, 1H), 2.18-2.07 (m, 2H), 2.02-1.92 (m, 1H), 1.911.83 (m, 1H), 1.37 (td, J=6.9, 13.9 Hz, 1H), 1.17 (s, 3H). 19F NMR (377 MHz, CDCh) δ = -125.5 (s, 1F). MS: 310 [M+H]+.
To a solution of (±)-6-fluoro-8-[(1F?*,2R*)-2-hydroxy-2-methylcyclopentyl]-2(methylsulfanyl)pyrido[2,3-d]pyrimidin-7(8/-/)-one (5A, 374 mg, 1.2 mmol) in DCM (30 mL) was added mCPBA (70%, 313 mg, 1.27 mmol) in one portion. The resulting mixture was stirred at room température for 30 min. The volatiles were removed under reduced pressure to give crude (±)-6-fluoro-8-[(1R*,2R*)-2-hydroxy-2-methylcyclopentyl]-2(methylsulfinyl)-pyrido-[2,3-d]pyrimidin-7(8/-/)-one (5B), which was used immediately without further purification in the following step. MS: 308 [M+H]+.
To the above crude (±)-6-fluoro-8-[(1R*,2R*)-2-hydroxy-2-methylcyclopentyl]-2(methylsulfinyl)pyrido[2,3-c(]pyrimidin-7(8/-/)-one (5B, ~1.2 mmol) was added DMSO (5 mL), 4-amino-1-methanesulfonylpiperidine (CAS# 402927-97-3, 237 mg, 1.33 mmol), and DIPEA (0.42 mL, 2.42 mmol). The mixture was stirred at 60 °C (oil bath température) under nitrogen for 2 h. Acetic acid (69 pL) was added, and the entire reaction mixture was purified by chiral préparative SFC on a Chiralpak AD-H 30mm x 250mm column at 40 °C and eluted with a mobile phase of 42% MeOH w/0.05% diethylamine (v:v) in CO2 held at 100 bar, flowing at 90 mL/min, using UV détection at 340 nm. After lyophilization of the product fractions, Example 5 (peak 1, 178 mg, 34%, >99% ee) and Example 6 (peak 2, 193 mg, 36%, ~98%ee) were obtained as off-white solids. The absolute stereochemistry of each isomer was not determined, but optical rotation measurements were obtained.
Example 5: (+)-6-fluoro-8-[(1 R*,2R*)-2-hydroxy-2-methylcyclopentyl]-2-{[1(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-d]pyrimidin-7(8/7)-one. 1H NMR (700 MHz, DMSO-d6) δ = 8.59 (br s, 1H), 7.85 (br s, 1H), 7.69 (d, J=7.0 Hz, 1H), 5.89 (br s,
126
1H), 4.41 (brs, 1H), 4.09-3.78 (m, 1H), 3.68-3.44 (m, 2H), 3.01-2.69 (m, 6H), 2.17 (brs, 2H), 1.96 (br s, 2H), 1.90-1.77 (m, 2H), 1.73-1.41 (m, 3H), 0.98 (br s, 3H). 19F NMR (377MHz, DMSO-d6) δ = -134.1 to -138.0 (m, 1F). MS 440 [M+H]+. Optical rotation: [q]d22 = +18.5 (c 0.1, CHCb). Chiral purity: >99% ee. Chiral SFC/MS analysis was performed on a Chiralpak AD-3 4.6mmx100mm column at rt, eluted with a mobile phase of 70% CO2/30% MeOH held at 120 bar and flowing at 4.0 mL/min. This peak had a rétention time of 1.33 min.
Example 6: (-)-6-fluoro-8-[(1 F?*,2F?*)-2-hydroxy-2-methylcyclopentyl]-2-{[1(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)-one. 1H NMR (700 MHz, DMSO-d6) δ = 8.59 (br s, 1 H), 7.84 (br s, 1 H), 7.72-7.58 (m, 1 H), 5.89 (br s, 1 H), 4.42 (br s, 1H), 4.06-3.84 (m, 1H), 3.63-3.48 (m, 2H), 2.96-2.73 (m, 6H), 2.40-2.12 (m, 2H), 1.96 (br s, 2H), 1.87 (br s, 2H), 1.73-1.41 (m, 3H), 0.97 (br s, 3H). 19F NMR (377MHz, DMSO-d6) δ = -136.0 (d, J=144.2 Hz, 1F). MS: 440 [M+H]+. Optical rotation: [o]d22 = -15.9 (c 0.2, CHCb). Chiral purity: ~98% ee. Chiral SFC/MS analysis was performed on a Chiralpak AD-3 4.6mmx100mm column at rt, eluted with a mobile phase of 70% CO2/30% MeOH held at 120 bar and flowing at 4.0 mL/min. This peak had a rétention time of 2.47 min.
Method C (Heck coupling/cyclization)
Example 7: (+)-6-(2,2-difluoroethyl)-8-[(1 F?*,2F?*)-2-hydroxv-2-methylcyclopentyll-2-{[1(methylsulfonvl)piperidin-4-yl1amino}pyrido[2,3-c/lpyrimidin-7(8H)-one.
Example 8: (-)-6-(2,2-difluoroethyl)-8-[(1 F?*,2F?*)-2-hydroxv-2-methylcyclopentyll-2-{[1(methvlsulfonyl)piperidin-4-yllamino}pyrido[2,3-cflpyrimidin-7(8/-/)-one·
BnOH
To a solution of 2,2-dimethyl-1,3-dioxane-4,6-dione (Meldrum’s acid, 3.76 g, 26.1 mmol) in DCM (100 mL) at 0 °C was added difluoroacetic anhydride (3.25 mL, 26 mmol) followed by triethylamine (9.09 mL, 65.2 mmol). The cooling bath was removed and stirring continued at room température for 3 h. The reaction was poured into a separatory funnel, washed with 6N HCl and sat. aq. NaCI, dried over MgSO4, and filtered. The filtrate was cooled to 0 °C and acidified with acetic acid (16.4 mL, 287 mmol). To this mixture was then added sodium borohydride (2.17 g, 57.4 mmol) in three portions over 0.5 h. The reaction was allowed to stand at 4 °C overnight, then quenched with sat. aq NaCI and stirred vigorously for 0.5 h. Additional water was added to dissolve solids, and the layers were separated. The organic layer washed with sat. aq NaCI and concentrated to give 5-(2,2-difluoroethyl)-2,2-dimethyl-1,3-dioxane-4,6-dione (7A, 2.78 g, 51%) as a light yellow solid. 1H NMR (400 MHz, CDCh) δ = 6.50-6.17 (m, 1H), 3.70 (t, J=Q.2 Hz, 1H), 2.64 (ddt, J=5.1, 6.1, 15.6 Hz, 2H), 1.86 (s, 3H), 1.81 (s, 3H).
A suspension of 5-(2,2-difluoroethyl)-2,2-dimethyl-1,3-dioxane-4,6-dione (7A,
2.78 g, 12.51 mmol) in benzyl alcohol (10 mL, 97 mmol) was treated with N,Ndimethylmethyleneiminium iodide (Eschenmoser's sait, 5.86 g, 31.7 mmol) and heated
128 at 65 °C for 6 h. The mixture was poured into MTBE and washed with water (2 x) and sat. aq NaCI. The organic layer was concentrated and purified by silica gel chromatography (eluting with 0-20% EtOAc in heptane) to give benzyl 4,4-difluoro-2methylidenebutanoate (7B, 2.52 g, 89%) as a clear oil. 1H NMR (400 MHz, CDCh) δ = 7.40-7.35 (m, 5H), 6.44 (s, 1H), 5.84 (s, 1H), 6.01 (tt, J=4.8, 56.9 Hz, 1H), 5.23 (s, 2H), 2.95-2.83 (m, 2H).
To a solution of 2,4-dichloro-5-bromo pyrimidine (0.735 g, 3.23 mmol) in ACN (20 mL) was added (±)-(1R*,2R*)-2-amino-1-methylcyclopentanol (Intermediate 1b, 0.400 g, 3.47 mmol) and triethylamine (0.50 mL, 3.6 mmol). The reaction was stirred at room température for 4 h, and then concentrated under vacuum. The resulting solid was purified by silica gel chromatography (eluting with 20-70% EtOAc in heptane) to give (±)-(1R*,2R*)-2-[(5-bromo-2-chloropyrimidin-4-yl)amino]-1-methylcyclopentanol (7C, 0.774 g, 78%) as a white solid. 1H NMR (400 MHz, CDCh) δ = 8.18 (s, 1H), 5.48 (br s, 1H), 4.28 (s, 1H), 4.23 (ddd, J=5.7, 8.1, 10.1 Hz, 1H), 2.36-2.26 (m, 1H), 2.05-1.98 (m, 1H), 1.93-1.69 (m, 3H), 1.63-1.52 (m, 1H), 1.16 (s, 3H). MS: 306, 308 [M+H]+ (Br+CI isotope splitting).
To a solution of (±)-(1R*,2R*)-2-[(5-bromo-2-chloropyrimidin-4-yl)amino]-1methylcyclopentanol (7C, 300 mg, 0.978 mmol) in DMSO (0.80 mL) was added 4amino-1-methanesulfonylpiperidine (CAS# 402927-97-3, 250 mg, 1.40 mmol) and DIPEA (0.20 mL, 1.15 mmol). The mixture was heated at 100 °C for 6 h and to 110 °C for 6 h more. The reaction was diluted with DCM and washed with water. The water layer was extracted with DCM, and the combined organic layers were concentrated and purified by silica gel chromatography (eluting with 50-90% EtOAc in heptane) to give (±)-(1R*,2R*)-2-[(5-bromo-2-{[1-(methylsulfonyl)piperidin-4-yl]amino}pyrimidin-4yl)amino]-1-methylcyclopentanol (7D, 0.264 g, 60%) as a white solid. MS; 448, 450 [M+H]+ (Br isotope splitting).
A solution of benzyl 4,4-difluoro-2-methylidenebutanoate (7B, 2.20 g, 9.72 mmol), (±)-(1R*,2R*)-2-[(5-bromo-2-{[1-(methylsulfonyl)piperidin-4-yl]amino}pyrimidin-4yl)amino]-1-methylcyclopentanol (7D, 235 mg, 0.524 mmol), and triethylamine (0.290 mL, 2.10 mmol) in DMA (5.00 mL) was degassed by sparging with nitrogen for 15 min. Palladium(ll) acetate (23.5 mg, 0.105 mmol) and tri(o-tolyl)phosphine (63.8 mg, 0.210 mmol) were added and the reaction heated at 100 °C for 3 h. After cooling the solution to rt, MeOH (1.00 mL), DBL) (1.0 mL, 6.4 mmol), and sodium thiomethoxide (65 mg, 0.93 mmol) were added, and the reaction heated at 60 °C for 2 h. The resulting mixture
129 was concentrated under vacuum and purified by silica gel chromatography (eluting with 0-10% MeOH in DCM). The resulting dark oil was further purified by préparative SFC on a Nacalai Cosmosil 3-Hydroxyphenyl bonded column (20 x 150 mm LD., 5 pm particle size) at a flow rate of 60mL/min and a gradient of 15-25% methanol in CO2 at 3%/min, with pressure set at 100 bar. The racemic mixture was separated by préparative SFC on a Chiralpak AD-H column (250 x 21 mm I.D., 5 pm particle size) with 26% methanol in CO2 at a of flow rate 60 mL/min and pressure set at 100 bar, affording Example 7 (peak 1, 18.54 mg, 7.2%, >99% ee) and Example 8 (peak 2, 19.56 mg, 7.7%, >99% ee) as white powders. The absolute stereochemistry of each isomer was not determined, but optical rotation measurements were obtained.
Example 7: (+)-6-(2,2-difluoroethyl)-8-[(1 R*,2R*)-2-hydroxy-2-methylcyclopentyl]-2-{[1-(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-c/]pyrimidin-7(8H)-one. 1H NMR (400 MHz, DMSO-d6, 80 °C) δ = 8.58 (s, 1H), 7.70 (s, 1H), 7.48 (br s, 1H), 6.19 (td, J=5.1, 57.2 Hz, 1H), 5.89 (t, J=8.6 Hz, 1H), 4.04 (s, 1H), 3.99 (br s, 1H), 3.68-3.55 (m, 2H), 3.10-2.99 (m, 2H), 2.87 (s, 3H), 2.97-2.84 (m, 2H), 2.29-2.17 (m, 1H), 2.141.83 (m, 5H), 1.76-1.53 (m, 3H), 1.00 (s, 3H). 19F NMR (377 MHz, DMSO-d6) δ = -114.9 to -114.2 (m, 2F). MS; 486 [M+H]+. Optical rotation: [o]d22 +31.9° (c 0.1, MeOH). Chiral purity: >99% ee. Chiral SFC/MS analysis was performed on a Chiralpak AD-3 (100 x 4.6 mm LD., 3 pm) column eluted with 30% methanol in CO2 and pressure set at 120 bar, flowing at 4 mL/min. This peak had a rétention time of 0.91 min
Example 8: (-)-6-(2,2-difluoroethyl)-8-[(1 F?*,2R*)-2-hydroxy-2-methylcyclopentyl]-2-{[1-(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)-one. 1H NMR (400 MHz, DMSO-d6, 80 °C) δ = 8.58 (s, 1H), 7.70 (s, 1H), 7.47 (br s, 1H), 6.19 (td, J=4.8, 57.1 Hz, 1H), 5.89 (t, J=8.3 Hz, 1H), 4.04 (s, 1H), 4.02-3.93 (m, 1H), 3.683.55 (m, 2H), 3.10-2.99 (m, 2H), 2.87 (s, 3H), 2.98-2.81 (m, 2H), 2.29-2.17 (m, 1H), 2.14-1.82 (m, 5H), 1.76-1.50 (m, 3H), 1.00 (s, 3H). 19F NMR (377 MHz, DMSO-d6) δ = -114.6 to -114.4 (m, 2F). MS; 486 [M+H]+. Optical rotation: [a]D22 -19.3 (c 0.1, MeOH). Chiral purity: >99% ee; . Chiral SFC/MS analysis was performed on a Chiralpak AD-3 (100 x 4.6 mm LD., 3 pm) column eluted with 30% methanol in CO2 and pressure set at 120 bar, flowing at4 mL/min. This peak had a rétention time of 1.615 min.
Method D (Chlorination at C-6 after cyclization)
130
Example 9: 6-chloro-8-[(1 R,2/?)-2-hvdroxy-2-methylcyclopentvll-2-{ri-(methylsulfonyl)piperidin-4-yl1amino}pyrido[2,3-cnpyrimidin-7(8/-/)-one.
A solution of 8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-{[1-(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)-one (Example 2, 4.22 g, 10 mmol) and NCS (1.53 g, 11 mmol) in 2-MeTHF (100 mL) was stirred in a 50 °C oil bath for 44 h. After cooling to room température, EtOH (1.75 mL, 30 mmol) was added and the mixture stirred at room température for 1 h. The solution was diluted with EtOAc (120 mL) and washed with a mixture of water (15 mL) and sat. aq NaHCOs (15 mL). The aqueous layer was further extracted with EtOAc (80 mL). The combined organic layers were washed with sat. aq NaCI (15 mL), dried over sodium sulfate, filtered, and concentrated to dryness. Ethanol (45 mL) was added to the residue, and the resulting suspension stirred in a 55 °C oil bath for 1 h, then allowed to gradually cool with stirring to room température overnight. The resulting white solid was collected by filtration, rinsed with EtOH (3 mL), and dried under vacuum (~10 mmHg, 50 °C) to give 6-chloro8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-{[1-(methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-c/]pyrimidin-7(8/-/)-one (Example 9, 3.86 g, 84%) as a white solid. 1H NMR (400 MHz, DMSO-d6, 20 °C) δ = 8.71-8.54 (m, 1H), 8.09 (s, 1H), 8.05-7.65 (m, 1H), 5.91 (t, J=8.2 Hz, 1H), 4.46-4.28 (m, 1H), 4.03-3.81 (m, 1H), 3.65-3.48 (m, 2H), 2.98-2.77 (m, 5H), 2.46-2.27 (m, 1H), 2.18 (d, J=10.3 Hz, 2H), 1.99-1.77 (m, 4H), 1.751.37 (m, 3H), 0.96 (br s, 3H). 1H NMR (400 MHz, DMSO-d6, 80 °C) δ = 8.60 (s, 1H), 8.02 (s, 1H), 7.61 (br s, 1H), 5.91 (dd, J=7.4, 9.2 Hz, 1H), 4.09 (s, 1H), 4.04-3.94 (m, 1H), 3.70-3.49 (m, 2H), 2.97-2.88 (m, 2H), 2.87 (s, 3H), 2.48-2.42 (m, 1H), 2.20 (dt, J=8.1, 11.4 Hz, 1H), 2.09 (d, J=12.3 Hz, 1H), 2.05-1.96 (m, 2H), 1.96-1.84 (m, 2H),
1.79-1.66 (m, 2H), 1.65-1.51 (m, 1H), 1.01 (s, 3H). MS: 456/458 (Cl isotope pattern) [M+H]+. Optical rotation: [o]d22 -31.4 (c 0.4, MeOH). Chiral analysis: >99% ee. Chiral SFC/MS analysis was performed on a Phenomenex Lux Cellulose-1 4.6 x 100mm 3μ column at room température and eluted with a mobile phase of 30% MeOH in CO2
131 maintained at 120 bar outlet pressure, flowing at 4 mL/min. The product peak had a rétention time of 1.52 min.
Method E (di- and tri-fluoromethylation at C-6 after cyclization)
Example 10:.6-(difluoromethvl)-8-[(1R,2R)-2-hvdroxv-2-methylcvclopentvll-2-{[1(methvlsulfonvl)piperidin-4-yllamino}pyrido[2,3-dlpyrimidin-7(8/7)-one
A solution of zinc difluoromethanesulfinate (3.34 g, 11.4 mmol) and iron (II) chloride (377 mg, 1.90 mmol) in water (10 mL) was added portionwise to a solution of 8[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-{[1-(methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one (Example 2, 1.60 g, 3.80 mmol) and TFA (0.290 mL, 3.80 mmol) in DMSO (60 mL) at room température. The resulting mixture was treated with TBHP (70 wt% solution in water, 0.400 mL, 342 mg, 3.80 mmol), causing a slight increase in internai température to 32 °C. Stirring was continued at room température for 19 h, at which time LCMS showed ~30% conversion. A second portion of TBHP solution (0.400 mL, 342 mg, 3.80 mmol was added and stirring continued for 3 h. A third portion of TBHP solution (0.400 mL, 342 mg, 3.80 mmol) was added and stirring continued at room température for 45 min, at which time LCMS showed -50% conversion. More zinc difluoromethanesulfinate (1.1 g, 3.7mmol) and TBHP solution (0.400 mL, 342 mg, 3.80 mmol) were added, and the mixture stirred at room température for 20 h. At this time, LCMS showed -90% conversion. The reaction solution was poured into a mixture of 10% aq sodium EDTA/ice, and extracted with EtOAc (50 mL). The aqueous layer was saturated with NaCI, and extracted furtherwith EtOAc (50 mL x 3). The combined organics were washed with dilute aq sodium EDTA (50 mL) and sat. aq NaCI (50 mL). The deep blue organic layer was treated with activated charcoal and sodium sulfate, filtered, and evaporated to dryness. The residue (1.49 g foam) was purified by préparative SFC (Diol/Monol column with MeOH/CCte) to
132 give 6-(difluoromethyl)-8-[(1 R,2R)-2-hydroxy-2-methylcyclopentyl]-2-{[1 -(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-c/]pyrimidin-7(8/-/)-one (Example 10, 568 mg, 32%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 8.72 (s, 1H), 8.03 (s, 1H), 7.76 (br s, 1H), 7.00-6.50 (m, 1H), 5.87 (t, J=8.3 Hz, 1H), 4.08 (s, 1H), 4.06-3.89 (m, 1H), 3.62 (t, J=11.7 Hz, 2H), 2.98-2.89 (m, 2H), 2.87 (s, 3H), 2.57-2.51 (m, 1H), 2.272.14 (m, 1H), 2.10 (d, J=9.4 Hz, 1H), 2.04-1.93 (m, 2H), 1.93-1.80 (m, 2H), 1.76-1.69 (m, 2H), 1.69-1.55 (m, 1H), 1.03 (s, 3H). 19F NMR (377 MHz, DMSO-d6) δ = -125.7 to -113.3 (m, 2F). 13C NMR (101 MHz, DMSO-d6) Shift 159.5, 159.2, 154.9, 133.4, 110.3, 102.6, 102.0, 78.9, 61.5, 45.8, 43.0, 42.8, 40.2, 32.9, 28.5, 25.1, 22.2, 21.8. MS: 472 [M+H]+. Optical rotation: [o]d22 -35.8 (c 0.7, MeOH); [o]d22 -25.3 (c 0.6, CHCh). Chiral SFC analysis: >99% ee. Rétention time 2.78 min on Phenomenex Lux Cellulose-1 4.6 x 100mm 3μ column (ambient temp); mobile phase: 15% MeOH in CO2, 120 bar, 4 mL/min.
Example 133: (-)-6-(difluoromethvl)-8-[(1R*,3R*)-3-hydroxvcvclopentvll-2-{[1(methvlsulfonyl)piperidin-4-vl1amino}pyridor2,3-cflpvrimidin-7(8/7)-one
Example 134: (+)-6-(difluoromethyl)-8-|(1R*,3F?*)-3-hydroxycyclopentyl]-2-{[1(methvlsulfonvl)piperidin-4-vl1amino}pvrido[2,3-cnpvrimidin-7(8/7)-one
Exam pie 133 Exam pie 134
In a flow reactor set up according to the scheme below the following solutions were prepared and passed through the corresponding mixing valves at 1 mL/min: tertbutyl hydroperoxide (TBHP, 0.632 g, 4.91 mmol, 0.675 mL) in 29 mL of DMSO; sodium difluoromethanesulfinate (882 mg, 6.39 mmol) and iron sulfate (11.2 mg, 0.0737 mmol) in 3 ml of water + 27 mL of DMSO; and (±)-8-[3-hydroxycyclopentyl]-2-{[1(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-cf]pyrimidin-7(8/-/)-one (synthesized from Intermediate 8 by the method of Example 1,500 mg, 1.23 mmol) in 30 mL of DMSO.
133
CF 2SO2Na mL/min
DMSO/ (j-—water
133A (+/-)0______
DMSO 1 mL/min mL
°C mL
RT
Example 133/134 racemate
TBHP (70 % aq.) Q-------DMSO 1 mL,min
The DMSO solution containing the product mixture was collected in a single bottle. After the substrate solution was consumed, the product mixture was poured over 5 a solution of ethylenediaminetetraacetic acid (1.080 g, 3.68 mmol) and sodium bicarbonate (2.4 g, 28.57 mmol) in 150 mL of water and ice, and the resulting solution extracted with ethyl acetate (3 x 100 mL). The organics were combined, washed with brine (3 x 100 mL), dried over sodium sulfate and evaporated. The crude concentrate was loaded into a silica column and eluted with ethyl acetate/heptane 0-80 %. The 10 fractions containing the product were combined and evaporated to give a yellow solid.
The enantiomers were resolved by SFC using a ChiralPak AD-H 21 x 250 mm column at 40°C eluted with 20% IPA in CO2 and held at 120 bar at a flow of 85 mL/min.
Example 133: (-)-6-(difluoromethyl)-8-[(1R*,3R*)-3-hydroxycyclopentyl]-2-{[1(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)-one (82 mg, 15%) 15 white solid. 1H NMR (400 MHz, DMSO-d6) δ = 8.76 (d, J=18.8 Hz, 1H), 8.06 (s, 1H), 8.21-7.98 (m, 1H), 6.87 (t, J=55.5 Hz, 1H), 6.23-6.02 (m, 1H), 4.64-4.50 (m, 1H), 4.43 (br. s., 1H), 4.12-3.83 (m, 1H), 3.65-3.52 (m, J=6.6 Hz, 2H), 2.94-2.81 (m, 5H), 2.422.10 (m, 2H), 2.09-1.87 (m, 3H), 1.75-1.52 (m, 4H). 19F NMR (376 MHz, DMSO-d6) δ = -120.0 to -115.8 (m, 2F). MS: 485 [M+H]+, Optical rotation [a]o22 -15.6 (c 0.1, MeOH); 20 >99% ee. Rétention time 1.828 min in a ChiralPak AD-3 4.6 x 100 mm 3μ column, mobile phase 20% IPA; 120 bar at4 mL/min.
Example 134: (+)-6-(difluoromethyl)-8-[(1 R*,3R*)-3-hydroxycyclopentyl]-2-{[1 (methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one (76 mg, 14%) white solid. 1H NMR (400 MHz, DMSO-d6) δ = 8.76 (d, J=18.7 Hz, 1H), 8.06 (s, 1H), 25 8.22-7.97 (m, 1H), 6.87 (t, J=55.3 Hz, 1H), 6.21-6.01 (m, 1H), 4.64-4.51 (m, 1H), 4.43 (br. s., 1H), 4.13-3.83 (m, 1H), 3.63-3.52 (m, J=5.9 Hz, 2H), 2.92-2.81 (m, 5H), 2.4119219
134
2.13 (m, 2H), 2.11-1.89 (m, 3H),1.75-1.53 (m, 4H). 19F NMR (376 MHz, DMSO-d6) δ = -121.8 to -115.6 (m, 2F). MS: 485 [M+H]+, Optical rotation [α]ο22 +14.8 (c0.1, MeOH); >99% ee. Rétention time 3.08 min in a ChiralPak AD-3 4.6 x 100 mm 3μ column, mobile phase 20% IPA; 120 bar at 4 mL/min
Method F (Post-cyclization amidation and déhydration to nitrile)
Example 135: (8-cvclopentyl-2-fl1-(methylsulfonyl)piperidin-4-vl1amino}-7-oxo-7,8dihvdropyrido[2,3-d|pvrimidin-6-yl)acetonitrile
TFAA
Et3N
DCM
Example 135
Diethyl succinate (6.61 g, 37.9 mmol) was added dropwise to a cooled (-70 °C) solution of LiHMDS (1.0 M in THF, 75.8 mL, 75.8 mmol) in THF (100 mL). After stirring for 10 minutes, a solution of 4-(cyclopentylamino)-2-(methylsulfanyl)pyrimidine-5carbaldehyde [VanderWel, et al. J. Med. Chem. 2005, 48, 2371] (6.00 g, 25.3 mmol) in THF (40 mL) was added and the mixture stirred at -70 °C for 30 minutes. The solution was allowed to warm to room température and stirred overnight. The mixture was partitioned between water (100 mL) and EtOAc (200 mL), and the aqueous layer further extracted with EtOAc (2 x 50 mL). No product was observed in the combined organic
135 layers by TLC. The aqueous layer was acidified to pH 2 with conc. HCl. The resulting precipitate was collected by suction filtration, washed with water and petroleum ether, dried under vacuum, and then purified by silica gel chromatography (eluting with 2-5% MeOH in DCM) to give 2-(8-cyclopentyl-2-(methylthio)-7-oxo-7,8-dihydropyrido[2,3d]pyrimidin-6-yl)acetic acid (135A, 5.00 g, 62%) as a yellow solid.
A suspension of 2-(8-cyclopentyl-2-(methylthio)-7-oxo-7,8-dihydropyrido[2,3d]pyrimidin-6-yl)acetic acid (135A, 5.00 g, 15.7 mmol) in EtOH (80 mL) was treated with conc. sulfuric acid (5 mL) and heated to 80 °C for 18 h, affording a clear yellow solution. After cooling to room température, the solution was concentrated to dryness, the residue dissolved in DCM (100 mL), and basified to pH ~8 with sat. aq. Na2COs. The layers were separated and the aqueous layer further extracted with DCM (2 x 50 mL). The combined organics were dried over sodium sulfate, filtered, concentrated, and purified by silica gel chromatography (eluting with 0-20% EtOAc in DCM) to give ethyl 2(8-cyclopentyl-2-(methylthio)-7-oxo-7,8-dihydropyrido[2,3-c/]pyrimidin-6-yl)acetate (135B, 4.90 g, 90%) as a yellow solid.
By the method of Example 1, 135B was used to produce ethyl 2-(8-cyclopentyl-2((1-(methylsulfonyl)piperidin-4-yl)amino)-7-oxo-7,8-dihydropyrido[2,3-c/]pyrimidin-6yl)acetate (135C, -87% purity) as a crude yellow gum. A sample of this crude gum (150 mg, 0.31 mmol) was dissolved in methanol (6 mL), and anhydrous gaseous ammonia bubbled in for 10 minutes. The mixture was stirred at 80 °C overnight. After cooling to room température, the solvent was evaporated, and the residue purified by préparative HPLC [column: DuraShell 150*25mm*5um; mobile phase: from 25% ACN in water (0.05% ammonium hydroxide v/v ) to 45% ACN in H20(0.05% ammonium hydroxide v/v)] to give 2-(8-cyclopentyl-2-((1-(methylsulfonyl)-piperidin-4-yl)amino)-7-oxo-7,8dihydropyrido[2,3-d]pyrimidin-6-yl)acetamide (135D, 40 mg, 28%) as white solid. 1H NMR (400 MHz, DMSO-d6) δ = 8.59 (s., 1H), 7.85-7.49 (m, 2H), 7.35 (s., 1H), 6.86 (s., 1H), 5.93-5.75 (m, 1H), 4.07-3.80 (m, 1H), 3.57 (d, J=11.0 Hz, 2H), 3.25 (s, 2H), 2.932.82 (m, 5H), 2.17 (m, 2H), 1.98 (m, 4H), 1.79-1.55 (m, 6H). MS: 448.9 [M+H]+.
A second run (135C, 260 mg, 0.54 mmol), in éthanol (120 °C for 12 h) yielded crude 135D (200 mg of -60% purity) as a brown solid, which was used without purification in the subséquent déhydration reaction.
A cooled (0 °C) solution of crude 2-(8-cyclopentyl-2-((1-(methylsulfonyl)-piperidin-
4-yl)amino)-7-oxo-7,8-dihydropyrido[2,3-c/]pyrimidin-6-yl)acetamide (136D, 100 mg,
0.13 mmol) and triethylamine (67.7 mg, 0.67 mmol) in DCM (5 mL) was treated with
136 trifluoroacetic acid anhydride (56.2 mg, 0.27 mmol). The cooling bath was removed and the mixture stirred at room température for 2 h. The resulting yellow suspension was washed with deionized water (20 mL), then with sat. aq. NaCI. The organic layer was dried over magnésium sulfate, filtered, and concentrated. This crude product was combined with that from another run (starting with 80 mg, 0.11 mmol, of 135D) for purification by préparative HPLC [column: DuraShell 150*25mm*5um ; mobile phase: from 36% ACN in water (0.05% ammonium hydroxide v/v ) to 56% ACN in H20(0.05% ammonium hydroxide v/v)] to give (8-cyclopentyl-2-{[1-(methylsulfonyl)piperidin-4yl]amino}-7-oxo-7,8-dihydropyrido[2,3-c/]pyrimidin-6-yl)acetonitrile (Example 135, 27.1 mg, 26% yield for the combined batches) as a white solid. 1H NMR (400 MHz, CDCh) δ = 8.49 (s, 1H), 7.70 (s, 1H), 5.87 (quin, J=8.9 Hz, 1H), 5.42 (br s, 1H), 4.05 (br s, 1H), 3.92-3.73 (m, 2H), 3.66 (d, J=1.0 Hz, 2H), 2.95 (br s, 2H), 2.85 (s, 3H), 2.32 (br s, 2H), 2.21 (brd, J=9.8 Hz, 2H), 2.04 (brs, 2H), 1.86 (brd, J=9.5 Hz, 2H), 1.70 (brs, 4H). MS: 431 [M+H]+.
Method G (Post-cyclization functionalization of piperidine)
Example 136: 8-cvclopentvl-6-(2-hvdroxvethvl)-2~fn-(propan-2-vlsulfonyl)piperidin-4vllamino}pvrido[2,3-ci|pvrimidin-7(8/-/)-one
8-Cyclopentyl-6-(2-hydroxyethyl)-2-(methylsulfonyl)pyrido[2,3-c/]pyrimidin-7(8/-/)one (136A), was synthesized from 4-(cyclopentylamino)-2-(methylsulfanyl)pyrimidine-519219
137 carbaldehyde [VanderWel, et al. J. Med. Chem. 2005, 48, 2371] and ethyl-yhydroxybutyrate by the method of Example 4. A solution of 136A (95 mg, 0.284 mmol), tert-butyl 4-aminopiperidine-1-carboxylate [CAS# 87120-72-7] (78.9 mg, 0.394), and DIPEA (0.187 mL, 1.13 mmol) in DMSO (2.5 mL) was heated at 65 °C for 15 h. The mixture was cooled to room température and diluted with water (8 mL), EtOAc (5mL) and 4 M NaOH (1 mL) and separated. The organic layer was concentrated to give crude terf-butyl 4-((8-cyclopentyl-6-(2-hydroxyethyl)-7-oxo-7,8-dihydropyrido[2,3-c/]pyrimidin-2yl)amino)piperidine-1-carboxylate (136B, 130 mg, 100%) which was used without further purification. MS: 458 [M+H]+.
Trifluoroacetic acid (2.0 mL, 26 mmol) was added to a solution of crude tert-butyl 4-((8-cyclopentyl-6-(2-hydroxyethyl)-7-oxo-7,8-dihydropyrido[2,3-c/]pyrimidin-2-yl)amino)piperidine-1-carboxylate (136B, 130 mg, 0.284 mmol) in dichloromethane (6 mL). The mixture was stirred at room température for 30 minutes, then concentrated to dryness. The residue was dissolved in dichloromethane (6 mL). Triethylamine (0.238 mL, 1.70 mmol) and isopropylsulfonyl chloride (0.035 mL, 0.313 mmol) were added, and the mixture stirred at room température. After 20 minutes, more isopropylsulfonyl chloride (0.015 mL, 0.134 mmol) was added, and after another 20 min an additional amount of isopropylsulfonyl chloride (0.030 mL, 0.269 mmol) was added. The mixture was stirred for 15 more minutes, then was quenched with 4 N NaOH (0.6 mL) and stirred vigorously. Extraction with dichloromethane and purification by préparative SFC afforded 8-cyclopentyl-6-(2-hydroxyethyl)-2-{[1-(propan-2-ylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-c(|pyrimidin-7(8/-/)-one (Example 136, 28.3 mg, 22%) as a solid. 1H NMR (400 MHz, DMSO-d6, 80°C) δ = 8.51 (s, 1H), 7.51 (s, 1H), 7.30 (d, J=4.4 Hz, 1H), 5.85 (quin, J=8.9 Hz, 1H), 3.99 (br s, 1H), 3.70 (d, J=13.0 Hz, 2H), 3.63 (t, J=6.5 Hz, 2H), 3.31 (td, J=6.8, 13.6 Hz, 1H), 2.62 (t, J=6.5 Hz, 2H), 2.32 (br s, 2H), 2.06-1.91 (m, 4H), 1.83-1.71 (m, 2H), 1.70-1.56 (m, 4H), 1.27 (d, J=6.7 Hz, 6H). 1H obscured by H2O. MS: 464 [M+H]+.
Method H (Curtius rearrangement at C-6)
Example 137: 6-amino-2-{n-(but-3-vn-1-vlsulfonyl)piperidin-4-vl]amino}-8cvclopentvlpyrido[2,3-cflpyrimidin-7(8/-0-one
138
Intermediate 13
DIPEA, DMSO
Diphenyl phosphoryl azide (5.41 g, 19.6 mmol) was added to a room température solution of 8-cyclopentyl-2-(methylthio)-7-oxo-7,8-dihydropyrido[2,3-c/]pyrimidine-6carboxylic acid [Toogood, et al. J. Med. Chem., 2005, 48, 2388 - 2406] (5.0 g, 16.37 mmol) and triethylamine (1.99 g, 19.6 mmol) in te/ï-butanol (60 mL). The resulting suspension was stirred at 79 °C for 18 h. The solids were removed by filtration. The filter cake was rinsed with ethyl acetate (50 mL) and the combined filtrâtes concentrated and purified by silica gel chromatography (eluting with pet. ether/ethyl acetate) to give te/ï-butyl (8-cyclopentyl-2-(methylthio)-7-oxo-7,8-dihydropyrido[2,3-cf|pyrimidin-6-yl)carbamate (137A, 4.1 g, 67%) as a light yellow solid. 1H NMR (400 MHz, CDCh): δ = 8.60 (s, 1H), 8.15 (s, 1H), 7.80 (s, 1H), 6.04-6.00 (m, 1H), 2.59 (s, 3H), 2.30-2.27 (m, 2H), 2.07-2.05 (m, 2H), 1.91-1.89 (m, 2H), 1.71-1.69 (m, 2H), 1.50 (s, 9H). MS: 377 [M+H]+.
To a solution of tert-butyl (8-cyclopentyl-2-(methylthio)-7-oxo-7,8dihydropyrido[2,3-c/]pyrimidin-6-yl)carbamate (137A, 495 mg, 1.3 mmol) in DCM (13 mL) was added mCPBA (-70%, 389 mg, 1.58 mmol). The mixture was stirred at room température for 1 hour. The reaction was diluted with DCM (30 mL), and washed with saturated Na2SOs (10 mL) and then with saturated aqueous NaHCOs (10 mL). The organic layer was dried over sodium sulfate and evaporated to give a white solid which was a 9:1 mixture of sulfoxide and sulfone intermediates. MS: 393 ([M+H]+ sulfoxide) and 409 ([M+H]+ sulfone). A portion of this mixture (235 mg, 0.6 mmol) was dissolved in DMSO (3 mL). Diisopropylethyl amine (0.52 mL, 3 mmol) and 1-(but-3-yn-1ylsulfonyl)piperidin-4-amine methanesulfonate (Intermediate 13, 225 mg, 0.72 mmol) were added. The mixture was heated at 55 °C for 16 h, then at 65 °C for 3 h. After
139 cooling to room température, the reaction mixture was partitioned between saturated aqueous NaHCOs (10 mL) and DCM (30 mL). The organic layer was dried over sodium sulfate, concentrated, and purified by silica gel chromatography (eluting with ethyl acetate/heptane) to give tert-butyl (2-((1 -(but-3-yn-1 -ylsulfonyl)piperidin-4-yl)amino)-8cyclopentyl-7-oxo-7,8-dihydropyrido[2,3-c(]pyrimidin-6-yl)carbamate (137B, 166 mg, 51%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 8.65 (br s, 1H), 8.03 (s, 1H), 7.89 (s, 1H), 7.75-7.36 (m, 1H), 5.92 (brs, 1H), 4.02-3.80 (m, 1H), 3.62 (d, 7=12.5 Hz, 2H), 3.28-3.23 (m, 2H), 3.08-2.92 (m, 3H), 2.59 (dt, 7=2.7, 7.5 Hz, 2H), 2.37-2.09 (m, 2H), 2.02-1.91 (m, 4H), 1.79 (d, 7=4.6 Hz, 2H), 1.71-1.53 (m, 4H), 1.47 (s, 9H). MS: 545 [M+H]+.
A solution of tert-butyl (2-((1-(but-3-yn-1-ylsulfonyl)piperidin-4-yl)amino)-8cyclopentyl-7-oxo-7,8-dihydropyrido[2,3-c/]pyrimidin-6-yl)carbamate (137B, 166 mg, 0.29 mmol) and methanesulfonic acid (195 pL, 2.9 mmol) in DCM (10 mL) was stirred at room température for 1 hour. The solution was concentrated to dryness, and the residue treated with ice (10 g) and saturated aqueous NaHCOs (10 mL), causing some gas évolution. The resulting suspension was stirred at room température for 1 hour, then the solids collected by filtration. The precipitate was washed with water and dried in a vacuum oven (45 °C, 10 mmHg) to give 6-amino-2-{[1-(but-3-yn-1-ylsulfonyl)piperidin-4yl]amino}-8-cyclopentylpyrido[2,3-c/]pyrimidin-7(8/7)-one (Example 137, 119 mg, 91%) as a light yellow solid. 1H NMR (400 MHz, DMSO-d6) δ = 8.41 (s, 1H), 7.16 (br s, 1H), 6.62 (s, 1H), 5.93 (t, 7=8.7 Hz, 1H), 5.70-4.31 (m, 2H), 3.89 (brs, 1H), 3.61 (d, 7=12.5 Hz, 2H), 3.28-3.24 (m, 2H), 3.07-2.94 (m, 3H), 2.59 (dt, 7=2.4, 7.4 Hz, 2H), 2.30-2.21 (m, 2H), 2.08-1.89 (m, 4H), 1.85-1.70 (m, 2H), 1.68-1.44 (m, 4H). MS: 445 [M+H]+.
Method I (Pd-catalyzed cross-coupling at C-6)
Example 138: 8-cyclopentyl-6-ethenyl-2-{f1-(methylsulfonyl)piperidin-4yl1amino}pyrido[2,3-cf]pyrimidin-7(8/7)-one
140
6-Bromo-8-cyclopentyl-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrido[2,3d]pyrimidin-7(8H)-one (138A) was synthesized from 6-bromo-8-cyclopentyl-2(methylsulfinyl)pyrido[2,3-d]pyrimidin-7(8/-/)-one [Toogood, et al. J. Med. Chem., 2005, 48, 2388 - 2406] by the method of Example 1. 1H NMR (400 MHz, DMSO-d6) δ = 8.55-
8.68 (m, 1H), 8.25 (s, 1H), 7.79-8.09 (m, 1H), 5.74-6.10 (m, 1H), 3.80-4.16 (m, 1H), 3.57 (d, J=11.2 Hz, 2H), 2.76-3.00 (m, 5H), 2.20-2.35 (m, 1H), 2.15 (br s, 1H), 1.97 (br s, 4H), 1.77 (br s, 2H), 1.61 (d, J=11.4 Hz, 4H). MS: 470/472 (Br isotope splitting, [M+H]+.
A solution of 6-Bromo-8-cyclopentyl-2-((1-(methylsulfonyl)piperidin-4yl)amino)pyrido[2,3-c/]pyrimidin-7(8/-/)-one (138A, 5.00 g, 12.0 mmol) and tri-nbutyl(ethenyl)stannane (3.80 g, 12.0 mmol) in THF (100 mL, 0.1 M) was degassed with nitrogen, then palladium tetrakis(triphenylphospine) (692 mg, 0.599 mmol) was added. The mixture was heated at 65 °C for 48 h. The volatiles were removed under reduced pressure and the residue purified on silica (eluting 0-20% ethyl acetate/dichloromethane). The product was then recrystallized from DCM/diethyl ether (1/10, 50 mL) to give 8-cyclopentyl-6-ethenyl-2-{[1-(methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-c(]pyrimidin-7(8/-/)-one (Example 138, 2.5 g, 50%), still containing 10% triphenylphosphine oxide.
For biological testing, a sample of this batch (102 mg, 0.244 mmol) was further purified by préparative SFC to give analytically pure 8-cyclopentyl-6-ethenyl-2-{[1(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-c/]pyrimidin-7(8/-/)-one (Example 138, 76.48 mg, 75% recovery) as a white solid. 1H NMR (400 MHz, CDCh) δ = 8.44 (s, 1H), 7.55 (s, 1H), 6.89 (dd, J=11.25, 17.73 Hz, 1H), 5.79-5.99 (m, 2H), 5.12-5.44 (m, 2H), 3.95-4.17 (m, 1H), 3.81 (d, J=12.2 Hz, 2H), 2.90-3.06 (m, 2H), 2.84 (s, 3H), 2.27-2.47
141 (m, 2H), 2.21 (dd, J=3.06, 13.08 Hz, 2H), 2.00-2.13 (m, 2H), 1.80-1.91 (m, 2H), 1.64-
1.79 (m, 4H). MS: 418 [M+H]+.
Example 139: 8-cvclopentvl-2-{f1-(methylsulfonvl)piperidin-4-yl1amino}-6-(prop-2-en-1vl)pyrido[2,3-cf]pyrimidin-7(8/-/)-one
To a vial with a stir bar was added 6-Bromo-8-cyclopentyl-2-((1(methylsulfonyl)piperidin-4-yl)amino)pyrido[2,3-d]pyrimidin-7(8/-/)-one (138A, 470 mg, 1 mmol), DME (10 mL, 0.1 M), 4,4,5,5-tetramethyl-2-(prop-2-en-1-yl)-1,3,2-dioxaborolane (281 pL, 1.5 mmol), CsF (304 mg, 2 mmol), and PdCl2(dppf) (37 mg, 0.05 mmol). The mixture was degassed with nitrogen for 1 minute, then the vial was capped and placed in an 80 °C heating block for 16 h. The reaction was diluted with ethyl acetate (100 mL) and saturated aqueous NaHCOa (20 mL). The organic layer was separated and the product was extracted with ethyl acetate (20 mL). The combined organic layers were dried over sodium sulfate, concentrated, and purified on silica (eluted with heptane/ethyl acetate) to give 8-cyclopentyl-2-{[1-(methylsulfonyl)piperidin-4-yl]amino}-6-(prop-2-en-1yl)pyrido[2,3-d]pyrimidin-7(8H)-one (Example 139, 154 mg, 40%) as a light-colored solid. 1H NMR (400 MHz, DMSO-d6) δ = 8.58 (brs, 1H), 7.48 (s, 1H), 5.95 (tdd, J=6.69, 10.16, 17.04 Hz, 1H), 5.05-5.19 (m, 2H), 3.57 (d, J=12.2 Hz, 3H), 3.18 (d, J=6.6 Hz, 2H), 2.79-2.96 (m, 7H), 1.99 (s, 6H), 1.53-1.69 (m, 4H). MS: 432 [M+H]+.
Method J (radical addition at C-6)
Example 140: 6-(2,2-difluoroethvl)-8-[(1R,3R)-3-hvdroxvcvclohexyll-2-{[1(methvlsulfonvl)piperidin-4-vllamino}pvrido[2,3-d|pyrimidin-7(8/-/)-one
142
o=s=o o=s=o
I I
Example 3 Example 140
To a solution 8-[(1R,3R)-3-hydroxycyclohexyl]-2-{[1-(methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-cf|pyrimidin-7(8H)-one (Example 3, 0.161 g, 0.382 mmol) in DMSO (1.5 mL) was added (4,4'-di-f-butyl-2,2'-bipyridine)bis[3,5-difluoro-2-[5-trifluoromethyl-2pyridinyl-kN)phenyl-kC]iridium(llI) hexafluorophosphate (0.012 g, 0.0107 mmol), 1,1difluoro-2-iodoethane (0.27 mL, 3.1 mmol), potassium carbonate (0.150 g, 0.960 mmol) and triethylamine (30 pL, 0.22 mmol). Nitrogen was bubbled through the mixture for ten minutes, and then the vial was sealed. The reaction was irradiated with blue light (Kessil, H150-Blue, 34W) for 16 h. The reaction was filtered and concentrated, and the residue purified by préparative HPLC (Waters SFC 200 Glacier / 2-Cosmosil 3HOP 150 x 21.1mm I.D., 5um columns. co-solvent methanol. 14% B for 2.5min, to 22% in 7.5min, to 50% in 1min, hold 1min @ 100bar, 35C, 80g/min.) to give 6-(2,2-difluoroethyl)-8[(1R,3R)-3-hydroxycyclohexyl]-2-{[1-(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3d]pyrimidin-7(8/-/)-one (Example 140, 29.35 mg, 16% yield). 1H NMR (400 MHz, DMSOd6) δ = 8.58 (s, 1H), 7.85 (d, J=7.0 Hz, 1H), 7.70 (s, 1H), 6.22 (tt, J=4.8, 57.2 Hz, 1H), 4.46 (br s, 1H), 4.12 (br s, 1H), 3.99 (br s, 1H), 3.66-3.55 (m, 2H), 3.02 (dt, J=4.0, 17.1 Hz, 2H), 2.89 (s, 3H), 2.87-2.77 (m, 2H), 2.18-1.38 (m, 11 H). MS: 486 [M+H]+. [o]d22 +18.0 (c 0.1, MeOH).
Additional compounds of the invention were prepared by modifications of the methods exemplified herein. Except where otherwise indicated, ail compounds having chiral centers were prepared and/or isolated as a single enantiomer having a known relative configuration. Compounds marked “absolute stereochemistry unknown” were typically prepared from racemic intermediates and resolved into single enantiomers by an appropriate chiral préparative SFC method before characterization and testing. Where the absolute stereochemistry is unknown for a pair of enantiomers, the stereochemistry represented in Table 1 is assigned based on the sign of the optical rotation ([o]d20) and the relative biological activity, by analogy to compounds having
143 known absolute configurations. Compounds marked “absolute stereochemistry known” were typically prepared from chiral intermediates having known stereochemistry.
Selected compounds and their corresponding characterization data are presented in Table 1 below.
Table 1
Ex. No. (Method) | Structure/IUPAC name | LCMS [M+H]+ | 1H NMR (ppm); 19F NMR (ppm); optical rotation; stereochem. notes |
1-10 | in methods text | ||
11 (A) | Λ/ Ό,ΐΧλ ό 4-[(8-cyclopentyl-7-oxo-7,8dihydropyrido[2,3-c/]pyrimidin-2yl)amino]-/V-methylpiperidine-1sulfonamide | 407 | 1H NMR (400 MHz, CDCI3) δ = 8.39 (s, 1H), 7.41 (d, X9.3 Hz, 1H), 6.36 (d, J=9.3 Hz, 1H), 5.84 (quin, J=9.0 Hz, 1H), 5.53-5.12 (m, 1H), 4.23-4.15 (m, 1H), 4.04 (br s, 1H), 3.74 (d, J=12.8 Hz, 2H), 3.09-2.97 (m, 2H), 2.76 (d, J=5.3 Hz, 3H), 2.37 (br s, 2H), 2.16 (dd, J=3.5, 13.1 Hz, 2H), 2.07-1.97 (m, 2H), 1.91-1.80 (m, 2H), 1.75-1.63 (m, 4H) |
12 (A) | ^Νχ9 ί O.XO, ô 4-[(8-cyclopentyl-7-oxo-7,8dihydropyrido[2,3-d]pyrimidin-2yl)amino]-A/,A/-dimethylpiperidine-1sulfonamide | 421 | 1H NMR (400 MHz, CDCb) δ = 8.40 (s, 1H), 7.42 (d, J=9.3 Hz, 1H), 6.37 (d, J=9.3 Hz, 1H), 5.84 (quin, J=8.9 Hz, 1H), 5.31 (br s, 1H), 4.04 (br s, 1H), 3.72 (d, J=13.1 Hz, 2H), 3.11-2.98 (m, 2H), 2.85 (s, 6H), 2.37 (br s, 2H), 2.14 (dd, J=3.5, 13.1 Hz, 2H), 2.03 (d, X7.0 Hz, 2H), 1.91-1.79 (m, 2H), 1.75-1.62 (m, 4H) |
13 (A) | H2N /9 ° i 1 Λ Â Λ | 393 | 1H NMR (400 MHz, DMSO-cfe) δ = 8.61-8.58 (m, 1H), 7.87-7.66 (m, 2H), 6.78 (s, 2H), 6.24-6.21 (m, 1H), 5.87- 5.73 (m, 1H), 3.89-3.79 (m, 1H), 3.48 (m, 2H), 2.65-2.60 (m, 2H), 2.36-2.18 |
144
4-[(8-cyclopentyl-7-oxo-7,8dihydropyrido[2,3-c/]pyrimidin-2yl)amino]piperidine-1-sulfonamide | (m, 2H), 1.97 (m, 4H), 1.73-1.56 (m, 6H) | ||
14 | F I n | 1H NMR (400 MHz, CDCh) δ = 8.40 (s, | |
1H), 7.42 (d, J=9.0 Hz, 1H), 6.42-6.30 | |||
° <11 JL 1 | (m, 1H), 6.23 (s, 1H), 5.83 (quin, J=8.9 | ||
(A) | \/ΛΝΑΝΑΝΛΟ H ό | 428 | Hz, 1H), 5.40 (br s, 1H), 4.11 (br s, 1H), 3.99 (d, J=13.1 Hz, 2H), 3.29 (t, J=11.5 Hz, 2H), 2.35 (br s, 2H), 2.242.13 (m, 2H), 2.02 (d, J=6.5 Hz, 2H), |
8-cyclopentyl-2-({1- [(difluoromethyl)sulfonyl]piperidin-4- | 1.91-1.78 (m, 2H), 1.67 (br s, 4H) | ||
yl}amino)pyrido[2,3-c/]pyrimidin-7(8/-/)- | 19F NMR (377MHz, DMSO-cfe) δ = | ||
one | -123.3 (br s, 2F) | ||
15 | 1H NMR (400 MHz, CDCh) δ = 8.39 (s, | ||
rû/Xl0 | 1H), 7.41 (d, J=9.5 Hz, 1H), 6.36 (d, | ||
H 1 | J=9.3 Hz, 1H), 5.84 (quin, J=8.9 Hz, | ||
(A) | ό 8-cyclopentyl-2-({1 -[(2- methoxyethyl)sulfonyl]piperidin-4yl}amino)pyrido[2,3-d]pyrimidin-7(8H)one | 436 | 1H), 5.37 (br s, 1H), 4.12-3.96 (m, 1H), 3.84-3.71 (m, 4H), 3.45-3.37 (m, 3H), 3.23 (t, J=5.8 Hz, 2H), 3.10-2.95 (m, 2H), 2.38 (br s, 2H), 2.15 (dd, J=3.5, 13.1 Hz, 2H), 2.02 (brs, 2H), 1.91-1.79 (m, 2H), 1.68 (d, J=7.5 Hz, 4H) |
16 | zo | ||
'/S N N | 1H NMR (400 MHz, CDCh) δ = 8.39 (s, | ||
0 i I Τι l L | 1H), 7.41 (d, J=9.3 Hz, 1H), 6.36 (d, | ||
H I | J=9.3 Hz, 1H), 5.84 (quin, J=9.0 Hz, | ||
(A) | ό | 406 | 1H), 5.33 (br s, 1H), 4.04 (br s, 1H), 3.83 (d, J=12.8 Hz, 2H), 3.09-2.92 (m, 4H), 2.45-2.24 (m, 2H), 2.22-2.12 (m, |
8-cyclopentyl-2-{[ 1 - | 2H), 2.03 (brs, 2H), 1.91-1.79 (m, 2H), | ||
(ethylsulfonyl)piperidin-4- | 1.63-1.62 (m, 1H), 1.77-1.62 (m, 3H), | ||
yl]amino}pyrido[2,3-c/]pyrimidin-7(8/-/)- one | 1.39 (t, J=7.4 Hz, 3H) |
145
17 | hoT/q χχχ | 1H NMR (400 MHz, DMSO-cfe, 80°C) δ = 8.55 (s, 1H), 7.63 (d, J=9.3 Hz, 1H), | |
N N N^O H 1 | 7.43 (d, J=5.4 Hz, 1H), 6.20 (d, J=9.3 | ||
(A) | ό 8-cyclopentyl-2-({1-[(2-hydroxy-2methylpropyl)sulfonyl]piperidin-4yl}amino)pyrido[2,3-d]pyrimidin-7(8/-/)one | 450 | Hz, 1H), 5.81 (quin, J=8.9 Hz, 1H), 4.45 (br s, 1H), 4.05-3.90 (m, 1H), 3.64 (td, J=3.4, 12.0 Hz, 2H), 3.14 (s, 2H), 3.01-2.91 (m, 2H), 2.39-2.26 (m, 2H), 2.03-1.92 (m, 4H), 1.84-1.72 (m, 2H), 1.71-1.58 (m, 4H), 1.34 (s, 6H) |
18 | /° | 1H NMR (400 MHz, DMSO-cfe, 80°C) δ | |
A/γρ f YT | = 8.55 (s, 1H), 7.63 (d, J=9.3 Hz, 1H), | ||
^νΛΑΛ | 7.45 (d, J=6.1 Hz, 1H), 6.20 (d, J=9.3 | ||
(A) | ό | 470 | Hz, 1H), 5.81 (quin, J=8.9 Hz, 1H), 5.11 (s, 2H), 4.04-3.92 (m, 1H), 3.74 |
8-cyclopentyl-2-[(1- {[(methylsulfonyl)methyl]sulfonyl}piperi din-4-yl)amino]pyrido[2,3-d]pyrimidin7(8H)-one | (td, J=3.4, 12.8 Hz, 2H), 3.18 (s, 3H), 3.15-3.05 (m, 2H), 2.39-2.27 (m, 2H), 2.04-1.92 (m, 4H), 1.84-1.73 (m, 2H), 1.73-1.59 (m, 4H) | ||
19 | /'Q jfXX | 1H NMR (700 MHz, DMSO-cfe) δ = 8.56 | |
(br s, 1H), 7.86 (br s, 1H), 7.66 (d, | |||
(A) | à | 420 | J=9.2 Hz, 1H), 6.35-6.12 (m, 1H), 5.68-5.21 (m, 1H), 4.03-3.75 (m, 1H), 3.60 (br s, 2H), 2.92-2.80 (m, 5H), 2.59 |
8-cycloheptyl-2-{[1 - (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-c(]pyrimidin-7(8/-/)- | (d, J=9.9 Hz, 1H), 2.37 (br s, 1H), 2.10-1.94 (m, 2H), 1.76 (br s, 2H), 1.70-1.54 (m, 8H), 1.49 (br s, 2H) | ||
one | |||
20 | H O | 1H NMR (400 MHz, CDCb) δ = 8.38 (s, | |
// °O XXI | 1H), 7.42-7.39 (d, J=9.2 Hz, 1H), 6.39- 6.34 (m, 1H), 5.56-5.31 (m, 2H), 4.18- | ||
(A) | N N N O ô | 435 | 4.17 (m, 1H), 4.07 (m, 1H), 3.78-3.75 (m, 2H), 3.06-3.01 (t, J=11.0 Hz, 2H), 2.77 (d, J=5.6 Hz, 3H), 2.59-2.56 (m, 2H), 2.20-2.18 (m, 2H), 1.77-1.64 (m, |
146
4-[(8-cycloheptyl-7-oxo-7,8dihydropyrido[2,3-d]pyrimidin-2yl)amino]-A/-methylpiperidine-1sulfonamide | 10H), 1.55-1.46 (m, 2H) | ||
21 (A) | H2N P 0 'ΓΊ jQQ ô 4-[(8-cycloheptyl-7-oxo-7,8dihydropyrido[2,3-d]pyrimidin-2yl)amino]piperidine-1-sulfonamide | 421 | 1H NMR (400 MHz, DMSO-cfe) δ = 8.56 (s, 1H), 7.86 (m, 1H), 7.65 (d, J=8.8 Hz, 1H), 6.84-6.78 (m, 2H), 6.24-6.18 (m, 1H), 5.56-5.28 (m, 1H), 3.86-3.72 (m, 1H), 3.51 (brs, 2H), 2.62-2.59 (m, 2H), 1.99 (m, 2H), 1.75 (m, 2H), 1.621.49 (m, 12H) |
22 (A) | ό 8-cyclopentyl-6-methyl-2-{[1 (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)one | 406 | 1H NMR (700 MHz, DMSO-cfe) δ = 8.52 (br s, 1H), 7.55 (br s, 2H), 6.00-5.73 (m, 1H), 4.06-3.76 (m, 1H), 3.56 (br s, 2H), 2.96-2.80 (m, 5H), 2.37-2.11 (m, 2H), 2.05-1.90 (m, 7H), 1.74 (br s, 2H), 1.67-1.47 (m, 4H) |
23 (A) | H Q ,N // ' οχιχ H ô 4-[(8-cyclopentyl-6-methyl-7-oxo-7,8dihydropyrido[2,3-c/]pyrimidin-2yl)amino]-/\/-methylpiperidine-1- I sulfonamide | 421 | 1H NMR (400 MHz, CDCh) δ = 8.35 (s, 1H), 7.30 (d, J=1.3 Hz, 1H), 5.89 (quin, J=8.9 Hz, 1H), 5.28 (br s, 1H), 4.20 (q, J=5.3 Hz, 1H), 4.02 (br s, 1H), 3.73 (d, J=12.5 Hz, 2H), 3.10-2.97 (m, 2H), 2.77 (d, J=5.3 Hz, 3H), 2.35 (br s, 2H), 2.22-2.12 (m, 5H), 2.04 (m, 2H), 1.91-1.78 (m, 2H), 1.68 (m, 4H) |
147
24 (A) | ό 4-[(8-cyclopentyl-6-methyl-7-oxo-7,8dihydropyrido[2,3-d]pyrimidin-2yl)amino]-A/,A/-dimethylpiperidine-1sulfonamide | 435 | 1H NMR (400 MHz, CDCk) δ = 8.35 (s, 1H), 7.30 (d, J=1.3 Hz, 1H), 5.89 (quin, 7=8.9 Hz, 1 H), 5.24 (br s, 1 H), 4.03 (d, 7=5.8 Hz, 1H), 3.72 (d, J=13.3 Hz, 2H), 2.98-3.11 (m, 2H), 2.84 (s, 6H), 2.33 (d, J=12.0 Hz, 2H), 2.10-2.19 (m, 5H), 2.00-2.09 (m, 2H), 1.78-1.91 (m, 2H), 1.68-1.76 (m, 2H), 1.56-1.65 ppm (m, 2H) |
25 (A) | H2N /P H ό 4-[(8-cyclopentyl-6-methyl-7-oxo-7,8dihydropyrido[2,3-d]pyrirnidin-2yl)amino]piperidine-1-sulfonamide | 407 | 1H NMR (400 MHz, DMSO-cfe) δ = 8.50 (s, 1H), 7.66-7.53 (m, 2H), 6.77 (s, 2H), 5.87-5.78 (m, 1H), 3.84-3.77 (m, 1H), 3.60-3.52 (m, 2H), 2.65-2.59 (m, 2H), 2.32-2.16 (m, 2H), 2.02-1.96 (m, 7H), 1.72-1.54 (m, 6H) |
26 (A) | F ό 8-cyclopentyl-2-({1[(difluoromethyl)sulfonyl]piperidin-4yl}amino)-6-methylpyrido[2,3cfjpyrimidin-7(8H)-one | 442 | 1H NMR (400 MHz, CDCI3) δ = 8.35 (s, 1H), 7.31 (s, 1H), 5.88 (quin, J=8.9 Hz, 1H), 5.22 (br s, 1H), 4.11 (br s, 1H), 3.98 (d, J=13.6 Hz, 2H), 3.30 (t, J=11.5 Hz, 2H), 2.33 (br s, 2H), 2.23-2.13 (m, 5H), 2.05 (br s, 2H), 1.90-1.79 (m, 2H), 1.74-1.63 (m, 4H) 19F NMR (377MHz, DMSO-cfe) δ = -123.2 (s, 2F) |
27 (A) | ^Nk'P ημ, H ά 4-{[8-cyclopentyl-6-(2-hydroxyethyl)-7- | 488 [M+Na]+ | 1H NMR (400 MHz, CDCI3) δ = 8.39 (s, 1H), 7.37 (s, 1H), 5.88 (quin, 7=8.9 Hz, 1H), 5.58-5.06 (m, 1H), 4.12-3.95 (m, 1H), 3.86 (d, 7=4.8 Hz, 2H), 3.76-3.60 (m, 2H), 3.10-2.97 (m, 3H), 2.86-2.79 (m, 8H), 2.34 (br s, 2H), 2.14 (dd, J=3.3, 13.1 Hz, 2H), 2.09-1.95 (m, 2H), |
148
oxo-7,8-dihyd ropyrido[2,3-d]pyrimidin- 2-yl]amino}-A/,/V-dirnethylpiperidine-1sulfonamide | 1.92-1.77 (m, 2H), 1.71-1.54 (m, 4H) | |||
28 | '' n η n (J I II | /NH2 | 1H NMR (400 MHz, DMSO-cfe) δ = 8.40 | |
I I Π k N N | A | (s, 1H), 7.13 (d, J=4.6 Hz, 1H), 6.60 (s, | ||
(H) | ό | 407 | 1H), 6.02-5.85 (m, 1H), 5.15 (s, 2H), 3.86 (br s, 1H), 3.55 (d, J=12.1 Hz, 2H), 2.93-2.80 (m, 2H), 2.88 (s, 3H), | |
6-am ino-8-cyclopentyl-2-{[1 - | 2.28 (d, J=10.4 Hz, 2H), 1.97 (d, | |||
(methylsu!fonyl)piperidin-4- | J=11.0 Hz, 4H), 1.83-1.71 (m, 2H), | |||
yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)- | 1.69-1.51 (m, 4H) | |||
one | ||||
29 | ^Cl | |||
ΐ I ΐ J | 1H NMR (700 MHz, DMSO-cfe) δ = | |||
H I | A) | 8.68-8.51 (m, 1H), 8.04 (br s, 1H), | ||
(D) | ô 6-chloro-8-cyclopentyl-2-{[1 - | 426 | 8.01-7.58 (m, 1H), 6.09-5.70 (m, 1H), 4.12-3.76 (m, 1H), 3.63-3.56 (m, 2H), 2.87 (d, J=11.3 Hz, 5H), 2.25 (br s, 1H), 2.12 (br s, 1H), 1.95 (br s, 4H), | |
(methylsulfonyl)piperidin-4- | 1.77 (brs, 2H), 1.68-1.51 (m, 4H) | |||
yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)- | ||||
one | ||||
30 | zo | F | 1H NMR (400 MHz, DMSO-cfe, 80 °C) δ | |
-T | = 8.72 (s, 1 H), 8.02 (s, 1 H), 7.77 (br s, 1H), 6.84 (t, J=55.0 Hz, 1H), 5.83 | |||
N N H A | XO | (quin, J=8.7 Hz, 1H), 4.01 (br s, 1H), | ||
(E) | ô | 442 | 3.63 (d, J=12.3 Hz, 2H), 2.97-2.90 (m, 2H), 2.88 (s, 3H), 2.32 (br s, 2H), 2.08- | |
8-cyclopentyl-6-(difluoromethyl)-2-{[1- (methylsulfonyl)piperidin-4- | 1.92 (m, 4H), 1.87-1.74 (m, 2H), 1.74- 1.58 (m, 4H) | |||
yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)- | 19F NMR (377MHz, DMSO-cfe, 80 °C) δ | |||
one | = -116.8 (brs, 2F) |
149 (A)
(8-cyclopentyl-2-{[1 (methylsulfonyl)piperidin-4-yl]amino}-7oxo-7,8-d ihyd ropyrido[2,3-c(|pyrim id i n6-yl)(difluoro)acetic acid
486 1H NMR (400 MHz, DMSO-de, 80 °C) δ = 8.65 (s, 1H), 7.85 (s, 1H), 7.56 (br s, 1H), 5.72-5.87 (m, 1H), 3.90-4.10 (m, 1H), 3.56-3.68 (m, 2H), 2.89-2.96 (m, 2H), 2.88 (s, 3H), 2.22-2.36 (m, 2H), 1.94-2.07 (m, 4H), 1.56-1.84 (m, 6H) 19F NMR (377 MHz, DMSO-cfe) δ = -100.9 (br s, 2F) (A)
(+)-8-[(1R*,3R*)-3-hydroxycyclohexyl]6-methyl-2-{[1(methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)one
436 1H NMR (400 MHz, CDCh) δ = 8.34 (s, 1H), 7.30 (s, 1H), 5.97 (br s, 1H), 5.38 (br s, 1H), 4.35 (br s, 1H), 3.97 (br s,
1H), 3.81 (dd, J=5.3, 10.3 Hz, 2H), 3.01-2.88 (m, 3H), 2.87-2.79 (m, 3H),
2.69 (d, J=10.0 Hz, 1H), 2.22 (d, J=12.0 Hz, 2H), 2.13 (s, 3H), 1.94-1.67 (m, 8H)
[α]ο20+11.8 (c 0.13, CHCh)
99% ee;
absolute stereochemistry unknown
Enantiomer of Ex. 33 (A)
436 (-)-8-[(1R*,3R*)-3-hydroxycyclohexylJ6-methyl-2-{[1(methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8H)one 1H NMR (400 MHz, CDCh) δ = 8.34 (s, 1H), 7.30 (d, J=1.0 Hz, 1H), 5.97 (br s, 1H), 5.35 (br s, 1H), 4.35 (br s, 1H), 3.96 (br s, 1H), 3.81 (dd, J=5.9, 10.2 Hz, 2H), 3.01-2.87 (m, 3H), 2.862.79 (m, 3H), 2.75-2.61 (m, 1H), 2.22 (d, J=12.8 Hz, 2H), 2.13 (s, 3H), 1.911.65 (m, 8H)
[o]d20 -17.8 (c 0.13, CHCh) >99% ee; absolute stereochemistry unknown
Enantiomer of Ex. 32
150
34 (D) | d' Ol Λα ô | ^Cl A 'ΌΗ | 478 | 1H NMR (400 MHz, DMSO-cfe) δ = 8.65-8.52 (m, 1H), 8.11-7.97 (m, 2H), 6.18-5.67 (m, 1H), 4.52 (br s, 1H), 4.12 (br s, 1H), 3.82 (br s, 1H), 3.59 (br s, 2H), 3.00-2.76 (m, 6H), 2.26-1.89 (m, 2H), 1.85-1.32 (m, 9H) |
(+)-6-chloro-8-[(1 R*,3R*)-3- | [M+Na]+ | [a]o20 +4.3 (c 0.2, DMSO) | ||
hydroxycyclohexyl]-2-{[1- | >99% ee; absolute stereochemistry | |||
(methylsulfonyl)piperidin-4- | unknown. | |||
yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)- | Enantiomer of Ex. 35 | |||
one | ||||
35 | \ '9 | 1H NMR (400 MHz, DMSO-cfe) δ = | ||
/'lO | Cl | 8.62-8.54 (m, 1H), 8.10-7.92 (m, 2H), | ||
Aw | % | 6.16-5.65 (m, 1H), 4.51 (br s, 1H), 4.13 | ||
H ? | (br s, 1H), 3.83 (br s, 1H), 3.60 (br s, | |||
luJ | Ί3Η | 478 | 2H), 2.95-2.74 (m, 6H), 2.20-1.89 (m, 2H), 1.89-1.36 (m, 9H) | |
(-)-6-chloro-8-[(1 R*,3R*)-3hydroxycyclohexyl]-2-{[1 (methylsulfonyl)piperidin-4- | [M+Na]+ | [α]ο20-8.7 (c 0.2, DMSO) 93% ee; absolute stereochemistry unknown. | ||
yl]amino}pyrido[2,3-c/]pyrimidin-7(8/7)- | Enantiomer of Ex. 34 | |||
one | ||||
36 | ^zP | 1H NMR (400 MHz, CDCI3) δ = 8.38 (s, | ||
(A) | h A | Λ | 406 | 1H), 7.41 (d, J=9.3 Hz, 1H), 6.34 (d, J=9.3 Hz, 1H), 6.01-5.86 (m, 1H), 4.10-3.95 (m, 1H), 3.79 (d, J=10.5 Hz, 2H), 2.93 (br s, 2H), 2.83 (s, 3H), 2.79- 2.51 (m, 1H), 2.34 (br s, 1H), 2.19 (d, |
8-[(1R,2S)-2-methylcyclopentyl]-2-{[1(methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-c(]pyrimidin-7(8/7)one | J=12.3 Hz, 2H), 2.10-1.99 (m, 1H), 1.89 (dd, J=7.7, 18.7 Hz, 4H), 1.761.61 (m, 2H), 1.60-1.45 (m, 1H), 0.78 (d, J=7.0 Hz, 3H) | |||
95% ee; Single enantiomer, absolute |
151
stereochemistry known. | |||
37 | ° L 1 Λ Λ 1 | 1H NMR (400 MHz, CDCh) δ = 8.34 (s, 1H), 7.30 (s, 1H), 6.04-5.91 (m, 1H), 4.08-3.95 (m, 1H), 3.85-3.72 (m, 2H), | |
(A) | H 6-methyl-8-[(1R,2S)-2- methylcyclopentyl]-2-{[1 - (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8H)one | 420 | 3.01-2.88 (m, 2H), 2.83 (s, 3H), 2.412.28 (m, 1H), 2.24-2.16 (m, 2H), 2.14 (s, 3H), 2.10-2.02 (m, 1H), 2.00-1.80 (m, 3H), 1.73 (br s, 4H), 1.63-1.53 (m, 1H), 0.76 (d, J=7.0 Hz, 3H); 96% ee; Single enantiomer, absolute stereochemistry known. |
38 (D) | ^,p '' N η N ° l 1 Λ Λ X N N N^O H | 1H NMR (400 MHz, CDCh) δ = 8.38 (s, 1H), 7.65 (s, 1H), 5.99 (d, 7=7.3 Hz, 1H), 4.10-3.93 (m, 1H), 3.79 (d, 7=8.8 Hz, 2H), 2.92 (br s, 2H), 2.83 (s, 3H), 2.41-2.27 (m, 1H), 2.18 (d, J=12.0 Hz, 2H), 2.11-2.02 (m, 1H), 2.00-1.76 (m, | |
6-chloro-8-[(1R,2S)-2- methylcyclopentyl]-2-{[1 (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)one | 440 | 4H), 1.74-1.63 (m, 2H), 1.61-1.48 (m, 1H), 0.77 (d, J=7.0 Hz, 3H); 96% ee; Single enantiomer, absolute stereochemistry known. Enantiomer of Ex. 39 | |
39 | \/P '' Nη N Af ° L 1 Λ A Λ H ” | 1H NMR (400 MHz, CDCh) δ = 8.39 (s, 1H), 7.65 (s, 1H), 6.00 (dt, J=7.0, 9.8 Hz, 1H), 4.02 (td, 7=2.1, 4.1 Hz, 1H), 3.88-3.72 (m, 2H), 3.01-2.90 (m, 2H), | |
(D) | 2.83 (s, 3H), 2.35 (tt, 7=7.0, 10.4 Hz, 1H), 2.24-2.16 (m, 2H), 2.12-2.03 (m, | ||
6-chloro-8-[(1 S,2R)-2methylcyclopentyl]-2-{[1 (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8H)one | 462 [M+Na]+ | 1H), 2.01-1.82 (m, 3H), 1.77-1.61 (m, 3H), 1.59-1.48 (m, 1H), 0.78 (d, 7=7.0 Hz, 3H); 97% ee; Single enantiomer, absolute stereochemistry known. Enantiomer of Ex. 38 |
152
40 (A) | ^P °'SO ρΤΓ H 6-(2-hydroxyethyl)-8-[(1R,2S)-2methylcyclopentyl]-2-{[1 - (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-cf]pyrimidin-7(8/-/)one | 450 | 1H NMR (400 MHz, CDCh) δ = 8.39 (s, 1H), 7.38 (s, 1H), 6.06-5.92 (m, 1H), 4.10-3.97 (m, 1H), 3.90-3.72 (m, 4H), 3.03-2.89 (m, 2H), 2.86-2.75 (m, 5H), 2.42-2.29 (m, 1H), 2.25-2.15 (m, 2H), 2.12-2.01 (m, 1H), 2.01-1.81 (m, 3H), 1.79-1.48 (m, 4H), 0.77 (d, J=7.0 Hz, 3H); 95% ee; Single enantiomer, absolute stereochemistry known. Enantiomer of Ex. 41 |
41 | 1H NMR (400 MHz, CDCh) δ = 8.39 (s, | ||
1H), 7.38 (s, 1H), 6.04-5.94 (m, 1H), 4.08-3.98 (m, 1H), 3.91-3.74 (m, 4H), | |||
H ? | 3.02-2.89 (m, 3H), 2.86-2.78 (m, 5H), | ||
(A) | O..... | 2.42-2.29 (m, 1H), 2.25-2.15 (m, 2H), 2.11-2.01 (m, 1H), 2.01-1.80 (m, 3H), | |
6-(2-hydroxyethyl)-8-[(1S,2R)-2- | 450 | 1.70-1.63 (m, 2H), 1.62-1.49 (m, 1H), | |
methylcyclopentyl]-2-{[1- | 0.77 (d, J=7.0 Hz, 3H); | ||
(methylsulfonyl)piperidin-4- yl]amino}pyrido[2,3-d]pyrimidin-7(8H)- | >99% ee ; Single enantiomer, absolute | ||
one | stereochemistry known. | ||
Enantiomer of Ex. 40 | |||
42 | H Q | 1H NMR (400 MHz, CDCh) δ = 8.45- | |
'N.'/ 6' Ό-,ΐΧζ | 8.24 (m, 1H), 7.29 (s, 1H), 6.03-5.93 (m, 1H), 5.38-5.11 (m, 1H), 4.22-4.10 | ||
H | (m, 1H), 4.08-3.94 (m, 1H), 3.78-3.67 | ||
(A) | A/-methyl-4-({6-methyl-8-[(1R,2S)-2- | 435 | (m, 2H), 3.10-2.95 (m, 2H), 2.76 (d, J=5.5 Hz, 3H), 2.41-2.27 (m, 1H), 2.20-2.13 (m, 4H), 2.10-2.01 (m, 1H), 2.00-1.79 (m, 3H), 1.73-1.59 (m, 5H), |
methylcyclopentyl]-7-oxo-7,8- dihydropyrido[2,3-c/]pyrimidin-2- | 0.76 (d, J=7.0 Hz, 3H); | ||
yl}amino)piperidine-1 -sulfonamide | 96% ee; Single enantiomer, absolute stereochemistry known. | ||
Enantiomer of Ex. 43 l |
153
43 (A) | A/ à 'C fYV N N N X) H 7 O..... /V-methyl-4-({6-methyl-8-[(1S,2R)-2methylcyclopentyl]-7-oxo-7,8dihydropyrido[2,3-d]pyrimidin-2yl}amino)piperidine-1-sulfonamide | 435 | 1H NMR (400 MHz, CDCI3) δ = 8.34 (s, 1H), 7.30 (d, >0.8 Hz, 1H), 6.01-5.93 (m, 1H), 4.20 (d, >5.0 Hz, 1H), 4.073.96 (m, 1H), 3.72 (dd, >2.8, 12.3 Hz, 2H), 3.08-2.97 (m, 2H), 2.76 (d, J=5.3 Hz, 3H), 2.39-2.28 (m, 1H), 2.17 (d, >3.8 Hz, 1H), 2.14 (s, 3H), 2.10-2.01 (m, 1H), 1.99-1.81 (m, 3H), 1.73-1.56 (m, 5H), 0.76 (d, >7.0, 3H); 96% ee; Single enantiomer, absolute stereochemistry known. Enantiomer of Ex. 42 |
44 | H o ,N> 0 'CVXko | 1H NMR (400 MHz, CDCI3) δ = 8.38 (s, 1H), 7.41 (d, >9.3 Hz, 1H), 6.34 (d, >9.3 Hz, 1H), 6.00-5.87 (m, 1H), | |
ΙΔ\ | H | 4.40-4.29 (m, 1H), 4.08-3.96 (m, 1H), | |
/V-methyl-4-({8-[(1 R,2S)-2methylcyclopentyl]-7-oxo-7,8dihydropyrido[2,3-d]pyrimidin-2- | 421 | 3.78-3.65 (m, 2H), 3.02 (br s, 2H), 2.75 (d, >5.3 Hz, 3H), 2.40-2.29 (m, 1H), 2.20-2.11 (m, 2H), 2.10-2.00 (m, 1H), 1.89 (d, >9.8 Hz, 3H), 1.75-1.55 (m, 4H), 0.78 (d, >7.0 Hz, 3H); | |
yl}amino)piperidine-1-sulfonamide | >99% ee; Single enantiomer, absolute stereochemistry known. | ||
Enantiomer of Ex. 45 | |||
45 | H O | 1H NMR (400 MHz, CDCI3) δ = 8.38 (s, 1H), 7.41 (d, >9.3 Hz, 1H), 6.34 (d, >9.3 Hz, 1H), 5.93 (dt, >7.5, 9.8 Hz, | |
(A) | N N O H ? O..... | 421 | 1H), 4.24 (q, >4.9 Hz, 1H), 4.10-3.96 (m, 1H), 3.78-3.68 (m, 2H), 3.08-2.98 (m, 2H), 2.76 (d, >5.3 Hz, 3H), 2.41- |
A/-methyl-4-({8-[(1 S,2R)-2methylcyclopentyl]-7-oxo-7,8dihydropyrido[2,3-d]pyrimidin-2- | 2.28 (m, 1H), 2.20-2.11 (m, 2H), 2.09- 1.98 (m, 1H), 1.96-1.82 (m, 3H), 1.73- 1.61 (m, 4H), 0.78 (d, >7.0 Hz, 3H); | ||
yl}amino)piperidine-1-sulfonamide | I | 97% ee; Single enantiomer, absolute stereochemistry known. |
154
Enantiomer of Ex. 44 | |||
46 (A) | H 0 ^Ns // °'s'Cl H 7 O..... 4-({6-(2-hydroxyethyl)-8-[( 1 S,2R)-2methylcyclopentyl]-7-oxo-7,8dihydropyrido[2,3-d]pyrimidin-2yl}amino)-/V-methylpiperidine-1 sulfonamide | 487 [M+Na]+ | 1H NMR (400 MHz, CDCh) δ = 8.39 (s, 1H), 7.38 (s, 1H), 6.07-5.91 (m, 1H), 5.69-5.30 (m, 1H), 4.47-4.26 (m, 1H), 4.12-3.96 (m, 1H), 3.85 (br s, 2H), 3.78-3.63 (m, 2H), 3.12-2.92 (m, 3H), 2.81 (s, 2H), 2.76 (d, J=5.3 Hz, 3H), 2.71-2.59 (m, 1H), 2.43-2.28 (m, 1H), 2.21-2.13 (m, 2H), 2.11-2.00 (m, 1H), 2.00-1.81 (m, 3H), 1.70-1.48 (m, 3H), 0.77 (d, J=7.0 Hz, 3H); >99% ee; Single enantiomer, absolute stereochemistry known. Enantiomer of Ex. 4 |
47 (F) | h 2-(8-[(1R,2S)-2-methylcyclopentyl]-2- {[1-(methylsulfonyl)piperidin-4- yl]amino}-7-oxo-7,8-dihydropyrido[2,3- cf]pyrimidin-6-yl)acetamide | 463 | 1H NMR (400 MHz, CDCh) δ = 8.43 (s, 1H), 7.56 (s, 1H), 6.74 (br s, 1H), 5.956.09 (m, 1H), 5.31 (s, 2H), 4.04 (br s, 1H), 3.70-3.89 (m, 2H), 3.36-3.56 (m, 2H), 2.95 (br s, 2H), 2.84 (s, 3H), 2.67 (br s, 1H), 2.30-2.44 (m, 1H), 2.20 (d, J=10.3 Hz, 2H), 2.01-2.13 (m, 1H), 1.83-1.98 (m, 3H), 1.72 (d, J=11.5 Hz, 2H), 1.51-1.62 (m, 1H), 0.76 ppm (d, J=7.0 Hz, 3H); 96% ee; Single enantiomer, absolute stereochemistry known. |
48 (A) | oz | Νι ΊΓ Ίί ° ^^N^N^N^O H <\T^‘ 6-(methoxymethyl)-8-[(1 R,2S)-2methylcyclopentyl]-2-{[1 (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-c/]pyrimidin-7(8H)- | 472 [M+Na]+ | 1H NMR (400 MHz, CDCh) δ = 8.42 (s, 1H), 7.53 (s, 1H), 5.97 (dt, J=7.5, 9.8 Hz, 1H), 4.39 (d, J=1.3 Hz, 2H), 4.083.97 (m, 1H), 3.84-3.72 (m, 2H), 3.50 (s, 3H), 3.00-2.87 (m, 2H), 2.83 (s, 3H), 2.39-2.28 (m, 1H), 2.25-2.15 (m, 2H), 2.09-1.99 (m, 1H), 1.99-1.82 (m, 3H), 1.74-1.65 (m, 2H), 1.60-1.48 (m, 2H), 0.76 (d, J=7.3 Hz, 3H); |
155
one | 95% ee; Single enantiomer, absolute stereochemistry known. Enantiomer of Ex. 49 | ||
49 (A) | 6 'Cl ;TÏ°Z H Ξ O..... 6-(methoxymethyl)-8-[(1 S,2R)-2methylcyclopentyl]-2-{[1 - (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-c(]pyrimidin-7(8/-/)one | 450 | 1H NMR (400 MHz, CDCh) δ = 8.42 (s, 1H), 7.54 (s, 1H), 5.97 (td, J=9.8, 7.5 Hz, 1H), 5.31 (brs„ 1H), 4.40 (d, J=1.3 Hz, 2H), 4.04 (d, J=6.8 Hz, 1H), 3.80 (d, J=10.8 Hz, 2H), 3.50 (s, 3H), 2.883.03 (m, 2H), 2.84 (s, 3H), 2.68 (d, J=16.1 Hz, 1H), 2.35 (tquin, J=10.4, 7.1 Hz, 1H), 2.21 (d, J=12.5 Hz, 2H), 2.02-2.12 (m, 1H), 1.80-1.99 (m, 3H), 1.67-1.77 (m, 2H), 1.49-1.61 (m, 1H), 0.77 ppm (d, J=7.0 Hz, 3H); 97% ee; Single enantiomer, absolute stereochemistry known. Enantiomer of Ex. 48 |
50 (A) | N η N VY OH N N Ύ 6- 6-(hydroxymethyl)-8-[(1 R,2S)-2methylcyclopentyl]-2-{[1- (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)one | 458 [M+Na]+ | 1H NMR (400 MHz, CDCh) δ = 8.42 (s, 1H), 7.45 (s, 1H), 5.97 (dt, J=7.3, 9.8 Hz, 1H), 4.56 (br s, 2H), 4.04 (dt, J=1.6, 3.2 Hz, 1H), 3.86-3.71 (m, 2H), 3.19-3.06 (m, 1H), 3.01-2.88 (m, 2H), 2.83 (s, 3H), 2.36 (ddd, J=3.0, 7.2, 10.1 Hz, 1H), 2.24-2.15 (m, 2H), 2.101.99 (m, 1H), 1.98-1.81 (m, 3H), 1.771.67 (m, 2H), 1.61-1.48 (m, 2H), 0.77 (d, J=7.0 Hz, 3H); 97% ee; Single enantiomer, absolute stereochemistry known. Enantiomer of Ex. 51 |
156
51 (A) | H - O..... 6-(hydroxymethyl)-8-[(1 S,2R)-2methylcyclopentyl]-2-{[1- (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)one | 458 [M+Na]+ | 1H NMR (400 MHz, CDCI3) δ = 8.42 (s, 1H), 7.45 (s, 1H), 6.01-5.93 (m, 1H), 4.56 (s, 2H), 4.09-3.98 (m, 1H), 3.863.72 (m, 2H), 3.19-3.04 (m, 1H), 3.01- 2.87 (m, 1H), 2.83 (s, 3H), 2.40-2.27 (m, 1H), 2.24-2.15 (m, 2H), 2.12-1.99 (m, 1H), 1.98-1.82 (m, 3H), 1.79-1.63 (m, 4H), 1.58-1.51 (m, 1H), 0.77 (d, J=7.0 Hz, 3H); 97% ee; Single enantiomer, absolute stereochemistry known. Enantiomer of Ex. 50 |
52 (A) | ° fl iTl H 2-({1-[(2- methoxyethyl)sulfonyl]piperidin-4yl}amino)-8-[(1 R,2S)-2methylcyclopentyl]pyrido[2,3d]pyrimidin-7(8/-/)-one | 472 [M+Na]+ | 1H NMR (400 MHz, CDCI3) δ = 8.39 (s, 1H), 7.41 (d, J=9.3 Hz, 1H), 6.35 (d, J=9.3 Hz, 1H), 6.05-5.87 (m, 1H), 5.38 (br s, 1H), 4.04 (br s, 1H), 3.86-3.71 (m, 4H), 3.39 (s, 3H), 3.23 (t, J=5.8 Hz, 2H), 3.10-2.96 (m, 2H), 2.69 (br s,, 1H), 2.45-2.26 (m, 1H), 2.21-2.10 (d, J=12.8 Hz, 2H), 2.08-1.97 (m, 1H), 1.95-1.79 (m, 3H), 1.64-1.47 (m, 3H), 0.79 (d, J=7.0 Hz, 3H); >99% ee; Single enantiomer, absolute stereochemistry known |
53 (A) | H ? (+)-8-((1 R*,3R*)-3-hydroxycyclopentyl]2-{[1-(methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8H)one | 408 | 1H NMR (400 MHz, DMSO-cfe) δ = 8.59 (br s, 1H), 7.90-7.69 (m, 1H), 7.67 (d, J=9.3 Hz, 1H), 6.21 (d, J=7.8 Hz, 1H), 6.11 (brs, 1H), 4.63-4.46 (m, 1H), 4.42 (br s, 1H), 4.08-3.79 (m, 1H), 3.60-3.53 (m, 2H), 2.88 (s, 3H), 2.87-2.81 (m, 2H), 2.20 (br s, 2H), 2.06-1.83 (m, 4H), 1.70-1.52 (m, 4H); [a]D 22+15.0 (c 0.1, MeOH) >99% ee Absolute stereochemistry unknown. |
157
Enantiomer of Ex. 54 | |||
54 (A) | Cq CQ H ô 'OH (-)-8-((1 R*,3R*)-3-hydroxycyclopentyl]- 2-{[1-(methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-c(]pyrimidin-7(8/-/)one | 408 | 1H NMR (400 MHz, DMSO-cfe) δ = 8.59 (br s, 1H), 7.91-7.69 (m, 1H), 7.67 (d, J=9.3 Hz, 1H), 6.21 (d, J=7.3 Hz, 1H), 6.11 (br s, 1 H), 4.62-4.47 (m, 1 H), 4.42 (br s, 1H), 4.13-3.80 (m, 1H), 3.60-3.53 (m, 2H), 2.88 (s, 3H), 2.87-2.82 (m, 2H), 2.20 (br s, 2H), 2.06-1.83 (m, 4H), 1.69-1.53 (m, 4H); [a]D 22 —16.1 (c0.1, MeOH) >99% ee; absolute stereochemistry unknown. Enantiomer of Ex. 53 |
55 (A) | ΰ 'CkXXX Ô0H 4-({8-[(1R,2R)-2-hydroxycyclopentyl]6-methyl-7-oxo-7,8-dihydropyrido[2,3c/]pyrimidin-2-yl}amino)-/\/methylpiperidine-1-sulfonamide | 459.0 [M+Na]+ | 1H NMR (400 MHz, CDCh) δ = 8.37 (s, 1H), 7.33 (d, J=1.3 Hz, 1H), 5.84-5.68 (m, 1H), 5.00 (m, 1H), 4.09 (m, 1H), 4.00 (br s, 1H), 3.73 (d, J=12.3 Hz, 2H), 3.03 (t, J=11.7 Hz, 2H), 2.76 (d, J=5.2, 3H), 2.42-2.26 (m, 2H), 2.15 (d, J=1.3 Hz, 5H), 2.08-1.96 (m, 2H), 1.90 (dd, J=6.1, 12.7 Hz, 1H), 1.77-1.63 (m, 3H); 98% ee; Single enantiomer, absolute stereochemistry known. |
56 (A) | ° Cl ΓΧ1 H (-)-4-({8-[(1R*,2R*)-2-hydroxy-2methylcyclopentyl]-7-oxo-7,8dihydropyrido[2,3-d]pyrimidin-2yl}amino)-/\/-methylpiperidine-1 sulfonamide | 459 [M+Na]+ | 1H NMR (400 MHz, CDCh) δ = 8.42 (s, 1H), 7.45 (d, J=9.3 Hz, 1H), 6.34 (d, J=9.0 Hz, 1H), 5.67 (br s, 2H), 4.774.35 (m, 1H), 4.03 (d, J=6.0 Hz, 1H), 3.75 (d, J=11.5 Hz, 2H), 3.03 (t, J=10.8 Hz, 2H), 2.93-2.79 (m, 1H), 2.75 (d, J=5.3 Hz, 3H), 2.28-2.09 (m, 3H), 2.06-1.80 (m, 4H), 1.72-1.58 (m, 3H), 1.17 (s, 3H); [a]D 20 -13.0 (c 0.20, CHCb) >99% ee; absolute stereochemistry |
158
unknown. Enantiomer of Ex. 57 | |||
57 | H Q /N '/ | 1H NMR (400 MHz, CDCb) δ = 8.42 (s, | |
0X0,. | 1H), 7.45 (d, J=9.3 Hz, 1H), 6.35 (d, J=9.5 Hz, 1H), 5.71 (br s, 1H), 5.51 (br | ||
(A) | s, 1H), 4.26 (br s, 1H), 4.01 (br s, 1H), | ||
H O/31 1 (+)-4-({8-[(1R*,2R*)-2-hydroxy-2methylcyclopentyl]-7-oxo-7,8dihydropyrido[2,3-c/]pyrimidin-2yl}amino)-A/-methylpiperidine-1 - | 459 [M+Na]+ | 3.65-3.83 (m, 2H), 2.97-3.13 (m, 2H), 2.78-2.95 (m, 1H), 2.76 (d, J=5.5 Hz, 3H), 2.11-2.29 (m, 3H), 1.80-2.08 (m, 4H), 1.62-1.74 (m, 3H), 1.17 ppm (s, 3H); | |
sulfonamide | [a]o20 +8.6 (cO.17, CHCb) >99% ee; absolute stereochemistry unknown. Enantiomer of Ex. 56 | ||
58 | 1H NMR (400 MHz, CDCb) δ = 8.43 (s, | ||
1H), 7.46 (d, J=9.3 Hz, 1H), 6.36 (d, | |||
J=9.0 Hz, 1H), 5.82-5.66 (m, 1H), 5.49 | |||
H ï ,OH | (br s, 1H), 5.14 (d, J=48 Hz, 2H), 4.05 | ||
(A) | (br s, 1H), 3.97-3.86 (m, 2H), 3.26-3.11 | ||
(-)-2-({1- | (m, 2H), 2.83 (br s, 1H), 2.30-2.16 (m, | ||
[(fluoromethyl)sulfonyl]piperidin-4- | 3H), 2.07-1.97 (m, 2H), 1.95-1.80 (m, | ||
yl}amino)-8-[(1R*,2R*)-2-hydroxy-2- | 462 | 2H), 1.67 (brs, 2H), 1.17 (s, 3H) | |
methylcyclopentyl]pyrido[2,3- | [M+Na]+ | 19F NMR (377 MHz, DMSO-cfe) δ = | |
c/]pyrimidin-7(8/-/)-one | -215.3 (s, 1F) [a]o22 -18.7 (c0.5, CHCb) [a]o22 -30.1 (c0.5, MeOH) 99% ee; absolute stereochemistry unknown. Enantiomer of Ex. 59 |
159
59 (A) | F 'O.NXXX (+)-2-({1- [(fluoromethyl)sulfonyl]piperidin-4yl}amino)-8-[(1R*,2R*)-2-hydroxy-2methylcyclopentyl]pyrido[2,3d]pyrimidin-7(8/-/)-one | 462 [M+Na]+ | 1H NMR (400 MHz, CDCh) δ = 8.43 (s, 1H), 7.45 (d, J=9.3 Hz, 1H), 6.36 (d, J=9.3 Hz, 1H), 5.73 (br s, 1H), 5.40 (br s, 1H), 5.26-5.02 (m, 2H), 4.07 (br s, 1H), 3.93 (t, J=11.9 Hz, 2H), 3.27-3.11 (m, 2H), 2.93-2.73 (m, 1H), 2.30-2.18 (m, 3H), 2.06-1.98 (m, 2H), 1.96-1.79 (m, 2H), 1.71-1.61 (m, 2H), 1.18 (s, 3H) 19F NMR (377 MHz, DMSO-cfe) δ = -215.3 (s, 1F) [a]o22 +33.3 (c0.5, MeOH) 99% ee; absolute stereochemistry unknown. Enantiomer of Ex. 58 |
60 | V h 0 \ Z\/N f/ | 1H NMR (400 MHz, CDCh) δ = 8.43 (s, | |
°?'O-naX10 | 1H), 7.45 (d, J=9.3 Hz, 1H), 6.35 (d, J=8.8 Hz, 1H), 5.72 (br s, 1H), 5.55- | ||
(A) | 5.23 (m, 1H), 4.64-4.57 (m, 1H), 4.13- 3.89 (m, 1H), 3.78-3.68 (m, 2H), 3.20 | ||
(-)-4-({8-[( 1 R*,2R*)-2-hyd roxy-2methylcyclopentyl]-7-oxo-7,8dihydropyrido[2,3-d]pyrimidin-2yl}amino)-A/-(2-methoxy-2methylpropyl)piperidine-1-sulfonamide | 531 [M+Na]+ | (s, 3H), 3.03 (d, J=5.8 Hz, 4H), 2.94- 2.77 (m, 1H), 2.68-2.36 (m, 1H), 2.17 (d, J=13.3 Hz, 3H), 2.04-1.82 (m, 4H), 1.66 (d, J=10.5 Hz, 2H), 1.22 (s, 6H), 1.17 (s, 3H); | |
[a]o20-13.3 (c 0.27, MeOH) 98% ee; absolute stereochemistry unknown. | |||
Enantiomer of Ex. 61 | |||
61 | \/ ÈH q | 1H NMR (400 MHz, CDCh) δ = 8.43 (s, | |
0 °'SO | 531 | 1H), 7.45 (d, J=9.3 Hz, 1H), 6.35 (d, J=9.5 Hz, 1H), 5.72 (br s, 1H), 5.55- | |
(A) | H c/0H | [M+Na]+ | 5.26 (m, 1H), 4.61 (t, J=5.6 Hz, 1H), 4.00 (br s, 1H), 3.74 (d, J=11.8 Hz, 2H), 3.20 (s, 3H), 3.05-2.96 (m, 4H), |
160
(+)-4-({8-[(1R*,2R*)-2-hydroxy-2- methylcyclopentyl]-7-oxo-7,8dihydropyrido[2,3-d]pyrimidin-2yl}amino)-A/-(2-methoxy-2methylpropyl)piperidine-1-sulfonamide | 2.86 (br s, 1H), 2.70-2.30 (m, 1H), 2.25-2.13 (m, 3H), 2.04-1.83 (m, 4H), 1.67-1.61 (m, 2H), 1.22 (s, 6H), 1.17 (s, 3H); [α]ο20 +13.8 (cO.27, MeOH) >99% ee; absolute stereochemistry unknown. Enantiomer of Ex. 60 | ||
62 | H o | 1H NMR (400 MHz, CD3OD) δ = 8.55 | |
(A) | \J-^N /P | (br s, 1H), 7.71 (d, J=9.3 Hz, 1H), 6.28 (d, J=9.3 Hz, 1H), 6.12-5.95 (m, 1H), 4.15-3.97 (m, 2H), 3.89 (m, 1H), 3.813.75 (m, 1H), 3.69 (m, 2H), 3.09 (m, 2H), 3.04-2.93 (m, 2H), 2.67-2.54 (m, | |
(-)-4-({8-[(1R*,2R*)-2-hydroxy-2- | 1H), 2.42-2.28 (m, 1H), 2.26-2.03 (m, | ||
methylcyclopentyl]-7-oxo-7,8- | 4H), 2.02-1.88 (m, 4H), 1.84-1.77 (m, | ||
dihydropyrido[2,3-c/]pyrimidin-2- | 529 | 2H), 1.69-1.59 (m, 2H), 1.12 (s, 3H); | |
yl}amino)-A/-[(2S)-tetrahydrofuran-2- ylmethyl]piperidine-1-sulfonamide | [M+Na]+ | [α]ο20-10.8 (c 0.12, MeOH) >99% de; Single diastereomer. Absolute stereochemistry known (S) at THF center; relative (but not absolute) stereochemistry known at the cyclopentyl chiral centers. | |
Made from (S)-tetrahydro-furfurylamine and racemic Intermediate 1. | |||
63 | /0 H r. / π Γ) N | 1H NMR (400 MHz, CD3OD) δ = 8.54 | |
θ'ΧνΤλ | (br s, 1H), 7.71 (d, J=9.3 Hz, 1H), 6.37-6.24 (m, 1H), 6.07 (br s, 1H), | ||
(A) | H C/°H | 4.14-3.98 (m, 2H), 3.89 (td, J=6.6, 8.1 | |
529 | Hz, 1H), 3.83-3.74 (m, 1H), 3.69 (br d, | ||
(+)-4-({8-[(1R*,2R*)-2-hydroxy-2methylcyclopentyl]-7-oxo-7,8dihydropyrido[2,3-d]pyrimidin-2yl}amino)-A/-[(2S)-tetrahydrofuran-2ylmethyl]piperidine-1-sulfonamide | [M+Na]+ | J=11.0 Hz, 2H), 3.15-3.04 (m, 2H), 2.99 (br s, 2H), 2.68-2.52 (m, 1H), 2.35 (br d, J=11.5 Hz, 1H), 2.27-2.02 (m, 4H), 2.02-1.86 (m, 4H), 1.83-1.71 (m, 2H), 1.69-1.51 (m, 2H), 1.12 (s, 3H); |
201
173 (A) | ^zP ° Q XXX Χλνλνανζ^ο H X..OH 8-[(1R,2R)-2-hydroxycyclopentyl]-6- methyl-2-{[1-(methylsulfonyl)piperidin- 4-yl]amino}pyrido[2,3-d]pyrimidin- 7(8A7)-one | 444 [M+Na]+ | 1H NMR (400 MHz, CDCh) δ = 8.38 (s, 1H), 7.34 (d, J=1.0 Hz, 1H), 5.83-5.70 (m, 1H), 5.26 (br s, 1H), 5.00 (d, J=5.5 Hz, 1H), 4.01 (br s, 1H), 3.79 (d, J=10.3 Hz, 2H), 2.95 (t, J=11.4 Hz, 2H), 2.83 (s, 3H), 2.47-2.28 (m, 2H), 2.20 (dd, J=4.1, 12.9 Hz, 2H), 2.16 (s, 3H), 2.06-1.86 (m, 3H), 1.71 (dd, J=6.5, 12.3 Hz, 3H) [α]ο22 +16.7 (c 0.1, MeOH) 98% ee; Single enantiomer, absolute stereochemistry known |
174 (A) | cX 8-[(1S,2S)-2-hydroxy-2methylcyclopentyl]-2-{[1- (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)one | 444 | 1H NMR (400 MHz, CDCh) δ = 8.43 (s, 1H), 7.45 (d, J=9.3 Hz, 1H), 6.36 (d, J=9.3 Hz, 1H), 5.73 (t, J=8.5 Hz, 1H), 5.52-5.30 (m, 1H), 4.10-3.89 (m, 1H), 3.82 (t, J=10.3 Hz, 2H), 3.01-2.86 (m, 2H), 2.83 (s, 3H), 2.33-2.13 (m, 3H), 2.09-1.96 (m, 2H), 1.96-1.80 (m, 2H), 1.75-1.62 (m, 3H), 1.18 (s, 3H) [a]o22 +7.28 (c 2.06, CHCb) 99% ee; Single enantiomer, absolute stereochemistry known. Enantiomer of Ex. 2 |
175 (D) | Xxxx 0° 6-chloro-8-[(1 S,2S)-2-hydroxy-2methylcyclopentyl]-2-{[1 (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8H)one | 456 | 1H NMR (400 MHz, DMSO-cfe) δ = 8.67-8.57 (m, 1H), 8.09 (s, 1H), 8.067.73 (m, 1H), 5.90 (t, J=7.9 Hz, 1H), 4.48-4.33 (m, 1H), 4.05-3.82 (m, 1H), 3.57 (br s, 2H), 2.88 (s, 4H), 2.86-2.76 (m, 1H), 2.45-2.29 (m, 1H), 2.17 (d, J=9.2 Hz, 2H), 2.03-1.77 (m, 4H), 1.73-1.40 (m, 3H), 0.87-1.07 [α]ο22 +15.4 (c0.1 MeOH) 99% ee; Single enantiomer, absolute stereochemistry known. |
202
Enantiomer of Ex. 9 | |||
176 (E) | AA ô' Aj A Jï 6-(difluoromethyl)-8-[(1S,2S)-2hydroxy-2-methylcyclopentyl]-2-{[1- (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)one | 472 | 1H NMR (400 MHz, DMSO-cfe, 80 °C) δ = 8.73 (s, 1H), 8.03 (s, 1H), 7.76 (br s, 1H), 6.83 (t, J=56.0 Hz, 1H), 5.87 (t, J=8.3 Hz, 1H), 4.11-3.96 (m, 2H), 3.62 (t, J=11.6 Hz, 2H), 2.97-2.89 (m, 2H), 2.87 (s, 3H), 2.26-2.14 (m, 1H), 2.141.82 (m, 5H), 1.79-1.51 (m, 3H), 1.03 (s, 3H) 19F NMR (376 MHz, DMSO-cfe) δ = -125.2 to -113.7 (m, 2F) [a]o22 +24.7 (c 0.2, CHCI3) >99% ee; Single enantiomer, absolute stereochemistry known. Enantiomer of Ex. 10 |
177 (I) | A ~ AA X N i ν Α^^Ί L 1 Λ /1 A ^^N N N^O X (-)-6-acetyl-8-[( 1 R*, 2R*)-2-hydroxy-2methylcyclopentyl]-5-methyl-2-{[1(methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8/7)one | 479 | 1H NMR (400 MHz, DMSO-cfe) δ = 8.91-8.71 (m, 1H), 8.12-7.64 (m, 1H), 5.87 (t, J=8.4 Hz, 1H), 4.44-4.22 (m, 1H), 3.91 (br s, 1H), 3.66-3.49 (m, 2H), 2.95-2.79 (m, 6H), 2.38 (s, 3H), 2.27 (s, 3H), 2.18 (d, X9.4 Hz, 2H), 2.021.89 (m, 3H), 1.85 (br s, 2H), 1.72-1.59 (m, 2H), 1.07-0.94 (m, 3H) [a]o22 -36.5 (c 0.1, MeOH) 99% ee; absolute stereochemistry unknown. Enantiomer of Ex. 178 |
178 (D | AA Ak ° L JL A JL  (J°H (+)-6-acetyl-8-[(1R*,2R*)-2-hydroxy-2- | 479 | 1H NMR (400 MHz, DMSO-cfe) δ = 8.86-8.77 (m, 1H), 8.08-7.74 (m, 1H), 5.94- 5.80 (m, 1H), 4.40-4.27 (m, 1H), 4.13-3.82 (m, 1H), 3.64-3.51 (m, 2H), 2.94- 2.82 (m, 5H), 2.38 (s, 3H), 2.27 (s, 3H), 2.18 (d, J=10.0 Hz, 2H), 2.071.90 (m, 3H), 1.85 (br s, 2H), 1.65 (br |
203
methylcyclopentyl]-5-methyl-2-{[1(methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)one | s, 3H), 0.99 (brs, 3H) [α]ο22 +27.0 (c0.1, MeOH) 99% ee; absolute stereochemistry unknown. Enantiomer of Ex. 177 | ||
179 (F) | ^,9 S. ,NH2 d' H (-)-2-(8-[(1R*,2R*)-2-hydroxy-2methylcyclopentyl]-2-{[1- (methylsulfonyl)piperidin-4-yl]amino}-7oxo-7,8-dihydropyrido[2,3-ci]pyrimidin6-yl)acetamide | 501 [M+Na]+ | 1H NMR (400 MHz, CDCh) δ = 8.45 (s, 1H), 7.58 (s, 1H), 6.61 (br s, 1H), 5.79 (br s, 1H), 5.58 (br s, 1H), 5.38 (br s, 1H), 3.99 (br s, 1H), 3.89-3.76 (m, 2H), 3.54-3.38 (m, 2H), 3.02-2.87 (m, 2H), 2.83 (s, 4H), 2.35-2.13 (m, 4H), 2.06- 1.82 (m, 4H), 1.75-1.69 (m, 2H), 1.15 (s, 3H) [a]o22 -11.81 (c0.11, MeOH)) 99% ee; absolute stereochemistry unknown. Enantiomer of Ex. 180 |
180 (F) | 0' N I N II l^ H L Λ Jk o N N N 0 (+)-2-(8-((1 R*,2R*)-2-hydroxy-2methylcyclopentyl]-2-{[1 (methylsulfonyl)piperidin-4-yl]amino}-7oxo-7,8-dihydropyrido[2,3-c/]pyrimidin6-yl)acetamide | 501 [M+Na]+ | 1H NMR (400 MHz, CDCh) δ = 8.45 (s, 1H), 7.58 (s, 1H), 6.60 (br s, 1H), 5.82 (br s, 1H), 5.53 (br s, 1H), 5.33 (br s, 1H), 3.98 (br s, 1H), 3.83 (d, J=10.5 Hz, 2H), 3.55-3.41 (m, 2H), 3.00-2.72 (m, 6H), 2.37-2.14 (m, 4H), 2.07-1.83 (m, 4H), 1.77-1.65 (m, 2H), 1.15 (s, 3H) [a]D 22 +10.90 (c0.11, MeOH) 99% ee; absolute stereochemistry unknown. Enantiomer of Ex. 179 |
204
181 (A) | F>L° ° o. m H V/^H (-)-8-((1 R*,2R*)-2-hydroxy-2methylcyclopentyl]-6-methyl-2-({1[(trifluoromethyl)sulfonyl]piperidin-4yl}amino)pyrido[2,3-d]pyrimidin-7(8/-/)one | 490 | 1H NMR (400 MHz, DMSO-cfe, 80 °C) δ = 8.51 (s, 1H), 7.53 (s, 1H), 7.40 (d, 7=7.7 Hz, 1H), 5.94-5.80 (m, 1H), 4.09 (d, J=7.2 Hz, 1H), 4.04 (s, 1H), 3.923.76 (m, 2H), 3.43-3.27 (m, 2H), 2.292.11 (m, 2H), 2.11-2.00 (m, 1H), 2.03 (s, 3H), 2.00-1.81 (m, 3H), 1.77-1.51 (m, 3H), 0.99 (s, 3H) 19F NMR (376 MHz, DMSO-cfe, 80 °C) δ = -75.41 (s, 3F) [a]D 22 -11.6 (c0.3, CHCb) 99% ee; absolute stereochemistry unknown. Enantiomer of Ex. 182 |
182 (A) | f>Lp ’ ’ο,χα X (+)-8-((1 R*,2R*)-2-hydroxy-2methylcyclopentyl]-6-methyl-2-({1[(trifluoromethyl)sulfonyl]piperidin-4yl}amino)pyrido[2,3-d]pyrimidin-7(8H)one | 490 | 1H NMR (400 MHz, DMSO-cfe, 80 °C) δ = 8.51 (s, 1H), 7.53 (s, 1H), 7.41 (d, J=7.0 Hz, 1H), 6.97 (br s, 1H), 5.87 (t, 7=8.3 Hz, 1H), 4.15-4.06 (m, 1H), 4.05 (s, 1H), 3.93-3.76 (m, 2H), 3.35 (q, J=10.8 Hz, 2H), 2.28-2.11 (m, 2H), 2.11-2.00 (m, 1H), 2.03 (s, 3H), 2.001.81 (m, 3H), 1.76-1.46 (m, 3H), 0.99 (s, 3H) 19F NMR (376 MHz, DMSO-cfe, 80 °C) δ = -75.41 (s, 3F) [a]D 22 +5.82 (c 0.33, CHCb) 99% ee; absolute stereochemistry unknown. Enantiomer of Ex. 181 |
183 (A) | H2N.'/° _ â uxa H | 423 | 1H NMR (400 MHz, DMSO-cfe, 80 °C) δ = 8.55 (s, 1H), 7.64 (d, 7=9.3 Hz, 1H), 7.42 (brs, 1H), 6.48 (brs, 2H), 6.19 (d, 7=9.2 Hz, 1H), 5.85 (t, 7=8.4 Hz, 1H), 4.03 (s, 1H), 3.97-3.82 (m, 1H), 3.53 (t, |
205
(-)-4-({8-[(1R*,2R*)-2-hydroxy-2- methylcyclopentyl]-7-oxo-7,8dihydropyrido[2,3-d]pynmidin-2yl}amino)piperidine-1-sulfonamide | J=10.6 Hz, 2H), 2.73 (t, J=11.6 Hz, 2H), 2.62-2.52 (m, 1H), 2.28-2.13 (m, 1H), 2.13-1.80 (m, 5H), 1.75-1.56 (m, 3H), 1.02 (s, 3H) [a]o22= -24.1 (c0.1, MeOH) 99% ee; absolute stereochemistry unknown Enantiomer of Ex. 184 | ||
184 (A) | H2N /P J O..ÇCX Qi (+)-4-({8-[(1R*,2R*)-2-hydroxy-2methylcyclopentyl]-7-oxo-7,8dihydropyrido[2,3-d]pyrimidin-2yl}amino)piperidine-1-sulfonamide | 423 | 1H NMR (400 MHz, DMSO-cfe, 80 °C) δ = 8.55 (s, 1H), 7.64 (d, J=9.3 Hz, 1H), 7.42 (brs, 1H), 6.49 (brs, 2H), 6.19 (d, J=9.2 Hz, 1H), 5.85 (t, J=8.3 Hz, 1H), 4.03 (s, 1H), 3.98-3.82 (m, 1H), 3.53 (t, J=10.6 Hz, 2H), 2.73 (t, J=11.6 Hz, 2H), 2.62-2.52 (m, 1H), 2.28-2.14 (m, 1H), 2.12-1.79 (m, 5H), 1.77-1.51 (m, 3H), 1.02 (s, 3H) [α]ο22= +18.0 (c 0.1, MeOH) 95% ee; absolute stereochemistry unknown Enantiomer of Ex. 183 |
185 (A) | 0 H (-)-6-(hydroxymethyl)-8-[(1R*,2R*)-2hydroxy-2-methylcyclopentyl]-2-{[1(methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-c(]pyrimidin-7(8/-/)one | 452 | 1H NMR (400 MHz, CDCh) δ = 8.47 (s, 1H), 7.49 (s, 1H), 5.82-5.73 (m, 1H), 5.44 (br s, 1 H), 4.57 (s, 2H), 4.02 (br d, J=7.8 Hz, 1H), 3.82 (br t, J=10.8 Hz, 2H), 2.97-2.89 (m, 2H), 2.83 (s, 3H), 2.31-2.18 (m, 3H), 2.12-1.78 (m, 5H), 1.74-1.64 (m, 2H), 1.17 (s, 3H) [a]o22 -20.7 (c 2, CHCh) 99% ee; absolute stereochemistry unknown I Enantiomer of Ex. 186 |
206
186 (A) | 452 | 1H NMR (400 MHz, CDCh) δ = 8.47 (s, 1H), 7.49 (s, 1H), 5.77 (br t, 7=7.9 Hz, 1H), 5.41 (br s, 1H), 4.57 (br s, 2H), 3.99 (br s, 1H), 3.87-3.68 (m, 2H), 2.99-2.89 (m, 2H), 2.83 (s, 3H), 2.292.17 (m, 3H), 2.13-1.77 (m, 5H), 1.69 (brs, 2H), 1.17 (s, 3H) [a]o22 +4.3 (c 2, CHCIs) 99% ee; absolute stereochemistry unknown Enantiomerof Ex. 185 | |
n'VA'Ah | |||
N N N O | |||
H A>0H | |||
Cf“ | |||
(+)-6-(hydroxymethyl)-8-[(1R*,2R*)-2- | |||
hydroxy-2-methylcyclopentyl]-2-{[1- | |||
(methylsulfonyl)piperidin-4- | |||
yl]amino}pyrido[2,3-d]pyrimidin-7(8H)- | |||
one | |||
187 | O F H2N /P Jl ό'ΥΑ | 1H NMR (400 MHz, DMSO-cfe) δ = 8.73 (s, 1H), 8.03 (s, 1H), 7.72 (d, 7=3.7 Hz, 1H), 7.01-6.65 (m, 1H), 6.48 (br s, 2H), | |
(E) | N N N Ο tY” (-)-4-({6-(difluoromethyl)-8-[(1R*,2R*)2-hydroxy-2-methylcyclopentyl]-7-oxo7,8-dihydropyrido[2,3-c/]pyrimidin-2yl}amino)piperidine-1-sulfonamide | 473 | 5.96-5.71 (m, 1H), 4.07 (s, 1H), 3.95 (d, 7=7.1 Hz, 1H), 3.55 (t, 7=10.4 Hz, 2H), 2.76 (t, 7=11.7 Hz, 2H), 2.60-2.54 (m, 1H), 2.27-2.16 (m, 1H), 2.14-1.95 (m, 3H), 1.95-1.84 (m, 2H), 1.77-1.72 (m, 1H), 1.71-1.54 (m, 2H), 1.04 (s, 3H) [a]D 22-18.3 (c 0.4, CHCb) 91% ee; absolute stereochemistry unknown Enantiomer of Ex. 188 |
188 | 0 F H2nJ Jl À' 'N^A Ν^Α^Ά 0 L A A A A H τ OH | 1H NMR (400 MHz, DMSO-cfe) δ = 8.73 (s, 1H), 8.03 (s, 1H), 7.72 (d, 7=3.7 Hz, 1H), 7.01-6.65 (m, 1H), 6.48 (br s, 2H), 5.96-5.71 (m, 1H), 4.07 (s, 1H), 3.95 | |
(E) | a- (+)-4-({6-(difluoromethyl)-8-[(1R*,2R*)2-hydroxy-2-methylcyclopentyl]-7-oxo7,8-dihydropyrido[2,3-d]pyrimidin-2yl}amino)piperidine-1-sulfonamide | 473 | (d, 7=7.1 Hz, 1H), 3.55 (t, 7=10.4 Hz, 2H), 2.76 (t, 7=11.7 Hz, 2H), 2.60-2.54 (m, 1H), 2.27-2.16 (m, 1H), 2.14-1.95 (m, 3H), 1.95-1.84 (m, 2H), 1.77-1.72 (m, 1H), 1.71-1.54 (m, 2H), 1.04 (s, 3H) |
207
[α]ο22 +15.8 (c0.1, CHCb) 99% ee; absolute stereochemistry unknown Enantiomer of Ex. 187 | |||
189 (A) | X Ό. aXX ΧΛ'νλνλνΧ H dx 8-[(1R,2R)-2-hydroxy-2methylcyclopentyl]-2-({1-[(2-hydroxy-2methylpropyl)sulfonyl]piperidin-4yl}amino)pyrido[2,3-c/]pyrimidin-7(8H)one | 462 [M- H2O+1]+ | 1H NMR (400 MHz, CDCb) δ = 8.42 (s, 1H), 7.45 (d, J=9.5 Hz, 1H), 6.34 (br d, J=9.3 Hz, 1H), 5.81-5.54 (m, 2H), 3.99 (br s, 1 H), 3.88-3.77(m, 2H), 3.65 (br s, 1H), 3.07 (s, 2H), 3.02-2.91 (m, 2H), 2.83 (br s, 1H), 2.31-2.12 (m, 3H), 2.06-1.83 (m, 5H), 1.76-1.56 (m, 2H), 1.45 (s, 6H), 1.16 (s, 3H) 99% ee; Single enantiomer, absolute stereochemistry known |
190 (A) | °x ,° x°' ïX OQ H 8-[(1R,2R)-2-hydroxy-2methylcyclopentyl]-2-[(1{[(methylsulfonyl)methyl]sulfonyl}piperi din-4-yl)amino]pyrido[2,3-cT]pyrimidin7(8H)-one | 500 | 1H NMR (400 MHz, CDCb) δ = 8.43 (s, 1H), 7.45 (d, J=9.3 Hz, 1H), 6.35 (d, J=9.3 Hz, 1H), 5.74 (br s, 1H), 5.46 (br s, 1H), 4.44 (s, 2H), 4.12-3.97 (m, 1H), 3.94- 3.82 (m, 2H), 3.36-3.24 (m, 1H), 3.24 (s, 3H), 3.20 (d, J=2.8 Hz, 1H), 2.94- 2.73 (m, 1H), 2.31-2.16 (m, 3H), 2.05-1.97 (m, 2H), 1.97-1.87 (m, 1H), 1.87-1.78 (m, 1H), 1.77-1.63 (m, 2H), 1.17 (s, 3H) Single enantiomer, absolute stereochemistry known |
191 (D) | ^,P ^^^N^N^N^O H (-)-6-chloro-2-{[(3R*,4S*)-3-fluoro-1(methylsulfonyl)piperidin-4-yl]amino}-8[(1R,2R)-2-hydroxy-2- methylcyclopentyl]pyrido[2,3- | 474 | 1H NMR (700 MHz, DMSO-cfe) δ = 8.65 (s, 1H), 8.20 (d, J=5.5 Hz, 1H), 8.127.83 (m, 1H), 5.87 (t, J=8.0 Hz, 1H), 5.41-4.82 (m, 1H), 4.48 (s, 1H), 4.283.95 (m, 1H), 3.81 (t, J=11.6 Hz, 1H), 3.70 (d, J=11.9 Hz, 1H), 3.20-2.99 (m, 2H), 2.92 (s, 3H), 2.48-2.33 (m, 1H), 2.23-2.07 (m, 1H), 2.06-1.89 (m, 2H), 1.88-1.73 (m, 3H), 1.68 (d, J=7.0 Hz, |
208
d]pyrimidin-7(8H)-one | 1H), 1.01-0.89 (m, 3H) 19F NMR (565 MHz, DMSO-cfe) δ = -201.1 (brs, 1F) [a]D 22 -99.6 (c0.1, CHCh) 98% de; Single diastereomer, absolute stereochemistry known R,R at cyclopentyl chiral centers, relative stereochemistry known to be cis at piperidine chiral centers. Diastereomer of Ex. 192 | ||
192 (D) | S. /^/Cl d'νΛΊ' jOTV H (+)-6-chloro-2-{[(3R*,4S*)-3-fluoro-1(methylsulfonyl)piperidin-4-yl]amino}-8[(1R,2R)-2-hydroxy-2- methylcyclopentyl]pyrido[2,3- d]pyrimidin-7(8H)-one | 474 | 1H NMR (700 MHz, DMSO-cfe) δ = 8.65 (d, J=7.9 Hz, 1H), 8.11 (br s, 1H), 7.88 (brs, 1H), 5.97-5.74 (m, 1H), 5.13-4.84 (m, 1H), 4.55-4.32 (m, 1H), 4.29-4.02 (m, 1H), 3.96-3.78 (m, 1H), 3.67 (d, J=11.9 Hz, 1H), 3.24-2.97 (m, 2H), 2.93 (d, J=7.5 Hz, 3H), 2.38 (br s, 1H), 2.24-2.09 (m, 1H), 2.04-1.75 (m, 5H), 1.68 (d, J=8.8 Hz, 1H), 0.98 (d, J=7.5 Hz, 3H) 19F NMR (565 MHz, DMSO-cfe) δ = -200.8 (brs, 1F) [a]o22 +8.9 (c 0.2, CHCh) 99% de; Single diastereomer, absolute stereochemistry known R,R at cyclopentyl chiral centers, relative stereochemistry known to be cis at piperidine chiral centers. Diastereomer of Ex. 191 |
193 (A) | /'N^> NZ<VA ° l A Λ A Λ H __ | 436 | 1H NMR (400 MHz, CDCh) δ = 8.42 (s, 1H), 7.45 (d, J=9.3 Hz, 1H), 6.35 (d, J=9.3 Hz, 1H), 5.75 (br s, 1H), 5.48 (br s, 1H), 3.99 (br s, 1H), 3.87-3.76 (m, 2H), 2.99-2.90 (m, 2H), 2.87-2.77 (m, 4H), 2.22 (d, J=12.3 Hz, 3H), 2.09-1.98 |
209
(-)-(8-((1 R*, 2R*)-2-ethyl-2hydroxycyclopentyl]-2-{[1 (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)one | (m, 2H), 1.95-1.87 (m, 1H), 1.78 (dd, J=6.7, 12.4 Hz, 1H), 1.73-1.65 (m, 3H), 1.57-1.45 (m, 1H), 1.27 (qd, J=7.3, 14.1 Hz, 1H), 0.87 (t, J=7.4 Hz, 3H) [a]o22 -5.26 (c 0.5, CHCh) 99% ee; absolute stereochemistry unknown Enantiomer of Ex. 194 | ||
194 | 1H NMR (400 MHz, CDCh) δ = 8.42 (s, | ||
Ν,Ύ^Ι | 1H), 7.45 (d, J=9.3 Hz, 1H), 6.35 (d, | ||
J=9.3 Hz, 1H), 5.75 (br s, 1H), 5.46 (br | |||
(A) | s, 1H), 3.98 (br s, 1H), 3.82 (t, J=10.8 Hz, 2H), 2.98-2.89 (m, 2H), 2.87-2.72 | ||
(+)-(8-((1 R*,2R*)-2-ethyl-2- hyd roxycyclopentyl]-2-{[1 (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)one | 436 | (m, 4H), 2.22 (d, J=11.8 Hz, 3H), 2.08- 1.99 (m, 2H), 1.96-1.85 (m, 1H), 1.78 (dd, J=6.7, 12.4 Hz, 1H), 1.72-1.63 (m, 3H), 1.56-1.47 (m, 1H), 1.32-1.23 (m, 1H), 0.87 (t, J=7.3 Hz, 3H) | |
[a]D 22 +2.73 (c 0.5, CHCh) 99% ee; absolute stereochemistry unknown | |||
Enantiomer of Ex. 193 | |||
195 | ^/P | 1H NMR (400 MHz, CDCh) δ = 8.43 (s, | |
(D) | H | 1H), 7.69 (s, 1H), 5.86 (br s, 1H), 5.49 (br s, 1H), 3.97 (br s, 1H), 3.89-3.77 (m, 2H), 2.99-2.88 (m, 2H), 2.83 (s, 3H), 2.66 (br s, 1H), 2.35-2.17 (m, 3H), | |
(-)-6-chloro-8-[(1R*,2R*)-2-ethyl-2- hydroxycyclopentyl]-2-{[1 - (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8H)one | 470 | 2.10-2.03 (m, 2H), 1.98-1.88 (m, 1H), 1.77 (dd, J=6.3, 12.5 Hz, 2H), 1.60 (s, 2H), 1.48 (dd, J=7.4, 13.9 Hz, 1H), 1.27 (qd, J=7.2, 14.2 Hz, 1H), 0.87 (t, J=7.4 Hz, 3H) | |
I | [a]D 22 -2.08 (c 0.4, CHCh) 99% ee; absolute stereochemistry unknown |
210
Enantiomer of Ex. 196 | |||
196 (D) | °''ΟΝΧΧΧ àP (+)-6-chloro-8-[(1R*,2R*)-2-ethyl-2hydroxycyclopentyl]-2-{[1- (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-c(]pyrimidin-7(8/-/)one | 470 | 1H NMR (400 MHz, CDCb) δ = 8.43 (s, 1H), 7.69 (s, 1H), 5.87 (br s, 1H), 5.50 (br s, 1H), 3.97 (br s, 1H), 3.89-3.73 (m, 2H), 3.00-2.88 (m,2H), 2.86-2.80 (m, 3H), 2.66 (br s, 1H), 2.36-2.16 (m, 3H), 2.12-2.02 (m, 2H), 1.99-1.87 (m, 1H), 1.77 (dd, J=7.0, 12.3 Hz, 2H), 1.61 (s, 2H), 1.54-1.44 (m, 1H), 1.27 (qd, J=7.3, 14.1 Hz, 1H), 0.87 (t, J=7.2 Hz, 3H) [o]d22 +1.66 (c0.4, CHCb) 99% ee; absolute stereochemistry unknown Enantiomer of Ex. 195 |
197 (A) | “ û aAX o—' (-)-8-[(3R*,4S*)-4-hydroxy-4methyltetrahydrofuran-3-yl]-6-methyl-2- {[1-(methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-c/]pyrimidin-7(8/-/)one | 438 | 1H NMR (400 MHz, CDCb) δ = 8.41 (s, 1H), 7.37 (s, 1H), 6.06 (br s, 1H), 5.51 (d, J=7.8 Hz, 1H), 4.65 (br s, 1H), 4.38-4.26 (m, 2H), 4.04 (br s, 1H), 3.91 (d, J=9.0 Hz, 1H), 3.83 (t, J=11.2 Hz, 2H), 2.96-2.87 (m, 2H), 2.83 (s, 3H), 2.29-2.14 (m, 5H), 1.77-1.68 (m, 2H), 1.16 (s, 3H) [a]o22 -20.5 (c 0.12, MeOH) 99% ee; absolute stereochemistry unknown Enantiomer of Ex. 198 |
198 (A) | όΎΐ aXX H A/0H qP (+)-8-[(3R*,4S*)-4-hydroxy-4- methyltetrahydrofuran-3-yl]-6-methyl-2- | 438 | 1H NMR (400 MHz, CDCb) δ = 8.41 (s, 1 H), 7.37 (d, J=1.0 Hz, 1 H), 6.06 (br s, 1H), 5.41 (br s, 1H), 4.65 (br s, 1H), 4.29 (t, J=9.0 Hz, 2H), 4.10-3.99 (m, 1H), 3.91 (d, J=8.8 Hz, 1H), 3.87-3.79 (m, 2H), 2.96-2.88 (m, 2H), 2.83 (s, 3H), 2.29-2.14 (m, 5H), 1.70 (m, J=12.8Hz, 2H), 1.16 (s, 3H) |
211
{[1-(methylsulfonyl)piperidin-4- yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)- one | [o]d22+11.21 (c 0.116, MeOH) 99% ee; absolute stereochemistry unknown Enantiomerof Ex. 197 | ||
199 | 1H NMR (400 MHz, CDCh) δ = 8.39 (s, | ||
/ y' j jfXA | 1H), 7.36 (d, J=1.3 Hz, 1H), 6.12-5.92 (m, 1H), 5.32 (br s, 1H), 4.43 (br d, | ||
N N 0 | |||
ίΛ\ | H A | J=6.3 Hz, 1H), 4.04 (br d, J=7.3 Hz, | |
lA) | HO | 1H), 3.88-3.50 (m, 3H), 2.98 (br d, J=14.8 Hz, 2H), 2.88-2.78 (m, 3H), | |
(-)-8-[(1R*,2S*,4R*)-4-hydroxy-2- | 458 | 2.57-2.41 (m, 3H), 2.28 (td, J=7.6, 12.7 | |
methylcyclopentyl]-6-methyl-2-{[1- | Hz, 1H), 2.23-2.13 (m, 5H), 2.08-1.95 | ||
(methylsulfonyl)piperidin-4- | [M+Naj | (m, 1H), 1.78-1.68 (m, 2H), 0.80 (d, | |
yl]amino}pyrido[2,3-c(]pyrimidin-7(8/-/)- | J=7.0 Hz, 3H) | ||
one | [o]d22 -14.5 (c 0.2, MeOH) 99% ee; absolute stereochemistry unknown | ||
Enantiomer of Ex. 200 | |||
200 | ^„0 | 1H NMR (400 MHz, CDCh) δ = 8.39 (s, | |
/'N'A | 1H), 7.36 (d, J=1.3 Hz, 1H), 6.13-5.90 | ||
° <1 a Λ X | (m, 1H), 5.29 (br s, 1H), 4.42 (br t, | ||
N N N^O | |||
H ? | J=6.4 Hz, 1H), 4.04 (br s, 1H), 3.88- | ||
(A) | O..... | 3.45 (m, 3H), 2.96 (br s, 2H), 2.83 (s, | |
HO' | 3H), 2.55-2.39 (m, 3H), 2.36-2.24 (m, | ||
(+)-8-[(1R*,2S*,4R*)-4-hydroxy-2- | 458 | 1H), 2.17 (d, J=1.3 Hz, 5H), 2.09-1.95 | |
methylcyclopentyl]-6-methyl-2-{[1- | [M+Na]+ | (m, 1H), 1.74-1.65 (m, 2H), 0.81 (d, | |
(methylsulfonyl)piperidin-4- | J=7.0 Hz, 3H) | ||
yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)- | [α]ο22 +18.1 (c0.1, MeOH) | ||
one | 99% ee; absolute stereochemistry | ||
unknown | |||
Enantiomerof Ex. 199 |
212
201 (A) | ’ à..... 'OH (-)-8-[(1R*,2S*,3R*)-3-hydroxy-2methylcyclopentyl]-2-{[1 (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8H)one | 422 | 1H NMR (400 MHz, DMSO-de) δ = 8.56 (s, 1H), 7.65 (d, >9.3 Hz, 1H), 7.47 (d, >4.8 Hz, 1H), 6.21 (d, >9.2 Hz, 1H), 5.84-5.63 (m, 1H), 4.23 (d, >3.7 Hz, 1H), 4.13 (br s, 1H), 4.00-3.88 (m, 1H), 3.70-3.50 (m, 2H), 2.95-2.89 (m, 3H), 2.89-2.79 (m, 3H), 2.31-2.17-(m, 2H), 2.03-1.86-(m, 2H), 1.77-1.56 (m, 3H), 0.84 (d, >6.8 Hz, 3H) [ct]D 22 -17.2 (c0.1, MeOH) 99% ee; absolute stereochemistry unknown Enantiomer of Ex. 202 |
202 (A) | ό' OzXXo H Ξ (+)-8-[(1R*,2S*,3R*)-3-hydroxy-2methylcyclopentyl]-2-{[1 - (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)one | 422 | 1H NMR (400 MHz, DMSO-cfe) δ = 8.56 (s, 1H), 7.65 (d, >9.3 Hz, 1H), 7.48 (br s, 1H), 6.21 (d, >9.3 Hz, 1H), 5.87-5.63 (m, 1H), 4.23 (d, >3.7 Hz, 1H), 4.13 (brs, 1H), 3.99-3.83 (m, 1H), 3.70-3.45 (m, 2H), 2.98-2.788 (m, 6H), 2.29-2.14 (m, 2H), 2.03-1.97 (m, 2H), 1.97-1.86 (m, 1H), 1.76-1.56 (m, 3H), 0.84 (d, >6.8 Hz, 3H) [α]ο22 +19.9 (c0.1, MeOH) 99% ee; absolute stereochemistry unknown Enantiomer of Ex. 201 |
203 (D) | à..... 'OH (-)-6-chloro-8-[(1R*,2S*,3R*)-3hydroxy-2-methylcyclopentyl]-2-{[1 (methylsulfonyl)piperidin-4- | 456 | 1H NMR (400 MHz, DMSO-cfe) δ = 8.61 (br s, 1H), 8.08 (s, 1H), 8.05-7.69 (m, 1H), 5.79 (br s, 1H), 4.53 (br s, 1H), 4.09 (br s, 1H), 4.04-3.74 (m, 1H), 3.57 (d, >10.5 Hz, 2H), 2.97-2.73 (m, 6H), 2.18 (br s, 2H), 1.96 (br s, 3H), 1.781.46 (m, 3H), 0.81 (d, >6.8 Hz, 3H) [a]o22 -9.5 (c0.1, MeOH) Single enantiomer, absolute |
213
yl]amino}pyrido[2,3-c/]pyrimidin-7(8/-/)- one | stereochemistry unknown Made from Ex. 201 | |||
204 | P | F | 1H NMR (400 MHz, DMSO-cfe, 80 °C) δ | |
// N^| N ^0X0 | r F | = 8.64 (s, 1H), 7.94 (s, 1H), 7.72 (br s, | ||
υ l 1 J! JL | 1H), 6.94-6.47 (m, 1H), 5.65 (d, J=6.7 | |||
^^N^N^N^ | X) | |||
(E) | à | t)H | Hz, 1H), 4.18 (d, J=3.3 Hz, 1H), 4.05 (br s, 1H), 3.87 (br s, 1H), 3.54 (dd, J=4.40, 11.49 Hz, 2H), 2.87-2.75 (m, | |
(-)-6-(difluoromethyl)-8- | 6H), 2.14 (br s, 2H), 1.99-1.80 (m, 3H), | |||
[(1 R*,2S*,3R*)-3-hydroxy-2- | 1.70-1.46 (m, 3H), 0.76 (d, J=6.8 Hz, | |||
methylcyclopentyl]-2-{[1- | 472 | 3H) | ||
(methylsulfonyl)piperidin-4- | 19F NMR (376 MHz, DMSO-cfe) δ = | |||
yl]amino}pyrido[2,3-d]pyrimidin-7(8H)- | -118.6 to-114.9 (m, 2F) | |||
one | [a]o22 -29.9 (c 0.4, MeOH) Single enantiomer, absolute stereochemistry unknown Made from Ex. 201 | |||
Enantiomer of Ex. 205 | ||||
205 | P | F | 1H NMR (400 MHz, DMSO-cfe) δ = 8.73 | |
(s, 1H), 8.04 (s, 1H), 7.83 (br s, 1H), | ||||
θ | 7.04-6.55 (m, 1H), 5.84-5.63 (m, 1H), | |||
N N N H | O | 4.27 (d, X3.8 Hz, 1H), 4.14 (br s, 1H), | ||
(+)-6-(difluoromethyl)-8- [(1R*,2S*,3R*)-3-hydroxy-2- | OH | 3.96 (br s, 1 H), 3.64 (dd, X4.03, 12.35 Hz, 2H), 2.96-2.82 (m, 6H), 2.23 (br s, 2H), 2.07-1.91 (m, 3H), 1.77-1.55 (m, 3H), 0.86 (d, J=6.8 Hz, 3H). | ||
472 | ||||
methylcyclopentyl]-2-{[1 - | 19F NMR (376 MHz, CDCb) δ = -119.9 | |||
(methylsulfonyl)piperidin-4- | to-118.0 (m, 2F). | |||
yl]amino}pyrido[2,3-cf|pyrimidin-7(8H)- | ||||
one | [o]d22 +19.6 (c 0.5, MeOH) Single enantiomer, absolute stereochemistry unknown Made from Ex. 202 | |||
Enantiomer of Ex. 204 |
214
206 (J) | O^XX'-O' à..... (DH (-)-6-(2,2-d ifluoroethyl)-8[(1R*,2S*,3R*)-3-hydroxy-2methylcyclopentyl]-2-{[1 (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)one | 486 | 1H NMR (400 MHz, DMSO-cfe, 80 °C) δ = 8.60 (br s, 1H), 7.88 (br s, 1H), 7.73 (s, 1H), 6.22 (tt, J=4.6, 57.1 Hz, 1H), 5.75 (br s, 1 H), 4.51 (br s, 1 H), 4.09 (br s, 1H), 4.05-3.74 (m, 1H), 3.65-3.51 (m, 2H), 3.04 (dt, J=4.2, 17.1 Hz, 2H), 2.89 (s, 3H), 2.88-2.77 (m, 3H), 2.20 (br s, 2H), 1.95 (br s, 3H), 1.78-1.45 (m, 3H), 0.80 (d, J=6.8 Hz, 3H) [a]o22-10.3 (c 0.1, MeOH) Single enantiomer, absolute stereochemistry unknown Made from Ex. 201 |
207 (A) | An ni H - O..... (DH (+)-8-[(1R*,2R*,3S*)-3-hydroxy-2methylcyclopentyl]-2-{[1 (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)one | 422 | 1H NMR (400 MHz, DMSO-cfe) δ = 8.57 (s, 1H), 7.69 (d, J=9.2 Hz, 1H), 7.56 (d, J=6.6 Hz, 1H), 6.19 (d, J=9.2 Hz, 1H), 6.16-5.95 (m, 1H), 4.96 (d, J=10.8 Hz, 1H), 4.00-3.73 (m, 2H), 3.63-3.42 (m, 2H), 2.91-2.811 (m, 2H), 2.79 (s, 3H), 2.70- 2.56 (m, 1H), 2.39-2.29 (m, 1H), 1.98-1.85 (m, 2H), 1.82-1.70 (m, 2H), 1.71- 1.49 (m, 3H), 0.57 (d, J=7.5 Hz, 3H) [a]D 22 +27.3 (c 0.1, MeOH) 99% ee; absolute stereochemistry unknown Enantiomer of Ex. 208 |
208 (A) | An m H àr OH (-)-8-[(1R*,2R*,3S*)-3-hydroxy-2methylcyclopentyl]-2-{[1 (methylsulfonyl)piperidin-4- | 422 | 1H NMR (400 MHz, DMSO-cfe) δ = 8.67 (s, 1H), 7.79 (d, J=9.3 Hz, 1H), 7.66 (d, J=6.5 Hz, 1H), 6.29 (d, J=9.2 Hz, 1H), 6.06-6.24 (m, 1H), 5.06 (d, J=10.5 Hz, 1H), 3.90-4.10 (m, 2H), 3.61 (dd, J=6.72, 10.88 Hz, 2H), 2.91-3.01 (m, 2H), 2.88 (s, 3H), 2.64-2.79 (m, 1H), 2.39-2.46 (m, 1H), 1.95-2.06 (m, 2H), 1.78-1.91 (m, 2H), 1.60-1.79 (m, 3H), |
215
yl]amino}pyrido[2,3-d]pyrimidin-7(8H)- | 0.67 (d, 7=7.3 Hz, 3H) | |||
one | [a]D 22 -33.1 (c0.1, MeOH) 99% ee; absolute stereochemistry unknown | |||
Enantiomer of Ex. 207 | ||||
209 | ^zP | 1H NMR (400 MHz, DMSO-cfe) δ = 8.47 | ||
(s, 1H), 7.56 (d, 7=9.3 Hz, 1H), 7.39 (d, | ||||
/Λ\ | '^Ν^ΙΨ'Ν'Χ) H ? | 7=6.2 Hz, 1H), 6.10 (d, 7=9.3 Hz, 1H), 5.98 (dt, 7=7.15, 10.06 Hz, 1H), 4.24 | ||
^OH | (d, 7=5.3 Hz, 1H), 4.18-4.07 (m, 1H), 3.97-3.82 (m, 1H), 3.57-3.46 (m, 2H), | |||
(+)-8-[(1R*,2R*,3R*)-3-hydroxy-2- methylcyclopentyl]-2-{[1- (methylsulfonyl)piperidin-4- yl]amino}pyrido[2,3-c/]pyrimidin-7(8/7)- | 422 | 2.91-2.81 (m, 2H), 2.79 (s, 3H), 2.142.02 (m, 1H), 1.99-1.88 (m, 3H), 1.881.76 (m, 1H), 1.66-1.45 (m, 2H), 1.45- 1.28 (m, 1H), 0.62 (d, 7=7.2 Hz, 3H) | ||
one | [α]ο22 +3.1 (c 0.1, MeOH) 99% ee; absolute stereochemistry unknown | |||
Enantiomer of Ex. 210 | ||||
210 | . ,p | 1H NMR (400 MHz, DMSO-cfe) δ = 8.56 | ||
(A) | S. 0' N l | I Jù J l H | (s, 1H), 7.66 (d, 7=9.3 Hz, 1H), 7.48 (d, 7=7.0 Hz, 1H), 6.20 (d, 7=9.3 Hz, 1H), 6.08 (dt, 7=6.91, 10.18 Hz, 1H), 4.33 (d, 7=5.1 Hz, 1H), 4.14-4.28 (m, 1H), | |
OH | 4.05-3.89 (m, 1H), 3.68-3.54 (m, 2H), | |||
(-)-8-[(1R*,2R*,3R*)-3-hydroxy-2methylcyclopentyl]-2-{[1 - (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-cf]pyrimidin-7(8/-/)one | 422 | 2.99-2.90 (m, 2H), 2.88 (s, 3H), 2.26- 2.11 (m, 1H), 2.09-1.99 (m, 3H), 1.92 (dtd, 7=2.51, 9.60, 12.41 Hz, 1H), 1.74-1.57 (m, 2H), 1.54-1.40 (m, 1H), 0.71 (d, 7=7.2 Hz, 3H) | ||
[a]o22 -5.1 (c 0.1, MeOH) 99% ee; absolute stereochemistry unknown | ||||
I | Enantiomer of Ex. 209 |
216
211 (A) | 1X1 'X' N N N X) H Ξ ^^*OH 8-((1 S,3S)-3-hydroxycyclohexyl]-2-{[1 (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-c(]pyrimidin-7(8/-/)one | 444 [M+Na]+ | 1H NMR (400 MHz, CDCb) δ = 8.38 (s, 1H), 7.41 (d, J=9.3 Hz, 1H), 6.32 (d, J=8.8 Hz, 1H), 5.95 (br s, 1H), 5.52 (br s, 1H), 4.35 (br s, 1H), 4.05-3.87 (m, 1H), 3.86-3.77 (m, 2H), 3.02-2.85 (m, 3H), 2.83 (s, 3H), 2.67 (d, J=11.3 Hz, 1H), 2.22 (d, J=12.0 Hz, 2H), 1.92-1.69 (m, 8H) [a]D 22 -11.52 (c0.11, CHCb) 98% ee; Single enantiomer, absolute stereochemistry known Enantiomer of Ex. 3 |
212 (E) | '' N η n XX F ° L JL A J L H ï XX'OH 6-(difluoromethyl)-8-[(1R,3R)-3hydroxycyclohexyl]-2-{[1(methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)one | 472 | 1H NMR (700 MHz, DMSO-cfa) δ = 8.78-8.65 (m, 1H), 8.15 (d, J=6.4 Hz, 1H), 8.06-7.82 (m, 1H), 6.98-6.71 (m, 1H), 6.18-5.49 (m, 1H), 4.49 (br s, 1H), 4.13 (br s, 1H), 4.05-3.75 (m, 1H), 3.68- 3.48 (m, 2H), 3.02-2.73 (m, 6H), 2.24-1.90 (m, 2H), 1.86-1.69 (m, 2H), 1.68- 1.44 (m, 6H), 1.43-1.31 (m, 1 H» [α]ο22+18.1 (c 0.1, CHCb) Single enantiomer, absolute stereochemistry known. |
213 (F) | xX (+)-2-(8-((1 R*,3R*)-3hydroxycyclohexyl]-2-{[1 - (methylsulfonyl)piperidin-4-yl]amino}-7oxo-7,8-dihydropyrido[2,3-d]pyrimidin6-yl)acetamide | 479 | 1H NMR (400 MHz, DMSO-cfe) δ = 8.56 (br s, 1H), 7.95-7.68 (m, 1H), 7.56 (br s, 1H), 7.34 (br s, 1H), 6.86 (br s, 1H), 6.08-5.60 (m, 1H), 4.49 (br s,1H), 4.12 (br s, 1H), 3.83 (br s, 1H), 3.68-3.46 (m, 2H), 3.22 (br s, 2H), 2.89 (br s, 3H), 2.84 (br s, 2H), 2.48-2.35 (m, 2H), 1.99 (br s, 2H), 1.77-1.32 (m, 8H) [a]o22 +9.67 (c 0.2, DMSO) 98% ee; absolute stereochemistry unknown Enantiomer of Ex. 214 |
217
214 (F) | S. /¾. /¾. /\ .NHo d' ^N^nCC ° H ? (-)-2-(8-((1 R*, 3R*)-3hydroxycyclohexyl]-2-{[1 (methylsulfonyl)piperidin-4-yl]amino}-7oxo-7,8-dihydropyrido[2,3-cOpyrimidin6-yl)acetamide | 479 | 1H NMR (400 MHz, DMSO-cfe) δ = 8.56 (br s, 1H), 7.94-7.70 (m, 1H), 7.56 (br s, 1H), 7.34 (br s, 1H), 6.86 (br s, 1H), 6.13-5.62 (m, 1H), 4.49 (br s, 1H), 4.12 (br s, 1H), 3.83 (br s, 1H), 3.68-3.50 (m, 2H), 3.22 (br s, 2H), 2.89 (br s, 3H), 2.83 (d, J=8.8 Hz, 2H), 2.48-2.35 (m, 2H), 2.13-1.90 (m, 2H), 1.86-1.33 (m, 8H) [a]o22 -26.33 (c 0.2, DMSO) 98% ee; absolute stereochemistry unknown Enantiomer of Ex. 213 |
215 | 0 OnaXX0 | 1H NMR (400 MHz, DMSO-cfe) δ = 8.58-8.51 (m, 1H), 7.83-7.74 (m, 1H), | |
H Λ | 7.65 (d, J=9.3 Hz, 1H), 6.28-6.19 (m, | ||
(A) | Φ OH | 422 | 1H), 5.23-5.08 (m, 1H), 4.56-4.43 (m, 1H), 4.41-4.19 (m, 1H), 3.96-3.87 (m, 1H), 3.58-3.48 (m, 2H), 3.29-2.89 (m, |
8-(c/s-4-hydroxycyclohexyl)-2-{[1- | 4H), 2.88-2.81 (m, 3H), 1.99-1.87 (m, | ||
(methylsulfonyl)piperidin-4- | 2H), 1.85-1.77 (m, 2H), 1.63-1.47 (m, | ||
yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)- | 4H), 1.30-1.21 (m, 2H) | ||
one | |||
216 | ^,P | 1H NMR (400 MHz, DMSO-cfe) δ = 8.54 | |
ίΛ\ | °,s~Cl XXX <x-'^N'TI'''n'X) H , Xk | (s, 1H), 7.64 (d, J=9.3 Hz, 1H), 7.51 (br s, 1H), 6.17 (br s, 1H), 5.92-5.23 (m, 1H), 4.23 (br s, 1H), 4.12 (br s, | |
Ô..,0H | 1 H), 3.93 (br d, J=7.3 Hz, 1 H), 3.65 (br d, J=12.0 Hz, 2H), 3.04-2.80 (m, 6H), | ||
8-((1 S,2S,5R)-5-hydroxy-2- | 436 | 2.79-2.62 (m, 1H), 2.26-1.89 (m, 2H), | |
methylcyclohexyl]-2-{[1 - | 1.85-1.47 (m, 7H), 0.65 (d, J=6.5 Hz, | ||
(methylsulfonyl)piperidin-4- | 3H) | ||
yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)- one | [α]ο22 +12.0 (c0.3, MeOH) | ||
Single enantiomer, absolute |
218
stereochemistry known | |||
217 | ^zp | 1H NMR (400 MHz, CDCb) δ = 8.41 (s, | |
(A) | ' Ô | 1H), 7.46 (d, J=9.4 Hz, 1H), 6.34 (br d, J=9.1 Hz, 1H), 6.25 (br s, 1H), 5.82- 5.55 (m, 2H), 4.28 (br d, J=2.9 Hz, 1H), 4.04-3.68 (m, 3H), 3.03-2.88 (m, | |
'ΌΗ | 2H), 2.84 (s, 3H), 2.23 (br d, J=12.1 | ||
(+)-8-[(1S*,2S*,5R*)-2-fluoro-5- | 440 | Hz, 2H), 2.18-2.03 (m, 2H), 1.98-1.75 | |
hydroxycyclohexyl]-2-{[1- | (m, 5H), 1.74-1.69 (m, 2H) | ||
(methylsulfonyl)piperidin-4- yl]amino}pyrido[2,3-d]pyrimidin-7(8H)- one | [a]o22 +3.67 (c 0.2, CHCb) 99% ee; absolute stereochemistry unknown | ||
Enantiomer of Ex. 218 | |||
218 | 1H NMR (400 MHz, CDCb) δ = 8.41 (s, | ||
(Al | JOTX H VS | 1H), 7.46 (d, J=9.3 Hz, 1H), 6.33 (br d, 7=8.8 Hz, 2H), 5.87-5.57 (m, 1H), 5.48 (brs, 1H), 4.29 (brs,1H), 4.13-3.75 (m, | |
3H), 3.03-2.88 (m, 2H), 2.84 (s, 3H), 2.24 (brs, 1H), 2.13 (brs, 2H), 1.91 (br | |||
(-)-8-[(1S*,2S*,5R*)-2-fluoro-5- | 440 | s, 1H), 1.80 (br d, J=15.3 Hz, 4H), | |
hyd roxycyclohexy l]-2-{[ 1 - | 1.69-1.59 (m, 3H) | ||
(methylsulfonyl)piperidin-4- yl]amino}pyrido[2,3-cf|pyrimidin-7(8/-/)- one | [a]o22 -2.98 (c 0.28, CHCb) 99% ee; absolute stereochemistry unknown | ||
Enantiomer of Ex. 217 | |||
219 | H Q | 1H NMR (400 MHz, CDCb) δ = 8.41 (s, | |
/ Λ\ | .Nx Λ oz ' v jOCX N N N 'X) H F ! | 1H), 7.46 (d, 7=9.4 Hz, 1H), 6.33 (br d, 7=9.4 Hz, 2H), 5.87-5.56 (m, 1H), 5.44 (br s, 1H), 4.28 (br s,1H), 4.15 (br d, | |
ri | 7=4.7 Hz, 1H), 3.93 (br d, 7=19.8 Hz, | ||
455 | 1H), 3.81-3.68 (m, 2H), 3.10-2.97 (m, | ||
(+)-4-({8-[(1S*,2S*,5R*)-2-fluoro-5hydroxycyclohexyl]-7-oxo-7,8dihydropyrido[2,3-d]pyrimidin-2- | 2H), 2.83 (br s, 1H), 2.76 (d, 7=5.4 Hz, 3H), 2.32-2.00 (m, 4H), 1.96-1.76 (m, 3H), 1.75-1.61 (m, 3H) | ||
yl}amino)-/\/-methylpiperidine-1- | [q]d22 +2.9 (c 0.25, CHCb) |
219
sulfonamide | 96% ee; absolute stereochemistry unknown Enantiomer of Ex. 220 | ||
220 | Η 0 A A J ΑΧΚλ | 1H NMR (400 MHz, CDCh) δ = 8.40 (s, 1H), 7.46 (d, J=9.3 Hz, 1H), 6.32 (br d, J=9.3 Hz, 2H), 5.85-5.59 (m, 1H), 5.53 | |
(Μ | Η F. A | (br d, J-6.8 Hz, 1H), 4.28 (br s, 2H), | |
X^f | 3.96 (br s, 1 H), 3.74 (br s, 2H), 3.01 (br | ||
t, J=10.7 Hz, 2H), 2.93-2.80 (m, 1H), | |||
(-)-4-({8-[(1S*,2S*,5R*)-2-fluoro-5- | 2.76 (d, J=5.0 Hz, 3H), 2.38-2.00(m, | ||
hydroxycyclohexyl]-7-oxo-7,8- | 455 | 4H), 1.98-1.69 (m, 6H) | |
dihydropyrido[2,3-c/]pyrimidin-2yl}amino)-A/-methylpiperidine-1sulfonamide | 19F NMR (376 MHz, DMSO-cfe) δ = -177.8 (d, J=48.6 Hz, 1F) | ||
[a]o22 -3.6 (c 0.3, CHCh) 99% ee; absolute stereochemistry unknown | |||
Enantiomer of Ex. 219 | |||
221 | ^/p | 1H NMR (400 MHz, DMSO-cfe, 80 °C) δ | |
(Δ\ | /'A ΓΤ1 AA- N N N A H ? | = 8.53 (s, 1H), 7.63 (d, J=9.3 Hz, 1H), 7.47 (br s, 1H), 6.19 (br s, 1H), 5.95- 5.22 (m, 1H), 4.16 (d, J=3.5 Hz, 1H), | |
\Α/ | 3.88 (br s, 2H), 3.71-3.57 (m, 2H), 2.94-2.78 (m, 6H), 2.23-1.95 (m, 2H), | ||
(-)-8-[(1S*,2R*,3S*)-3-hydroxy-2- | 1.95-1.71 (m, 3H), 1.73-1.60 (m, 2H), | ||
methylcyclohexyl]-2-{[1 - | 436 | 1.54 (t, J=11.1 Hz, 3H), 0.65 (d, J=6.4 | |
(methylsulfonyl)piperidin-4- | Hz, 3H) | ||
yl]amino}pyrido[2,3-c(]pyrimidin-7(8H)- one | [a]o22 -12.3 (c0.1, MeOH) 99% ee; absolute stereochemistry unknown | ||
Enantiomer of Ex. 222 |
220
222 (A) | m ’ :ô (+)-8-[(1S*,2R*,3S*)-3-hydroxy-2methylcyclohexyl]-2-{[1 - (methylsulfonyl)piperidin-4yl]amino}pyrido[2,3-c/]pyrimidin-7(8/-/)one | 436 | 1H NMR (400 MHz, DMSO-cfe, 80 °C) δ = 8.53 (s, 1H), 7.63 (d, J=9.3 Hz, 1H), 7.46 (br s, 1H), 6.18 (br s, 1H), 5.885.27 (m, 1H), 4.16 (d, J=3.4 Hz, 1H), 3.87 (br s, 2H), 3.65 (s, 2H), 2.95-2.81 (m, 6H), 2.24-1.93 (m, 2H), 1.94-1.73 (m, 3H), 1.73-1.59 (m, 2H), 1.54 (t, J=10.9 Hz, 3H), 0.65 (d, J=6.5 Hz, 3H) [a]D 22 +9.4 (c 0.2, MeOH) 99% ee; absolute stereochemistry unknown Enantiomer of Ex. 221 |
223 | ^/9 | 1H NMR (400 MHz, DMSO-cfe, 80 °C) δ | |
= 8.48 (s, 1H), 7.51 (s, 1H), 7.30 (d, J=5.8 Hz, 1H), 5.51 (br s, 1H), 4.18 (d, | |||
H ï | J=2.0 Hz, 1H), 3.96 (br s, 1H), 3.77- | ||
\ /~OH | 3.69 (m, 1H), 3.65 (d, J=12.5 Hz, 2H), 2.98-2.90 (m, 3H), 2.88 (s, 3H), 2.04 | ||
8-(3-hydroxycycloheptyl)-6-methyl-2- | (s, 3H), 2.11-2.00 (m, 2H), 1.93 (br s, | ||
{[1-(methylsulfonyl)piperidin-4- yl]amino}pyrido[2,3-c/]pyrimidin-7(8/7)- | 1H), 1.83-1.45 (m, 10H)\ | ||
one - Isomer A | 450 | Peak 1 of 4, rt 3.91 min; Chiralcel OJ-3 4.6 x 100 mm 3μ column; 10% MeOH @ 120 bar, 4 mL/min | |
[a]o22-1.2 (c0.1, MeOH) >98% de, single diastereomer, absolute and relative stereochemistry unknown | |||
Enantiomer of Ex. 224 | |||
224 | ^'9 | 1H NMR (400 MHz, DMSO-cfe, 80 °C) δ | |
= 8.48 (s, 1H), 7.51 (s, 1H), 7.31 (d, J=5.0 Hz, 1H), 5.50 (br s, 1H), 4.19 (br | |||
H JL | 450 | s, 1H), 3.95 (br s, 1H), 3.79-3.69 (m, | |
(A) | \ /^QH | J=8.7 Hz, 1H), 3.65 (d, J=12.4 Hz, 2H), 2.98-2.90 (m, 3H), 2.88 (s, 3H), 2.04 | |
8-(3-hydroxycycloheptyl)-6-methyl-2- | (s, 3H), 2.07 (br s, 2H), 1.99-1.90 (m, |
221
{[1-(methylsulfonyl)piperidin-4- yl]amino}pyrido[2,3-d]pyrimidin-7(8H)- one - Isomer B | 1H), 1.83-1.49 (m, 10H) Peak 2 of 4, rt 4.52 min [a]D 22+1.6 (c 0.1, MeOH) -95% de, single diastereomer, absolute and relative stereochemistry unknown Enantiomer of Ex. 223 | ||
225 | 1H NMR (400 MHz, DMSO-cfe, 80 °C) δ | ||
χχχχ | = 8.47 (s, 1H), 7.49 (s, 1H), 7.26 (br s, 1H), 5.88 (br s, 1H), 4.09 (br s, 1H), | ||
(Δ\ | H | 4.06-3.88 (m, 2H), 3.65 (d, J=12.1 Hz, | |
\_V0H | 2H), 2.97-2.90 (m, 2H), 2.88 (s, 3H), 2.81-2.69 (m, J=11.9 Hz, 1H), 2.48- | ||
8-(3-hydroxycycloheptyl)-6-methyl-2- {[1-(methylsulfonyl)piperidin-4- yl]amino}pyrido[2,3-d]pyrimidin-7(8/7)- | 450 | 2.36 (m, 1H), 2.15-2.05 (m, 2H), 2.04 (s, 3H), 1.87-1.50 (m, 9H), 1.50-1.36 (m, 1H) | |
one - Isomer C | Peak 3 of 4, rt 5.15 min | ||
[α]ο22 +21.4 (c0.1, MeOH) -95% de, single diastereomer, absolute and relative stereochemistry unknown | |||
Enantiomer of Ex. 226 | |||
226 | ^,p | 1H NMR (400 MHz, DMSO-cfe, 80 °C) δ | |
ΧλίΧΧ | = 8.47 (s, 1H), 7.49 (s, 1H), 7.26 (br s, 1H), 5.88 (br s, 1H), 4.09 (br s, 1H), | ||
( Λ\ | H | 4.06-3.89 (m, 2H), 3.71-3.60 (m, 2H), | |
\ /~~OH | 2.98-2.90 (m, 2H), 2.88 (s, 3H), 2.75 (t, J=10.3 Hz, 1H), 2.48-2.37 (m, 1H), | ||
8-(3-hydroxycycloheptyl)-6-methyl-2- | 450 | 2.17-2.06 (m, 2H), 2.04 (s, 3H), 1.85- | |
{[1-(methylsulfonyl)piperidin-4- yl]amino}pyrido[2,3-d]pyrimidin-7(8/-/)- | 1.52 (m, 9H), 1.50-1.35 (m, 1H) | ||
one - Isomer D | Peak 4 of 4, rt 5.89 min | ||
[o]d22 -22.9 (c 0.1, MeOH) -95% de, single diastereomer, |
222 absolute and relative stereochemistry unknown
Enantiomer of Ex. 225
Biological Assays and Data
CDK2/Cyclin E1 mobility shift assay
The purpose of the CDK2/Cyclin E1 assay is to evaluate the inhibition (% inhibition, Kiapp and Ki values) of small molécule inhibitors by using a fluorescence-based microfluidic mobility shift assay. CDK2/Cyclin E1 catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the substrate peptide FL-Peptide-18 (5-FAM-QSPKKG-CONH2) (SEQ ID NO:1). (CPC Scientific, Sunnyvale, CA). The mobility shift assay electrophoretically séparâtes the fluorescently labeled peptides (substrate and phosphorylated product) following the kinase reaction. Both substrate and product are measured and the ratio of these values is used to generate %conversion of substrate to product by the LabChip EZ Reader. Wild-type full length CDK2/wild-type full length Cyclin E1 enzyme complex was produced in-house (baculoviral expression, LJIC-2080/LJIC-2103) and phosphorylated by CDK7/Cyclin H1/Mat1 enzyme complex with CDK2:CDK7 ratio of 50:1 (concentration mg/mL) in the presence of 10 mM MgCI2 and 5 mM ATP at room température for one hour. Typical reaction solutions (50 pL final reaction volume) contained 2% DMSO (± inhibitor), 4 mM MgCI2, 1 mM DTT, 150 μΜ ATP (ATP Km = 67.4 pM) , 0.005% Tween-20, 3 pM FL-Peptide-18, and 0.36 nM (catalytically competent active site) phosphorylated wild-type full length CDK2/Cyclin E1 enzyme complex in 25 mM HEPES buffer at pH 7.15. The assay was initiated with the addition of ATP, following a fifteen minutes pre-incubation of enzyme and inhibitor at room température in the reaction mixture. The reaction was stopped after 45 minutes at room température by the addition of 50 pL of 80 mM EDTA, pH 7.5. The Ki value was determined from the fit of the data to the Morrison tight-binding compétitive inhibition équation with the enzyme concentration as a variable.
CDK6/Cyclin D1 mobility shift assay
The purpose of the CDK6/Cyclin D1 assay is to evaluate the inhibition (% inhibition, KiaPP and K values) in the presence of small molécule inhibitors by using a fluorescence based microfluidic mobility shift assay. CDK6/Cyclin D1 catalyzes the
223 production of ADP from ATP that accompanies the phosphoryl transfer to the substrate peptide 5-FAM-Dyrktide (5-FAM-RRRFRPASPLRGPPK) (SEQ ID NO:2). The mobility shift assay electrophoretically séparâtes the fluorescently labeled peptides (substrate and phosphorylated product) following the kinase reaction. Both substrate and product are measured and the ratio of these values is used to generate %conversion of substrate to product by the LabChip EZ Reader. Typical reaction solutions contained 2% DMSO (± inhibitor), 10 mM MgCI2> 1 mM DTT, 2 mM ATP, 0.005% Tween 20 (TW-20), 3 μΜ 5-FAM-Dyrktide, 3 nM (active sites) CDK6/Cyclin D1 in 40 mM HEPES buffer at pH 7.5.
Inhibitor K déterminations for non-phosphorylated CDK6/CyclinD1 (LJIC-2003A2/1865) were initiated with the addition of ATP (50 μΙ_ final reaction volume), following a twelve minute pre-incubation of enzyme and inhibitor at 22 °C in the reaction mix. The reaction was stopped after 35 minutes by the addition of 50 μ!_ of 25 mM EDTA. K déterminations were made from a plot of the fractional velocity as a function of inhibitor concentration fit to the Morrison équation with the enzyme concentration as a variable.
For CDK2, CDK4 and CDK6 mobility shift assays, see also Morrison, J. F. (1969) Kinetics of the réversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors, Biochimica et biophysica acta 185, 269-286; and Murphy, D. J. (2004) Détermination of accurate Kl values for tight-binding enzyme inhibitors: an in silico study of experimental error and assay design, Analytical biochemistry 327, 61-67.
CDK4/Cyclin D3 mobility shift assay
The purpose CDK4/Cyclin D3 assay is to evaluate the inhibition (% inhibition, Kiapp and Ki values) in the presence of small molécule inhibitors by using a fluorescence based microfluidic mobility shift assay. CDK4/Cyclin D3 catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the substrate peptide
5-FAM-Dyrktide (5-FAM-RRRFRPASPLRGPPK) (SEQ ID NO:2). The mobility shift assay electrophoretically séparâtes the fluorescently labeled peptides (substrate and phosphorylated product) following the kinase reaction. Both substrate and product are measured and the ratio of these values is used to generate %Conversion of substrate to product by the LabChip EZ Reader. Typical reaction solutions contained 2% DMSO (± inhibitor), 10 mM MgCI2, 1 mM DTT, 2 mM ATP, 0.005% TW-20, 3 μΜ 5-FAM-Dyrktide, 2 nM (active sites) CDK4/Cyclin D3 in 40 mM HEPES buffer at pH 7.5.
224
Inhibitor Ki déterminations for non-phosphorylated CDK4/Cyclin D3 (LJIC-2007/2010) were initiated with the addition of ATP (50 μΙ_ final reaction volume), following a twelve minute pre-incubation of enzyme and inhibitor at 22 °C in the reaction mix. The reaction was stopped after 35 minutes by the addition of 50 μΐ_ of 25 mM 5 EDTA. Ki déterminations were made from a plot of the fractional velocity as a fonction of inhibitor concentration fit to the Morrison équation with the enzyme concentration as a variable.
Bioloqical Activity
Biological activity data for selected compounds in the CDK2, CDK6 and CDK4 mobility shift assays are provided in Table 2 as Ki (nM).
Table 2.
Example # | CDK2_Ki (nM) | CDK6 KÎ (nM) | CDK4 KÎ (nM) |
1 | 0.71 | 1.20 | |
2 | 0.20 | 2.91 | 1.55 |
3 | 0.26 | 1.17 | 3.43 |
4 | 0.06 | 0.12 | |
5 | 4.75 | 13.07 | |
6 | 0.48 | 2.38 | 3.94 |
7 | 1.87 | 2.04 | |
8 | 0.09 | 0.13 | 0.16 |
9 | 0.16 | 0.25 | 1.12 |
10 | 0.12 | 0.08 | 1.37 |
11 | 0.67 | 2.99 | |
12 | 1.12 | ||
13 | 0.19 | 0.88 | |
14 | 2.50 | ||
15 | 0.46 | 0.76 | |
16 | 0.48 | 1.14 | |
17 | 1.79 | 2.33 | |
18 | 1.19 | 2.44 |
225
19 | 0.35 | 0.96 | |
20 | 0.42 | 1.95 | |
21 | 0.29 | 7.00 | |
22 | 0.63 | 0.33 | |
23 | 0.78 | 0.62 | |
24 | 1.59 | ||
25 | 0.22 | 0.23 | |
26 | 3.84 | ||
27 | 3.85 | ||
28 | 1.88 | 1.20 | |
29 | 1.40 | 0.31 | 0.66 |
30 | 1.35 | 0.34 | |
31 | 2.43 | 0.87 | |
32 | 0.84 | 1.10 | |
33 | 42.61 | ||
34 | 1.34 | 0.42 | |
35 | 19.19 | 7.82 | |
36 | 0.09 | 0.13 | |
37 | 0.06 | 0.06 | |
38 | 0.27 | 0.42 | |
39 | 1.28 | ||
40 | 0.08 | 0.14 | |
41 | 0.48 | 0.36 | |
42 | 155.10 | 46.13 | |
43 | 1.56 | ||
44 | 0.09 | 0.82 | |
45 | 0.93 | ||
46 | 0.77 | ||
47 | 0.27 | 1.09 | |
48 | 1.39 | 0.54 | |
49 | 4.43 | 1.63 |
226
50 | 0.27 | 0.08 | |
51 | 1.74 | 0.13 | |
52 | 0.12 | 0.24 | |
53 | 1.09 | 3.79 | |
54 | 1.44 | ||
55 | 4.66 | ||
56 | 0.28 | 1.77 | |
57 | 5.21 | ||
58 | 0.27 | 0.49 | |
59 | 4.13 | 3.37 | |
60 | 0.48 | 3.18 | |
61 | 4.55 | 19.66 | |
62 | 0.35 | 5.69 | |
63 | 4.51 | 16.54 | |
64 | 0.35 | 4.69 | |
65 | 4.85 | 25.55 | |
66 | 0.21 | 2.47 | |
67 | 4.05 | 21.58 | |
68 | 0.41 | 3.23 | |
69 | 4.48 | 22.25 | |
70 | 0.35 | 0.83 | |
71 | 0.25 | 1.55 | |
72 | 0.42 | 1.09 | |
73 | 5.03 | 8.95 | |
74 | 0.20 | 1.01 | |
75 | 3.85 | 4.96 | |
76 | 0.21 | 1.24 | |
77 | 4.07 | 6.60 | |
78 | 0.25 | 1.63 | |
79 | 7.32 | 9.59 | |
80 | 0.25 | 1.53 |
227
81 | 7.03 | 6.24 | |
82 | 0.10 | 1.21 | |
83 | 1.98 | 9.77 | |
84 | 0.08 | 0.92 | |
85 | 1.98 | 8.29 | |
86 | 0.45 | 1.60 | |
87 | 4.38 | 8.23 | |
88 | 1.34 | 1.99 | |
89 | 17.61 | 11.33 | |
90 | 0.25 | 0.88 | |
91 | 3.01 | 2.72 | |
92 | 0.08 | 0.26 | |
93 | 1.67 | 5.74 | |
94 | 0.09 | 0.33 | |
95 | 1.39 | ||
96 | 0.24 | 1.06 | |
97 | 2.47 | 11.83 | |
98 | 0.33 | 0.74 | |
99 | 2.88 | 14.33 | |
100 | 0.27 | 1.07 | |
101 | 3.59 | 23.51 | |
102 | 0.24 | 0.80 | |
103 | 3.46 | 19.55 | |
104 | 0.14 | 0.77 | |
105 | 3.35 | 22.74 | |
106 | 0.16 | 0.11 | |
107 | 9.91 | 184.11 | |
108 | 3.27 | 3.99 | |
109 | 0.14 | 0.19 | |
110 | 0.10 | 0.28 | |
111 | 2.14 | 4.90 |
228
112 | 0.12 | 1.24 | |
113 | 1.99 | 4.15 | |
114 | 0.17 | 0.15 | |
115 | 2.39 | 3.17 | |
116 | 0.15 | 0.21 | |
117 | 1.74 | 2.46 | |
118 | 0.34 | 4.36 | |
119 | 2.87 | 4.15 | |
120 | 0.16 | 0.18 | 0.34 |
121 | 2.15 | 0.82 | |
122 | 0.11 | 0.23 | 0.92 |
123 | 0.76 | 6.14 | |
124 | 0.69 | 3.84 | |
125 | 6.21 | 36.60 | |
126 | 0.20 | 0.96 | |
127 | 3.46 | 12.56 | |
128 | 0.12 | 0.53 | |
129 | 1.47 | 5.73 | |
130 | 0.17 | 0.43 | |
131 | 3.24 | 23.10 | |
132 | 0.57 | 0.37 | |
133 | 2.37 | 0.94 | |
134 | 1.25 | 0.53 | |
135 | 0.84 | 0.44 | |
136 | 3.14 | 1.35 | |
137 | 4.08 | 6.30 | |
138 | 0.87 | ||
139 | 4.05 | ||
140 | 1.97 | 0.63 | |
141 | 1.25 | 0.37 | |
142 | 1.88 | 0.55 |
229
143 | 2.42 | 0.19 | |
144 | 2.16 | 10.50 | |
145 | 1.41 | 1.40 | |
146 | 1.51 | 1.10 | |
147 | 1.57 | 0.45 | |
148 | 4.18 | 0.26 | |
149 | 2.29 | ||
150 | 2.63 | 1.32 | |
151 | 7.29 | ||
152 | 1.36 | 0.43 | |
153 | 63.24 | 2.23 | |
154 | 1.91 | 0.27 | |
155 | 35.94 | 2.26 | |
156 | 1.40 | 1.94 | |
157 | 36.03 | ||
158 | 3.89 | 0.66 | |
159 | 95.18 | ||
160 | 4.07 | 3.55 | |
161 | 134.51 | ||
162 | 3.92 | 12.34 | |
163 | 63.16 | ||
164 | 2.13 | 2.82 | |
165 | 1.51 | 2.65 | |
166 | 2.23 | 6.71 | |
167 | 1.47 | 1.63 | |
168 | 1.31 | 1.34 | |
169 | 2.76 | 1.11 | |
170 | 6.03 | 1.82 | |
171 | 1.73 | 1.55 | |
172 | 4.38 | 2.08 | |
173 | 2.95 | 3.52 |
230
174 | 3.07 | 6.94 | |
175 | 3.14 | 3.49 | |
176 | 1.27 | 1.87 | |
177 | 1.22 | 0.14 | |
178 | 9.04 | ||
179 | 0.38 | 2.18 | |
180 | 3.76 | 28.93 | |
181 | 1.32 | 0.85 | |
182 | 12.58 | 9.50 | |
183 | 0.10 | 1.99 | |
184 | 1.46 | 11.79 | |
185 | 0.43 | 0.38 | |
186 | 5.65 | 3.62 | |
187 | 0.08 | 0.29 | |
188 | 0.70 | 2.40 | |
189 | 1.20 | 1.98 | |
190 | 0.51 | 184.11 | |
191 | 0.40 | 0.58 | |
192 | 20.89 | 10.06 | |
193 | 2.55 | 2.27 | |
194 | 4.01 | 5.37 | |
195 | 5.49 | 4.68 | |
196 | 5.72 | 3.84 | |
197 | 4.26 | 4.78 | |
198 | 26.90 | 30.96 | |
199 | 2.92 | 1.09 | |
200 | 9.51 | 4.72 | |
201 | 0.12 | 0.85 | |
202 | 0.80 | 2.44 | |
203 | 0.51 | 1.53 | |
204 | 0.51 | 0.18 |
231
205 | 5.22 | 1.27 | |
206 | 0.57 | ||
207 | 5.05 | ||
208 | 12.37 | ||
209 | 0.50 | 0.75 | |
210 | 5.36 | 3.15 | |
211 | 2.19 | 2.22 | |
212 | 1.20 | 0.17 | |
213 | 1.73 | 9.15 | |
214 | 27.78 | 83.34 | |
215 | 1.57 | 2.84 | |
216 | 1.48 | ||
217 | 0.55 | 2.00 | |
218 | 6.28 | 14.35 | |
219 | 0.78 | 3.90 | |
220 | 7.46 | 18.29 | |
221 | 0.13 | 0.36 | |
222 | 2.06 | ||
223 | 57.15 | 20.99 | |
224 | 24.91 | 12.00 | |
225 | 4.63 | 3.13 | |
226 | 310.07 | 6.58 |
Cell Based Assays
Cell prolifération assay
0VCAR3 or HCC1806 cells were seeded 3000 cells/well in 96-well plates in 5 growth media containing 10% FBS and cultured overnight at 37°C 5% CO2. The following day, compounds were serially diluted from a 10 mM top dose for an 11-point 3 fold dilution curve in DMSO. Compounds were intermediately diluted 1:200 into growth media prior to diluting 1:5 on cells for final concentration 10 μΜ to 0.1 nM in 0.1% DMSO on cells. Cells were incubated at 37°C 5% CO2 for 7 days. CYQUANT Direct 10 Cell Prolifération Assay (Molecular Probes, Eugene, OR) was then performed following
232 manufacturer recommendations to détermine the relative viable cell numbers on the Perkin Elmer Envision 2104 Multi Label Reader at 508nM excitation and 527nM émission wavelengths. ICso values were calculated by concentration-response curve fitting utilizing a four-parameter analytical method using GraphPad Prism software.
Figure 2(C) shows ICso results for Example 10 and palbociclib in the OVCAR3 cell prolifération assay. Figure 2(D) shows ICso results for Example 10 and palbociclib in the HCC1806 cell prolifération assay.
Phospho-Serine 807/811 Rb ELISA
OVCAR3 or HCC1806 cells were seeded at 25,000 cells/well in 100 pL growth media and allowed to adhéré at 37°C with 5% CO2 overnight. The following day, compounds were serially diluted from a 10 mM top dose for an 11-point 3 fold dilution curve in DMSO. Compounds were intermediately diluted 1:200 into growth media prior to diluting 1:5 on cells for final concentration 10 μΜ to 0.1 nM in 0.1% DMSO on cells. OVCAR3 cells were treated for 1 hour, while HCC1806 cells were treated overnight, at 37°C with 5% CO2. Cells were lysed in 100 pL/well CST lysis buffer on ice and transferred to pre-coated and blocked anti-phospho-Ser807/811 Rb ELISA plates for overnight incubation at 4°C. Plates were washed to remove residual, unbound cellular proteins and total Rb détection antibody added for 90 minutes at 37°C. Following wash to remove unbound total Rb antibody, HRP tagged antibody was allowed to bind for 30 minutes at 37°C. Following wash to remove unbound HRP antibody, Glo Substrate Reagent was added and incubated protected from light for 5 to 10 minutes. Plates were read in luminescence mode and IC50 values calculated.
Figure 2(A) shows IC50 results for Example 10 and palbociclib in the OVCAR3 Rb ELISA assay. Figure 2(B) shows IC50 results for Example 10 and palbociclib in the HCC1806 Rb ELISA assay.
Tumor Models
Ovcar3 tumor model
Ovcar3 tumor cell line, purchased from ATCC (ATCC HTB-161™) was cultured in RPMI1640 (1x) media (Gibco™ cat# 11875-093) with 10% FBS (Gibco™ cat # 26140-079). To establish a Ovcar3 xenograft model, 5 x 106 cells per mouse was implanted subcutaneously into right hind flank NSG mice (#5557-NOD.cg-Prkdc<scid> Jackson Lab). Cells were suspended in 50% matrigel (Cultrex Basement Membrane
233
Extract (BME), Trevigen’s Basement Membrane Matrix) and 50% RPMI1640 (1x) media (Gibco™ cat# 11875-093) sérum free media prior to implantation.
Animais were randomized 39 days after cells implantation with each group consisted of 4 mice. Treatment began when tumors reached 100mm3 - 190mm3 in size. Test compounds were prepared in 40% Captisol and dosed PO at 10 and 50 mg/kg QD or at 50 mg/kg BID as a suspension for 14 days. Animais were taken down at designated time. Mice receiving no drugs were given vehicle QD or BID for 14 days. Tumor volumes were measured once prior to randomization with an electric caliper, with tumor volumes were calculated using Length x Width x Width/2 formulation. Tumor volumes were measured twice a week with an electric caliper, with tumor volumes calculated using Length x Width x Width/2 formula. Animal weights were recorded twice weekly.
Figure 3 shows dose dépendent inhibition of tumor growth (mm3) for Example 2 in the OVCAR3 mouse tumor xenograft model dosed at 10mpk PO QD, 50mpk PO QD and 50mpk PO BID.
HCC1806 Tumor model
Source: HCC1806 (# CRL 2335, ATCC, Manassas, VA)
The HCC1806 tumor cell line was cultured in RPMI1640 media supplemented with 10% Fêtai Bovine Sérum (FBS). To establish a HCC1806 xenograft model, 5 x 106 cells per mouse were implanted subcutaneously into right hind flank NU/NU female mice. Cells were suspended in 50% Cultrex Basement Membrane Extract and 50% RPMI 1640 media sérum free media prior to implantation.
Animais were randomized 7 days after cells implantation with each group consisting of 13 mice. Treatment began when tumors reached 100 mm3 to 170 mm3 in size on Day 7. Test compounds were prepared in 0.1 %Tween, 0.5% Methyl cellulose in water and dosed PO at 30, 50, and 75 mg/kg as a suspension BID for 14 days. Mice receiving no drugs were given vehicle BID for 14 days. Tumor volumes were measured twice a week with an electric caliper, with tumor volumes calculated using Length x Width x Width/2 formula. Animal weights were recorded twice weekly.
Figure 4 shows dose dépendent inhibition of tumor growth (mm3) for Example 2 in the HCC1806 mouse tumor xenograft model dosed at 30mpk PO BID, 50mpk PO BID and 75mpk PO BID.
234
Ail publications and patent applications cited in the spécification are herein incorporated by reference in their entirety. It will be apparent to those of ordinary skill in the art that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended daims.
Claims (10)
- Claims1. A compound of Formula (VI):I5 R5A (VI), or a pharmaceutically acceptable sait thereof, wherein:R2A and R2B are independently H, OH or C1-C4 alkyl, provided at least one ofR2A and R2B is not H;10 R3 is C1-C4 fluoroalkyl, where said C1-C4 fluoroalkyl is optionally substituted byOH;R4 is H;R5Ais SO2R7; andR7 is C1-C4 alkyl.
- 2. A compound of Formula (Vl-B):236 or a pharmaceutically acceptable sait thereof, wherein:R2A and R2B are independently H, OH or C1-C4 alkyl, provided at least one of R2A and R2B is not H;R3 is C1-C4 fluoroalkyl, where said C1-C4 fluoroalkyl is optionally substituted by OH;R4 is H;R5Ais SO2R7; andR7 is C1-C4 alkyl.
- 3. The compound of claim 1 or 2, or a pharmaceutically acceptable sait thereof, wherein R2A is OH and R2B is CH3.
- 4. The compound of claim 1, 2 or 3, or a pharmaceutically acceptable sait thereof, wherein R3 is C1-C2 fluoroalkyl.
- 5. The compound of claim 4, or a pharmaceutically acceptable sait thereof, wherein R3 is CF2H orOH2CF2H.
- 6. The compound of any one of daims 1 to 5, or a pharmaceutically acceptable sait thereof, wherein R7 is CH3.
- 7. A compound having the structure:or a pharmaceutically acceptable sait thereof.
- 8. The compound of claim 7, in the form of a free base.
- 9.The compound of claim 7, in the form of a pharmaceutically acceptable sait.237
- 10. A pharmaceutical composition comprising a compound of any one of daims 1 to9, or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier or excipient.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62/371,602 | 2016-08-15 | ||
US62/533,347 | 2017-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA19219A true OA19219A (en) | 2020-04-24 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220324872A1 (en) | CDK2/4/6 Inhibitors | |
RU2762557C1 (en) | Derivatives of 2-aminopyridine or 2-aminopyrimidine as cyclin-dependent kinase inhibitors | |
CA2894298C (en) | Substituted dihydroisoquinolinone compounds | |
US20230063457A1 (en) | Dna-pk inhibiting compounds | |
EA036060B1 (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
OA19219A (en) | Pyridopyrimdinone CDK2/4/6 inhibitors. | |
NZ787918A (en) | Pyridopyrimdinone CDK2/4/6 inhibitors | |
RU2790006C2 (en) | 2-aminopyridine or 2-aminopyrimidine derivatives as cyclin-dependent kinase inhibitors | |
EA042105B1 (en) | 2-AMINO-PYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | |
CA3213823A1 (en) | Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof | |
OA19876A (en) | 2-Amino-Pyridine or 2-Amino-Pyrimidine derivatives as cyclin dependent kinase inhibitors. | |
EA046965B1 (en) | 3-CARBONYLAMINO-5-CYCLOPENTYL-1H-PYRAZOLE COMPOUNDS WITH CDK2 INHIBITORY ACTIVITY |